Right now, our nation’s brightest scientific minds, most innovative companies, and leading universities are moving at unprecedented speed to deliver the pandemic-ending treatments, vaccines, diagnostics, and cures we need.
| State | District | Study Title | Enrollment | Facilities | Sponsors | Intervention |
|---|---|---|---|---|---|---|
| Delaware | DE-00 | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 5000 | Alfred I. DuPont Hospital for Children, | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: |
| Delaware | DE-00 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Beebe South Coastal Health Campus, Beebe Medical Center, Delaware Clinical and Laboratory Physicians PA, Helen F Graham Cancer Center, Medical Oncology Hematology Consultants PA, Christiana Care Health System-Christiana Hospital, Beebe Health Campus, Nanticoke Memorial Hospital, Christiana Care Health System-Wilmington Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| District of Columbia | DC-00 | Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients | 100 | Children s National Hospital, | Novartis Pharmaceuticals, Novartis | Drug: Crizanlizumab |
| District of Columbia | DC-00 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| District of Columbia | DC-00 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | George Washington University Hospital, | Gilead Sciences | Drug: Remdesivir |
| District of Columbia | DC-00 | Convalescent Plasma to Stem Coronavirus (CSSC-001) | 500 | Medstar Georgetown University Hospital, | Johns Hopkins University | Biological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma |
| District of Columbia | DC-00 | Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects | 120 | Blade Research Site, Blade Research Site, | Blade Therapeutics, Clinipace Worldwide | Drug: BLD-2660 |
| District of Columbia | DC-00 | Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19) | 384 | Georgetown University Hospital, GW Medical Faculty Associates, | I-Mab Biopharma Co. Ltd. | Drug: TJ003234, Drug: Placebo |
| District of Columbia | DC-00 | Awake Prone Position for Early Hypoxemia in COVID-19 | 560 | Medstar Georgetown University Hospital, | Boston University | Other: Self-prone position recommendation, Other: Usual care |
| District of Columbia | DC-00 | Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen | 120 | Georgetown University Medical Center, | Biohaven Pharmaceuticals, Inc. | Drug: Zavegepant (BHV-3500), Drug: Placebo |
| District of Columbia | DC-00 | Evaluating the Use of Polymyxin B Cartridge Hemoperfusion for Patients With Septic Shock and COVID 19 | 0 | George Washington University, | Spectral Diagnostics (US) Inc. | Device: Toraymyxin PMX-20R (PMX Cartridge) |
| District of Columbia | DC-00 | WGS Analysis of COVID-19 Positive Patients | 5000 | Vanda Pharmaceuticals, | Vanda Pharmaceuticals | |
| District of Columbia | DC-00 | Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19 | 20 | Whitman-Walker Health CRS, | National Institute of Allergy and Infectious Diseases (NIAID), Teva Pharmaceuticals Industries LTD | Drug: Hydroxychloroquine (HCQ), Drug: Azithromycin (Azithro), Drug: Placebo for Hydroxychloroquine, Drug: Placebo for Azithromycin |
| District of Columbia | DC-00 | Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults | 1000 | MedStar Washington Hospital Center, | Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS) | Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo |
| District of Columbia | DC-00 | Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection | 180 | Medstar Washington Medical Center, | National Cancer Institute (NCI), National Institutes of Health Clinical Center (CC) | |
| District of Columbia | DC-00 | A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia | 100 | Medstar Georgetown University Hospital, | Hoffmann-La Roche | Drug: Tociliuzumab |
| District of Columbia | DC-00 | Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia | 270 | MedStar Georgetown University Hospital, | Alexion Pharmaceuticals | Biological: Ravulizumab, Other: Best Supportive Care |
| District of Columbia | DC-00 | Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury | 46 | MedStar Washington Hospital Center, GW Medical Faculty Associates, | AbbVie, Janssen Research & Development, LLC, Pharmacyclics LLC (An AbbVie Company) | Drug: Ibrutinib, Drug: Placebo |
| District of Columbia | DC-00 | COVID-19: Human Epidemiology and Response to SARS-CoV-2 | 5605 | Children's National Medical Center, | National Institute of Allergy and Infectious Diseases (NIAID), Rho Federal Systems Division, Inc. (Rho) | Procedure: Collection of Biological Samples, Procedure: Symptom and Exposure Surveys |
| District of Columbia | DC-00 | Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) | 500 | Georgetown University Medical Center, | Incyte Corporation | Drug: Placebo, Drug: Ruxolitinib |
| District of Columbia | DC-00 | Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. | 62 | Research Site, | AstraZeneca, Acerta Pharma B.V. | Drug: Acalabrutinib |
| District of Columbia | DC-00 | Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants | 52 | MedStar Health Research Institute, | BeiGene | Drug: Zanubrutinib, Drug: Supportive Care, Drug: Placebo |
| District of Columbia | DC-00 | Study of Efficacy and Safety of MAS825 in Patients With COVID-19 | 140 | Novartis Investigative Site, | Novartis Pharmaceuticals, Novartis | Drug: MAS825, Drug: Matching placebo |
| District of Columbia | DC-00 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Kaiser Permanente-Capitol Hill Medical Center, Sibley Memorial Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| District of Columbia | DC-00 | An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic | 0 | MedStar Washington Hosp Center, | Genentech, Inc. | Drug: Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration (PH FDC SC) |
| District of Columbia | DC-00 | Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) | 190 | Atea Study Site, | Atea Pharmaceuticals, Inc. | Drug: AT-527, Other: Placebo |
| District of Columbia | DC-00 | Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression | 208 | Octapharma Research Site, | Octapharma | Biological: Octagam 10%, Other: Placebo |
| District of Columbia | DC-00 | COVID-19 Associated Lymphopenia Pathogenesis Study in Blood (CALYPSO) | 175 | Medstar Georgetown University Hospital, Washington Hospital Center, | National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health Clinical Center (CC) | |
| District of Columbia | DC-00 | Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons | 180 | MedStar Washington Hospital Center, | National Institutes of Health Clinical Center (CC) | |
| District of Columbia | DC-00 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | Georgetown University Medical Center, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| District of Columbia | DC-00 | Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19 | 727 | George Washington University CRS, | HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials Network | Other: Sample collection |
| District of Columbia | DC-00 | A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia | 500 | Medstar Georgetown University Hospital, | Hoffmann-La Roche, Gilead Sciences | Drug: Remdesivir, Drug: Tocilizumab, Drug: Placebo |
| Florida | FL-10 | Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19 | 200000 | OMNI Medical Services, | OMNI Medical Services, LLC, OMNI Medical Services Inc | Drug: Cannabis, Medical |
| Florida | FL-10 | Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine | 1363 | AdventHealth, | Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke University | Drug: Hydroxychloroquine, Drug: Placebo oral tablet |
| Florida | FL-10 | Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) | 190 | Atea Study Site, | Atea Pharmaceuticals, Inc. | Drug: AT-527, Other: Placebo |
| Florida | FL-11 | Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine | 1363 | University of Florida Health Central Florida, | Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke University | Drug: Hydroxychloroquine, Drug: Placebo oral tablet |
| Florida | FL-12 | Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19 | 200000 | OMNI Medical Services, | OMNI Medical Services, LLC, OMNI Medical Services Inc | Drug: Cannabis, Medical |
| Florida | FL-13 | COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial | 38 | Johns Hopkins All Children's Hospital, | Neil Goldenberg, Johns Hopkins All Children's Hospital | Drug: Enoxaparin Prefilled Syringe [Lovenox] |
| Florida | FL-13 | Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection | 4000 | DMI Research, | Romark Laboratories L.C. | Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex |
| Florida | FL-13 | A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia | 410 | Bay Pines VA Medical Center, | Genentech, Inc. | Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo |
| Florida | FL-13 | Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19) | 124 | Theia Clinical Research LLC, | CSL Behring | Biological: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody, Drug: Placebo |
| Florida | FL-14 | Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19 | 200000 | OMNI Medical Services, | OMNI Medical Services, LLC, OMNI Medical Services Inc | Drug: Cannabis, Medical |
| Florida | FL-14 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| Florida | FL-14 | Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine | 1363 | University of South Florida, | Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke University | Drug: Hydroxychloroquine, Drug: Placebo oral tablet |
| Florida | FL-14 | Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects | 120 | Blade Research Site, | Blade Therapeutics, Clinipace Worldwide | Drug: BLD-2660 |
| Florida | FL-14 | Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19) | 390 | James A. Haley Veterans' Hospital, | CytoDyn, Inc. | Drug: Placebos, Drug: Leronlimab (700mg) |
| Florida | FL-14 | A Human Clinical Study to Collect Calibration and Performance Data for the RBA-2 Device | 300 | Tampa General Hospital, University of South Florida, AdventHealth Tampa, | Kaligia Biosciences, LLC, University of South Florida | Diagnostic Test: RBA-2 |
| Florida | FL-14 | Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection | 4000 | Tampa General Hospital, | Romark Laboratories L.C. | Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex |
| Florida | FL-14 | Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) | 500 | Tampa General Hospital, University of South Florida, | Incyte Corporation | Drug: Placebo, Drug: Ruxolitinib |
| Florida | FL-14 | Immunophenotyping Assessment in a COVID-19 Cohort | 2000 | University of South Florida Health Tampa, | National Institute of Allergy and Infectious Diseases (NIAID), Benaroya Research Institute, Boston Children's Hospital | Procedure: Biological sample collection, Procedure: Data Collection: Clinical Care Assessments |
| Florida | FL-14 | Compassionate Use of Hyperbaric Oxygen Therapy | 100 | Innovative Healing Systems, | SerenaGroup, Inc., SerenaGroup Research Foundation | |
| Florida | FL-14 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Moffitt Cancer Center-International Plaza, Moffitt Cancer Center, Moffitt Cancer Center - McKinley Campus, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Florida | FL-14 | Treatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite | 0 | Participating Research Facility, | Hope Pharmaceuticals | Drug: Sodium Nitrite, Drug: Normal Saline |
| Florida | FL-15 | Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects | 120 | Blade Research Site, | Blade Therapeutics, Clinipace Worldwide | Drug: BLD-2660 |
| Florida | FL-15 | Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection | 4000 | Meris Clinical Research, | Romark Laboratories L.C. | Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex |
| Florida | FL-15 | Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) | 500 | Teradan Clinical Trials, | Incyte Corporation | Drug: Placebo, Drug: Ruxolitinib |
| Florida | FL-16 | Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19 | 200000 | OMNI Medical Services, | OMNI Medical Services, LLC, OMNI Medical Services Inc | Drug: Cannabis, Medical |
| Florida | FL-16 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Sarasota Memorial Hospital, | Gilead Sciences | Drug: Remdesivir |
| Florida | FL-16 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Florida Cancer Specialists - Bradenton, Florida Cancer Specialists - Sarasota, Florida Cancer Specialists - Sarasota Downtown, Sarasota Memorial Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Florida | FL-16 | Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19) | 124 | Nova Clinical Research LLC, | CSL Behring | Biological: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody, Drug: Placebo |
| Florida | FL-17 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Florida Cancer Specialists - Venice Island, Florida Cancer Specialists - Venice Healthpark, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Florida | FL-18 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Lawnwood Regional Medical Center, | Gilead Sciences | Drug: Remdesivir |
| Florida | FL-18 | Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects | 120 | Blade Research Site, | Blade Therapeutics, Clinipace Worldwide | Drug: BLD-2660 |
| Florida | FL-18 | Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia | 270 | Jupiter Medical Center, | Alexion Pharmaceuticals | Biological: Ravulizumab, Other: Best Supportive Care |
| Florida | FL-18 | Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury | 46 | Midway Immunology and Research, | AbbVie, Janssen Research & Development, LLC, Pharmacyclics LLC (An AbbVie Company) | Drug: Ibrutinib, Drug: Placebo |
| Florida | FL-18 | Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. | 62 | Research Site, | AstraZeneca, Acerta Pharma B.V. | Drug: Acalabrutinib |
| Florida | FL-18 | Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure | 524 | Wellington Regional Medical Center, | Chimerix | Drug: Dociparastat sodium, Drug: Placebo |
| Florida | FL-19 | Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19 | 200000 | OMNI Medical Services, | OMNI Medical Services, LLC, OMNI Medical Services Inc | Drug: Cannabis, Medical |
| Florida | FL-19 | Convalescent Plasma to Stem Coronavirus (CSSC-001) | 500 | Lee Memorial Health System, | Johns Hopkins University | Biological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma |
| Florida | FL-20 | Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection | 60 | St. Mary's Medical Center, | Denver Health and Hospital Authority, Genentech, Inc., University of Colorado, Denver, National Jewish Health, Beth Israel Deaconess Medical Center, Long Island Jewish Medical Center, Scripps Health, St. Mary's Medical Center, University of Miami, Ben Taub Hospital, Methodist Dallas Medical Center | Drug: Alteplase 50 MG [Activase] |
| Florida | FL-20 | Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury | 46 | Triple O Research Institute, | AbbVie, Janssen Research & Development, LLC, Pharmacyclics LLC (An AbbVie Company) | Drug: Ibrutinib, Drug: Placebo |
| Florida | FL-22 | Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19 | 200000 | OMNI Medical Services, OMNI Medical Services, OMNI Medical Services, | OMNI Medical Services, LLC, OMNI Medical Services Inc | Drug: Cannabis, Medical |
| Florida | FL-22 | The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection | 100 | Invesclinic US LLC, | Pulmotect, Inc. | Drug: PUL-042 Inhalation Solution, Drug: Placebo |
| Florida | FL-22 | The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2 | 200 | Invesclinic US LLC, | Pulmotect, Inc. | Drug: PUL-042 Inhalation Solution, Drug: Placebo |
| Florida | FL-22 | Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection | 4000 | Invesclinica US LLC, | Romark Laboratories L.C. | Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex |
| Florida | FL-22 | Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease | 800 | GSK Investigational Site, | GlaxoSmithKline | Biological: Otilimab, Biological: Placebo, Drug: Standard of care |
| Florida | FL-22 | Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. | 62 | Research Site, | AstraZeneca, Acerta Pharma B.V. | Drug: Acalabrutinib |
| Florida | FL-22 | A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19 | 270 | Holy Cross Hospital, | Janssen Pharmaceutica N.V., Belgium | Drug: Sirukumab, Drug: Placebo, Other: Standard of Care (SOC) |
| Florida | FL-22 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Broward Health North, Holy Cross Hospital, Broward Health Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Florida | FL-22 | LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19) | 60 | Broward Health Medical Center, | Arch Biopartners Inc. | Drug: LSALT peptide, Drug: Placebo |
| Florida | FL-22 | A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia | 500 | Holy Cross Hospital Inc, | Hoffmann-La Roche, Gilead Sciences | Drug: Remdesivir, Drug: Tocilizumab, Drug: Placebo |
| Florida | FL-22 | Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19 | 44 | Holy Cross Hospital, | ViralClear Pharmaceuticals, Inc. | Drug: Merimepodib, Drug: Matching Placebo, Drug: Remdesivir |
| Florida | FL-23 | The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection | 100 | DBC Research Corp., | Pulmotect, Inc. | Drug: PUL-042 Inhalation Solution, Drug: Placebo |
| Florida | FL-23 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Aventura Hospital and Medical Center, | Gilead Sciences | Drug: Remdesivir |
| Florida | FL-23 | Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation | 520 | Cleveland Clinic, | The Cleveland Clinic | Dietary Supplement: Ascorbic Acid, Dietary Supplement: Zinc Gluconate, Dietary Supplement: Ascorbic Acid and Zinc Gluconate, Other: Standard of Care |
| Florida | FL-23 | Canakinumab in Covid-19 Cardiac Injury (The Three C Study) | 45 | Cleveland Clinic Florida, | The Cleveland Clinic, Novartis | Drug: Canakinumab Injection 600mg, Drug: Canakinumab Injection 300mg, Drug: Placebos |
| Florida | FL-23 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Research Centers of America, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Florida | FL-23 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Mount Sinai Comprehensive Cancer Center at Aventura, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Florida | FL-23 | Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation | 30 | Cleveland Clinic Florida, | The Cleveland Clinic, Kiniksa Pharmaceuticals, Ltd. | Drug: Mavrilimumab, Drug: Placebos |
| Florida | FL-24 | Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients | 100 | Joe DiMaggio Childrens Hospital, | Novartis Pharmaceuticals, Novartis | Drug: Crizanlizumab |
| Florida | FL-24 | Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19 | 200000 | OMNI Medical Services, | OMNI Medical Services, LLC, OMNI Medical Services Inc | Drug: Cannabis, Medical |
| Florida | FL-24 | Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure | 165 | University of Miami Medical Center, | NeuroRx, Inc., Lavin Consulting, LLC | Drug: Aviptadil by intravenous infusion + standard of care, Drug: Normal Saline Infusion + standard of care |
| Florida | FL-24 | Acute Encephalopathy in Critically Ill Patients With COVID-19 | 250 | University of Miami Miller School of Medicine, | Ictal Group | Other: Follow up |
| Florida | FL-24 | A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia | 450 | University of Miami Miller School of Medicine, | Hoffmann-La Roche | Drug: Tocilizumab (TCZ), Drug: Placebo |
| Florida | FL-24 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Memorial Regional Hospital, | Gilead Sciences | Drug: Remdesivir |
| Florida | FL-24 | Convalescent Plasma to Stem Coronavirus (CSSC-001) | 500 | University of Miami Clinical Translational Research Site, | Johns Hopkins University | Biological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma |
| Florida | FL-24 | Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine | 1363 | University of Miami Florida, | Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke University | Drug: Hydroxychloroquine, Drug: Placebo oral tablet |
| Florida | FL-24 | Effects of DPP4 Inhibition on COVID-19 | 20 | University of Miami, | University of Miami | Drug: Linagliptin, Drug: Insulin regimen |
| Florida | FL-24 | Collection of Anti-SARS-CoV-2 Immune Plasma | 1500 | University of Miami Infectious Diseases Research Unit, | National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health Clinical Center (CC) | |
| Florida | FL-24 | Use of UC-MSCs for COVID-19 Patients | 24 | University of Miami Infectious Diseases Research Unit, | Camillo Ricordi, University of Miami | Biological: Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care., Other: Vehicle + Heparin along with best supportive care |
| Florida | FL-24 | Convalescent Plasma in Outpatients With COVID-19 | 600 | Jackson Memorial Hospital, | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network | Biological: Convalescent Plasma, Biological: Saline |
| Florida | FL-24 | Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection | 60 | University of Miami Hospital, | Denver Health and Hospital Authority, Genentech, Inc., University of Colorado, Denver, National Jewish Health, Beth Israel Deaconess Medical Center, Long Island Jewish Medical Center, Scripps Health, St. Mary's Medical Center, University of Miami, Ben Taub Hospital, Methodist Dallas Medical Center | Drug: Alteplase 50 MG [Activase] |
| Florida | FL-24 | Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19 | 50 | University of Miami Miller School of Medicine, | Fujifilm Pharmaceuticals U.S.A., Inc. | Drug: Favipiravir + Standard of Care, Drug: Standard of Care |
| Florida | FL-24 | CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients | 300 | University of Miami Hospital and Clinics, | NYU Langone Health, National Center for Advancing Translational Science (NCATS), Albert Einstein College of Medicine, Yale University, The University of Texas Health Science Center, Houston, The University of Texas Health Science Center at Tyler, University of Miami | Biological: Convalescent Plasma, Other: Saline solution |
| Florida | FL-24 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Acevedo Clinical Research Associates, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Florida | FL-24 | A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia | 379 | Miami Veterans Administration Healthcare System, University of Miami Pulmonary, | Genentech, Inc. | Drug: Placebo, Drug: Tocilizumab |
| Florida | FL-24 | Convalescent Plasma to Limit SARS-CoV-2 Associated Complications | 1344 | University of Miami Clinical Translational Research Site, | Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID) | Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor |
| Florida | FL-24 | Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury | 46 | University of Miami, | AbbVie, Janssen Research & Development, LLC, Pharmacyclics LLC (An AbbVie Company) | Drug: Ibrutinib, Drug: Placebo |
| Florida | FL-24 | Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization | 198 | Miami VA Healthcare System, | VA Office of Research and Development | Drug: Degarelix, Other: Saline |
| Florida | FL-24 | iNOPulse for COVID-19 | 0 | University of Miami Hospitals & Clinics, | Roger Alvarez, Bellerophon Therapeutics, University of Miami | Drug: Inhaled nitric oxide (iNO), Drug: Nitrogen gas, Drug: Oxygen gas |
| Florida | FL-24 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | University of Miami Miller School of Medicine, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| Florida | FL-24 | A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia | 500 | University of Miami Miller School of Medicine, | Hoffmann-La Roche, Gilead Sciences | Drug: Remdesivir, Drug: Tocilizumab, Drug: Placebo |
| Florida | FL-25 | Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) | 6000 | South Florida Research Organization, | Montreal Heart Institute, National Heart, Lung, and Blood Institute (NHLBI), Bill and Melinda Gates Foundation, The Government of Quebec, DACIMA Software | Drug: Colchicine, Drug: Placebo oral tablet |
| Florida | FL-25 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Indago Research & Health Center, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Florida | FL-25 | Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia | 270 | Alternative Research Associates, | Alexion Pharmaceuticals | Biological: Ravulizumab, Other: Best Supportive Care |
| Florida | FL-25 | A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia | 379 | Larkin Community Hospital Palm Springs Campus, | Genentech, Inc. | Drug: Placebo, Drug: Tocilizumab |
| Florida | FL-25 | Zofin (Organicell Flow) for Patients With COVID-19 | 20 | Larkin Community Hospital, | Organicell Regenerative Medicine | Biological: Zofin, Other: Placebo |
| Florida | FL-25 | A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia | 410 | Larkin Community Hospital, | Genentech, Inc. | Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo |
| Florida | FL-25 | A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19 | 204 | Indago Research and Health Center, | Ridgeback Biotherapeutics, LP | Drug: EIDD-2801, Drug: Placebo (PBO) |
| Florida | FL-25 | A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia | 500 | Larkin Community Hospital Palm Springs Campus, | Hoffmann-La Roche, Gilead Sciences | Drug: Remdesivir, Drug: Tocilizumab, Drug: Placebo |
| Florida | FL-26 | Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection | 4000 | New Horizon Research Center, | Romark Laboratories L.C. | Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex |
| Florida | FL-27 | The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection | 100 | Clinical Research of South Florida Alliance for Multispecialty Research, | Pulmotect, Inc. | Drug: PUL-042 Inhalation Solution, Drug: Placebo |
| Florida | FL-27 | The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2 | 200 | Clinical Research of South Florida Alliance for Multispecialty Research, | Pulmotect, Inc. | Drug: PUL-042 Inhalation Solution, Drug: Placebo |
| Florida | FL-27 | Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) | 6000 | Miami Center for Advanced Cardiology, | Montreal Heart Institute, National Heart, Lung, and Blood Institute (NHLBI), Bill and Melinda Gates Foundation, The Government of Quebec, DACIMA Software | Drug: Colchicine, Drug: Placebo oral tablet |
| Florida | FL-27 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Mount Sinai Medical Center, | Gilead Sciences | Drug: Remdesivir |
| Florida | FL-27 | Convalescent Plasma to Stem Coronavirus (CSSC-001) | 500 | University of Miami, | Johns Hopkins University | Biological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma |
| Florida | FL-27 | Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection | 202 | Miami Cancer Institute at Baptist Health, | Karyopharm Therapeutics Inc | Drug: Selinexor, Other: Placebo |
| Florida | FL-27 | A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE) | 227 | Miami Cancer Institute, | Kinevant Sciences GmbH, Roivant Sciences, Inc. | Drug: Gimsilumab, Drug: Placebo |
| Florida | FL-27 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Alliance for Multispecialty Research LLC, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Florida | FL-27 | A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia | 379 | Larkin Community Hospital, | Genentech, Inc. | Drug: Placebo, Drug: Tocilizumab |
| Florida | FL-27 | Convalescent Plasma to Limit SARS-CoV-2 Associated Complications | 1344 | University of Miami, | Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID) | Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor |
| Florida | FL-27 | Mindfulness Training for Seniors | 53 | University of Miami, | University of Miami | Behavioral: Mindfulness training (MT) Connect |
| Florida | FL-27 | Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease | 682 | Westchester Research Center, | Algernon Pharmaceuticals, Novotech (Australia) | Drug: NP-120 (Ifenprodil) |
| Florida | FL-27 | Zofin (Organicell Flow) for Patients With COVID-19 | 20 | Larkin Community Hospital, | Organicell Regenerative Medicine | Biological: Zofin, Other: Placebo |
| Florida | FL-27 | A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia | 410 | Larkin Community Hospital, | Genentech, Inc. | Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo |
| Florida | FL-27 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Mount Sinai Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Florida | FL-27 | A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19 | 66 | Westchester General Hospital, | Apellis Pharmaceuticals, Inc. | Drug: APL-9, Other: Vehicle Control |
| Florida | FL-27 | A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia | 500 | Larkin Community Hospital, | Hoffmann-La Roche, Gilead Sciences | Drug: Remdesivir, Drug: Tocilizumab, Drug: Placebo |
| Florida | FL-09 | Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy | 12123 | Tabula Rasa HealthCare Precision Pharmacotherapy Research and Development Institute, | Tabula Rasa HealthCare | Other: Simulation of Repurposed Drugs for COVID-19 |
| Florida | FL-09 | Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF) | 800 | Chappel Group Research, | Romark Laboratories L.C. | Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex |
| Florida | FL-09 | Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection | 4000 | Chappel Group Research, | Romark Laboratories L.C. | Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex |
| Florida | FL-09 | Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Adults With Polypharmacy Using Data From Large Medicare and Commercially Insured Populations | 100 | Tabula Rasa HealthCare Precision Pharmacotherapy Research, | Tabula Rasa HealthCare, Cambia Health Solutions | |
| Florida | FL-04 | CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment | 243 | Baptist Health Research Institute, | OncoImmune, Inc. | Drug: CD24Fc, Drug: Placebo |
| Florida | FL-04 | Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) | 6000 | Mayo Clinic - Jacksonville, | Montreal Heart Institute, National Heart, Lung, and Blood Institute (NHLBI), Bill and Melinda Gates Foundation, The Government of Quebec, DACIMA Software | Drug: Colchicine, Drug: Placebo oral tablet |
| Florida | FL-04 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Mayo Clinic in Florida, | Gilead Sciences | Drug: Remdesivir |
| Florida | FL-04 | Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry | 50000 | Mayo Clinic in Florida, | Mayo Clinic, Society of Critical Care Medicine, Boston University | Other: observational |
| Florida | FL-04 | Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19 | 0 | Mayo Clinic in Florida, | Mayo Clinic | Biological: COVID-19 convalescent plasma |
| Florida | FL-04 | Breath Analysis Based Disease Biomarkers of COVID-19 and Other Diseases | 120 | Mayo Clinic Florida, | Mayo Clinic | Diagnostic Test: Collection of breath sample |
| Florida | FL-04 | Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19 | 300 | Baptist Medical Center, Mayo Clinic, | Humanigen, Inc. | Biological: Lenzilumab, Drug: Standard of Care |
| Florida | FL-04 | Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP) | 0 | Naval Hospital Jacksonville, | U.S. Army Medical Research and Development Command | Biological: Anti-Sars-CoV-2 Convalescent Plasma |
| Florida | FL-04 | A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia | 100 | Mayo Clinic, | Hoffmann-La Roche | Drug: Tociliuzumab |
| Florida | FL-04 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Jacksonville Center for Clinical Research, Clinical Neuroscience Solutions, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Florida | FL-04 | Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia | 270 | Mayo Clinic Florida, | Alexion Pharmaceuticals | Biological: Ravulizumab, Other: Best Supportive Care |
| Florida | FL-04 | Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. | 62 | Research Site, | AstraZeneca, Acerta Pharma B.V. | Drug: Acalabrutinib |
| Florida | FL-04 | Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers | 300 | Mayo Clinic, | Mayo Clinic | Other: Serologic testing |
| Florida | FL-04 | Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19 | 140 | Baptist Health Medical Center, | Pluristem Ltd. | Biological: PLX-PAD, Biological: Placebo |
| Florida | FL-04 | A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19 | 66 | Baptist Medical Center Beaches, | Apellis Pharmaceuticals, Inc. | Drug: APL-9, Other: Vehicle Control |
| Florida | FL-04 | PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer | 364 | Ascension St. Vincent's Riverside Hospital, | CTI BioPharma | Drug: Pacritinib, Drug: Placebo |
| Florida | FL-04 | Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19 | 44 | Mayo Clinic in Florida, | ViralClear Pharmaceuticals, Inc. | Drug: Merimepodib, Drug: Matching Placebo, Drug: Remdesivir |
| Florida | FL-01 | Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19 | 200000 | OMNI Medical Services, | OMNI Medical Services, LLC, OMNI Medical Services Inc | Drug: Cannabis, Medical |
| Florida | FL-01 | Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP) | 0 | Eglin Air Force Base, | U.S. Army Medical Research and Development Command | Biological: Anti-Sars-CoV-2 Convalescent Plasma |
| Florida | FL-05 | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 5000 | University of Florida Jacksonville Shands Medical Center, | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: |
| Florida | FL-05 | Losartan for Patients With COVID-19 Requiring Hospitalization | 200 | University of Florida Health, | University of Minnesota, Bill and Melinda Gates Foundation | Drug: Losartan, Other: Placebo |
| Florida | FL-05 | Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine | 1363 | University of Florida Jacksonville, | Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke University | Drug: Hydroxychloroquine, Drug: Placebo oral tablet |
| Florida | FL-05 | A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia | 100 | University of Florida Health Services Center, | Hoffmann-La Roche | Drug: Tociliuzumab |
| Florida | FL-05 | Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia | 270 | University of Florida, | Alexion Pharmaceuticals | Biological: Ravulizumab, Other: Best Supportive Care |
| Florida | FL-05 | Immunophenotyping Assessment in a COVID-19 Cohort | 2000 | University of Florida Health Jacksonville, | National Institute of Allergy and Infectious Diseases (NIAID), Benaroya Research Institute, Boston Children's Hospital | Procedure: Biological sample collection, Procedure: Data Collection: Clinical Care Assessments |
| Florida | FL-05 | Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. | 62 | Research Site, | AstraZeneca, Acerta Pharma B.V. | Drug: Acalabrutinib |
| Florida | FL-08 | Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19 | 200000 | OMNI Medical Services, | OMNI Medical Services, LLC, OMNI Medical Services Inc | Drug: Cannabis, Medical |
| Florida | FL-06 | A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study) | 252 | Renibus Therapeutics, | Renibus Therapeutics, Inc. | Drug: RBT-9 (90 mg), Drug: 0.9% sodium chloride (normal saline) |
| Florida | FL-06 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | DeLand Clinical Research Unit, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Florida | FL-03 | Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients | 100 | University of Florida College of Medicine, | Novartis Pharmaceuticals, Novartis | Drug: Crizanlizumab |
| Florida | FL-03 | Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19 | 200000 | OMNI Medical Services, | OMNI Medical Services, LLC, OMNI Medical Services Inc | Drug: Cannabis, Medical |
| Florida | FL-03 | Losartan for Patients With COVID-19 Requiring Hospitalization | 200 | University of Florida Health, | University of Minnesota, Bill and Melinda Gates Foundation | Drug: Losartan, Other: Placebo |
| Florida | FL-03 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| Florida | FL-03 | Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease | 479 | University of Florida, | Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI) | Drug: Hydroxychloroquine, Drug: Placebo |
| Florida | FL-03 | Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine | 1363 | University of Florida, | Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke University | Drug: Hydroxychloroquine, Drug: Placebo oral tablet |
| Florida | FL-03 | A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE) | 227 | University of Florida, | Kinevant Sciences GmbH, Roivant Sciences, Inc. | Drug: Gimsilumab, Drug: Placebo |
| Florida | FL-03 | Convalescent Plasma in Outpatients With COVID-19 | 600 | UF Health Shands Hospital, | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network | Biological: Convalescent Plasma, Biological: Saline |
| Florida | FL-03 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Fleming Island Center for Clinical Research, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Florida | FL-03 | Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease | 800 | GSK Investigational Site, | GlaxoSmithKline | Biological: Otilimab, Biological: Placebo, Drug: Standard of care |
| Florida | FL-03 | Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) | 500 | University of Florida, | Incyte Corporation | Drug: Placebo, Drug: Ruxolitinib |
| Florida | FL-03 | Immunophenotyping Assessment in a COVID-19 Cohort | 2000 | University of Florida at Gainesville, | National Institute of Allergy and Infectious Diseases (NIAID), Benaroya Research Institute, Boston Children's Hospital | Procedure: Biological sample collection, Procedure: Data Collection: Clinical Care Assessments |
| Florida | FL-03 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | University of Florida Health Science Center – Gainesville, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Florida | FL-03 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | University of Florida Health, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| Florida | FL-07 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| Florida | FL-07 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | AdventHealth Orlando, | Gilead Sciences | Drug: Remdesivir |
| Florida | FL-07 | A COVID-19 Symptom, Exposure and Immune Response Registry | 10000 | ObvioHealth, | ObvioHealth | |
| Florida | FL-07 | Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19 | 300 | AdventHealth Orlando, | Humanigen, Inc. | Biological: Lenzilumab, Drug: Standard of Care |
| Florida | FL-07 | Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection | 4000 | Clinical Neuroscience Solutions Inc., | Romark Laboratories L.C. | Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex |
| Florida | FL-07 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Clinical Neuroscience Solutions Inc, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Florida | FL-07 | SARSCoV2 (COVID-19) Convalescent Plasma (CP) Expanded Access Protocol (EAP) | 0 | AdventHealth Orlando, | AdventHealth | Biological: SARSCoV2 Convalescent Plasma |
| Florida | FL-02 | Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects | 120 | Blade Research Site, | Blade Therapeutics, Clinipace Worldwide | Drug: BLD-2660 |
| Georgia | GA-11 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| Georgia | GA-11 | Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF) | 800 | Clinical Trial Specialists Inc., | Romark Laboratories L.C. | Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex |
| Georgia | GA-11 | A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia | 410 | WellStar Research Institute, | Genentech, Inc. | Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo |
| Georgia | GA-12 | Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP) | 0 | Eisenhower Army Medical Center, | U.S. Army Medical Research and Development Command | Biological: Anti-Sars-CoV-2 Convalescent Plasma |
| Georgia | GA-12 | Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants | 52 | Augusta University, | BeiGene | Drug: Zanubrutinib, Drug: Supportive Care, Drug: Placebo |
| Georgia | GA-12 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Augusta Oncology Associates PC-Wheeler, Augusta University Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Georgia | GA-12 | Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19 | 140 | Medical College of Georgia at Augusta University, | Pluristem Ltd. | Biological: PLX-PAD, Biological: Placebo |
| Georgia | GA-13 | The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2 | 200 | Clinical Research Atlanta, | Pulmotect, Inc. | Drug: PUL-042 Inhalation Solution, Drug: Placebo |
| Georgia | GA-13 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Piedmont Fayette Hospital, | Gilead Sciences | Drug: Remdesivir |
| Georgia | GA-13 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Clinical Research Atlanta, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Georgia | GA-08 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | John D. Archbold Memorial Hospital, | Gilead Sciences | Drug: Remdesivir |
| Georgia | GA-08 | Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants | 52 | John D. Archbold Memorial Hospital, | BeiGene | Drug: Zanubrutinib, Drug: Supportive Care, Drug: Placebo |
| Georgia | GA-02 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Piedmont Columbus Regional, | Gilead Sciences | Drug: Remdesivir |
| Georgia | GA-02 | Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP) | 0 | Martin Army Community Hospital, | U.S. Army Medical Research and Development Command | Biological: Anti-Sars-CoV-2 Convalescent Plasma |
| Georgia | GA-02 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | IACT Health, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Georgia | GA-02 | A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19 | 270 | Corporation of Mercer University, | Janssen Pharmaceutica N.V., Belgium | Drug: Sirukumab, Drug: Placebo, Other: Standard of Care (SOC) |
| Georgia | GA-02 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Phoebe Putney Memorial Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Georgia | GA-02 | Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19 | 140 | Sarah Cannon Research Institute, LLC, | Pluristem Ltd. | Biological: PLX-PAD, Biological: Placebo |
| Georgia | GA-01 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Memorial Health University Medical Center, | Gilead Sciences | Drug: Remdesivir |
| Georgia | GA-01 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Meridian Clinical Research LLC, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Georgia | GA-01 | Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant | 1419 | Meridian Clinical Research, | Novavax, Coalition for Epidemic Preparedness Innovations (CEPI) | Biological: SARS-CoV-2 rS - Phase 1, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1, Other: Normal saline solution (NSS), Placebo - Phase 1, Other: Normal saline solution (NSS), Placebo - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1, Other: Normal saline solution (NSS), Placebo, Day 21 - Phase 1, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Days 0 and 21 - Phase 2, Other: Normal saline solution (NSS), Placebo, Day 189 - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 2, Other: Normal saline solution (NSS), Placebo, Day 21 - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Day 189 - Phase 2 |
| Georgia | GA-01 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Memorial Health University Medical Center, Lewis Cancer and Research Pavilion at Saint Joseph's/Candler, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Georgia | GA-01 | Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older | 600 | Meridian Clinical Research, | ModernaTX, Inc., Biomedical Advanced Research and Development Authority | Biological: Biological: mRNA-1273: 50 mcg, Other: Placebo, Biological: Biological: mRNA-1273: 100 mcg |
| Georgia | GA-05 | Losartan for Patients With COVID-19 Requiring Hospitalization | 200 | Grady Memorial Hospital, | University of Minnesota, Bill and Melinda Gates Foundation | Drug: Losartan, Other: Placebo |
| Georgia | GA-05 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site, Regeneron Study Site, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| Georgia | GA-05 | Acute Encephalopathy in Critically Ill Patients With COVID-19 | 250 | Wellstar Atlanta Medical Center, | Ictal Group | Other: Follow up |
| Georgia | GA-05 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Piedmont Atlanta Hospital, Wellstar Atlanta Medical Center, | Gilead Sciences | Drug: Remdesivir |
| Georgia | GA-05 | Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19 | 2 | Emory University Hospital, | Emory University | Device: GO2 PEEP MOUTHPIECE |
| Georgia | GA-05 | Awake Prone Position for Early Hypoxemia in COVID-19 | 560 | Piedmont Atlanta, | Boston University | Other: Self-prone position recommendation, Other: Usual care |
| Georgia | GA-05 | Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection | 202 | Emory University, | Karyopharm Therapeutics Inc | Drug: Selinexor, Other: Placebo |
| Georgia | GA-05 | Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19 | 300 | Emory University, | Humanigen, Inc. | Biological: Lenzilumab, Drug: Standard of Care |
| Georgia | GA-05 | A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE) | 227 | Piedmont Healthcare, Emory University School of Medicine, | Kinevant Sciences GmbH, Roivant Sciences, Inc. | Drug: Gimsilumab, Drug: Placebo |
| Georgia | GA-05 | Convalescent Plasma in Outpatients With COVID-19 | 600 | Grady Memorial Hospital, | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network | Biological: Convalescent Plasma, Biological: Saline |
| Georgia | GA-05 | Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection) | 0 | Emory University Hospital, | Emory University, National Cancer Institute (NCI) | Other: Best Practice, Biological: Tocilizumab |
| Georgia | GA-05 | Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID) | 432 | Novartis Investigative Site, | Novartis Pharmaceuticals, Incyte Corporation, Novartis | Drug: Ruxolitinib, Drug: Placebo |
| Georgia | GA-05 | Radiation Eliminates Storming Cytokines and Unchecked Edema as a 1-Day Treatment for COVID-19 | 10 | Emory University Hospital Midtown, | Emory University | Radiation: Low Dose Radiation Therapy |
| Georgia | GA-05 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Atlanta Center for Medical Research, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Georgia | GA-05 | Trans Thoracic Manipulation of Ventilation/Perfusion: the V/Q Vest for COVID-19 | 24 | Emory University Hospital, | Emory University, Georgia Tech Research Foundation, Georgia Clinical & Translational Science Alliance | Device: V/Q Vest |
| Georgia | GA-05 | MSCs in COVID-19 ARDS | 223 | Emory University, | Icahn School of Medicine at Mount Sinai, Mesoblast, Inc., National Heart, Lung, and Blood Institute (NHLBI) | Biological: Remestemcel-L, Drug: Placebo |
| Georgia | GA-05 | Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC) | 3000 | Emory University Hospital Midtown, | University of Manitoba, University Health Network, Toronto | Drug: Heparin |
| Georgia | GA-05 | Immunophenotyping Assessment in a COVID-19 Cohort | 2000 | Emory University School of Medicine, | National Institute of Allergy and Infectious Diseases (NIAID), Benaroya Research Institute, Boston Children's Hospital | Procedure: Biological sample collection, Procedure: Data Collection: Clinical Care Assessments |
| Georgia | GA-05 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Atlanta VA Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Georgia | GA-05 | Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) | 190 | Atea Study Site, | Atea Pharmaceuticals, Inc. | Drug: AT-527, Other: Placebo |
| Georgia | GA-05 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | Atlanta VA Medical Center, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| Georgia | GA-05 | Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19 | 727 | Ponce de Leon Center CRS, | HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials Network | Other: Sample collection |
| Georgia | GA-05 | PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer | 364 | Grady Memorial Hospital, | CTI BioPharma | Drug: Pacritinib, Drug: Placebo |
| Georgia | GA-05 | A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19 | 24 | Emory University, | Eli Lilly and Company, AbCellera Biologics Inc. | Drug: LY3819253, Drug: Placebo |
| Georgia | GA-09 | Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19 | 86 | Center for Advanced Research & Education, | CytoDyn, Inc. | Drug: Placebos, Drug: Leronlimab (700mg) |
| Georgia | GA-09 | Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19) | 390 | Center for Advanced Research & Education, | CytoDyn, Inc. | Drug: Placebos, Drug: Leronlimab (700mg) |
| Georgia | GA-09 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | University Cancer and Blood Center LLC, Northeast Georgia Medical Center Braselton, Northeast Georgia Medical Center-Gainesville, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Georgia | GA-06 | Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients | 100 | Childrens Healthcare of Atlanta, | Novartis Pharmaceuticals, Novartis | Drug: Crizanlizumab |
| Georgia | GA-06 | Treating COVID-19 With a Bidirectional Oxygenation Valve | 30 | Emory Saint Joseph's Hospital, | TMC HealthCare, PEEP Medical, LLC | Device: bidirectional oxygenation mouthpiece |
| Georgia | GA-06 | Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19 | 2 | Emory Saint Joseph's Hospital, | Emory University | Device: GO2 PEEP MOUTHPIECE |
| Georgia | GA-06 | Radiation Eliminates Storming Cytokines and Unchecked Edema as a 1-Day Treatment for COVID-19 | 10 | Emory Saint Joseph's Hosptial, | Emory University | Radiation: Low Dose Radiation Therapy |
| Georgia | GA-06 | A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia | 410 | Northside Hospital, | Genentech, Inc. | Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo |
| Georgia | GA-06 | Use of Convalescent Plasma for COVID-19 | 700 | Northside Hospital, | Northside Hospital, Inc. | Biological: Convalescent Plasma |
| Georgia | GA-04 | Adaptive COVID-19 Treatment Trial (ACTT) | 1062 | Emory Vaccine Center, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir |
| Georgia | GA-04 | Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19) | 120 | Emory Vaccine Center, | National Institute of Allergy and Infectious Diseases (NIAID) | Biological: mRNA-1273 |
| Georgia | GA-04 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Grady Memorial Hospital, | Gilead Sciences | Drug: Remdesivir |
| Georgia | GA-04 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | Emory Vaccine Center, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| Georgia | GA-04 | Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19 | 727 | Hope Clinic of the Emory Vaccine Center CRS, | HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials Network | Other: Sample collection |
| Hawaii | HI-01 | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 5000 | Kapiolani Womens and Childrens Medical Center, | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: |
| Hawaii | HI-01 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Kaiser Permanente Hawaii Moanalua Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Hawaii | HI-01 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Kaiser Permanente Hawaii Moanalua Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Hawaii | HI-01 | A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients | 17 | Queen's Medical Centre, | Queen's Medical Centre | Drug: Hydroxychloroquine |
| Hawaii | HI-01 | Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP) | 0 | Tripler Army Medical Center, | U.S. Army Medical Research and Development Command | Biological: Anti-Sars-CoV-2 Convalescent Plasma |
| Hawaii | HI-01 | Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients | 40 | University of Hawaii - Manoa, | University of Hawaii | Drug: Telmisartan 40mg, Drug: Placebo |
| Hawaii | HI-01 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | East-West Medical Research Institute, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Hawaii | HI-01 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Kaiser Permanente Moanalua Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Hawaii | HI-01 | Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression | 208 | Octapharma Research Site, | Octapharma | Biological: Octagam 10%, Other: Placebo |
| Idaho | ID-02 | Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects | 120 | Blade Research Site, | Blade Therapeutics, Clinipace Worldwide | Drug: BLD-2660 |
| Idaho | ID-02 | Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID) | 432 | Novartis Investigative Site, | Novartis Pharmaceuticals, Incyte Corporation, Novartis | Drug: Ruxolitinib, Drug: Placebo |
| Idaho | ID-02 | A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia | 379 | St. Lukes Boise Medical Center, | Genentech, Inc. | Drug: Placebo, Drug: Tocilizumab |
| Idaho | ID-02 | Study of Efficacy and Safety of MAS825 in Patients With COVID-19 | 140 | Novartis Investigative Site, | Novartis Pharmaceuticals, Novartis | Drug: MAS825, Drug: Matching placebo |
| Idaho | ID-02 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Saint Alphonsus Cancer Care Center-Boise, Saint Luke's Mountain States Tumor Institute, Saint Luke's Mountain States Tumor Institute-Twin Falls, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Idaho | ID-02 | A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia | 500 | St Luke's Health System, | Hoffmann-La Roche, Gilead Sciences | Drug: Remdesivir, Drug: Tocilizumab, Drug: Placebo |
| Idaho | ID-01 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Solaris Clinical Research, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Idaho | ID-01 | Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant | 1419 | Advanced Clinical Research, | Novavax, Coalition for Epidemic Preparedness Innovations (CEPI) | Biological: SARS-CoV-2 rS - Phase 1, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1, Other: Normal saline solution (NSS), Placebo - Phase 1, Other: Normal saline solution (NSS), Placebo - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1, Other: Normal saline solution (NSS), Placebo, Day 21 - Phase 1, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Days 0 and 21 - Phase 2, Other: Normal saline solution (NSS), Placebo, Day 189 - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 2, Other: Normal saline solution (NSS), Placebo, Day 21 - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Day 189 - Phase 2 |
| Idaho | ID-01 | Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial | 120 | Kootenai Health, | Kootenai Health, Washington State University | Drug: Hydroxychloroquine |
| Idaho | ID-01 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Saint Alphonsus Cancer Care Center-Caldwell, Kootenai Medical Center, Walter Knox Memorial Hospital, Saint Luke's Mountain States Tumor Institute – Fruitland, Idaho Urologic Institute-Meridian, Saint Luke's Mountain States Tumor Institute – Meridian, Saint Alphonsus Medical Center-Nampa, Saint Luke's Mountain States Tumor Institute – Nampa, Kootenai Cancer Center, Kootenai Cancer Clinic, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Illinois | IL-10 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Northwestern Lake Forest Hospital, | Gilead Sciences | Drug: Remdesivir |
| Illinois | IL-10 | COVID-19 Patient Positioning Pragmatic Trial | 503 | NorthShore University HealthSystem, | Vanderbilt University Medical Center | Other: Prone, Other: Usual Care |
| Illinois | IL-10 | Leflunomide in Mild COVID-19 Patients | 20 | University of Chicago, | University of Chicago | Drug: Leflunomide |
| Illinois | IL-11 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Rush - Copley Medical Center, UC Comprehensive Cancer Center at Silver Cross, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Illinois | IL-12 | A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection | 152 | BJC, | Washington University School of Medicine | Drug: Fluvoxamine, Drug: Placebo |
| Illinois | IL-12 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Memorial Hospital of Carbondale, SIH Cancer Institute, Good Samaritan Regional Health Center, Cancer Care Center of O'Fallon, Southwest Illinois Health Services LLP, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Illinois | IL-13 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Cancer Care Specialists of Illinois – Decatur, Decatur Memorial Hospital, Southern Illinois University School of Medicine, Springfield Clinic, Memorial Medical Center, Carle Cancer Center, The Carle Foundation Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Illinois | IL-14 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Rush-Copley Healthcare Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Illinois | IL-15 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Centralia Oncology Clinic, Carle on Vermilion, Carle Physician Group-Effingham, Crossroads Cancer Center, Carle Physician Group-Mattoon/Charleston, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Illinois | IL-16 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Illinois CancerCare-Dixon, Illinois CancerCare-Ottawa Clinic, Illinois CancerCare-Peru, Valley Radiation Oncology, Illinois CancerCare-Princeton, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Illinois | IL-17 | Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19) | 384 | OSF Healthcare Saint Francis Medical Center, | I-Mab Biopharma Co. Ltd. | Drug: TJ003234, Drug: Placebo |
| Illinois | IL-17 | Observational Study of COVID-19 Treatment Efficacy | 1000 | OSF HealthCare St Francis Medical Center, | OSF Healthcare System | Other: No intervention |
| Illinois | IL-17 | A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19 | 270 | University of Illinois College of Medicine, | Janssen Pharmaceutica N.V., Belgium | Drug: Sirukumab, Drug: Placebo, Other: Standard of Care (SOC) |
| Illinois | IL-17 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Illinois CancerCare-Canton, Illinois CancerCare-Galesburg, Western Illinois Cancer Treatment Center, Illinois CancerCare-Kewanee Clinic, Illinois CancerCare-Pekin, Methodist Medical Center of Illinois, Saint Jude Midwest Affiliate, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Illinois | IL-18 | Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects | 120 | Blade Research Site, | Blade Therapeutics, Clinipace Worldwide | Drug: BLD-2660 |
| Illinois | IL-18 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Optimal Research LLC, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Illinois | IL-18 | Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. | 62 | Research Site, | AstraZeneca, Acerta Pharma B.V. | Drug: Acalabrutinib |
| Illinois | IL-18 | Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants | 52 | SIU School of Medicine, | BeiGene | Drug: Zanubrutinib, Drug: Supportive Care, Drug: Placebo |
| Illinois | IL-18 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Illinois CancerCare-Bloomington, Illinois CancerCare-Carthage, Illinois CancerCare-Eureka, Illinois CancerCare-Macomb, Illinois CancerCare-Peoria, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Illinois | IL-09 | Convalescent Plasma to Stem Coronavirus (CSSC-001) | 500 | NorthShore University HealthSystem, | Johns Hopkins University | Biological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma |
| Illinois | IL-09 | A Study of LY3127804 in Participants With COVID-19 | 95 | NorthShore University HealthSystem, | Eli Lilly and Company | Drug: LY3127804, Drug: Placebo |
| Illinois | IL-09 | Dapagliflozin in Respiratory Failure in Patients With COVID-19 | 900 | NorthShore University HealthSystem, | Saint Luke's Health System, AstraZeneca, George Clinical Pty Ltd | Drug: Dapagliflozin 10 MG, Drug: Placebo |
| Illinois | IL-09 | A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE) | 227 | NorthShore University HealthSystem, | Kinevant Sciences GmbH, Roivant Sciences, Inc. | Drug: Gimsilumab, Drug: Placebo |
| Illinois | IL-09 | A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia | 100 | Advocate Christ Medical Center, | Hoffmann-La Roche | Drug: Tociliuzumab |
| Illinois | IL-09 | Convalescent Plasma to Limit SARS-CoV-2 Associated Complications | 1344 | NorthShore University HealthSystem, | Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID) | Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor |
| Illinois | IL-09 | A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19 | 270 | Great Lakes Clinical Trials, | Janssen Pharmaceutica N.V., Belgium | Drug: Sirukumab, Drug: Placebo, Other: Standard of Care (SOC) |
| Illinois | IL-09 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Advocate Lutheran General Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Illinois | IL-09 | Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19 | 160 | NorthShore University HealthSystem, | University of Michigan | Drug: Dipyridamole 100 Milligram(mg), Drug: Placebo oral tablet |
| Illinois | IL-09 | The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID) | 80 | Advocate Christ Medical Center, | Ridgeback Biotherapeutics, LP | Drug: EIDD-2801, Drug: Placebo (PB0) |
| Illinois | IL-07 | Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients | 100 | Ann and Robert H Lurie Childrens Hospital of Chicago, | Novartis Pharmaceuticals, Novartis | Drug: Crizanlizumab |
| Illinois | IL-07 | Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study | 250 | Ann & Robert H. Lurie Children's Hospital of Chicago, Loyola University Medical Center, | Ansun Biopharma, Inc. | Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL |
| Illinois | IL-07 | Adaptive COVID-19 Treatment Trial (ACTT) | 1062 | Northwestern Hospital, University of Illinois at Chicago College of Medicine, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir |
| Illinois | IL-07 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Cook County General Hospital, Rush University Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Illinois | IL-07 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | John H. Stroger Hospital of Cook County, Rush University Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Illinois | IL-07 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site, Regeneron Study Site, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| Illinois | IL-07 | A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia | 450 | Rush University Medical Center, | Hoffmann-La Roche | Drug: Tocilizumab (TCZ), Drug: Placebo |
| Illinois | IL-07 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Mercy Hospital & Medical Center, Loyola University Medical Center, | Gilead Sciences | Drug: Remdesivir |
| Illinois | IL-07 | Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS | 346 | Rush University Medical Center, | Rush University Medical Center | Device: high flow nasal cannula (HFNC), Procedure: Prone positioning (PP) |
| Illinois | IL-07 | Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine | 1363 | Northwestern Medicine, Rush University, | Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke University | Drug: Hydroxychloroquine, Drug: Placebo oral tablet |
| Illinois | IL-07 | Non-contact ECG Sensor System for COVID19 | 100 | Northwestern Medicine, | Northwestern Medicine | Device: Non-contact ECG |
| Illinois | IL-07 | Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia | 30 | Loyola University Medical Center, | University of Cincinnati | Drug: Sirolimus, Drug: Placebo |
| Illinois | IL-07 | Dapagliflozin in Respiratory Failure in Patients With COVID-19 | 900 | Loyola University, | Saint Luke's Health System, AstraZeneca, George Clinical Pty Ltd | Drug: Dapagliflozin 10 MG, Drug: Placebo |
| Illinois | IL-07 | Treatment for COVID-19 in High-Risk Adult Outpatients | 300 | Ruth M. Rothstein CORE Center, | University of Washington, Bill and Melinda Gates Foundation | Drug: Ascorbic Acid, Drug: Hydroxychloroquine Sulfate, Drug: Azithromycin, Drug: Folic Acid, Drug: Lopinavir 200 MG / Ritonavir 50 MG [Kaletra] |
| Illinois | IL-07 | Convalescent Plasma in Outpatients With COVID-19 | 600 | Rush University Medical Center, University of Illinois Hospital, | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network | Biological: Convalescent Plasma, Biological: Saline |
| Illinois | IL-07 | COVID-19 Survey Study on Dietary Intake, Physical Activity and Overall Well-being | 500 | Clinical Nutrition Research Center, | Clinical Nutrition Research Center, Illinois Institute of Technology | |
| Illinois | IL-07 | Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19 | 20 | Northwestern University CRS, Rush University CRS, | National Institute of Allergy and Infectious Diseases (NIAID), Teva Pharmaceuticals Industries LTD | Drug: Hydroxychloroquine (HCQ), Drug: Azithromycin (Azithro), Drug: Placebo for Hydroxychloroquine, Drug: Placebo for Azithromycin |
| Illinois | IL-07 | Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease | 20 | Novartis Investigative Site, | Novartis Pharmaceuticals, Novartis | Drug: HCQ, Drug: HCQ+AZT, Drug: Placebo |
| Illinois | IL-07 | Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection | 4000 | Chicago Clinical Research Institute, Chicago Clinical Research Institute, | Romark Laboratories L.C. | Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex |
| Illinois | IL-07 | Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults | 1000 | Loyola University Medical Center, | Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS) | Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo |
| Illinois | IL-07 | Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia | 451 | Novartis Investigative Site, | Novartis Pharmaceuticals, Novartis | Drug: Canakinumab, Drug: Placebo |
| Illinois | IL-07 | Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia | 270 | Rush University Medical Center, | Alexion Pharmaceuticals | Biological: Ravulizumab, Other: Best Supportive Care |
| Illinois | IL-07 | COVID-19: Human Epidemiology and Response to SARS-CoV-2 | 5605 | Ann & Robert H. Lurie Children's Hospital of Chicago, | National Institute of Allergy and Infectious Diseases (NIAID), Rho Federal Systems Division, Inc. (Rho) | Procedure: Collection of Biological Samples, Procedure: Symptom and Exposure Surveys |
| Illinois | IL-07 | Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) | 500 | Northshore University Health System, Loyola University Medical Center, | Incyte Corporation | Drug: Placebo, Drug: Ruxolitinib |
| Illinois | IL-07 | A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19 | 270 | Loyola University Medical Center, | Janssen Pharmaceutica N.V., Belgium | Drug: Sirukumab, Drug: Placebo, Other: Standard of Care (SOC) |
| Illinois | IL-07 | Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants | 52 | Loyola University Medical Center, | BeiGene | Drug: Zanubrutinib, Drug: Supportive Care, Drug: Placebo |
| Illinois | IL-07 | Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease | 682 | Affinity Health - Loretto Hospital, | Algernon Pharmaceuticals, Novotech (Australia) | Drug: NP-120 (Ifenprodil) |
| Illinois | IL-07 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Lurie Children's Hospital-Chicago, Northwestern University, University of Illinois, Edward Hines Jr VA Hospital, West Suburban Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Illinois | IL-07 | Predictors of Severe COVID-19 Outcomes | 1500 | University of Illinois at Chicago, Rush University Medical Center, | Verily Life Sciences LLC | |
| Illinois | IL-07 | Wearable Sensor to Monitor COVID-19 Like Signs and Symptoms | 100 | Shirley Ryan AbilityLab, | Shirley Ryan AbilityLab | Device: ADAM Sensor |
| Illinois | IL-07 | Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) | 190 | Atea Study Site, Atea Study Site, | Atea Pharmaceuticals, Inc. | Drug: AT-527, Other: Placebo |
| Illinois | IL-07 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | Northwestern Hospital, University of Illinois at Chicago College of Medicine, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| Illinois | IL-07 | A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19 | 66 | Northwestern University, Feinberg School of Medicine, Loyola University Medical Center, | Apellis Pharmaceuticals, Inc. | Drug: APL-9, Other: Vehicle Control |
| Illinois | IL-07 | Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19 | 727 | Adolescent & Young Adult Research at The CORE Center, | HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials Network | Other: Sample collection |
| Illinois | IL-07 | The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID) | 80 | Cook County Hospital, | Ridgeback Biotherapeutics, LP | Drug: EIDD-2801, Drug: Placebo (PB0) |
| Illinois | IL-06 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Northwestern Medicine Central Hospital, | Gilead Sciences | Drug: Remdesivir |
| Illinois | IL-06 | Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease | 800 | GSK Investigational Site, | GlaxoSmithKline | Biological: Otilimab, Biological: Placebo, Drug: Standard of care |
| Illinois | IL-02 | Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection | 4000 | Chicago Clinical Research LLC, | Romark Laboratories L.C. | Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex |
| Illinois | IL-02 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Ingalls Memorial Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Illinois | IL-08 | Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry | 50000 | Society of Critical Care Medicine, | Mayo Clinic, Society of Critical Care Medicine, Boston University | Other: observational |
| Illinois | IL-03 | Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection | 202 | Advocate Christ Medical Center, | Karyopharm Therapeutics Inc | Drug: Selinexor, Other: Placebo |
| Illinois | IL-03 | A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia | 100 | Advocate Christ Medical Center, | Hoffmann-La Roche | Drug: Tociliuzumab |
| Illinois | IL-03 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | University of Chicago Medicine-Orland Park, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Illinois | IL-03 | The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID) | 80 | Advocate Christ Medical Center, | Ridgeback Biotherapeutics, LP | Drug: EIDD-2801, Drug: Placebo (PB0) |
| Illinois | IL-03 | A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia | 500 | Advocate Christ Medical Center, | Hoffmann-La Roche, Gilead Sciences | Drug: Remdesivir, Drug: Tocilizumab, Drug: Placebo |
| Illinois | IL-01 | Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients | 100 | University of Chicago Hospital, | Novartis Pharmaceuticals, Novartis | Drug: Crizanlizumab |
| Illinois | IL-01 | Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study | 250 | University of Chicago, | Ansun Biopharma, Inc. | Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL |
| Illinois | IL-01 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | University of Chicago, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Illinois | IL-01 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | University of Chicago, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Illinois | IL-01 | A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia | 450 | University of Chicago, | Hoffmann-La Roche | Drug: Tocilizumab (TCZ), Drug: Placebo |
| Illinois | IL-01 | Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis | 32 | University of Chicago Medicine, | University of Chicago | Drug: Tocilizumab |
| Illinois | IL-01 | Beat COVID-19 - Observational Trial | 100000 | Beat COVID LLC, | Beat COVID LLC | |
| Illinois | IL-01 | COVID-19 Convalescent Plasma | 10 | University of Chicago Medicine, | University of Chicago | Biological: anti-SARS-CoV-2 convalescent plasma |
| Illinois | IL-01 | High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19 | 20 | University of Chicago, | University of Chicago | Drug: Hydroxychloroquine |
| Illinois | IL-01 | Convalescent Plasma in Outpatients With COVID-19 | 600 | University of Chicago Medical Center, | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network | Biological: Convalescent Plasma, Biological: Saline |
| Illinois | IL-01 | Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection | 4000 | Quad Clinical Research, | Romark Laboratories L.C. | Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex |
| Illinois | IL-01 | Long Term Outcomes of Patients With COVID-19 | 500 | University of Chicago Medicine, | University of Chicago | Other: Quality of Life, Other: Impact Event Score, Other: Hospital anxiety and depression scale |
| Illinois | IL-01 | Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults | 1000 | University of Chicago, | Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS) | Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo |
| Illinois | IL-01 | Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC) | 3000 | University of Chicago, | University of Manitoba, University Health Network, Toronto | Drug: Heparin |
| Illinois | IL-01 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | University of Chicago Comprehensive Cancer Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Illinois | IL-01 | Registry of CytoSorb Therapy in COVID-19 ICU Patients | 500 | University of Chicago Medicine, | CytoSorbents, Inc | Device: CytoSorb 300 mL device |
| Illinois | IL-05 | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 5000 | Ann and Robert H. Lurie Childrens Hospital of Chicago, | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: |
| Illinois | IL-05 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Swedish Hospital, | Gilead Sciences | Drug: Remdesivir |
| Illinois | IL-05 | Home Pulse Oximeter Use in Patients With COVID-19 | 209 | Swedish Hospital, | Swedish Hospital | Device: Home Pulse Oximetry Monitoring |
| Indiana | IN-05 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | IU Health Methodist Hospital, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Indiana | IN-05 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | IU Health Methodist Hospital, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Indiana | IN-05 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | St. Vincent Hospital and Health Care Center, Riverview Health, | Gilead Sciences | Drug: Remdesivir |
| Indiana | IN-05 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | IU Health North Hospital, Saint Vincent Hospital and Health Care Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Indiana | IN-05 | PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer | 364 | St. Vincent Medical Group inc., | CTI BioPharma | Drug: Pacritinib, Drug: Placebo |
| Indiana | IN-02 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Goshen Center for Cancer Care, Memorial Hospital of South Bend, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Indiana | IN-03 | A Study of LY3127804 in Participants With COVID-19 | 95 | Parkview Research Center, | Eli Lilly and Company | Drug: LY3127804, Drug: Placebo |
| Indiana | IN-03 | MSCs in COVID-19 ARDS | 223 | Lutheran Hospital, | Icahn School of Medicine at Mount Sinai, Mesoblast, Inc., National Heart, Lung, and Blood Institute (NHLBI) | Biological: Remestemcel-L, Drug: Placebo |
| Indiana | IN-03 | Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. | 62 | Research Site, | AstraZeneca, Acerta Pharma B.V. | Drug: Acalabrutinib |
| Indiana | IN-03 | A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19 | 66 | Lutheran Health Physicians, | Apellis Pharmaceuticals, Inc. | Drug: APL-9, Other: Vehicle Control |
| Indiana | IN-06 | Compassionate Use of Hyperbaric Oxygen Therapy | 100 | Decatur Memorial Hospital, | SerenaGroup, Inc., SerenaGroup Research Foundation | |
| Indiana | IN-06 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Reid Health, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Indiana | IN-07 | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 5000 | Riley Hospital for Children at Indiana University, | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: |
| Indiana | IN-07 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Richard L Roudebush Indianapolis VA, | Gilead Sciences | Drug: Remdesivir |
| Indiana | IN-07 | Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19) | 384 | Indiana University Health, | I-Mab Biopharma Co. Ltd. | Drug: TJ003234, Drug: Placebo |
| Indiana | IN-07 | A Study of LY3127804 in Participants With COVID-19 | 95 | Franciscan St. Francis Health, | Eli Lilly and Company | Drug: LY3127804, Drug: Placebo |
| Indiana | IN-07 | Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) | 500 | Indiana University Simon Cancer Center, Indiana University Health Central Indiana Cancer Centers, | Incyte Corporation | Drug: Placebo, Drug: Ruxolitinib |
| Indiana | IN-07 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Indiana University/Melvin and Bren Simon Cancer Center, IU Health Methodist Hospital, Richard L. Roudebush Veterans Affairs Medical Center, Sidney and Lois Eskenazi Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Indiana | IN-07 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | Indiana University School of Medicine, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| Iowa | IA-02 | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 5000 | University of Iowa Stead Family Children's Hospital, | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: |
| Iowa | IA-02 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | University of Iowa Hospitals & Clinics, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Iowa | IA-02 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | University of Iowa Hospitals & Clinics, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Iowa | IA-02 | Acceptance and Commitment Therapy Delivered by Automated Software Messaging | 90 | University of Iowa Hospitals and Clinics, | University of Iowa | Behavioral: Software Messaging |
| Iowa | IA-02 | Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine | 1363 | University of Iowa, | Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke University | Drug: Hydroxychloroquine, Drug: Placebo oral tablet |
| Iowa | IA-02 | Awake Prone Position for Early Hypoxemia in COVID-19 | 560 | University of Iowa Hospitals and Clinics, | Boston University | Other: Self-prone position recommendation, Other: Usual care |
| Iowa | IA-02 | Convalescent Plasma in Outpatients With COVID-19 | 600 | University of Iowa Hospitals & Clinics, | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network | Biological: Convalescent Plasma, Biological: Saline |
| Iowa | IA-02 | Covid-19 Associated Coagulopathy | 170 | University of Iowa, | University of Iowa | Drug: Intermediate dose thromboprophylaxis, Drug: Standard of Care thromboprophylaxis |
| Iowa | IA-02 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | University of Iowa Hospitals & Clinics, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Iowa | IA-02 | Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants | 52 | University of Iowa, | BeiGene | Drug: Zanubrutinib, Drug: Supportive Care, Drug: Placebo |
| Iowa | IA-02 | A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia | 410 | University Of Iowa Hospitals And Clinics, | Genentech, Inc. | Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo |
| Iowa | IA-02 | Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression | 208 | Octapharma Research Site, | Octapharma | Biological: Octagam 10%, Other: Placebo |
| Iowa | IA-02 | A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19 | 66 | University of Iowa Hospitals and Clinics, | Apellis Pharmaceuticals, Inc. | Drug: APL-9, Other: Vehicle Control |
| Iowa | IA-01 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Physicians' Clinic of Iowa PC, Mercy Hospital, Oncology Associates at Mercy Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Iowa | IA-01 | Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19) | 124 | Northeast Iowa Medical Education Foundation, | CSL Behring | Biological: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody, Drug: Placebo |
| Iowa | IA-04 | Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects | 120 | Blade Research Site, | Blade Therapeutics, Clinipace Worldwide | Drug: BLD-2660 |
| Iowa | IA-04 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Trinity Regional Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Iowa | IA-03 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Medical Oncology and Hematology Associates-West Des Moines, Mercy Cancer Center-West Lakes, Alegent Health Mercy Hospital, Greater Regional Medical Center, Blank Children's Hospital, Iowa Methodist Medical Center, Medical Oncology and Hematology Associates-Des Moines, Broadlawns Medical Center, Medical Oncology and Hematology Associates-Laurel, Mercy Medical Center - Des Moines, Iowa Lutheran Hospital, Mercy Medical Center-West Lakes, Methodist West Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Kansas | KS-04 | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 5000 | Wesley Medical Center, | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: |
| Kansas | KS-04 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Alliance for Multispecialty Research LLC, Alliance for Multispecialty Research LLC, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Kansas | KS-04 | Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant | 1419 | Alliance for Multispecialty Research, Alliance for Multispecialty Research, | Novavax, Coalition for Epidemic Preparedness Innovations (CEPI) | Biological: SARS-CoV-2 rS - Phase 1, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1, Other: Normal saline solution (NSS), Placebo - Phase 1, Other: Normal saline solution (NSS), Placebo - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1, Other: Normal saline solution (NSS), Placebo, Day 21 - Phase 1, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Days 0 and 21 - Phase 2, Other: Normal saline solution (NSS), Placebo, Day 189 - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 2, Other: Normal saline solution (NSS), Placebo, Day 21 - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Day 189 - Phase 2 |
| Kansas | KS-04 | Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older | 600 | Heartland Research Associates, | ModernaTX, Inc., Biomedical Advanced Research and Development Authority | Biological: Biological: mRNA-1273: 50 mcg, Other: Placebo, Biological: Biological: mRNA-1273: 100 mcg |
| Kansas | KS-03 | Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study | 250 | University of Kansas Medical Center, | Ansun Biopharma, Inc. | Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL |
| Kansas | KS-03 | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 5000 | University of Kansas Medical Center, | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: |
| Kansas | KS-03 | Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine | 1363 | University of Kansas Medical Center, | Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke University | Drug: Hydroxychloroquine, Drug: Placebo oral tablet |
| Kansas | KS-03 | Study of Open Label Losartan in COVID-19 | 34 | University of Kansas Medical Center, | University of Kansas Medical Center | Drug: Losartan |
| Kansas | KS-03 | Awake Prone Position for Early Hypoxemia in COVID-19 | 560 | University of Kansas Medical Center, | Boston University | Other: Self-prone position recommendation, Other: Usual care |
| Kansas | KS-03 | Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection | 202 | University of Kansas Medical Center, | Karyopharm Therapeutics Inc | Drug: Selinexor, Other: Placebo |
| Kansas | KS-03 | Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults | 1000 | University of Kansas Medical Center, | Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS) | Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo |
| Kansas | KS-03 | Compassionate Use of Hyperbaric Oxygen Therapy | 100 | Providence Medical Wound Care Center, | SerenaGroup, Inc., SerenaGroup Research Foundation | |
| Kansas | KS-03 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | University of Kansas Clinical Research Center, University of Kansas Cancer Center, Olathe Health Cancer Center, University of Kansas Cancer Center-Overland Park, University of Kansas Hospital-Indian Creek Campus, University of Kansas Hospital-Westwood Cancer Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Kansas | KS-02 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Lawrence Memorial Hospital, Ascension Via Christi – Pittsburg, University of Kansas Health System Saint Francis Campus, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Kansas | KS-01 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | HaysMed University of Kansas Health System, Salina Regional Health Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Kentucky | KY-02 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Kentucky Pediatric/ Adult Research, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Kentucky | KY-02 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Flaget Memorial Hospital, Jewish Hospital Medical Center South, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Kentucky | KY-03 | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 5000 | University of Louisville Norton Childrens Hospital, | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: |
| Kentucky | KY-03 | Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure | 165 | University of Louisville, | NeuroRx, Inc., Lavin Consulting, LLC | Drug: Aviptadil by intravenous infusion + standard of care, Drug: Normal Saline Infusion + standard of care |
| Kentucky | KY-03 | Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects | 120 | Blade Research Site, | Blade Therapeutics, Clinipace Worldwide | Drug: BLD-2660 |
| Kentucky | KY-03 | Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection | 202 | Norton Healthcare, | Karyopharm Therapeutics Inc | Drug: Selinexor, Other: Placebo |
| Kentucky | KY-03 | Convalescent Plasma in Outpatients With COVID-19 | 600 | University of Louisville Hospital, | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network | Biological: Convalescent Plasma, Biological: Saline |
| Kentucky | KY-03 | Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia | 270 | Norton Healthcare, | Alexion Pharmaceuticals | Biological: Ravulizumab, Other: Best Supportive Care |
| Kentucky | KY-03 | INB03 for the Treatment of Pulmonary Complications From COVID-19 | 366 | Jewish Hospital, | Inmune Bio, Inc. | Drug: INB03, Drug: Placebo |
| Kentucky | KY-03 | Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. | 62 | Research Site, | AstraZeneca, Acerta Pharma B.V. | Drug: Acalabrutinib |
| Kentucky | KY-03 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | James Graham Brown Cancer Center at University of Louisville, Jewish Hospital, Saints Mary and Elizabeth Hospital, Jewish Hospital Medical Center Northeast, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Kentucky | KY-03 | A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19 | 66 | Norton Women's and Children's Hospital, Audobon Hospital, | Apellis Pharmaceuticals, Inc. | Drug: APL-9, Other: Vehicle Control |
| Kentucky | KY-06 | Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease | 479 | University of Kentucky, | Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI) | Drug: Hydroxychloroquine, Drug: Placebo |
| Kentucky | KY-06 | Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects | 120 | Blade Research Site, | Blade Therapeutics, Clinipace Worldwide | Drug: BLD-2660 |
| Kentucky | KY-06 | Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers | 120 | Central Kentucky Research Associates, | Inovio Pharmaceuticals, Coalition for Epidemic Preparedness Innovations (CEPI) | Drug: INO-4800, Device: CELLECTRA® 2000 |
| Kentucky | KY-06 | COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients | 300 | University of Kentucky, | Alexandra Kejner, University of Kentucky | Drug: Povidone-Iodine Nasal Spray and Gargle |
| Kentucky | KY-06 | Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant | 1419 | Central Kentucky Research Associates Inc, | Novavax, Coalition for Epidemic Preparedness Innovations (CEPI) | Biological: SARS-CoV-2 rS - Phase 1, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1, Other: Normal saline solution (NSS), Placebo - Phase 1, Other: Normal saline solution (NSS), Placebo - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1, Other: Normal saline solution (NSS), Placebo, Day 21 - Phase 1, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Days 0 and 21 - Phase 2, Other: Normal saline solution (NSS), Placebo, Day 189 - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 2, Other: Normal saline solution (NSS), Placebo, Day 21 - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Day 189 - Phase 2 |
| Kentucky | KY-06 | Novel Agents for Treatment of High-risk COVID-19 Positive Patients | 240 | University of Kentucky, | Susanne Arnold, University of Kentucky | Drug: Ivermectin, Drug: Camostat Mesilate, Dietary Supplement: Artemesia annua, Drug: Artesunate |
| Kentucky | KY-06 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Saint Joseph Radiation Oncology Resource Center, Saint Joseph Hospital East, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Kentucky | KY-06 | Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections | 30 | University of Kentucky, | SeaStar Medical | Device: SCD |
| Kentucky | KY-04 | The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection | 100 | St. Elizabeth Healthcare, | Pulmotect, Inc. | Drug: PUL-042 Inhalation Solution, Drug: Placebo |
| Kentucky | KY-04 | Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19 | 300 | St. Elizabeth Healthcare, | Humanigen, Inc. | Biological: Lenzilumab, Drug: Standard of Care |
| Kentucky | KY-05 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Commonwealth Cancer Center-Corbin, Saint Joseph London, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Louisiana | LA-05 | Study of Efficacy and Safety of MAS825 in Patients With COVID-19 | 140 | Novartis Investigative Site, | Novartis Pharmaceuticals, Novartis | Drug: MAS825, Drug: Matching placebo |
| Louisiana | LA-05 | Compassionate Use of Hyperbaric Oxygen Therapy | 100 | Wound Treatment Center, | SerenaGroup, Inc., SerenaGroup Research Foundation | |
| Louisiana | LA-05 | A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia | 410 | DM Clinical Research, | Genentech, Inc. | Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo |
| Louisiana | LA-05 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Ochsner LSU Health Monroe Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Louisiana | LA-05 | A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19 | 66 | Cambridge Medical Trials, | Apellis Pharmaceuticals, Inc. | Drug: APL-9, Other: Vehicle Control |
| Louisiana | LA-06 | A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia | 450 | Ochsner Clinic Foundation, | Hoffmann-La Roche | Drug: Tocilizumab (TCZ), Drug: Placebo |
| Louisiana | LA-06 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Our Lady of the Lakes Regional Medical Center, | Gilead Sciences | Drug: Remdesivir |
| Louisiana | LA-06 | A Study of Auxora in Patients With Severe COVID-19 Pneumonia | 400 | Baton Rouge General, | CalciMedica, Inc. | Drug: Auxora, Drug: Placebo |
| Louisiana | LA-06 | Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease | 20 | Novartis Investigative Site, | Novartis Pharmaceuticals, Novartis | Drug: HCQ, Drug: HCQ+AZT, Drug: Placebo |
| Louisiana | LA-06 | Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults | 1000 | Our Lady of the Lake Regional Medical Center, | Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS) | Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo |
| Louisiana | LA-06 | SQuISH-COVID: A Pilot Study | 300 | Our Lady of the Lake Regional Medical Center, | Cytovale, Inc., Biomedical Advanced Research and Development Authority | |
| Louisiana | LA-06 | Study of Efficacy and Safety of MAS825 in Patients With COVID-19 | 140 | Novartis Investigative Site, | Novartis Pharmaceuticals, Novartis | Drug: MAS825, Drug: Matching placebo |
| Louisiana | LA-06 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Louisiana Hematology Oncology Associates LLC, Mary Bird Perkins Cancer Center, Our Lady of the Lake Physicians Group - Medical Oncology, Medical Center of Baton Rouge, Woman's Hospital, Ochsner High Grove, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Louisiana | LA-06 | Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure | 524 | Our Lady of the Lake, | Chimerix | Drug: Dociparastat sodium, Drug: Placebo |
| Louisiana | LA-06 | GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19) in Health Care Personnel | 225 | Sinus and Nasal Specialists of Louisiana, | GeneOne Life Science, Inc. | Drug: GLS-1200, Drug: Placebo |
| Louisiana | LA-01 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Ochsner Clinic Foundation, Slidell Memorial Hospital, | Gilead Sciences | Drug: Remdesivir |
| Louisiana | LA-01 | Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP) | 829 | Tulane University, | University of Washington, Bill and Melinda Gates Foundation | Drug: Hydroxychloroquine Sulfate, Drug: Ascorbic Acid |
| Louisiana | LA-01 | Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine | 1363 | Ochsner Clinic Foundation, | Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke University | Drug: Hydroxychloroquine, Drug: Placebo oral tablet |
| Louisiana | LA-01 | Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19) | 384 | MedPharmics, Ochsner Medical Center, | I-Mab Biopharma Co. Ltd. | Drug: TJ003234, Drug: Placebo |
| Louisiana | LA-01 | A Study of LY3127804 in Participants With COVID-19 | 95 | Ochsner Clinic Foundation, | Eli Lilly and Company | Drug: LY3127804, Drug: Placebo |
| Louisiana | LA-01 | Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19 (COVID-19) Infection | 48 | Ochsner Health System, | Ochsner Health System | Device: Hyperbaric Oxygen Therapy |
| Louisiana | LA-01 | Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19 | 80 | Covidcraz 19 LLC, Covidcraz 19 LLC, | Perseverance Research Center, LLC, Athena Medical Group | Drug: Hydroxychloroquine, Drug: Indomethacin, Drug: Zithromax Oral Product |
| Louisiana | LA-01 | A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE) | 227 | East Jefferson General Hospital, | Kinevant Sciences GmbH, Roivant Sciences, Inc. | Drug: Gimsilumab, Drug: Placebo |
| Louisiana | LA-01 | Treatment for COVID-19 in High-Risk Adult Outpatients | 300 | Tulane University, | University of Washington, Bill and Melinda Gates Foundation | Drug: Ascorbic Acid, Drug: Hydroxychloroquine Sulfate, Drug: Azithromycin, Drug: Folic Acid, Drug: Lopinavir 200 MG / Ritonavir 50 MG [Kaletra] |
| Louisiana | LA-01 | A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia | 100 | MedPharmics, | Hoffmann-La Roche | Drug: Tociliuzumab |
| Louisiana | LA-01 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Benchmark Research, Ochsner Clinici Foundation, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Louisiana | LA-01 | MSCs in COVID-19 ARDS | 223 | Ochsner Clinic, | Icahn School of Medicine at Mount Sinai, Mesoblast, Inc., National Heart, Lung, and Blood Institute (NHLBI) | Biological: Remestemcel-L, Drug: Placebo |
| Louisiana | LA-01 | A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia | 379 | Ochsner Clinic, | Genentech, Inc. | Drug: Placebo, Drug: Tocilizumab |
| Louisiana | LA-01 | Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC) | 3000 | Ochsner Clinic, | University of Manitoba, University Health Network, Toronto | Drug: Heparin |
| Louisiana | LA-01 | Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) | 500 | East Jefferson General Hospital, | Incyte Corporation | Drug: Placebo, Drug: Ruxolitinib |
| Louisiana | LA-01 | A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia | 410 | MedPharmics, | Genentech, Inc. | Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo |
| Louisiana | LA-01 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Mary Bird Perkins Cancer Center – Covington, Northshore Oncology Associates-Covington, Ochsner Hematology Oncology North Shore - Covington, Women's Cancer Care-Covington, Mary Bird Perkins Cancer Center – Houma, Terrebonne General Medical Center, Ochsner Medical Clinic, East Jefferson General Hospital, LSU Healthcare Network / Metairie Multi-Specialty Clinic, Ochsner Medical Center Jefferson, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Louisiana | LA-01 | Blood Collection Study From COVID-19 Convalescents Previously Hospitalized to Identify Immunogenic Viral Epitopes | 80 | Ochsner Clinic Foundation, | TScan Therapeutics, Inc. | |
| Louisiana | LA-01 | Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression | 208 | Octapharma Research Site, | Octapharma | Biological: Octagam 10%, Other: Placebo |
| Louisiana | LA-01 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | Ochsner Medical Clinic, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| Louisiana | LA-01 | A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia | 500 | Ochsner Clinic Foundation, | Hoffmann-La Roche, Gilead Sciences | Drug: Remdesivir, Drug: Tocilizumab, Drug: Placebo |
| Louisiana | LA-02 | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 5000 | Tulane University Health Science Center, Ochsner Baptist Clinical Trials Unit, | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: |
| Louisiana | LA-02 | Adaptive COVID-19 Treatment Trial (ACTT) | 1062 | Southeast Louisiana Veterans Health Care System, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir |
| Louisiana | LA-02 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Tulane University, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Louisiana | LA-02 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Tulane University, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Louisiana | LA-02 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| Louisiana | LA-02 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Touro Infirmary, | Gilead Sciences | Drug: Remdesivir |
| Louisiana | LA-02 | Convalescent Plasma to Stem Coronavirus (CSSC-001) | 500 | Tulane University, | Johns Hopkins University | Biological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma |
| Louisiana | LA-02 | Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease | 479 | University Medical Center, | Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI) | Drug: Hydroxychloroquine, Drug: Placebo |
| Louisiana | LA-02 | Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine | 1363 | University Medical Center New Orleans, | Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke University | Drug: Hydroxychloroquine, Drug: Placebo oral tablet |
| Louisiana | LA-02 | Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease | 600 | University Medical Center New Orleans, | LCMC Health | Drug: Hydroxychloroquine, Drug: Azithromycin |
| Louisiana | LA-02 | Expanded Access to Convalescent Plasma to Treat and Prevent Pulmonary Complications Associated With COVID-19 | 0 | Tulane Medical Center, | Nakhle Saba, MD, Tulane University | Biological: Biological: COVID-19 convalescent plasma |
| Louisiana | LA-02 | Convalescent Plasma to Limit SARS-CoV-2 Associated Complications | 1344 | Tulane University, | Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID) | Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor |
| Louisiana | LA-02 | A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19 | 270 | Louisiana State University Health Sciences Center, | Janssen Pharmaceutica N.V., Belgium | Drug: Sirukumab, Drug: Placebo, Other: Standard of Care (SOC) |
| Louisiana | LA-02 | Compassionate Use of Hyperbaric Oxygen Therapy | 100 | West Jefferson Medical Center, | SerenaGroup, Inc., SerenaGroup Research Foundation | |
| Louisiana | LA-02 | A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia | 410 | Southeast Louisiana Veterans Health Care System, | Genentech, Inc. | Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo |
| Louisiana | LA-02 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | LSU Health Baton Rouge-North Clinic, Louisiana State University Health Science Center, Tulane University Health Sciences Center, University Medical Center New Orleans, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Louisiana | LA-02 | Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure | 524 | Tulane University, University Medical Center, | Chimerix | Drug: Dociparastat sodium, Drug: Placebo |
| Louisiana | LA-02 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | Southeast Louisiana Veterans Health Care System, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| Louisiana | LA-02 | Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19 | 727 | New Orleans Adolescent Trials Unit CRS, | HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials Network | Other: Sample collection |
| Louisiana | LA-02 | A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19 | 204 | NOLA Research, | Ridgeback Biotherapeutics, LP | Drug: EIDD-2801, Drug: Placebo (PBO) |
| Louisiana | LA-03 | Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF) | 800 | Centex Studies Inc., | Romark Laboratories L.C. | Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex |
| Louisiana | LA-03 | Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection | 4000 | Centex Studies Inc, | Romark Laboratories L.C. | Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex |
| Louisiana | LA-03 | Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP) | 1700 | Lafayette General Medical Center, University Hospital and Clinics, | Louisiana State University Health Sciences Center in New Orleans, Lafayette General Health, University of Louisiana at Lafayette | Drug: Hydroxychloroquine, Drug: Placebo |
| Louisiana | LA-03 | Study of Efficacy and Safety of MAS825 in Patients With COVID-19 | 140 | Novartis Investigative Site, | Novartis Pharmaceuticals, Novartis | Drug: MAS825, Drug: Matching placebo |
| Louisiana | LA-04 | Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study | 250 | Louisiana State University, | Ansun Biopharma, Inc. | Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL |
| Louisiana | LA-04 | Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19 | 70 | Louisiana State Health Shreveport, | Massachusetts General Hospital, University of Alabama at Birmingham | Drug: Nitric Oxide |
| Louisiana | LA-04 | Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19 | 200 | Louisiana State Health Shreveport, | Massachusetts General Hospital, Xijing Hospital, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Niguarda Hospital | Drug: Nitric Oxide Gas |
| Louisiana | LA-04 | The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2 | 200 | Willis-Knighton Physcian Network, | Pulmotect, Inc. | Drug: PUL-042 Inhalation Solution, Drug: Placebo |
| Louisiana | LA-04 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | LSUHSC-Shreveport Clinical Trials Office, LSUHSC-Shreveport, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Louisiana | LA-04 | Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia | 270 | Overton Brooks VA Medical Center, | Alexion Pharmaceuticals | Biological: Ravulizumab, Other: Best Supportive Care |
| Louisiana | LA-04 | Compassionate Use of Hyperbaric Oxygen Therapy | 100 | Christus Shreveport Bossier Hyperbaric, | SerenaGroup, Inc., SerenaGroup Research Foundation | |
| Louisiana | LA-04 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | LSU Health Sciences Center at Shreveport, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Louisiana | LA-04 | LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19) | 60 | LSU Health Shreveport, | Arch Biopartners Inc. | Drug: LSALT peptide, Drug: Placebo |
| Louisiana | LA-04 | A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia | 500 | Louisiana State University Health Sciences Center, | Hoffmann-La Roche, Gilead Sciences | Drug: Remdesivir, Drug: Tocilizumab, Drug: Placebo |
| Maine | ME-01 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Maine Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Maine | ME-01 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Maine Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Maine | ME-01 | Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease | 479 | Maine Medical Center, | Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI) | Drug: Hydroxychloroquine, Drug: Placebo |
| Maine | ME-01 | A Study of Auxora in Patients With Severe COVID-19 Pneumonia | 400 | Maine Medical Center, | CalciMedica, Inc. | Drug: Auxora, Drug: Placebo |
| Maine | ME-01 | Convalescent Plasma in Outpatients With COVID-19 | 600 | Maine Medical Center, | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network | Biological: Convalescent Plasma, Biological: Saline |
| Maine | ME-01 | Sarilumab for Patients With Moderate COVID-19 Disease | 120 | VA Maine Healthcare System, | Westyn Branch-Elliman, VA Boston Healthcare System | Biological: SARILUMAB |
| Maine | ME-01 | MSCs in COVID-19 ARDS | 223 | Maine Medical Center, | Icahn School of Medicine at Mount Sinai, Mesoblast, Inc., National Heart, Lung, and Blood Institute (NHLBI) | Biological: Remestemcel-L, Drug: Placebo |
| Maine | ME-01 | Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC) | 3000 | Maine Medical Center, | University of Manitoba, University Health Network, Toronto | Drug: Heparin |
| Maine | ME-01 | Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease | 800 | GSK Investigational Site, | GlaxoSmithKline | Biological: Otilimab, Biological: Placebo, Drug: Standard of care |
| Maine | ME-01 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Harold Alfond Center for Cancer Care, Waldo County General Hospital, MaineHealth/SMHC Cancer Care and Blood Disorders-Biddeford, Southern Maine Health Center/Biddeford Medical Center, Maine Medical Center-Bramhall Campus, Penobscot Bay Medical Center, MaineHealth/SMHC Cancer Care and Blood Disorders-Sanford, Maine Medical Center- Scarborough Campus, Maine Medical Partners - South Portland, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Maine | ME-02 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Eastern Maine Medical Center, Lafayette Family Cancer Center-EMMC, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Maryland | MD-06 | CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment | 243 | Shady Grove Medical Center, | OncoImmune, Inc. | Drug: CD24Fc, Drug: Placebo |
| Maryland | MD-06 | Tocilizumab for Patients With Cancer and COVID-19 Disease | 217 | National Cancer Institute, | National Cancer Institute (NCI) | Biological: Tocilizumab |
| Maryland | MD-06 | A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia | 379 | Holy Cross Germantown Hospital, | Genentech, Inc. | Drug: Placebo, Drug: Tocilizumab |
| Maryland | MD-06 | Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease | 800 | GSK Investigational Site, | GlaxoSmithKline | Biological: Otilimab, Biological: Placebo, Drug: Standard of care |
| Maryland | MD-06 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | FMH James M Stockman Cancer Institute, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Maryland | MD-06 | Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury | 50 | Frederick Health Hospital, | Frederick Health | Drug: Heparin, Drug: 0.9% Sodium-chloride |
| Maryland | MD-04 | Adaptive COVID-19 Treatment Trial (ACTT) | 1062 | University of Maryland School of Medicine, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir |
| Maryland | MD-04 | Convalescent Plasma to Limit SARS-CoV-2 Associated Complications | 1344 | MedStar Washington Hospital Center, | Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID) | Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor |
| Maryland | MD-07 | Pilot RCT of Therapeutic Hypothermia Plus Neuromuscular Blockade in COVID-19 Patients With ARDS | 20 | University of Maryland Medical Center, | University of Maryland, Baltimore | Device: Hypothermia, Drug: Neuromuscular Blocking Agents, Device: Standard of Care |
| Maryland | MD-07 | Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID) | 200 | Johns Hopkins, | Vanderbilt University Medical Center, United States Department of Defense | |
| Maryland | MD-07 | Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study | 250 | University of Maryland, Johns Hopkins Hospital, | Ansun Biopharma, Inc. | Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL |
| Maryland | MD-07 | Adaptive COVID-19 Treatment Trial (ACTT) | 1062 | Johns Hopkins Hospital, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir |
| Maryland | MD-07 | CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment | 243 | Institute of Human Virology, | OncoImmune, Inc. | Drug: CD24Fc, Drug: Placebo |
| Maryland | MD-07 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | University of Maryland Medical Center, Mercy Medical Center, | Gilead Sciences | Drug: Remdesivir |
| Maryland | MD-07 | Convalescent Plasma to Stem Coronavirus (CSSC-001) | 500 | Johns Hopkins University, | Johns Hopkins University | Biological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma |
| Maryland | MD-07 | Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP) | 829 | University of Maryland Medical Center, | University of Washington, Bill and Melinda Gates Foundation | Drug: Hydroxychloroquine Sulfate, Drug: Ascorbic Acid |
| Maryland | MD-07 | Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine | 1363 | Johns Hopkins University, | Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke University | Drug: Hydroxychloroquine, Drug: Placebo oral tablet |
| Maryland | MD-07 | Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects | 120 | Blade Research Site, | Blade Therapeutics, Clinipace Worldwide | Drug: BLD-2660 |
| Maryland | MD-07 | Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19) | 384 | University of Maryland Medical Center, | I-Mab Biopharma Co. Ltd. | Drug: TJ003234, Drug: Placebo |
| Maryland | MD-07 | Incline Positioning in COVID-19 Patients for Improvement in Oxygen Saturation | 70 | Johns Hopkins Hospital, | Johns Hopkins University | Other: Postural Positioning |
| Maryland | MD-07 | Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection | 164 | Johns Hopkins Hospital, | Johns Hopkins University, Eiger BioPharmaceuticals | Drug: Peginterferon lambda alfa-1a subcutaneous injection, Other: Saline |
| Maryland | MD-07 | Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure | 60 | Johns Hopkins University, | Noah Merin, Johns Hopkins University, Cedars-Sinai Medical Center | Biological: Multiple Doses of Anti-SARS-CoV-2 convalescent plasma |
| Maryland | MD-07 | Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease | 20 | Novartis Investigative Site, | Novartis Pharmaceuticals, Novartis | Drug: HCQ, Drug: HCQ+AZT, Drug: Placebo |
| Maryland | MD-07 | Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults | 1000 | University of Maryland Medical Center, | Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS) | Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo |
| Maryland | MD-07 | Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia | 451 | Novartis Investigative Site, | Novartis Pharmaceuticals, Novartis | Drug: Canakinumab, Drug: Placebo |
| Maryland | MD-07 | Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection | 30 | Johns Hopkins Hospital, | Johns Hopkins University | Drug: Clazakizumab, Drug: Placebo |
| Maryland | MD-07 | A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia | 100 | University of Maryland Medical Center, | Hoffmann-La Roche | Drug: Tociliuzumab |
| Maryland | MD-07 | Prazosin to Prevent COVID-19 (PREVENT-COVID Trial) | 220 | Johns Hopkins Hospital, | Johns Hopkins University, Fast Grants | Drug: Prazosin, Other: Standard of care |
| Maryland | MD-07 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Pharmaron CPC, University of Maryland - Center for Vaccine Development, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Maryland | MD-07 | Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia | 270 | Baltimore VA Medical Center, | Alexion Pharmaceuticals | Biological: Ravulizumab, Other: Best Supportive Care |
| Maryland | MD-07 | MSCs in COVID-19 ARDS | 223 | University of Maryland Medical Center, | Icahn School of Medicine at Mount Sinai, Mesoblast, Inc., National Heart, Lung, and Blood Institute (NHLBI) | Biological: Remestemcel-L, Drug: Placebo |
| Maryland | MD-07 | Convalescent Plasma to Limit SARS-CoV-2 Associated Complications | 1344 | Johns Hopkins University, | Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID) | Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor |
| Maryland | MD-07 | Prevalence of SARS-CoV-2 in Conjunctival Swab Samples Among Patients With Conjunctivitis During the COVID-19 Pandemic | 50 | Wilmer Eye Institute, | Johns Hopkins University | |
| Maryland | MD-07 | Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease | 800 | GSK Investigational Site, | GlaxoSmithKline | Biological: Otilimab, Biological: Placebo, Drug: Standard of care |
| Maryland | MD-07 | Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19) | 30 | Johns Hopkins Hospital, | Johns Hopkins University | Biological: Anti-SARS-CoV-2 Human Convalescent Plasma |
| Maryland | MD-07 | Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. | 62 | Research Site, | AstraZeneca, Acerta Pharma B.V. | Drug: Acalabrutinib |
| Maryland | MD-07 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | University of Maryland/Greenebaum Cancer Center, Mercy Medical Center, Sinai Hospital of Baltimore, Kaiser Permanente-Woodlawn Medical Center, Johns Hopkins University/Sidney Kimmel Cancer Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Maryland | MD-07 | Trial of Imatinib for Hospitalized Adults With COVID-19 | 204 | University of Maryland Medical Center, | University of Maryland, Baltimore | Drug: Imatinib, Drug: Placebo oral tablet |
| Maryland | MD-07 | Pathogenesis of BTK-mediated Hyper-Inflammatory Responses in COVID-19 (RESPOND) | 120 | Johns Hopkins Hospital, | National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health Clinical Center (CC) | |
| Maryland | MD-07 | An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic | 0 | University of Maryland School of Medicine, | Genentech, Inc. | Drug: Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration (PH FDC SC) |
| Maryland | MD-07 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | University of Maryland School of Medicine, Johns Hopkins Hospital, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| Maryland | MD-07 | Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19 | 727 | Johns Hopkins University CRS, | HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials Network | Other: Sample collection |
| Maryland | MD-07 | The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID) | 80 | Johns Hopkins Hospital, Howard County General Hospital, | Ridgeback Biotherapeutics, LP | Drug: EIDD-2801, Drug: Placebo (PB0) |
| Maryland | MD-07 | A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia | 500 | University of Maryland School of Medicine, | Hoffmann-La Roche, Gilead Sciences | Drug: Remdesivir, Drug: Tocilizumab, Drug: Placebo |
| Maryland | MD-08 | Viral Infections in Healthy and Immunocompromised Hosts | 1000 | National Institutes of Health Clinical Center, | National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health Clinical Center (CC) | |
| Maryland | MD-08 | Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologics | 20 | Medicine Invention Design Incorporation, | Han Xu, M.D., Ph.D., Sponsor-Investigator, IRB Chair, PPD, Medicine Invention Design, Inc | Biological: COVID-19 Therapeutic Biologics - Spike-GM-CSF Protein Lactated Ringer's Injection |
| Maryland | MD-08 | Discovery Stage (Proof-of-concept) COVID-19 Antigen Presentation Therapeutic Biologics (COVID-19--AP) | 20 | Medicine Invention Design Incorporation, | Han Xu, M.D., Ph.D., Sponsor-Investigator, IRB Chair, Medicine Invention Design, Inc | Biological: COVID-19 Therapeutic Biologics - Spike-GM-CSF Protein Lactated Ringer's Injection |
| Maryland | MD-08 | Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine | 300 | National Institutes of Health Clinical Center, | National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health Clinical Center (CC) | Biological: Flucelvax, Biological: Fluvirin, Biological: Fluzone High Dose |
| Maryland | MD-08 | Adaptive COVID-19 Treatment Trial (ACTT) | 1062 | Walter Reed National Medical Center, National Institutes of Health Clinical Center, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir |
| Maryland | MD-08 | Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19) | 120 | National Institutes of Health Clinical Center, | National Institute of Allergy and Infectious Diseases (NIAID) | Biological: mRNA-1273 |
| Maryland | MD-08 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Holy Cross Hospital, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Maryland | MD-08 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Holy Cross Hospital, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Maryland | MD-08 | SARS-COV2 Pandemic Serosurvey and Blood Sampling | 15000 | National Institutes of Health Clinical Center, | National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health Clinical Center (CC) | |
| Maryland | MD-08 | Mental Health Impact of COVID-19 Pandemic on NIMH Research Participants and Volunteers | 10000 | National Institute of Mental Health, | National Institute of Mental Health (NIMH), National Institutes of Health Clinical Center (CC) | |
| Maryland | MD-08 | Transmissibility and Viral Load of SARS-CoV-2 in Oral Secretions | 90 | National Institutes of Health Clinical Center, | National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health Clinical Center (CC) | |
| Maryland | MD-08 | Plasma Collection From Convalescent and/or Immunized Donors for the Treatment of COVID-19 | 1500 | National Institutes of Health Clinical Center, | National Institutes of Health Clinical Center (CC) | |
| Maryland | MD-08 | Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection | 180 | National Institutes of Health Clinical Center, | National Cancer Institute (NCI), National Institutes of Health Clinical Center (CC) | |
| Maryland | MD-08 | Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant | 1419 | Meridian Clinical Research, | Novavax, Coalition for Epidemic Preparedness Innovations (CEPI) | Biological: SARS-CoV-2 rS - Phase 1, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1, Other: Normal saline solution (NSS), Placebo - Phase 1, Other: Normal saline solution (NSS), Placebo - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1, Other: Normal saline solution (NSS), Placebo, Day 21 - Phase 1, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Days 0 and 21 - Phase 2, Other: Normal saline solution (NSS), Placebo, Day 189 - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 2, Other: Normal saline solution (NSS), Placebo, Day 21 - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Day 189 - Phase 2 |
| Maryland | MD-08 | Genetics of COVID-19 Susceptibility and Manifestations | 2500 | National Institutes of Health Clinical Center, | National Human Genome Research Institute (NHGRI), National Institutes of Health Clinical Center (CC) | |
| Maryland | MD-08 | A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia | 379 | Holy Cross Hospital, | Genentech, Inc. | Drug: Placebo, Drug: Tocilizumab |
| Maryland | MD-08 | Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease | 800 | GSK Investigational Site, | GlaxoSmithKline | Biological: Otilimab, Biological: Placebo, Drug: Standard of care |
| Maryland | MD-08 | Impact on Anxiety and Motivation of COVID-19 and Predictors of Individual Responses | 5000 | National Institute of Mental Health, | National Institute of Mental Health (NIMH), National Institutes of Health Clinical Center (CC) | Behavioral: Computer task questionnaires |
| Maryland | MD-08 | Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. | 62 | Research Site, Research Site, Research Site, | AstraZeneca, Acerta Pharma B.V. | Drug: Acalabrutinib |
| Maryland | MD-08 | Surveillance of Individuals Following SARS-CoV-2 Infection | 1050 | National Institutes of Health Clinical Center, | National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health Clinical Center (CC) | |
| Maryland | MD-08 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Kaiser Permanente - Kensington Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Maryland | MD-08 | COVID-19 Pandemic Impact on Alcohol (PIA) - A Natural History Study | 700 | NIAAA Section on Human Psychopharmacology, | National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health Clinical Center (CC) | |
| Maryland | MD-08 | Pathogenesis of BTK-mediated Hyper-Inflammatory Responses in COVID-19 (RESPOND) | 120 | Walter Reed National Medical Center, National Institutes of Health Clinical Center, | National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health Clinical Center (CC) | |
| Maryland | MD-08 | COVID-19 Associated Lymphopenia Pathogenesis Study in Blood (CALYPSO) | 175 | National Institutes of Health Clinical Center, | National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health Clinical Center (CC) | |
| Maryland | MD-08 | Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons | 180 | National Institutes of Health Clinical Center, | National Institutes of Health Clinical Center (CC) | |
| Maryland | MD-08 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | Walter Reed National Medical Center, National Institutes of Health Clinical Center, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| Maryland | MD-08 | The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID) | 80 | Suburban Hospital, | Ridgeback Biotherapeutics, LP | Drug: EIDD-2801, Drug: Placebo (PB0) |
| Maryland | MD-08 | A Longitudinal Study of COVID-19 Sequelae and Immunity | 900 | National Institutes of Health Clinical Center, | National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health Clinical Center (CC) | |
| Maryland | MD-05 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | CalvertHealth Medical Center, | Gilead Sciences | Drug: Remdesivir |
| Maryland | MD-03 | CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment | 243 | Anne Arundel Medical Center, White Oak Medical Center, | OncoImmune, Inc. | Drug: CD24Fc, Drug: Placebo |
| Maryland | MD-03 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | University of Maryland St. Joseph Medical, | Gilead Sciences | Drug: Remdesivir |
| Maryland | MD-03 | Convalescent Plasma to Stem Coronavirus (CSSC-001) | 500 | Anne Arundel Medical Center, | Johns Hopkins University | Biological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma |
| Maryland | MD-03 | Incline Positioning in COVID-19 Patients for Improvement in Oxygen Saturation | 70 | Johns Hopkins Bayview Medical Center, | Johns Hopkins University | Other: Postural Positioning |
| Maryland | MD-03 | Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection | 180 | Medstar Montgomery Medical Center, | National Cancer Institute (NCI), National Institutes of Health Clinical Center (CC) | |
| Maryland | MD-03 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Center for Immunization Research Inpatient Unit, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Maryland | MD-03 | Convalescent Plasma to Limit SARS-CoV-2 Associated Complications | 1344 | Anne Arundel Medical Center, | Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID) | Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor |
| Maryland | MD-03 | Trial to Promote Recovery From COVID-19 With Endocrine Therapy | 60 | Johns Hopkins Hospital, | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Drug: Bicalutamide 150 Mg Oral Tablet |
| Maryland | MD-03 | Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) | 500 | Johns Hopkins University, | Incyte Corporation | Drug: Placebo, Drug: Ruxolitinib |
| Maryland | MD-03 | Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. | 62 | Research Site, | AstraZeneca, Acerta Pharma B.V. | Drug: Acalabrutinib |
| Maryland | MD-03 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Greater Baltimore Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Maryland | MD-03 | PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer | 364 | St. Agnes Healthcare, | CTI BioPharma | Drug: Pacritinib, Drug: Placebo |
| Maryland | MD-03 | The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID) | 80 | Johns Hopkins Bayview Medical Center, | Ridgeback Biotherapeutics, LP | Drug: EIDD-2801, Drug: Placebo (PB0) |
| Maryland | MD-01 | Study of Sargramostim in Patients With COVID-19 | 120 | TidalHealth Peninsula Regional, Inc, | Partner Therapeutics, Inc. | Drug: Sargramostim, Drug: Standard of care |
| Maryland | MD-02 | Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection | 180 | Medstar Franklin Square Medical Center, | National Cancer Institute (NCI), National Institutes of Health Clinical Center (CC) | |
| Massachusetts | MA-04 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Charlton Memorial Hospital, | Gilead Sciences | Drug: Remdesivir |
| Massachusetts | MA-04 | SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19 | 0 | Newton-Wellesley Hospital, | Alexion Pharmaceuticals | Biological: eculizumab |
| Massachusetts | MA-04 | Convalescent Plasma in Outpatients With COVID-19 | 600 | Newton-Wellesley Hospital, | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network | Biological: Convalescent Plasma, Biological: Saline |
| Massachusetts | MA-04 | Efficacy of Tocilizumab on Patients With COVID-19 | 243 | Newton-Wellesley Hospital, | Massachusetts General Hospital, Genentech, Inc. | Drug: Tocilizumab, Drug: Placebos |
| Massachusetts | MA-04 | Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults | 1000 | Newton-Wellelsey Hospital, | Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS) | Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo |
| Massachusetts | MA-04 | Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial | 750 | Brigham and Women's Hospital, | The TIMI Study Group | Drug: Unfractionated Heparin IV, Drug: Enoxaparin 1 mg/kg, Drug: Clopidogrel, Drug: Unfractionated heparin SC, Drug: Enoxaparin 40 Mg/0.4 mL Injectable Solution |
| Massachusetts | MA-08 | A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19) | 242 | Massachusetts General Hospital, | Millennium Pharmaceuticals, Inc., Takeda | Drug: TAK-981, Drug: Standard of care |
| Massachusetts | MA-08 | Adaptive COVID-19 Treatment Trial (ACTT) | 1062 | Massachusetts General Hospital, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir |
| Massachusetts | MA-08 | Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19 | 70 | Massachusetts General Hospital, | Massachusetts General Hospital, University of Alabama at Birmingham | Drug: Nitric Oxide |
| Massachusetts | MA-08 | Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19 | 200 | Massachusetts General Hospital, | Massachusetts General Hospital, Xijing Hospital, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Niguarda Hospital | Drug: Nitric Oxide Gas |
| Massachusetts | MA-08 | NO Prevention of COVID-19 for Healthcare Providers | 470 | Massachusetts General Hospital, | Massachusetts General Hospital | Drug: Inhaled nitric oxide gas |
| Massachusetts | MA-08 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| Massachusetts | MA-08 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | South Shore Hospital, | Gilead Sciences | Drug: Remdesivir |
| Massachusetts | MA-08 | COVID-19 Symptom Tracker | 10000000 | Massachusetts General Hospital, | King's College London, Zoe Global Limited, Massachusetts General Hospital, Harvard School of Public Health, Stanford University | Other: No Intervention |
| Massachusetts | MA-08 | Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease | 479 | Massachusetts General Hospital, | Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI) | Drug: Hydroxychloroquine, Drug: Placebo |
| Massachusetts | MA-08 | Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED | 260 | Massachusetts General Hospital, | Massachusetts General Hospital, Department of Anesthesia, MGH | Drug: Nitric Oxide Gas, Other: Inhaled Supplemental Oxygen |
| Massachusetts | MA-08 | Pegylated Interferon Lambda Treatment for COVID-19 | 20 | Massachusetts General Hospital, | Raymond Chung, Eiger BioPharmaceuticals, Massachusetts General Hospital | Drug: Pegylated interferon lambda |
| Massachusetts | MA-08 | Non-Invasive Monitoring of Respiratory Function in Spontaneously Breathing Patients With COVID-19 Infection | 500 | Massachusetts General Hospital, | Massachusetts General Hospital | Device: AirGo Respiratory Monitor |
| Massachusetts | MA-08 | Efficacy of Tocilizumab on Patients With COVID-19 | 243 | Massachusetts General Hospital, | Massachusetts General Hospital, Genentech, Inc. | Drug: Tocilizumab, Drug: Placebos |
| Massachusetts | MA-08 | Sarilumab for Patients With Moderate COVID-19 Disease | 120 | VA Boston Healthcare System, | Westyn Branch-Elliman, VA Boston Healthcare System | Biological: SARILUMAB |
| Massachusetts | MA-08 | Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia | 270 | Massachusetts General Hospital, | Alexion Pharmaceuticals | Biological: Ravulizumab, Other: Best Supportive Care |
| Massachusetts | MA-08 | COVID-19: Human Epidemiology and Response to SARS-CoV-2 | 5605 | Massachusetts General Hospital, | National Institute of Allergy and Infectious Diseases (NIAID), Rho Federal Systems Division, Inc. (Rho) | Procedure: Collection of Biological Samples, Procedure: Symptom and Exposure Surveys |
| Massachusetts | MA-08 | Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants | 52 | Massachusetts General Hospital, | BeiGene | Drug: Zanubrutinib, Drug: Supportive Care, Drug: Placebo |
| Massachusetts | MA-08 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | Massachusetts General Hospital, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| Massachusetts | MA-08 | COVID-19 and Mental Health | 2000 | Northeastern University, | Northeastern University | Other: Exposure to the SARS-CoV-2 |
| Massachusetts | MA-08 | A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19 | 24 | Massachusetts General Hospital, | Eli Lilly and Company, AbCellera Biologics Inc. | Drug: LY3819253, Drug: Placebo |
| Massachusetts | MA-01 | A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia | 450 | Baystate Health System, | Hoffmann-La Roche | Drug: Tocilizumab (TCZ), Drug: Placebo |
| Massachusetts | MA-01 | Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease | 479 | Baystate Health System, | Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI) | Drug: Hydroxychloroquine, Drug: Placebo |
| Massachusetts | MA-01 | Convalescent Plasma in Outpatients With COVID-19 | 600 | Baystate Medical Center, | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network | Biological: Convalescent Plasma, Biological: Saline |
| Massachusetts | MA-01 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Mercy Medical Center, Baystate Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Massachusetts | MA-01 | A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia | 500 | Baystate Medical Center, | Hoffmann-La Roche, Gilead Sciences | Drug: Remdesivir, Drug: Tocilizumab, Drug: Placebo |
| Massachusetts | MA-03 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Lawrence General Hospital, Lowell General Hospital, | Gilead Sciences | Drug: Remdesivir |
| Massachusetts | MA-03 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Lowell General Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Massachusetts | MA-03 | Photobiomodulation Laser Therapy for COVID-19 Positive Patients With Pulmonary Disease | 10 | Lowell General Hospital, | Lowell General Hospital | Device: MLS Laser, Other: Regular Inpatient Medical Care |
| Massachusetts | MA-05 | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 5000 | Massachusetts General Hospital, | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: |
| Massachusetts | MA-05 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Cambridge Health Alliance, | Gilead Sciences | Drug: Remdesivir |
| Massachusetts | MA-05 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Winchester Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Massachusetts | MA-07 | Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients | 100 | Childrens Hospital Boston, | Novartis Pharmaceuticals, Novartis | Drug: Crizanlizumab |
| Massachusetts | MA-07 | Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID) | 200 | Beth Israel Deaconess Medical Center, | Vanderbilt University Medical Center, United States Department of Defense | |
| Massachusetts | MA-07 | Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study | 250 | Brigham and Women's Hospital, Beth Israel Deaconess Medical Center, | Ansun Biopharma, Inc. | Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL |
| Massachusetts | MA-07 | Persuasion in Medicine: Experimental Evidence on Sender and Signal Effects | 3350 | Harvard University, | Harvard University, Stanford University, Massachusetts Institute of Technology | Behavioral: Video about safety and effectiveness of adult seasonal flu vaccination, Behavioral: Message directing subjects to information on COVID-19 vaccine safety and efficacy |
| Massachusetts | MA-07 | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 5000 | Boston Children's Hospital, | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: |
| Massachusetts | MA-07 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Tufts Medical Center, Brigham & Women's Hospital, Beth Israel Deaconess Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Massachusetts | MA-07 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Tufts Medical Center, Brigham & Women's Hospital, Beth Israel Deaconess Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Massachusetts | MA-07 | Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19 | 200 | Beth Israel Deaconess Medical Center, | Massachusetts General Hospital, Xijing Hospital, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Niguarda Hospital | Drug: Nitric Oxide Gas |
| Massachusetts | MA-07 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site, Regeneron Study Site, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| Massachusetts | MA-07 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Steward St. Elizabeth's Medical Center, | Gilead Sciences | Drug: Remdesivir |
| Massachusetts | MA-07 | Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP) | 829 | Boston University, | University of Washington, Bill and Melinda Gates Foundation | Drug: Hydroxychloroquine Sulfate, Drug: Ascorbic Acid |
| Massachusetts | MA-07 | Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease | 479 | Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, | Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI) | Drug: Hydroxychloroquine, Drug: Placebo |
| Massachusetts | MA-07 | Hydroxychloroquine in Outpatient Adults With COVID-19 | 8 | Investigational Site Number 8400001, | Sanofi | Drug: Hydroxychloroquine SAR321068, Drug: Placebo |
| Massachusetts | MA-07 | COVID-19 Risk Stratification | 1326 | Brigham and Women's Hospital, | Brigham and Women's Hospital | |
| Massachusetts | MA-07 | Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19) | 384 | Brigham and Women's Hospital, | I-Mab Biopharma Co. Ltd. | Drug: TJ003234, Drug: Placebo |
| Massachusetts | MA-07 | Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19 | 86 | Beth Israel Deaconess Medical Center, | CytoDyn, Inc. | Drug: Placebos, Drug: Leronlimab (700mg) |
| Massachusetts | MA-07 | Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19 | 5220 | Brigham and Women's Hospital, | Brigham and Women's Hospital, Icahn School of Medicine at Mount Sinai, Montefiore Medical Center, Baylor College of Medicine, Baylor Health Care System, Beth Israel Deaconess Medical Center, University of Colorado, Denver, Cook County Hospital, The Cooper Health System, Duke University, Georgetown University, Hackensack mountainside hospital, Hackensack Meridian Health, Indiana University Health Methodist Hospital, Johns Hopkins University, Loma Linda University, Mayo Clinic, Medical College of Wisconsin, Northwestern, Weill Medical College of Cornell University, NYU Langone Health, Ochsner Health System, Oregon Health and Science University, Renown Health, Rush University Medical Center, New Jersey Medical School, Rutgers Robert Wood Johnson Medical School, Stanford University, Temple University, Tufts Medical Center, Tulane University, University of California, Davis, University of California, Los Angeles, University of California, San Diego, University of California, San Francisco, University of North Carolina, Chapel Hill, University Hospitals Cleveland Medical Center, University Medical Center of Southern Nevada, University of Alabama at Birmingham, University of Chicago, University of Florida, University of Illinois at Chicago, University of Kentucky, University of Miami, University of Michigan, University of Oklahoma, University of Pennsylvania, University of Pittsburgh Medical Center, University of Tennessee Health Science Center, University of Washington, University of Texas, Southwestern Medical Center at Dallas, Yale University | Other: No intervention |
| Massachusetts | MA-07 | Awake Prone Position for Early Hypoxemia in COVID-19 | 560 | Boston Medical Center, | Boston University | Other: Self-prone position recommendation, Other: Usual care |
| Massachusetts | MA-07 | A Study of Auxora in Patients With Severe COVID-19 Pneumonia | 400 | Brigham and Women's Hospital, | CalciMedica, Inc. | Drug: Auxora, Drug: Placebo |
| Massachusetts | MA-07 | Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19) | 390 | Beth Israel Deaconess Medical Center, | CytoDyn, Inc. | Drug: Placebos, Drug: Leronlimab (700mg) |
| Massachusetts | MA-07 | Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection | 202 | Boston Medical Center, | Karyopharm Therapeutics Inc | Drug: Selinexor, Other: Placebo |
| Massachusetts | MA-07 | A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE) | 227 | Brigham & Women's Hospital, | Kinevant Sciences GmbH, Roivant Sciences, Inc. | Drug: Gimsilumab, Drug: Placebo |
| Massachusetts | MA-07 | Treatment for COVID-19 in High-Risk Adult Outpatients | 300 | Boston University, | University of Washington, Bill and Melinda Gates Foundation | Drug: Ascorbic Acid, Drug: Hydroxychloroquine Sulfate, Drug: Azithromycin, Drug: Folic Acid, Drug: Lopinavir 200 MG / Ritonavir 50 MG [Kaletra] |
| Massachusetts | MA-07 | SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19 | 0 | Boston Medical Center, | Alexion Pharmaceuticals | Biological: eculizumab |
| Massachusetts | MA-07 | Convalescent Plasma in Outpatients With COVID-19 | 600 | Tufts Medical Center, Beth Israel Deaconess Medical Center, | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network | Biological: Convalescent Plasma, Biological: Saline |
| Massachusetts | MA-07 | Etoposide in Patients With COVID-19 Infection | 64 | Boston Medical Center, | Boston Medical Center | Drug: Etoposide |
| Massachusetts | MA-07 | Efficacy of Tocilizumab on Patients With COVID-19 | 243 | Brigham and Women's Hospital, | Massachusetts General Hospital, Genentech, Inc. | Drug: Tocilizumab, Drug: Placebos |
| Massachusetts | MA-07 | Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection | 60 | Beth Israel Deaconess Medical Center, | Denver Health and Hospital Authority, Genentech, Inc., University of Colorado, Denver, National Jewish Health, Beth Israel Deaconess Medical Center, Long Island Jewish Medical Center, Scripps Health, St. Mary's Medical Center, University of Miami, Ben Taub Hospital, Methodist Dallas Medical Center | Drug: Alteplase 50 MG [Activase] |
| Massachusetts | MA-07 | Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19 | 50 | Brigham and Women's Hospital, Boston Medical Center, Massachusetts General Hospital, | Fujifilm Pharmaceuticals U.S.A., Inc. | Drug: Favipiravir + Standard of Care, Drug: Standard of Care |
| Massachusetts | MA-07 | Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy | 220 | Brigham and Women's Hospital, | Brigham and Women's Hospital | Biological: High-Titer COVID-19 Convalescent Plasma (HT-CCP), Biological: Standard Plasma (FFP) |
| Massachusetts | MA-07 | Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults | 1000 | Beth Israel Deaconess Medical Center, | Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS) | Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo |
| Massachusetts | MA-07 | Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia | 451 | Novartis Investigative Site, Novartis Investigative Site, | Novartis Pharmaceuticals, Novartis | Drug: Canakinumab, Drug: Placebo |
| Massachusetts | MA-07 | COVID-19 Active Research Experience (CARE) | 100000 | IQVIA, | Iqvia Pty Ltd | |
| Massachusetts | MA-07 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Boston Medical Center, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Massachusetts | MA-07 | Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia | 270 | Brigham and Women's Hospital, Boston Medical Center, | Alexion Pharmaceuticals | Biological: Ravulizumab, Other: Best Supportive Care |
| Massachusetts | MA-07 | MSCs in COVID-19 ARDS | 223 | Brigham and Women's Hospital, | Icahn School of Medicine at Mount Sinai, Mesoblast, Inc., National Heart, Lung, and Blood Institute (NHLBI) | Biological: Remestemcel-L, Drug: Placebo |
| Massachusetts | MA-07 | COVID-19 Health Messaging to Underserved Communities | 15475 | JPAL North America, | National Bureau of Economic Research, Inc., Massachusetts General Hospital, Stanford University, Yale University, Massachusetts Institute of Technology, Harvard University | Behavioral: Messaging |
| Massachusetts | MA-07 | Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19 | 600 | Beth Israel Deaconess Medical Center, | Vanderbilt University Medical Center, AbbVie | Drug: Lopinavir/Ritonavir 400 mg/100 mg, Other: Placebo |
| Massachusetts | MA-07 | Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury | 46 | Brigham and Women's Hospital, Beth Israel Deaconess Medical Center, | AbbVie, Janssen Research & Development, LLC, Pharmacyclics LLC (An AbbVie Company) | Drug: Ibrutinib, Drug: Placebo |
| Massachusetts | MA-07 | COVID-19: Human Epidemiology and Response to SARS-CoV-2 | 5605 | Boston Children's Hospital, Boston Medical Center, | National Institute of Allergy and Infectious Diseases (NIAID), Rho Federal Systems Division, Inc. (Rho) | Procedure: Collection of Biological Samples, Procedure: Symptom and Exposure Surveys |
| Massachusetts | MA-07 | Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) | 500 | Boston Medical Center, | Incyte Corporation | Drug: Placebo, Drug: Ruxolitinib |
| Massachusetts | MA-07 | Immunophenotyping Assessment in a COVID-19 Cohort | 2000 | Brigham and Women's Hospital, | National Institute of Allergy and Infectious Diseases (NIAID), Benaroya Research Institute, Boston Children's Hospital | Procedure: Biological sample collection, Procedure: Data Collection: Clinical Care Assessments |
| Massachusetts | MA-07 | Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants | 52 | Brigham and Women's Hospital, | BeiGene | Drug: Zanubrutinib, Drug: Supportive Care, Drug: Placebo |
| Massachusetts | MA-07 | Study of Efficacy and Safety of MAS825 in Patients With COVID-19 | 140 | Novartis Investigative Site, Novartis Investigative Site, Novartis Investigative Site, | Novartis Pharmaceuticals, Novartis | Drug: MAS825, Drug: Matching placebo |
| Massachusetts | MA-07 | Inhaled Sedation in COVID-19-related Acute Respiratory Distress Syndrome (ISCA): an International Research Data Study in the Recent Context of Widespread Disease Resulting From the 2019 (SARS-CoV2) Coronavirus Pandemics (COVID-19) | 400 | Beth Israel Deaconess Medical Center, Inc., | University Hospital, Clermont-Ferrand, Hospital Clínico Universitario de Valencia, University Hospital Schleswig-Holstein, Groupe Hospitalier Pitie-Salpetriere | Drug: Intravenous sedation, Drug: Inhaled sedation |
| Massachusetts | MA-07 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Tufts Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Massachusetts | MA-07 | Inhaled Nitric Oxide for Preventing Progression in COVID-19 | 42 | Tufts Medical Center, | Tufts Medical Center, Bellerophon | Drug: Nitric Oxide |
| Massachusetts | MA-07 | The Safety and Preliminary Efficacy of Lucinactant in Adults With COVID-19 | 30 | Brigham and Women's Hospital, | Windtree Therapeutics | Drug: Lucinactant |
| Massachusetts | MA-07 | Lung Irradiation for COVID-19 Pneumonia | 48 | Brigham and Women's Hospital, | Brigham and Women's Hospital | Radiation: Phase 1, Radiation: Phase 2 |
| Massachusetts | MA-07 | An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic | 0 | Dana Farber Cancer Institute, | Genentech, Inc. | Drug: Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration (PH FDC SC) |
| Massachusetts | MA-07 | Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) | 190 | Atea Study Site, | Atea Pharmaceuticals, Inc. | Drug: AT-527, Other: Placebo |
| Massachusetts | MA-07 | Niclosamide for Mild to Moderate COVID-19 | 100 | Tufts Medical Center, | Tufts Medical Center | Drug: Niclosamide, Drug: Placebo, Other: Telehealth monitoring |
| Massachusetts | MA-07 | Pulmozyme to Improve COVID-19 ARDS Outcomes | 60 | Brigham and Women's Hospital, | Boston Children's Hospital, Brigham and Women's Hospital | Drug: Pulmozyme, Drug: Placebo |
| Massachusetts | MA-07 | Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19 | 727 | Brigham and Women's Hospital CRS, Fenway Health Clinical Research Site CRS, | HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials Network | Other: Sample collection |
| Massachusetts | MA-07 | PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer | 364 | Brigham and Women's Hospital, | CTI BioPharma | Drug: Pacritinib, Drug: Placebo |
| Massachusetts | MA-07 | A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia | 500 | Boston Medical Center, | Hoffmann-La Roche, Gilead Sciences | Drug: Remdesivir, Drug: Tocilizumab, Drug: Placebo |
| Massachusetts | MA-06 | A Study of LY3127804 in Participants With COVID-19 | 95 | Lahey Hospital and Medical Center, | Eli Lilly and Company | Drug: LY3127804, Drug: Placebo |
| Massachusetts | MA-06 | Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) | 500 | Lahey Clinic Inc, | Incyte Corporation | Drug: Placebo, Drug: Ruxolitinib |
| Massachusetts | MA-06 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Beverly Hospital, Lahey Hospital and Medical Center, Addison Gilbert Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Massachusetts | MA-06 | Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19) | 124 | Lahey Hospital and Medical Center, | CSL Behring | Biological: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody, Drug: Placebo |
| Massachusetts | MA-02 | Adaptive COVID-19 Treatment Trial (ACTT) | 1062 | University of Massachusetts Medical School, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir |
| Massachusetts | MA-02 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | UMass Memorial Medical Center, | Gilead Sciences | Drug: Remdesivir |
| Massachusetts | MA-02 | Convalescent Plasma to Stem Coronavirus (CSSC-001) | 500 | University of Massachusetts Worcester, | Johns Hopkins University | Biological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma |
| Massachusetts | MA-02 | Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease | 479 | St. Vincent's Hospital, | Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI) | Drug: Hydroxychloroquine, Drug: Placebo |
| Massachusetts | MA-02 | Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19 | 50 | UMass Memorial Health Care, | Fujifilm Pharmaceuticals U.S.A., Inc. | Drug: Favipiravir + Standard of Care, Drug: Standard of Care |
| Massachusetts | MA-02 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | UMass Memorial Medical Center, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Massachusetts | MA-02 | Convalescent Plasma to Limit SARS-CoV-2 Associated Complications | 1344 | University of Massachusetts Worcester, | Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID) | Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor |
| Massachusetts | MA-02 | Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) | 500 | UMass MMC - University Campus, | Incyte Corporation | Drug: Placebo, Drug: Ruxolitinib |
| Massachusetts | MA-02 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | University of Massachusetts Medical School, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| Massachusetts | MA-02 | A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19 | 24 | University of Massachusetts Medical Center, | Eli Lilly and Company, AbCellera Biologics Inc. | Drug: LY3819253, Drug: Placebo |
| Michigan | MI-10 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Caro Cancer Center, Great Lakes Cancer Management Specialists-Doctors Park, Great Lakes Cancer Management Specialists-Macomb Medical Campus, Michigan Breast Specialists-Macomb Township, Saint Mary's Oncology/Hematology Associates of Marlette, McLaren-Port Huron, Henry Ford Macomb Health Center - Shelby Township, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Michigan | MI-11 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Huron Valley-Sinai Hospital, | Gilead Sciences | Drug: Remdesivir |
| Michigan | MI-11 | Convalescent Plasma in Outpatients With COVID-19 | 600 | William Beaumont Hospital-Troy, | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network | Biological: Convalescent Plasma, Biological: Saline |
| Michigan | MI-11 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | IHA Hematology Oncology Consultants-Canton, Saint Joseph Mercy Canton, Hope Cancer Clinic, Saint Mary Mercy Hospital, Ascension Providence Hospitals – Novi, Henry Ford Medical Center-Columbus, William Beaumont Hospital – Troy, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Michigan | MI-11 | Feasibility Study of Anti-SARS-CoV-2 Plasma Transfusions in COVID-19 Patients With SRD | 90 | Ascension Providence Hospital Novi Campus, | Ascension South East Michigan | Drug: SARS-CoV-2 plasma |
| Michigan | MI-12 | Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study | 250 | University of Michigan, | Ansun Biopharma, Inc. | Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL |
| Michigan | MI-12 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | University of Michigan Hospitals and Health Systems, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Michigan | MI-12 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | University of Michigan Hospitals and Health Systems, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Michigan | MI-12 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| Michigan | MI-12 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | St. Joseph Mercy Hospital, | Gilead Sciences | Drug: Remdesivir |
| Michigan | MI-12 | Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease | 479 | University of Michigan Medical Center, | Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI) | Drug: Hydroxychloroquine, Drug: Placebo |
| Michigan | MI-12 | Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine | 1363 | University of Michigan, | Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke University | Drug: Hydroxychloroquine, Drug: Placebo oral tablet |
| Michigan | MI-12 | The Role of Resistant Starch in COVID-19 Infection | 1500 | University of Michigan, | Yale University, University of Michigan, University of Minnesota | Drug: Dietary Supplement containing resistant starch, Dietary Supplement: Placebo Starch |
| Michigan | MI-12 | Awake Prone Position for Early Hypoxemia in COVID-19 | 560 | University of Michigan, | Boston University | Other: Self-prone position recommendation, Other: Usual care |
| Michigan | MI-12 | Convalescent Plasma in Outpatients With COVID-19 | 600 | University of Michigan, | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network | Biological: Convalescent Plasma, Biological: Saline |
| Michigan | MI-12 | Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection | 4000 | Vida Clinical Studies, | Romark Laboratories L.C. | Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex |
| Michigan | MI-12 | Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID) | 432 | Novartis Investigative Site, | Novartis Pharmaceuticals, Incyte Corporation, Novartis | Drug: Ruxolitinib, Drug: Placebo |
| Michigan | MI-12 | MSCs in COVID-19 ARDS | 223 | University of Michigan, | Icahn School of Medicine at Mount Sinai, Mesoblast, Inc., National Heart, Lung, and Blood Institute (NHLBI) | Biological: Remestemcel-L, Drug: Placebo |
| Michigan | MI-12 | Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC) | 3000 | Henry Ford University, | University of Manitoba, University Health Network, Toronto | Drug: Heparin |
| Michigan | MI-12 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Saint Joseph Mercy Hospital, University of Michigan Comprehensive Cancer Center, Henry Ford Cancer Institute-Downriver, Beaumont Hospital – Dearborn, Henry Ford Medical Center-Fairlane, Huron Gastroenterology PC, IHA Hematology Oncology Consultants-Ann Arbor, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Michigan | MI-12 | Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19 | 160 | University of Michigan, | University of Michigan | Drug: Dipyridamole 100 Milligram(mg), Drug: Placebo oral tablet |
| Michigan | MI-12 | Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections | 30 | University of Michigan, | SeaStar Medical | Device: SCD |
| Michigan | MI-12 | PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer | 364 | University of Michigan, | CTI BioPharma | Drug: Pacritinib, Drug: Placebo |
| Michigan | MI-12 | A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19 | 24 | University of Michigan, | Eli Lilly and Company, AbCellera Biologics Inc. | Drug: LY3819253, Drug: Placebo |
| Michigan | MI-13 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Henry Ford Health System, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Michigan | MI-13 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Henry Ford Health System, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Michigan | MI-13 | Losartan for Patients With COVID-19 Requiring Hospitalization | 200 | Henry Ford Hospital, | University of Minnesota, Bill and Melinda Gates Foundation | Drug: Losartan, Other: Placebo |
| Michigan | MI-13 | CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment | 243 | Henry Ford Health System, | OncoImmune, Inc. | Drug: CD24Fc, Drug: Placebo |
| Michigan | MI-13 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Wayne State University/ Detroit Hospital, Henry Ford Health System, | Gilead Sciences | Drug: Remdesivir |
| Michigan | MI-13 | Convalescent Plasma to Stem Coronavirus (CSSC-001) | 500 | Wayne State University, | Johns Hopkins University | Biological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma |
| Michigan | MI-13 | Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects | 120 | Blade Research Site, | Blade Therapeutics, Clinipace Worldwide | Drug: BLD-2660 |
| Michigan | MI-13 | Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19) | 384 | Henry Ford Health System, | I-Mab Biopharma Co. Ltd. | Drug: TJ003234, Drug: Placebo |
| Michigan | MI-13 | Will Hydroxychloroquine Impede or Prevent COVID-19 | 624 | Henry Ford Hospital, | Henry Ford Health System | Drug: Hydroxychloroquine - Daily Dosing, Drug: Hydroxychloroquine - Weekly Dosing, Other: Placebo oral tablet, Diagnostic Test: Monitoring Visit - Baseline, Diagnostic Test: Monitoring Visit - Week 4, Diagnostic Test: Monitoring Visit - Week 8, Other: Weekly Assessment |
| Michigan | MI-13 | A Study of LY3127804 in Participants With COVID-19 | 95 | Henry Ford Hospital, | Eli Lilly and Company | Drug: LY3127804, Drug: Placebo |
| Michigan | MI-13 | A Study of Auxora in Patients With Severe COVID-19 Pneumonia | 400 | Detroit Receiving Hospital, Harper Hospital, Henry Ford Hospital, | CalciMedica, Inc. | Drug: Auxora, Drug: Placebo |
| Michigan | MI-13 | Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection | 202 | Karmanos, | Karyopharm Therapeutics Inc | Drug: Selinexor, Other: Placebo |
| Michigan | MI-13 | Convalescent Plasma in Outpatients With COVID-19 | 600 | Detroit Receiving Hospital, Harper University Hospital, Henry Ford Hospital, | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network | Biological: Convalescent Plasma, Biological: Saline |
| Michigan | MI-13 | Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia | 270 | Henry Ford Hospital, | Alexion Pharmaceuticals | Biological: Ravulizumab, Other: Best Supportive Care |
| Michigan | MI-13 | A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia | 379 | Henry Ford Health System, | Genentech, Inc. | Drug: Placebo, Drug: Tocilizumab |
| Michigan | MI-13 | Convalescent Plasma to Limit SARS-CoV-2 Associated Complications | 1344 | Wayne State University, | Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID) | Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor |
| Michigan | MI-13 | Early Short Course Corticosteroids in COVID-19 | 250 | Henry Ford Health System, | Henry Ford Health System | Drug: Methylprednisolone |
| Michigan | MI-13 | COVID-19: Human Epidemiology and Response to SARS-CoV-2 | 5605 | Henry Ford Health System, | National Institute of Allergy and Infectious Diseases (NIAID), Rho Federal Systems Division, Inc. (Rho) | Procedure: Collection of Biological Samples, Procedure: Symptom and Exposure Surveys |
| Michigan | MI-13 | Risk Factors for Anxiety and Depression Among Pregnant Women During the COVID-19 Pandemic | 8500 | Wayne State University, | Żelazna Medical Centre, LLC, University of Medicine, Tirana, Royal Prince Alfred Hospital, Sydney, Australia, Charles University, Czech Republic, Hôpital Necker-Enfants Malades, Charite University, Berlin, Germany, Chinese University of Hong Kong, Meir Medical Center, Università degli Studi di Brescia, American University of Beirut Medical Center, Karolinska Institutet, Pomeranian Medical University Szczecin, Nicolaus Copernicus University, Centre of Postgraduate Medical Education, Polish Academy of Sciences, Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland, Fundación Para la Investigación y el Desarrollode la Medicina Materno-Fetal y Neonatal "iMaterna", Madrid, Taiji Clinic, Taipei, Wayne State University, Chang Gung University, University of Tromso | Other: Pandemic control measures |
| Michigan | MI-13 | A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19 | 270 | Henry Ford Hospital, | Janssen Pharmaceutica N.V., Belgium | Drug: Sirukumab, Drug: Placebo, Other: Standard of Care (SOC) |
| Michigan | MI-13 | Convalescent Plasma for Patients With COVID-19 | 30 | Henry Ford Hospital, | Henry Ford Health System | Biological: Convalescent plasma |
| Michigan | MI-13 | A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia | 410 | Henry Ford Health System, | Genentech, Inc. | Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo |
| Michigan | MI-13 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Wayne State University/Karmanos Cancer Institute, Henry Ford Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Michigan | MI-13 | A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia | 500 | Henry Ford Hospital, | Hoffmann-La Roche, Gilead Sciences | Drug: Remdesivir, Drug: Tocilizumab, Drug: Placebo |
| Michigan | MI-14 | Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects | 120 | Blade Research Site, | Blade Therapeutics, Clinipace Worldwide | Drug: BLD-2660 |
| Michigan | MI-14 | Will Hydroxychloroquine Impede or Prevent COVID-19 | 624 | Detroit Department of Transportation, Detroit Fire Department & Detroit EMS, Detroit Police Department, | Henry Ford Health System | Drug: Hydroxychloroquine - Daily Dosing, Drug: Hydroxychloroquine - Weekly Dosing, Other: Placebo oral tablet, Diagnostic Test: Monitoring Visit - Baseline, Diagnostic Test: Monitoring Visit - Week 4, Diagnostic Test: Monitoring Visit - Week 8, Other: Weekly Assessment |
| Michigan | MI-14 | A Study of Auxora in Patients With Severe COVID-19 Pneumonia | 400 | Sinai Grace, | CalciMedica, Inc. | Drug: Auxora, Drug: Placebo |
| Michigan | MI-14 | Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection | 202 | Michigan Center of Medical Research, | Karyopharm Therapeutics Inc | Drug: Selinexor, Other: Placebo |
| Michigan | MI-14 | Convalescent Plasma in Outpatients With COVID-19 | 600 | Sinai-Grace Hospital, | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network | Biological: Convalescent Plasma, Biological: Saline |
| Michigan | MI-14 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Michigan Center for Medical Research, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Michigan | MI-14 | A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia | 379 | Sinai Grace Hospital, | Genentech, Inc. | Drug: Placebo, Drug: Tocilizumab |
| Michigan | MI-14 | Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC) | 3000 | Beaumont Hospital, | University of Manitoba, University Health Network, Toronto | Drug: Heparin |
| Michigan | MI-14 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Ascension St. John Hospital, Weisberg Cancer Treatment Center, Beaumont Hospital - Farmington Hills, Academic Hematology Oncology Specialists, Great Lakes Cancer Management Specialists-Van Elslander, Michigan Breast Specialists-Grosse Pointe Woods, 21st Century Oncology-Pontiac, Hope Cancer Center, Newland Medical Associates-Pontiac, Saint Joseph Mercy Oakland, Ascension Providence Hospitals – Southfield, Henry Ford West Bloomfield Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Michigan | MI-14 | A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19 | 66 | Ascension Providence Hospital, | Apellis Pharmaceuticals, Inc. | Drug: APL-9, Other: Vehicle Control |
| Michigan | MI-14 | Comparison of the ID NOW and Accula Point-of-Care Assays for Detection of COVID-19 | 100 | Ascension St. John Hospital, | Ascension South East Michigan | Diagnostic Test: ID NOW vs. Accula |
| Michigan | MI-14 | PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer | 364 | Ascension St. John Hospital, Ascension Providence Hospital- Novi Campus, Providence Cancer Institute, | CTI BioPharma | Drug: Pacritinib, Drug: Placebo |
| Michigan | MI-14 | Feasibility Study of Anti-SARS-CoV-2 Plasma Transfusions in COVID-19 Patients With SRD | 90 | Ascension Providence Hospital Southfield Campus, | Ascension South East Michigan | Drug: SARS-CoV-2 plasma |
| Michigan | MI-07 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | IHA Hematology Oncology Consultants-Chelsea, Saint Joseph Mercy Chelsea, Allegiance Health, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Michigan | MI-06 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Bronson Methodist Hospital, | Gilead Sciences | Drug: Remdesivir |
| Michigan | MI-06 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Bronson Methodist Hospital, West Michigan Cancer Center, Borgess Medical Center, Lakeland Hospital Niles, Lakeland Medical Center Saint Joseph, Marie Yeager Cancer Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Michigan | MI-05 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | McLaren Health Care Corporation, | Gilead Sciences | Drug: Remdesivir |
| Michigan | MI-05 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | McLaren Cancer Institute-Bay City, Genesee Cancer and Blood Disease Treatment Center, Genesee Hematology Oncology PC, Genesys Hurley Cancer Institute, Hurley Medical Center, McLaren Cancer Institute-Flint, Singh and Arora Hematology Oncology PC, Ascension Saint Mary's Hospital, Oncology Hematology Associates of Saginaw Valley PC, Ascension Saint Joseph Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Michigan | MI-09 | A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19) | 242 | Barbara Ann Karmanos Cancer Institute, | Millennium Pharmaceuticals, Inc., Takeda | Drug: TAK-981, Drug: Standard of care |
| Michigan | MI-09 | Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2 | 25 | Beaumont Health System, | William Beaumont Hospitals | Device: CT-V |
| Michigan | MI-09 | Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease | 479 | Henry Ford Medical Center, | Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI) | Drug: Hydroxychloroquine, Drug: Placebo |
| Michigan | MI-09 | Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection | 202 | Michigan Center of Medical Research, | Karyopharm Therapeutics Inc | Drug: Selinexor, Other: Placebo |
| Michigan | MI-09 | Beaumont Health Large-scale Automated Serologic Testing for COVID-19 | 56000 | Beaumont Health System, | William Beaumont Hospitals | Diagnostic Test: EUROIMMUN assay |
| Michigan | MI-09 | A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE) | 227 | Beaumont Health System, | Kinevant Sciences GmbH, Roivant Sciences, Inc. | Drug: Gimsilumab, Drug: Placebo |
| Michigan | MI-09 | Convalescent Plasma in Outpatients With COVID-19 | 600 | William Beaumont Hospital, | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network | Biological: Convalescent Plasma, Biological: Saline |
| Michigan | MI-09 | Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19 | 500 | William Beaumont Hospital, | William Beaumont Hospitals | Drug: Naltrexone, Drug: Ketamine, Other: Placebo |
| Michigan | MI-09 | A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19 | 270 | Beaumont Health Systems, | Janssen Pharmaceutica N.V., Belgium | Drug: Sirukumab, Drug: Placebo, Other: Standard of Care (SOC) |
| Michigan | MI-09 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Henry Ford Macomb Hospital-Clinton Township, McLaren Cancer Institute-Macomb, William Beaumont Hospital-Royal Oak, Bhadresh Nayak MD PC-Sterling Heights, Advanced Breast Care Center PLLC, Great Lakes Cancer Management Specialists-Macomb, Macomb Hematology Oncology PC, Michigan Breast Specialists-Warren, Saint John Macomb-Oakland Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Michigan | MI-09 | Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure | 524 | William Beaumont Hospital, | Chimerix | Drug: Dociparastat sodium, Drug: Placebo |
| Michigan | MI-09 | Feasibility Study of Anti-SARS-CoV-2 Plasma Transfusions in COVID-19 Patients With SRD | 90 | Ascension Providence Hospital Warren Campus, | Ascension South East Michigan | Drug: SARS-CoV-2 plasma |
| Michigan | MI-04 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Mid-Michigan Medical Center - Midland, McLaren Cancer Institute-Central Michigan, Spectrum Health Reed City Hospital, Saint Mary's Oncology/Hematology Associates of West Branch, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Michigan | MI-04 | Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression | 208 | Octapharma Research Site, | Octapharma | Biological: Octagam 10%, Other: Placebo |
| Michigan | MI-02 | Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults | 1000 | Mercy Health Muskegon, | Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS) | Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo |
| Michigan | MI-02 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Mercy Health Mercy Campus, Cancer and Hematology Centers of Western Michigan - Norton Shores, Metro Health Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Michigan | MI-01 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | McLaren Cancer Institute-Northern Michigan, Munson Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Michigan | MI-03 | Reducing Hopelessness Through Improved Physical Activity in Adults With Heart Disease: With COVID-19 Considerations | 225 | Spectrum Health, | University of Illinois at Chicago, National Institute of Nursing Research (NINR) | Behavioral: Motivational social support from nurse, Behavioral: Motivational social support from nurse with additional support from significant other, Behavioral: Attention control |
| Michigan | MI-03 | Convalescent Plasma in Outpatients With COVID-19 | 600 | Spectrum Health Hospitals Butterworth Hospital, | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network | Biological: Convalescent Plasma, Biological: Saline |
| Michigan | MI-03 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Bronson Battle Creek, Helen DeVos Children's Hospital at Spectrum Health, Mercy Health Saint Mary's, Spectrum Health at Butterworth Campus, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Michigan | MI-08 | Compassionate Use of Hyperbaric Oxygen Therapy | 100 | Ascension Providence Rochester Hospital, | SerenaGroup, Inc., SerenaGroup Research Foundation | |
| Michigan | MI-08 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | IHA Hematology Oncology Consultants-Brighton, Saint Joseph Mercy Brighton, Hematology Oncology Consultants-Clarkston, McLaren Cancer Institute-Clarkston, Newland Medical Associates-Clarkston, Michigan State University Clinical Center, McLaren-Greater Lansing, Mid-Michigan Physicians-Lansing, Sparrow Hospital, Great Lakes Cancer Management Specialists-Rochester Hills, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Minnesota | MN-05 | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 5000 | University of Minnesota, | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: |
| Minnesota | MN-05 | Adaptive COVID-19 Treatment Trial (ACTT) | 1062 | University of Minnesota Medical Center, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir |
| Minnesota | MN-05 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Hennepin Healthcare, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Minnesota | MN-05 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Hennepin Healthcare, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Minnesota | MN-05 | Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2 | 1309 | University of Minnesota, | University of Minnesota, McGill University Health Centre/Research Institute of the McGill University Health Centre, University of Manitoba, University of Alberta | Drug: Hydroxychloroquine, Other: Placebo |
| Minnesota | MN-05 | Losartan for Patients With COVID-19 Not Requiring Hospitalization | 580 | Hennepin County Medical Center, M Health Fairview University of Minnesota, University of Minnesota, Mayo Clinic Health System, | University of Minnesota, The Minnesota Foundation | Drug: Losartan, Other: Placebo |
| Minnesota | MN-05 | Losartan for Patients With COVID-19 Requiring Hospitalization | 200 | Hennepin County Medical Center, M Health Fairview University of Minnesota, University of Minnesota, North Memorial Health Hospital, | University of Minnesota, Bill and Melinda Gates Foundation | Drug: Losartan, Other: Placebo |
| Minnesota | MN-05 | Pre-exposure Prophylaxis for SARS-Coronavirus-2 | 1500 | University of Minnesota, | University of Minnesota | Drug: Hydroxychloroquine, Other: Placebo |
| Minnesota | MN-05 | Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine | 1363 | Allina Health, | Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke University | Drug: Hydroxychloroquine, Drug: Placebo oral tablet |
| Minnesota | MN-05 | Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS) | 500 | University of Minnesota Medical Center, | University of Minnesota | Diagnostic Test: Point-of-Care Ultrasonography (POCUS) |
| Minnesota | MN-05 | A Study of LY3127804 in Participants With COVID-19 | 95 | Alina Hospital Network, | Eli Lilly and Company | Drug: LY3127804, Drug: Placebo |
| Minnesota | MN-05 | A Study of Auxora in Patients With Severe COVID-19 Pneumonia | 400 | Methodist Hospital, | CalciMedica, Inc. | Drug: Auxora, Drug: Placebo |
| Minnesota | MN-05 | Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19 | 300 | Hennepin County Medical Center, | Humanigen, Inc. | Biological: Lenzilumab, Drug: Standard of Care |
| Minnesota | MN-05 | Convalescent Plasma in Outpatients With COVID-19 | 600 | HealthPartners Methodist Hospital, | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network | Biological: Convalescent Plasma, Biological: Saline |
| Minnesota | MN-05 | Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults | 1000 | University of Minnesota, | Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS) | Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo |
| Minnesota | MN-05 | Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia | 12 | University of Minnesota, | Masonic Cancer Center, University of Minnesota | Drug: FT516 |
| Minnesota | MN-05 | Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease | 800 | GSK Investigational Site, | GlaxoSmithKline | Biological: Otilimab, Biological: Placebo, Drug: Standard of care |
| Minnesota | MN-05 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Unity Hospital, Abbott-Northwestern Hospital, Hennepin County Medical Center, Health Partners Inc, University of Minnesota / Masonic Cancer Center, North Memorial Medical Health Center, Park Nicollet Clinic - Saint Louis Park, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Minnesota | MN-05 | COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111 | 40 | Methodist Hospital, | Veru Inc. | Drug: Veru-111 |
| Minnesota | MN-05 | The Professional Peer Resilience Initiative | 1200 | University of Minnesota, | University of Minnesota | Behavioral: MinnRAP Peer Support Program |
| Minnesota | MN-05 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | University of Minnesota Medical Center, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| Minnesota | MN-06 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Monticello Cancer Center, Fairview Northland Medical Center, Coborn Cancer Center at Saint Cloud Hospital, Ridgeview Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Minnesota | MN-02 | Losartan for Patients With COVID-19 Requiring Hospitalization | 200 | M Health Fairview Ridges Hospital, | University of Minnesota, Bill and Melinda Gates Foundation | Drug: Losartan, Other: Placebo |
| Minnesota | MN-02 | Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19 | 0 | Mayo Clinic Health System in Cannon Falls, Mayo Clinic Health System in Lake City, Mayo Clinic Health System in Red Wing, | Mayo Clinic | Biological: COVID-19 convalescent plasma |
| Minnesota | MN-02 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Fairview Ridges Hospital, Minnesota Oncology - Burnsville, Saint Francis Regional Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Minnesota | MN-07 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Sanford Joe Lueken Cancer Center, Rice Memorial Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Minnesota | MN-04 | A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19) | 242 | HealthPartners Cancer Care Center - Regions Hospital, | Millennium Pharmaceuticals, Inc., Takeda | Drug: TAK-981, Drug: Standard of care |
| Minnesota | MN-04 | Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection. | 16 | Regions Hospital, | Swedish Orphan Biovitrum | Biological: Emapalumab, Biological: Anakinra |
| Minnesota | MN-04 | Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS) | 500 | M Health Fairview Bethesda Hospital, | University of Minnesota | Diagnostic Test: Point-of-Care Ultrasonography (POCUS) |
| Minnesota | MN-04 | A Study of Auxora in Patients With Severe COVID-19 Pneumonia | 400 | Regions Hospital, | CalciMedica, Inc. | Drug: Auxora, Drug: Placebo |
| Minnesota | MN-04 | Convalescent Plasma in Outpatients With COVID-19 | 600 | Regions Hospital, | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network | Biological: Convalescent Plasma, Biological: Saline |
| Minnesota | MN-04 | Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease | 800 | GSK Investigational Site, | GlaxoSmithKline | Biological: Otilimab, Biological: Placebo, Drug: Standard of care |
| Minnesota | MN-04 | Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) | 500 | Healthpartners Cancer Care Center - Regions Hospital, | Incyte Corporation | Drug: Placebo, Drug: Ruxolitinib |
| Minnesota | MN-04 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Minnesota Oncology Hematology PA-Maplewood, Saint John's Hospital – Healtheast, Regions Hospital, United Hospital, Lakeview Hospital, Minnesota Oncology Hematology PA-Woodbury, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Minnesota | MN-04 | COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111 | 40 | Regions Hospital, | Veru Inc. | Drug: Veru-111 |
| Minnesota | MN-08 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Cambridge Medical Center, Fairview Lakes Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Minnesota | MN-01 | Steroid Dosing by bioMARker Guided Titration in Critically Ill Patients With Pneumonia | 90 | Mayo Clinic, | Mayo Clinic | Drug: Methylprednisolone, Other: Usual Care |
| Minnesota | MN-01 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Mayo Clinic, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Minnesota | MN-01 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Mayo Clinic, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Minnesota | MN-01 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| Minnesota | MN-01 | A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia | 450 | Mayo Clinic, | Hoffmann-La Roche | Drug: Tocilizumab (TCZ), Drug: Placebo |
| Minnesota | MN-01 | Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) | 6000 | Mayo Clinic - Rochester, | Montreal Heart Institute, National Heart, Lung, and Blood Institute (NHLBI), Bill and Melinda Gates Foundation, The Government of Quebec, DACIMA Software | Drug: Colchicine, Drug: Placebo oral tablet |
| Minnesota | MN-01 | Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry | 50000 | Mayo Clinic, | Mayo Clinic, Society of Critical Care Medicine, Boston University | Other: observational |
| Minnesota | MN-01 | Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine | 1363 | Mayo Clinic Hospital, | Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke University | Drug: Hydroxychloroquine, Drug: Placebo oral tablet |
| Minnesota | MN-01 | Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19 | 0 | Mayo Clinic Health System in Albert Lea, Mayo Clinic Health System in Austin, Mayo Clinic Health System in Mankato, Mayo Clinic Health System in Owatonna, Mayo Clinic Health System in Rochester, | Mayo Clinic | Biological: COVID-19 convalescent plasma |
| Minnesota | MN-01 | Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19 | 300 | Mayo Clinic, | Humanigen, Inc. | Biological: Lenzilumab, Drug: Standard of Care |
| Minnesota | MN-01 | SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19 | 0 | Mayo Clinic, | Alexion Pharmaceuticals | Biological: eculizumab |
| Minnesota | MN-01 | Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia | 270 | Mayo Clinic Health System, Mayo Clinic, | Alexion Pharmaceuticals | Biological: Ravulizumab, Other: Best Supportive Care |
| Minnesota | MN-01 | Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC) | 3000 | Mayo Clinic, | University of Manitoba, University Health Network, Toronto | Drug: Heparin |
| Minnesota | MN-01 | Risks of COVID19 in the Pregnant Population | 100 | Mayo Clinic, | Mayo Clinic | Other: Biospecimen collection |
| Minnesota | MN-01 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Mayo Clinic Health Systems-Mankato, New Ulm Medical Center, Mayo Clinic in Rochester, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Minnesota | MN-01 | Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19 | 44 | Mayo Clinic, | ViralClear Pharmaceuticals, Inc. | Drug: Merimepodib, Drug: Matching Placebo, Drug: Remdesivir |
| Minnesota | MN-03 | Losartan for Patients With COVID-19 Requiring Hospitalization | 200 | M Health Fairview Southdale Hospital, | University of Minnesota, Bill and Melinda Gates Foundation | Drug: Losartan, Other: Placebo |
| Minnesota | MN-03 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Mercy Hospital, Fairview Southdale Hospital, Fairview Clinics and Surgery Center Maple Grove, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Mississippi | MS-03 | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 5000 | University of Mississippi Medical Center, Mississippi Center for Advanced Medicine, | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: |
| Mississippi | MS-03 | Losartan for Patients With COVID-19 Requiring Hospitalization | 200 | University of Mississippi Medical Center, | University of Minnesota, Bill and Melinda Gates Foundation | Drug: Losartan, Other: Placebo |
| Mississippi | MS-03 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | University of Mississippi Medical Center, | Gilead Sciences | Drug: Remdesivir |
| Mississippi | MS-03 | Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease | 479 | University of Mississippi Medical Center, | Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI) | Drug: Hydroxychloroquine, Drug: Placebo |
| Mississippi | MS-03 | Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19) | 384 | University of Mississippi Medical Center, | I-Mab Biopharma Co. Ltd. | Drug: TJ003234, Drug: Placebo |
| Mississippi | MS-03 | Dapagliflozin in Respiratory Failure in Patients With COVID-19 | 900 | University of Mississippi Medical Center, | Saint Luke's Health System, AstraZeneca, George Clinical Pty Ltd | Drug: Dapagliflozin 10 MG, Drug: Placebo |
| Mississippi | MS-03 | Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults | 1000 | University of Mississippi Medical Center, | Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS) | Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo |
| Mississippi | MS-03 | Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19 | 600 | University of Mississippi Medical Center, | Vanderbilt University Medical Center, AbbVie | Drug: Lopinavir/Ritonavir 400 mg/100 mg, Other: Placebo |
| Mississippi | MS-03 | Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease | 800 | GSK Investigational Site, | GlaxoSmithKline | Biological: Otilimab, Biological: Placebo, Drug: Standard of care |
| Mississippi | MS-03 | Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19 | 140 | University of Mississippi Medical Center, | Pluristem Ltd. | Biological: PLX-PAD, Biological: Placebo |
| Mississippi | MS-03 | Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19) | 124 | University of Mississippi Medical Center, | CSL Behring | Biological: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody, Drug: Placebo |
| Mississippi | MS-01 | Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) | 6000 | North Mississippi Medical Clinics, | Montreal Heart Institute, National Heart, Lung, and Blood Institute (NHLBI), Bill and Melinda Gates Foundation, The Government of Quebec, DACIMA Software | Drug: Colchicine, Drug: Placebo oral tablet |
| Mississippi | MS-01 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Baptist Memorial Hospital and Cancer Center-Golden Triangle, Baptist Memorial Hospital and Cancer Center-Union County, Baptist Memorial Hospital and Cancer Center-Oxford, Baptist Memorial Hospital and Cancer Center-Desoto, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Mississippi | MS-01 | Registry of CytoSorb Therapy in COVID-19 ICU Patients | 500 | Baptist Memorial Hospital, | CytoSorbents, Inc | Device: CytoSorb 300 mL device |
| Mississippi | MS-04 | Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP) | 0 | Keesler Medical Center,, | U.S. Army Medical Research and Development Command | Biological: Anti-Sars-CoV-2 Convalescent Plasma |
| Mississippi | MS-04 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | MedPharmics LLC, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Mississippi | MS-04 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Gulfport Memorial Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Mississippi | MS-02 | INB03 for the Treatment of Pulmonary Complications From COVID-19 | 366 | Mississippi Baptist, | Inmune Bio, Inc. | Drug: INB03, Drug: Placebo |
| Mississippi | MS-02 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Baptist Cancer Center-Grenada, Mississippi Baptist Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Missouri | MO-06 | Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease | 682 | Heartland Regional Medical Center, | Algernon Pharmaceuticals, Novotech (Australia) | Drug: NP-120 (Ifenprodil) |
| Missouri | MO-06 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | University of Kansas Cancer Center – North, University of Kansas Cancer Center - Lee's Summit, Heartland Regional Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Missouri | MO-05 | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 5000 | Childrens Mercy Hospital, Childrens Mercy Hospital, | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: |
| Missouri | MO-05 | Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers | 120 | Center for Pharmaceutical Research, | Inovio Pharmaceuticals, Coalition for Epidemic Preparedness Innovations (CEPI) | Drug: INO-4800, Device: CELLECTRA® 2000 |
| Missouri | MO-05 | Dapagliflozin in Respiratory Failure in Patients With COVID-19 | 900 | Saint Luke's Mid America Heart Institute, | Saint Luke's Health System, AstraZeneca, George Clinical Pty Ltd | Drug: Dapagliflozin 10 MG, Drug: Placebo |
| Missouri | MO-05 | The COVID-19 ICU PRAYER Study | 1000 | Research Medical Center, | Kansas City Heart Rhythm Institute | Behavioral: prayer |
| Missouri | MO-05 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Truman Medical Centers, University of Kansas Cancer Center at North Kansas City Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Missouri | MO-05 | Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older | 600 | Heartland Research Associates, | ModernaTX, Inc., Biomedical Advanced Research and Development Authority | Biological: Biological: mRNA-1273: 50 mcg, Other: Placebo, Biological: Biological: mRNA-1273: 100 mcg |
| Missouri | MO-07 | Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) | 500 | Mercy Research, | Incyte Corporation | Drug: Placebo, Drug: Ruxolitinib |
| Missouri | MO-07 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Cox Cancer Center Branson, Freeman Health System, Mercy Hospital Joplin, Mercy Hospital Springfield, CoxHealth South Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Missouri | MO-04 | COVID-19 in Patients With HIV | 500 | University of Missouri-Columbia, | University of Missouri-Columbia | Other: No intervention |
| Missouri | MO-04 | Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine | 1363 | University of Missouri-Columbia, | Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke University | Drug: Hydroxychloroquine, Drug: Placebo oral tablet |
| Missouri | MO-04 | Long Term Functional Outcomes of COVID-19 Patients Treated by Rehabilitation Services viaTelehealth | 72 | Missouri Orthopedic Institute, | University of Missouri-Columbia | Behavioral: Therapy Intervention |
| Missouri | MO-04 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | University of Missouri, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Missouri | MO-04 | Dornase Alfa for ARDS in Patients With SARS-CoV-2 | 20 | University of Missouri Hospital and Clinics, | University of Missouri-Columbia | Drug: Dornase Alfa Inhalation Solution |
| Missouri | MO-04 | Study of Sargramostim in Patients With COVID-19 | 120 | University of Missouri Health Care, | Partner Therapeutics, Inc. | Drug: Sargramostim, Drug: Standard of care |
| Missouri | MO-08 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Saint Francis Medical Center, Southeast Cancer Center, Parkland Health Center – Farmington, Delbert Day Cancer Institute at PCRMC, Mercy Clinic-Rolla-Cancer and Hematology, Sainte Genevieve County Memorial Hospital, Missouri Baptist Sullivan Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Missouri | MO-01 | Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study | 250 | Washington University, | Ansun Biopharma, Inc. | Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL |
| Missouri | MO-01 | Adaptive COVID-19 Treatment Trial (ACTT) | 1062 | Saint Louis University, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir |
| Missouri | MO-01 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Washington University School of Medicine, | Gilead Sciences | Drug: Remdesivir |
| Missouri | MO-01 | CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION | 30000 | Washington University School of Medicine, | Washington University School of Medicine, COVID -19 Therapeutics Accelerator | Drug: MR or M-M-R II ® vaccine, Drug: Placebo |
| Missouri | MO-01 | Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection | 500 | Washington University School of Medicine, | Washington University School of Medicine | Drug: Hydroxychloroquine Sulfate, Drug: Azithromycin, Drug: Chloroquine Sulfate |
| Missouri | MO-01 | A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection | 152 | Washington University School of Medicine, | Washington University School of Medicine | Drug: Fluvoxamine, Drug: Placebo |
| Missouri | MO-01 | Dapagliflozin in Respiratory Failure in Patients With COVID-19 | 900 | Washington University School of Medicine, | Saint Luke's Health System, AstraZeneca, George Clinical Pty Ltd | Drug: Dapagliflozin 10 MG, Drug: Placebo |
| Missouri | MO-01 | Evaluation of Antibody Tests for COVID-19 | 461 | Washington University School of Medicine, | Washington University School of Medicine | Diagnostic Test: Diagnostic test |
| Missouri | MO-01 | Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia | 270 | Washington University School of Medicine, | Alexion Pharmaceuticals | Biological: Ravulizumab, Other: Best Supportive Care |
| Missouri | MO-01 | Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC) | 3000 | St. Louis University School of Medicine/St. Louis VA Medical Center, | University of Manitoba, University Health Network, Toronto | Drug: Heparin |
| Missouri | MO-01 | Duvelisib to Combat COVID-19 | 28 | Washington University School of Medicine, | Washington University School of Medicine, Verastem, Inc. | Drug: Duvelisib, Procedure: Peripheral blood draw, Drug: Placebo |
| Missouri | MO-01 | COVID-19: Human Epidemiology and Response to SARS-CoV-2 | 5605 | St. Louis Children's Hospital, | National Institute of Allergy and Infectious Diseases (NIAID), Rho Federal Systems Division, Inc. (Rho) | Procedure: Collection of Biological Samples, Procedure: Symptom and Exposure Surveys |
| Missouri | MO-01 | A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19 | 270 | Washington University School of Medicine, | Janssen Pharmaceutica N.V., Belgium | Drug: Sirukumab, Drug: Placebo, Other: Standard of Care (SOC) |
| Missouri | MO-01 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Cardinal Glennon Children's Medical Center, Saint Louis Cancer and Breast Institute-South City, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Missouri | MO-01 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | Saint Louis University, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| Missouri | MO-03 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Capital Region Southwest Campus, Mercy Hospital Washington, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Missouri | MO-02 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Clinical Research Professionals, Sundance Clinical Research LLC, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Missouri | MO-02 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Saint Louis Cancer and Breast Institute-Ballwin, Mercy Hospital South, Missouri Baptist Medical Center, Mercy Hospital Saint Louis, Missouri Baptist Outpatient Center-Sunset Hills, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Montana | MT-00 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Providence St Patrick Hospital, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Montana | MT-00 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Providence St Patrick Hospital, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Montana | MT-00 | Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection | 10 | Robert W. Alexander MD, | Black Tie Medical, Inc., Robert W. Alexander, MD | Procedure: Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF), Device: Centricyte 1000, Procedure: IV Deployment Of cSVF In Sterile Normal Saline IV Solution, Drug: Liberase Enzyme (Roche), Drug: Sterile Normal Saline for Intravenous Use |
| Montana | MT-00 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Bozeman Health Deaconess Hospital, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Montana | MT-00 | A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19 | 270 | Mercury Street Medical Group PLLC, | Janssen Pharmaceutica N.V., Belgium | Drug: Sirukumab, Drug: Placebo, Other: Standard of Care (SOC) |
| Montana | MT-00 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Community Hospital of Anaconda, Billings Clinic Cancer Center, Saint Vincent Healthcare, Saint Vincent Frontier Cancer Center, Bozeman Deaconess Hospital, Saint James Community Hospital and Cancer Treatment Center, Benefis Healthcare- Sletten Cancer Institute, Great Falls Clinic, Kalispell Regional Medical Center, Saint Patrick Hospital - Community Hospital, Community Medical Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Montana | MT-00 | Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) | 190 | Atea Study Site, | Atea Pharmaceuticals, Inc. | Drug: AT-527, Other: Placebo |
| Nebraska | NE-02 | Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study | 250 | University of Nebraska Medical Center, | Ansun Biopharma, Inc. | Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL |
| Nebraska | NE-02 | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 5000 | University of Nebraska Medical Center, | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: |
| Nebraska | NE-02 | Adaptive COVID-19 Treatment Trial (ACTT) | 1062 | University of Nebraska Medical Center, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir |
| Nebraska | NE-02 | Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine | 1363 | University of Nebraska Medical Center, | Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke University | Drug: Hydroxychloroquine, Drug: Placebo oral tablet |
| Nebraska | NE-02 | Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects | 120 | Blade Research Site, | Blade Therapeutics, Clinipace Worldwide | Drug: BLD-2660 |
| Nebraska | NE-02 | Awake Prone Position for Early Hypoxemia in COVID-19 | 560 | Creighton University, | Boston University | Other: Self-prone position recommendation, Other: Usual care |
| Nebraska | NE-02 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Quality Clinical Research Inc, Meridian Clinical Research LLC, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Nebraska | NE-02 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Nebraska Methodist Hospital, Nebraska Medicine-Village Pointe, Alegent Health Immanuel Medical Center, Alegent Health Bergan Mercy Medical Center, Alegent Health Lakeside Hospital, Creighton University Medical Center, University of Nebraska Medical Center, Midlands Community Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Nebraska | NE-02 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | University of Nebraska Medical Center, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| Nebraska | NE-02 | Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older | 600 | Meridian Clinical Research, | ModernaTX, Inc., Biomedical Advanced Research and Development Authority | Biological: Biological: mRNA-1273: 50 mcg, Other: Placebo, Biological: Biological: mRNA-1273: 100 mcg |
| Nebraska | NE-02 | A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19 | 24 | Quality Clinical Research Inc., | Eli Lilly and Company, AbCellera Biologics Inc. | Drug: LY3819253, Drug: Placebo |
| Nebraska | NE-01 | Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection | 4000 | Beacom Family Health Connection, | Romark Laboratories L.C. | Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex |
| Nebraska | NE-01 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Methodist Physicians Clinic, Meridian Clinical Research LLC, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Nebraska | NE-01 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Nebraska Medicine-Bellevue, Saint Elizabeth Regional Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Nebraska | NE-01 | Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older | 600 | Meridian Clinical Research LLC, | ModernaTX, Inc., Biomedical Advanced Research and Development Authority | Biological: Biological: mRNA-1273: 50 mcg, Other: Placebo, Biological: Biological: mRNA-1273: 100 mcg |
| Nebraska | NE-01 | A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia | 500 | Saint Elizabeth Regional Medical Center, | Hoffmann-La Roche, Gilead Sciences | Drug: Remdesivir, Drug: Tocilizumab, Drug: Placebo |
| Nebraska | NE-03 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | CHI Health Saint Francis, CHI Health Good Samaritan, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Nebraska | NE-03 | Study of Sargramostim in Patients With COVID-19 | 120 | Great Plains Health, | Partner Therapeutics, Inc. | Drug: Sargramostim, Drug: Standard of care |
| Nevada | NV-02 | A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia | 100 | Renown Institute for Heath & Vascular Health, | Hoffmann-La Roche | Drug: Tociliuzumab |
| Nevada | NV-02 | Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease | 800 | GSK Investigational Site, | GlaxoSmithKline | Biological: Otilimab, Biological: Placebo, Drug: Standard of care |
| Nevada | NV-02 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Carson Tahoe Regional Medical Center, Renown Regional Medical Center, Saint Mary's Regional Medical Center, Radiation Oncology Associates, Cancer Care Specialists - Reno, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Nevada | NV-03 | Tocilizumab for Patients With Cancer and COVID-19 Disease | 217 | Summerlin Hospital Medical Center, | National Cancer Institute (NCI) | Biological: Tocilizumab |
| Nevada | NV-03 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Cancer and Blood Specialists-Henderson, Comprehensive Cancer Centers of Nevada - Henderson, Comprehensive Cancer Centers of Nevada-Horizon Ridge, Las Vegas Cancer Center-Henderson, OptumCare Cancer Care at Seven Hills, 21st Century Oncology-Henderson, Comprehensive Cancer Centers of Nevada-Southeast Henderson, Las Vegas Urology-Green Valley, Las Vegas Urology-Pebble, Urology Specialists of Nevada - Green Valley, Las Vegas Urology - Pecos, HealthCare Partners Medical Group Oncology/Hematology-San Martin, Las Vegas Prostate Cancer Center, Las Vegas Urology - Sunset, Urology Specialists of Nevada - Northwest, Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Comprehensive Cancer Centers of Nevada - Town Center, Comprehensive Cancer Centers of Nevada-Summerlin, Summerlin Hospital Medical Center, 21st Century Oncology-Fort Apache, Comprehensive Cancer Centers of Nevada, Las Vegas Cancer Center-Medical Center, OptumCare Cancer Care at Fort Apache, Urology Specialists of Nevada - Southwest, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Nevada | NV-01 | CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment | 243 | University Medical Center of Southern Nevada, | OncoImmune, Inc. | Drug: CD24Fc, Drug: Placebo |
| Nevada | NV-01 | Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19) | 384 | University Medical Center of Southern Nevada, | I-Mab Biopharma Co. Ltd. | Drug: TJ003234, Drug: Placebo |
| Nevada | NV-01 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Wr-Crcn LLC, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Nevada | NV-01 | Tocilizumab for Patients With Cancer and COVID-19 Disease | 217 | University Medical Center of Southern Nevada, | National Cancer Institute (NCI) | Biological: Tocilizumab |
| Nevada | NV-01 | A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia | 379 | Optum Health Care, | Genentech, Inc. | Drug: Placebo, Drug: Tocilizumab |
| Nevada | NV-01 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Desert West Surgery, OptumCare Cancer Care at Oakey, University Medical Center of Southern Nevada, Hope Cancer Care of Nevada, Radiation Oncology Centers of Nevada Central, Urology Specialists of Nevada - Central, 21st Century Oncology, HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway, Sunrise Hospital and Medical Center, Radiation Oncology Centers of Nevada Southeast, HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills, Comprehensive Cancer Centers of Nevada - Central Valley, University Cancer Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Nevada | NV-01 | Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression | 208 | Octapharma Research Site, | Octapharma | Biological: Octagam 10%, Other: Placebo |
| Nevada | NV-04 | Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP) | 0 | Nellis Air Force Base, | U.S. Army Medical Research and Development Command | Biological: Anti-Sars-CoV-2 Convalescent Plasma |
| Nevada | NV-04 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | 21st Century Oncology-Vegas Tenaya, Ann M Wierman MD LTD, Comprehensive Cancer Centers of Nevada - Northwest, HealthCare Partners Medical Group Oncology/Hematology-Tenaya, Las Vegas Urology - Cathedral Rock, Las Vegas Urology - Smoke Ranch, OptumCare Cancer Care at MountainView, Hope Cancer Care of Nevada-Pahrump, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| New Hampshire | NH-02 | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 5000 | Dartmouth-Hitchcock Medical Center, | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: |
| New Hampshire | NH-02 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Darmouth-Hitchhock Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| New Hampshire | NH-02 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Darmouth-Hitchhock Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| New Hampshire | NH-02 | Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19 | 300 | Dartmouth-Hitchcock, | Humanigen, Inc. | Biological: Lenzilumab, Drug: Standard of Care |
| New Hampshire | NH-02 | MSCs in COVID-19 ARDS | 223 | Dartmouth-Hitchcock, | Icahn School of Medicine at Mount Sinai, Mesoblast, Inc., National Heart, Lung, and Blood Institute (NHLBI) | Biological: Remestemcel-L, Drug: Placebo |
| New Hampshire | NH-02 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Dartmouth Hitchcock Medical Center, Norris Cotton Cancer Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| New Hampshire | NH-01 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Wentworth-Douglass Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| New Jersey | NJ-10 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Robert Wood Johnson University Hospital Somerset, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| New Jersey | NJ-10 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Robert Wood Johnson University Hospital Somerset, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| New Jersey | NJ-10 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| New Jersey | NJ-10 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | St. Michael's Medical Center, University Hospital, | Gilead Sciences | Drug: Remdesivir |
| New Jersey | NJ-10 | Rutgers COVID-19 Cohort Study | 750 | Clinical Research Unit Rutgers New Jersey Medical School, Rutgers School of Dental Medicine, University Hospital, | Rutgers, The State University of New Jersey | Other: Non-Interventional |
| New Jersey | NJ-10 | Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19 | 160 | University Hospital, | Rutgers, The State University of New Jersey | Combination Product: Hydroxychloroquine Sulfate + Azithromycin, Drug: Hydroxychloroquine Sulfate |
| New Jersey | NJ-10 | Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection | 4000 | North Jersey Community Research Initiative, | Romark Laboratories L.C. | Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex |
| New Jersey | NJ-10 | Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID) | 432 | Novartis Investigative Site, | Novartis Pharmaceuticals, Incyte Corporation, Novartis | Drug: Ruxolitinib, Drug: Placebo |
| New Jersey | NJ-10 | Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) | 500 | Rutgers Njms Clinical Research Unit, | Incyte Corporation | Drug: Placebo, Drug: Ruxolitinib |
| New Jersey | NJ-10 | A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19 | 270 | St. Michael's Medical Center, | Janssen Pharmaceutica N.V., Belgium | Drug: Sirukumab, Drug: Placebo, Other: Standard of Care (SOC) |
| New Jersey | NJ-10 | Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants | 52 | Rutgers University Hospital, | BeiGene | Drug: Zanubrutinib, Drug: Supportive Care, Drug: Placebo |
| New Jersey | NJ-10 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Newark Beth Israel Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| New Jersey | NJ-10 | Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients | 308 | Beth Israel Newark, | Northwell Health | Drug: Enoxaparin, Drug: Prophylactic/Intermediate Dose Enoxaparin |
| New Jersey | NJ-10 | Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19 | 727 | New Jersey Medical School Clinical Research Center CRS, | HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials Network | Other: Sample collection |
| New Jersey | NJ-10 | A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia | 500 | St. Michael's Medical Center, | Hoffmann-La Roche, Gilead Sciences | Drug: Remdesivir, Drug: Tocilizumab, Drug: Placebo |
| New Jersey | NJ-10 | Aggrenox To Treat Acute Covid-19 | 132 | Rutgers New Jersey Medical School University Hospital, | Rutgers, The State University of New Jersey, Boehringer Ingelheim | Drug: Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care, Other: Standard of care |
| New Jersey | NJ-11 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site, Regeneron Study Site, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| New Jersey | NJ-11 | CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment | 243 | Atlantic Health System, | OncoImmune, Inc. | Drug: CD24Fc, Drug: Placebo |
| New Jersey | NJ-11 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Morristown Medical Center, | Gilead Sciences | Drug: Remdesivir |
| New Jersey | NJ-11 | Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19 | 160 | Saint Barnabas Medical Center, Morristown Medical Center, | Rutgers, The State University of New Jersey | Combination Product: Hydroxychloroquine Sulfate + Azithromycin, Drug: Hydroxychloroquine Sulfate |
| New Jersey | NJ-11 | Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19 | 86 | Atlantic Health System Hospital, | CytoDyn, Inc. | Drug: Placebos, Drug: Leronlimab (700mg) |
| New Jersey | NJ-11 | Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19) | 390 | Saint Barnabas Medical Center, Atlantic Health System Hospital, | CytoDyn, Inc. | Drug: Placebos, Drug: Leronlimab (700mg) |
| New Jersey | NJ-11 | Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19 | 300 | Saint Barnabas Medical Center, | Humanigen, Inc. | Biological: Lenzilumab, Drug: Standard of Care |
| New Jersey | NJ-11 | Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19 | 50 | Atlantic Health System, | Fujifilm Pharmaceuticals U.S.A., Inc. | Drug: Favipiravir + Standard of Care, Drug: Standard of Care |
| New Jersey | NJ-11 | A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia | 100 | St Joseph's Regional Medical Center, | Hoffmann-La Roche | Drug: Tociliuzumab |
| New Jersey | NJ-11 | Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 | 86 | Atlantic Health System, | Celularity Incorporated, IDRI, Lung Biotechnology PBC, California Institute for Regenerative Medicine (CIRM) | Biological: CYNK-001 |
| New Jersey | NJ-11 | Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants | 52 | Morristown Medical Center, Atlantic Health System, | BeiGene | Drug: Zanubrutinib, Drug: Supportive Care, Drug: Placebo |
| New Jersey | NJ-11 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Saint Barnabas Medical Center, Morristown Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| New Jersey | NJ-11 | Blood Collection Study From COVID-19 Convalescents Previously Hospitalized to Identify Immunogenic Viral Epitopes | 80 | Atlantic Health System, | TScan Therapeutics, Inc. | |
| New Jersey | NJ-11 | PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer | 364 | Atlantic Melanoma Center, Chilton Medical Center, Overlook Medical Center, | CTI BioPharma | Drug: Pacritinib, Drug: Placebo |
| New Jersey | NJ-11 | Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19 | 44 | Atlantic Health System / Morristown Medical Center, | ViralClear Pharmaceuticals, Inc. | Drug: Merimepodib, Drug: Matching Placebo, Drug: Remdesivir |
| New Jersey | NJ-12 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Capital Health, | Gilead Sciences | Drug: Remdesivir |
| New Jersey | NJ-03 | Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC) | 3000 | Deborah Heart and Lung Center, | University of Manitoba, University Health Network, Toronto | Drug: Heparin |
| New Jersey | NJ-03 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Community Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| New Jersey | NJ-04 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| New Jersey | NJ-04 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | CentraState Medical Center, Robert Wood Johnson University Hospital, Jersey Shore University Medical Center, Ocean Medical Center, | Gilead Sciences | Drug: Remdesivir |
| New Jersey | NJ-04 | A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy | 132 | Memorial Sloan Kettering Monmouth, | Memorial Sloan Kettering Cancer Center | Drug: Hydroxychloroquine, Other: Placebo, Radiation: Radiation therapy |
| New Jersey | NJ-01 | Losartan for Patients With COVID-19 Requiring Hospitalization | 200 | Cooper University Hospital, | University of Minnesota, Bill and Melinda Gates Foundation | Drug: Losartan, Other: Placebo |
| New Jersey | NJ-01 | CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment | 243 | Cooper University Hospital, | OncoImmune, Inc. | Drug: CD24Fc, Drug: Placebo |
| New Jersey | NJ-01 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Cooper University Hospital, Virtua Health Voorhees Campus, | Gilead Sciences | Drug: Remdesivir |
| New Jersey | NJ-01 | Convalescent Plasma in Outpatients With COVID-19 | 600 | Cooper University Hospital, | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network | Biological: Convalescent Plasma, Biological: Saline |
| New Jersey | NJ-01 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Cooper Hospital University Medical Center, Kennedy Health Systems-Cancer Center, Inspira Medical Center Woodbury, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| New Jersey | NJ-01 | Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19 | 140 | Cooper Research Institute, | Pluristem Ltd. | Biological: PLX-PAD, Biological: Placebo |
| New Jersey | NJ-05 | Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients | 100 | Institute for Pediatric Cancer and Blood Disorders, | Novartis Pharmaceuticals, Novartis | Drug: Crizanlizumab |
| New Jersey | NJ-05 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Hackensack University Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| New Jersey | NJ-05 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Hackensack University Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| New Jersey | NJ-05 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site, Regeneron Study Site, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| New Jersey | NJ-05 | A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia | 450 | Hackensack University Medical Center, | Hoffmann-La Roche | Drug: Tocilizumab (TCZ), Drug: Placebo |
| New Jersey | NJ-05 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | The Valley Hospital, Holy Name Medical Center, | Gilead Sciences | Drug: Remdesivir |
| New Jersey | NJ-05 | Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection. | 16 | Valley Hospital, | Swedish Orphan Biovitrum | Biological: Emapalumab, Biological: Anakinra |
| New Jersey | NJ-05 | Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects | 120 | Blade Research Site, | Blade Therapeutics, Clinipace Worldwide | Drug: BLD-2660 |
| New Jersey | NJ-05 | Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection | 52 | Hackensack University Medical Center, | Hackensack Meridian Health | Biological: Convalescent Plasma |
| New Jersey | NJ-05 | Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19) | 390 | Holy Name Medical Center, | CytoDyn, Inc. | Drug: Placebos, Drug: Leronlimab (700mg) |
| New Jersey | NJ-05 | A Prospective "Universal" Observational Database for COVID-19 | 5000 | Hackensack Meridian Health - John Theurer Cancer Center, | Hackensack Meridian Health | |
| New Jersey | NJ-05 | Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 | 86 | Hackensack University Medical Center, | Celularity Incorporated, IDRI, Lung Biotechnology PBC, California Institute for Regenerative Medicine (CIRM) | Biological: CYNK-001 |
| New Jersey | NJ-05 | Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) | 500 | Hackensack University Medical Center, Holy Name Medical Center, | Incyte Corporation | Drug: Placebo, Drug: Ruxolitinib |
| New Jersey | NJ-05 | Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. | 62 | Research Site, | AstraZeneca, Acerta Pharma B.V. | Drug: Acalabrutinib |
| New Jersey | NJ-05 | A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy | 132 | Memorial Sloan Kettering Bergen, | Memorial Sloan Kettering Cancer Center | Drug: Hydroxychloroquine, Other: Placebo, Radiation: Radiation therapy |
| New Jersey | NJ-05 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Newton Medical Center, Holy Name Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| New Jersey | NJ-05 | Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19 | 140 | Holy Name Medical Center, | Pluristem Ltd. | Biological: PLX-PAD, Biological: Placebo |
| New Jersey | NJ-05 | Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19) | 124 | Holy Name Hospital, | CSL Behring | Biological: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody, Drug: Placebo |
| New Jersey | NJ-06 | Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients | 100 | UMDNJ, | Novartis Pharmaceuticals, Novartis | Drug: Crizanlizumab |
| New Jersey | NJ-06 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Robert Wood Johnson University Hospital Somerset, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| New Jersey | NJ-06 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Robert Wood Johnson University Hospital Somerset, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| New Jersey | NJ-06 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| New Jersey | NJ-06 | A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia | 450 | Robert Wood Johnson University Hospital/Rutgers, | Hoffmann-La Roche | Drug: Tocilizumab (TCZ), Drug: Placebo |
| New Jersey | NJ-06 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Hackensack Meridian Health - JFK Medical, Monmouth Medical Center, Saint Peter's University Hospital, Bayshore Medical Center, | Gilead Sciences | Drug: Remdesivir |
| New Jersey | NJ-06 | Rutgers COVID-19 Cohort Study | 750 | Robert Wood Johnson Medical School, Robert Wood Johnson University Hospital, Environmental and Occupational Health Sciences Institute, RUCDR Infinite Biologics, | Rutgers, The State University of New Jersey | Other: Non-Interventional |
| New Jersey | NJ-06 | Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19 | 160 | Monmouth Medical Center, Robert Wood Johnson University Hospital, Rutgers Cancer Institute of New Jersey, | Rutgers, The State University of New Jersey | Combination Product: Hydroxychloroquine Sulfate + Azithromycin, Drug: Hydroxychloroquine Sulfate |
| New Jersey | NJ-06 | Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers | 44 | Hackensack Meridian Health, | Hackensack Meridian Health | Drug: Hydroxychloroquine Sulfate (HCQ) |
| New Jersey | NJ-06 | SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19 | 0 | Robert Wood Johnson University Hospital, | Alexion Pharmaceuticals | Biological: eculizumab |
| New Jersey | NJ-06 | Asymptomatic COVID-19 Trial | 0 | Robert Wood Johnson University Hospital, | Rutgers, The State University of New Jersey | Drug: Hydroxychloroquine sulfate &Azithromycin, Drug: Placebo |
| New Jersey | NJ-06 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Monmouth Medical Center, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson University Hospital Somerset, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| New Jersey | NJ-06 | COVID-19 Wellness Survey | 593 | Rutgers - The State University of New Jersey, | Rutgers, The State University of New Jersey | Other: Survey |
| New Jersey | NJ-06 | A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19 | 66 | Rutgers University - Robert Wood Johnson Medical School, | Apellis Pharmaceuticals, Inc. | Drug: APL-9, Other: Vehicle Control |
| New Jersey | NJ-02 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | South Jersey Infectious Disease, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| New Jersey | NJ-02 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Inspira Medical Center Mullica Hill, Inspira Medical Center Vineland, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| New Jersey | NJ-02 | COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111 | 40 | Inspira Medical Center, | Veru Inc. | Drug: Veru-111 |
| New Jersey | NJ-02 | Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19) | 124 | Inspira Health Center Vineland, | CSL Behring | Biological: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody, Drug: Placebo |
| New Jersey | NJ-07 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Robert Wood Johnson University Hospital Somerset, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| New Jersey | NJ-07 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Robert Wood Johnson University Hospital Somerset, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| New Jersey | NJ-07 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Hunterdon Medical Center, Overlook Medical Center, | Gilead Sciences | Drug: Remdesivir |
| New Jersey | NJ-07 | Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19 | 160 | Overlook Hospital, | Rutgers, The State University of New Jersey | Combination Product: Hydroxychloroquine Sulfate + Azithromycin, Drug: Hydroxychloroquine Sulfate |
| New Jersey | NJ-07 | Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 | 86 | Atlantic Health System, | Celularity Incorporated, IDRI, Lung Biotechnology PBC, California Institute for Regenerative Medicine (CIRM) | Biological: CYNK-001 |
| New Jersey | NJ-07 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Amici Clinical Research, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| New Jersey | NJ-07 | A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy | 132 | Memorial Sloan Kettering Basking Ridge, | Memorial Sloan Kettering Cancer Center | Drug: Hydroxychloroquine, Other: Placebo, Radiation: Radiation therapy |
| New Jersey | NJ-07 | Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants | 52 | Overlook Hospital, | BeiGene | Drug: Zanubrutinib, Drug: Supportive Care, Drug: Placebo |
| New Jersey | NJ-07 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Hunterdon Medical Center, Overlook Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| New Jersey | NJ-07 | Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19 | 44 | Atlantic Health System / Overlook Medical Center, | ViralClear Pharmaceuticals, Inc. | Drug: Merimepodib, Drug: Matching Placebo, Drug: Remdesivir |
| New Jersey | NJ-09 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | St. Joseph's University Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| New Jersey | NJ-09 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | St. Joseph's University Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| New Jersey | NJ-09 | The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2 | 200 | Englewood Health, | Pulmotect, Inc. | Drug: PUL-042 Inhalation Solution, Drug: Placebo |
| New Jersey | NJ-09 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Englewood Health, | Gilead Sciences | Drug: Remdesivir |
| New Jersey | NJ-09 | A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia | 379 | St. Joseph's Regional Medical Center, | Genentech, Inc. | Drug: Placebo, Drug: Tocilizumab |
| New Jersey | NJ-09 | A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia | 410 | St. Joseph's Regional Medical Center, | Genentech, Inc. | Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo |
| New Jersey | NJ-08 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | CarePoint Health Bayonne Medical Center, Clara Maass Medical Center, Trinitas Regional Medical Center, Jersey City Medical Center, Christ Hospital- Carepoint Health, | Gilead Sciences | Drug: Remdesivir |
| New Jersey | NJ-08 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Trinitas Hospital and Comprehensive Cancer Center - Williamson Street Campus, Rutgers New Jersey Medical School, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| New Mexico | NM-03 | Convalescent Plasma to Stem Coronavirus (CSSC-001) | 500 | Center for American Indian Health, Center for American Indian Health, | Johns Hopkins University | Biological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma |
| New Mexico | NM-03 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Johns Hopkins Center for American Indian Health, Johns Hopkins Center for American Indian Health, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| New Mexico | NM-03 | A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia | 379 | San Juan Oncology Associates, | Genentech, Inc. | Drug: Placebo, Drug: Tocilizumab |
| New Mexico | NM-03 | Convalescent Plasma to Limit SARS-CoV-2 Associated Complications | 1344 | Center for American Indian Health, Center for American Indian Health, | Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID) | Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor |
| New Mexico | NM-03 | A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia | 410 | San Juan Oncology Associates, | Genentech, Inc. | Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo |
| New Mexico | NM-01 | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 5000 | University of New Mexico Health Science Center, | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: |
| New Mexico | NM-01 | Convalescent Plasma to Stem Coronavirus (CSSC-001) | 500 | University of New Mexico Health Sciences Center, | Johns Hopkins University | Biological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma |
| New Mexico | NM-01 | Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19) | 384 | UNM Hospitals, | I-Mab Biopharma Co. Ltd. | Drug: TJ003234, Drug: Placebo |
| New Mexico | NM-01 | Plasma Adsorption in Patients With Confirmed COVID-19 | 2000 | UNM Health Science Center, | Marker Therapeutics AG, Terumo BCT | Device: Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol) |
| New Mexico | NM-01 | Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults | 1000 | University of New Mexico Health Sciences Center, | Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS) | Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo |
| New Mexico | NM-01 | Convalescent Plasma to Limit SARS-CoV-2 Associated Complications | 1344 | University of New Mexico Health Sciences Center, | Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID) | Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor |
| New Mexico | NM-01 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | University of New Mexico Cancer Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| New Mexico | NM-01 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | University of New Mexico Clinical Center, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| New Mexico | NM-01 | Effects of the COVID-19 Health Emergency on Biopsychosocial Health | 500 | University of New Mexico Department of Pediatrics, | University of New Mexico | Other: WHOQOL-BREF survey |
| New York | NY-10 | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | 1500 | Massive Bio Inc, | Massive Bio, Inc. | Other: Clinical Trial Matching |
| New York | NY-10 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Icahn School of Medicine at Mount Sinai, Icahn School of Medicine at Mount Sinai, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| New York | NY-10 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Icahn School of Medicine at Mount Sinai, Icahn School of Medicine at Mount Sinai, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| New York | NY-10 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site, Regeneron Study Site 1, Regeneron Study Site 2, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| New York | NY-10 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Maimonides Medical Center, New York-Presbyterian Lower Manhattan Hospital, | Gilead Sciences | Drug: Remdesivir |
| New York | NY-10 | CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1) | 1200 | New York-Presbyterian Lower Manhattan Hospital, | Hamilton Health Sciences Corporation, Canadian Blood Services, Héma-Québec, University of Toronto, Université de Montréal, Weill Cornell Medicine/New York-Presbyterian, New York Blood Centre, McMaster University | Biological: Convalescent plasma |
| New York | NY-10 | A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE) | 227 | Mount Sinai West, | Kinevant Sciences GmbH, Roivant Sciences, Inc. | Drug: Gimsilumab, Drug: Placebo |
| New York | NY-10 | Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia | 451 | Novartis Investigative Site, | Novartis Pharmaceuticals, Novartis | Drug: Canakinumab, Drug: Placebo |
| New York | NY-10 | COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19 | 70 | Maimonides Medical Center, | Maimonides Medical Center | Drug: Colchicine, Drug: Usual Care |
| New York | NY-10 | Study of Efficacy and Safety of MAS825 in Patients With COVID-19 | 140 | Novartis Investigative Site, | Novartis Pharmaceuticals, Novartis | Drug: MAS825, Drug: Matching placebo |
| New York | NY-10 | Myeloproliferative Neoplasms (MPN) and COVID-19 | 80 | Mount Sinai West, | Fondazione per la Ricerca Ospedale Maggiore, European Leukemia Net | |
| New York | NY-10 | Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19 | 140 | Maimonides Medical Center, | Pluristem Ltd. | Biological: PLX-PAD, Biological: Placebo |
| New York | NY-11 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | New York Harbor VA Medical Center, NYC Health + Hospitals/Coney Island, Staten Island University Hospital, | Gilead Sciences | Drug: Remdesivir |
| New York | NY-11 | A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia | 410 | Staten Island University Hospital, | Genentech, Inc. | Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo |
| New York | NY-11 | Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization | 198 | Brooklyn Campus of the VA, | VA Office of Research and Development | Drug: Degarelix, Other: Saline |
| New York | NY-11 | Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients | 308 | Staten Island University Hospital, | Northwell Health | Drug: Enoxaparin, Drug: Prophylactic/Intermediate Dose Enoxaparin |
| New York | NY-11 | Study of Sargramostim in Patients With COVID-19 | 120 | Richmond University Medical Center, | Partner Therapeutics, Inc. | Drug: Sargramostim, Drug: Standard of care |
| New York | NY-12 | Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study | 250 | Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, | Ansun Biopharma, Inc. | Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL |
| New York | NY-12 | A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy | 90 | Memorial Sloan Kettering Cancer Center, | Memorial Sloan Kettering Cancer Center | Drug: Anakinra |
| New York | NY-12 | Adaptive COVID-19 Treatment Trial (ACTT) | 1062 | New York University School of Medicine, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir |
| New York | NY-12 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Icahn School of Medicine at Mount Sinai, Weill Cornell Medical College/NYU Presbyterian Hospital, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| New York | NY-12 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Icahn School of Medicine at Mount Sinai, New York Presbyterian Hospital, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| New York | NY-12 | Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure | 165 | NYU Langone Medical Center, | NeuroRx, Inc., Lavin Consulting, LLC | Drug: Aviptadil by intravenous infusion + standard of care, Drug: Normal Saline Infusion + standard of care |
| New York | NY-12 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site, Regeneron Study Site, Regeneron Study Site, Regeneron Study Site, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| New York | NY-12 | Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) | 6000 | New York University School of Medicine, | Montreal Heart Institute, National Heart, Lung, and Blood Institute (NHLBI), Bill and Melinda Gates Foundation, The Government of Quebec, DACIMA Software | Drug: Colchicine, Drug: Placebo oral tablet |
| New York | NY-12 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Mount Sinai Queens, NYU Langone Health, Hospital for Special Surgery, Memorial Sloan-Kettering Cancer Center, | Gilead Sciences | Drug: Remdesivir |
| New York | NY-12 | ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection | 300 | Lenox Hill Hospital Northwell Health, | Vanda Pharmaceuticals | Drug: Tradipitant, Drug: Placebo |
| New York | NY-12 | Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP) | 829 | NYU Langone Medical Center, | University of Washington, Bill and Melinda Gates Foundation | Drug: Hydroxychloroquine Sulfate, Drug: Ascorbic Acid |
| New York | NY-12 | Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine | 1363 | Hospital for Special Surgery, Weill Cornell Medicine, | Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke University | Drug: Hydroxychloroquine, Drug: Placebo oral tablet |
| New York | NY-12 | A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection | 90 | NYU Langone Health, | NYU Langone Health | Drug: Clazakizumab 25 mg, Drug: Clazakizumab 12.5 mg, Other: Placebo |
| New York | NY-12 | Gargling and Nasal Rinses to Reduce Oro- and Nasopharyngeal Viral Load in Patients With COVID-19 | 48 | NYU Langone Health, | NYU Langone Health | Drug: Saline oral/nasal rinse, Drug: 0.5% Povidone/Iodine oral/nasal rinse, Drug: 0.12% Chlorhexidine oral/nasal rinse |
| New York | NY-12 | CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1) | 1200 | Weill Cornell Medical Center, | Hamilton Health Sciences Corporation, Canadian Blood Services, Héma-Québec, University of Toronto, Université de Montréal, Weill Cornell Medicine/New York-Presbyterian, New York Blood Centre, McMaster University | Biological: Convalescent plasma |
| New York | NY-12 | Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection | 202 | Weill Cornell Medical Center, | Karyopharm Therapeutics Inc | Drug: Selinexor, Other: Placebo |
| New York | NY-12 | A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE) | 227 | Mount Sinai Beth Israel, | Kinevant Sciences GmbH, Roivant Sciences, Inc. | Drug: Gimsilumab, Drug: Placebo |
| New York | NY-12 | HEalth Care Worker pROphylaxis Against COVID-19: The HERO Trial | 374 | New York Center for Travel and Tropical Medicine, | GeoSentinel Foundation | Drug: Hydroxychloroquine Pre-Exposure Prophylaxis, Drug: Placebo oral tablet |
| New York | NY-12 | COVID-19 PrEP HCW HCQ Study | 130 | NYU Langone Health, | NYU Langone Health | Drug: Hydroxychloroquine (HCQ) |
| New York | NY-12 | A Randomized Trial of Anticoagulation Strategies in COVID-19 | 77 | NYU Langone Health, | NYU Langone Health | Drug: Enoxaparin Higher Dose, Drug: Lower-dose prophylactic anticoagulation |
| New York | NY-12 | Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection | 4000 | New York Center for Travel and Tropical Medicine, | Romark Laboratories L.C. | Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex |
| New York | NY-12 | CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients | 300 | NYU Langone Health, | NYU Langone Health, National Center for Advancing Translational Science (NCATS), Albert Einstein College of Medicine, Yale University, The University of Texas Health Science Center, Houston, The University of Texas Health Science Center at Tyler, University of Miami | Biological: Convalescent Plasma, Other: Saline solution |
| New York | NY-12 | Cardiovascular Effects of COVID-19 | 500 | NYU Langone Health, | NYU Langone Health | Drug: AT-001 |
| New York | NY-12 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | NYU Langone Medical Center, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| New York | NY-12 | Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia | 270 | NYU Langone Health Center, | Alexion Pharmaceuticals | Biological: Ravulizumab, Other: Best Supportive Care |
| New York | NY-12 | Treating COVID-19 With Hydroxychloroquine (TEACH) | 626 | NYU Langone Health, | NYU Langone Health, State University of New York - Downstate Medical Center | Drug: Hydroxychloroquine (HCQ), Other: Pacebo: Calcium citrate |
| New York | NY-12 | Multi-site Adaptive Trials for COVID-19 | 233 | Lenox Hill Hospital, | Northwell Health | Drug: SOC + Intravenous Famotidine, Drug: SOC + Placebo |
| New York | NY-12 | MSCs in COVID-19 ARDS | 223 | NYU Langone Health, Northwell Health, | Icahn School of Medicine at Mount Sinai, Mesoblast, Inc., National Heart, Lung, and Blood Institute (NHLBI) | Biological: Remestemcel-L, Drug: Placebo |
| New York | NY-12 | A Study of N-acetylcysteine in Patients With COVID-19 Infection | 84 | Memorial Sloan Kettering Cancer Center, | Memorial Sloan Kettering Cancer Center | Drug: N-acetylcysteine, Other: Peripheral Blood |
| New York | NY-12 | Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection | 9 | Memorial Sloan Kettering Cancer Center, | Memorial Sloan Kettering Cancer Center | Drug: Tocilizumab |
| New York | NY-12 | A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19 | 0 | Memorial Sloan Kettering Cancer Center, | Memorial Sloan Kettering Cancer Center | Drug: Hydroxychloroquine, Other: Placebo |
| New York | NY-12 | Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. | 62 | Research Site, | AstraZeneca, Acerta Pharma B.V. | Drug: Acalabrutinib |
| New York | NY-12 | A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy | 132 | Memorial Sloan Kettering Cancer Center, | Memorial Sloan Kettering Cancer Center | Drug: Hydroxychloroquine, Other: Placebo, Radiation: Radiation therapy |
| New York | NY-12 | Myeloproliferative Neoplasms (MPN) and COVID-19 | 80 | New York-Presbyterian/Weill Cornell Medical Center, New York-Presbyterian/Weill Cornell Medical Center, | Fondazione per la Ricerca Ospedale Maggiore, European Leukemia Net | |
| New York | NY-12 | Meditation and Kundalini Yoga for Heightened Anxiety Related to COVID-19 | 360 | ProofPilot Online App, | Research Foundation for Mental Hygiene, Inc. | Behavioral: Anxiety Reduction Training, Behavioral: Kundalini Yoga and Anxiety Reduction Training, Behavioral: Meditation and Anxiety Reduction Training |
| New York | NY-12 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Memorial Sloan Kettering Cancer Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| New York | NY-12 | HSS Covid-19 Antibody Serology Among Surgeons & Anesthesiologists | 300 | Hospital for Special Surgery, | Hospital for Special Surgery, New York | Diagnostic Test: SARS-CoV2 serum antibody testing |
| New York | NY-12 | Registry of CytoSorb Therapy in COVID-19 ICU Patients | 500 | New York University Medical Center, | CytoSorbents, Inc | Device: CytoSorb 300 mL device |
| New York | NY-12 | At-Home COVID-19 Antibody Test Usability Assessment & Behavior Change Study | 600 | ProofPilot Online App, | ProofPilot, Radish Health, Sanesco | Device: Premier Biotech COVID-19 IgG/IgM Rapid test Cassette |
| New York | NY-12 | Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization | 198 | Manhattan Campus of the VA, | VA Office of Research and Development | Drug: Degarelix, Other: Saline |
| New York | NY-12 | Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients | 308 | Lenox Hill Hospital, | Northwell Health | Drug: Enoxaparin, Drug: Prophylactic/Intermediate Dose Enoxaparin |
| New York | NY-12 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | New York University School of Medicine, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| New York | NY-12 | Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19 | 727 | New York Blood Center CRS, | HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials Network | Other: Sample collection |
| New York | NY-12 | PH94B in the Treatment of Adjustment Disorder With Anxiety | 30 | Medical Research Network, | VistaGen Therapeutics, Inc. | Drug: PH94B |
| New York | NY-12 | Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial) | 186 | Weill Cornell Medicine, | Weill Medical College of Cornell University | Drug: Enoxaparin sodium, Drug: Unfractionated heparin, Drug: Fondapariniux, Drug: Argatroban |
| New York | NY-12 | A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19 | 24 | Alexandria Center for Life, | Eli Lilly and Company, AbCellera Biologics Inc. | Drug: LY3819253, Drug: Placebo |
| New York | NY-13 | Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients | 100 | Children's Hospital at Montefiore, | Novartis Pharmaceuticals, Novartis | Drug: Crizanlizumab |
| New York | NY-13 | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 5000 | Kravis Children's Hospital at Mt. Sinai, | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: |
| New York | NY-13 | Adaptive COVID-19 Treatment Trial (ACTT) | 1062 | Montefiore Medical Center, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir |
| New York | NY-13 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | James J Peters Veterans Administration Medical Center, Icahn School of Medicine at Mount Sinai, Columbia University Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| New York | NY-13 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | James J Peters Veterans Administration Medical Center, Icahn School of Medicine at Mount Sinai, Columbia University Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| New York | NY-13 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site, Regeneron Study Site, Regeneron Study Site, Regeneron Study Site, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| New York | NY-13 | Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19) | 1600 | Columbia University Irving Medical Center, | Columbia University | Drug: Hydroxychloroquine, Drug: Placebo oral tablet |
| New York | NY-13 | A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia | 450 | James J Peters Veterans Administration Medical Center, | Hoffmann-La Roche | Drug: Tocilizumab (TCZ), Drug: Placebo |
| New York | NY-13 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Montefiore Medical Center, NYC Health + Hospitals/Metropolitan, Columbia University Irving Medical Center, New York City Hospitals - Harlem, | Gilead Sciences | Drug: Remdesivir |
| New York | NY-13 | Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease | 479 | Montefiore Medical Center, | Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI) | Drug: Hydroxychloroquine, Drug: Placebo |
| New York | NY-13 | Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine | 1363 | Columbia University Irving Medical Center, | Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke University | Drug: Hydroxychloroquine, Drug: Placebo oral tablet |
| New York | NY-13 | Acquiring Convalescent Specimens for COVID-19 Antibodies | 50 | Columbia University Irving Medical Center, | Columbia University | Procedure: Blood draw |
| New York | NY-13 | Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19 | 86 | Montefiore Medical Center, | CytoDyn, Inc. | Drug: Placebos, Drug: Leronlimab (700mg) |
| New York | NY-13 | Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19 | 138 | Columbia University Irving Medical Center, | Matthew Dallos, Bristol-Myers Squibb, Columbia University | Drug: BMS-986253 |
| New York | NY-13 | Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19) | 390 | Montefiore Medical Center, | CytoDyn, Inc. | Drug: Placebos, Drug: Leronlimab (700mg) |
| New York | NY-13 | Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection | 202 | Columbia University, | Karyopharm Therapeutics Inc | Drug: Selinexor, Other: Placebo |
| New York | NY-13 | Saved From COVID-19 | 350 | Columbia University Irving Medical Center, | Columbia University | Drug: Chloroquine, Drug: Placebo oral tablet |
| New York | NY-13 | Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore | 0 | Montefiore Medical Center, | Montefiore Medical Center | Drug: Hydroxychloroquine |
| New York | NY-13 | A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE) | 227 | Icahn School of Medicine at Mount Sinai, | Kinevant Sciences GmbH, Roivant Sciences, Inc. | Drug: Gimsilumab, Drug: Placebo |
| New York | NY-13 | The Covid-19 HEalth caRe wOrkErS (HEROES) Study | 2000 | Columbia University, | University of Chile | Other: Exposure to the SARS-CoV-2 and its consequences |
| New York | NY-13 | SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19 | 0 | Icahn School of Medicine at Mount Sinai, | Alexion Pharmaceuticals | Biological: eculizumab |
| New York | NY-13 | Cardiac Arrhythmias In Patients With Coronavirus Disease (COVID-19) | 10000 | Icahn School of Medicine at Mount Sinai, | Vivek Reddy, Icahn School of Medicine at Mount Sinai | |
| New York | NY-13 | Plasma Therapy of COVID-19 in Severely Ill Patients | 219 | Columbia University Irving Medical Center, | Max R. O'Donnell, New York Blood Center, Amazon.com, Inc., Columbia University | Biological: Convalescent Plasma (anti-SARS-CoV-2 plasma), Biological: Non-convalescent Plasma (control plasma) |
| New York | NY-13 | CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients | 300 | Montefiore Medical Center, | NYU Langone Health, National Center for Advancing Translational Science (NCATS), Albert Einstein College of Medicine, Yale University, The University of Texas Health Science Center, Houston, The University of Texas Health Science Center at Tyler, University of Miami | Biological: Convalescent Plasma, Other: Saline solution |
| New York | NY-13 | Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection | 0 | Mount Sinai Medical Center, | Mesoblast International Sàrl, Mesoblast, Ltd. | Drug: Remestemcel-L |
| New York | NY-13 | Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19 | 100 | Columbia University Medical Center, | Columbia University | Drug: Enoxaparin Prophylactic Dose, Drug: Heparin Infusion, Drug: Heparin SC, Drug: Enoxaparin/Lovenox Intermediate Dose |
| New York | NY-13 | ARMOR Study: COVID-19 Seroprevalence Among Healthcare Workers | 1000 | Columbia University Irving Medical Center, | Columbia University | Other: COVID-19 Serology, Behavioral: Health Care Worker Survey |
| New York | NY-13 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Icahn School of Medicine at Mount Sinai, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| New York | NY-13 | Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia | 270 | Icahn School of Medicine at Mount Sinai, | Alexion Pharmaceuticals | Biological: Ravulizumab, Other: Best Supportive Care |
| New York | NY-13 | MSCs in COVID-19 ARDS | 223 | Mount Sinai Medical Center, | Icahn School of Medicine at Mount Sinai, Mesoblast, Inc., National Heart, Lung, and Blood Institute (NHLBI) | Biological: Remestemcel-L, Drug: Placebo |
| New York | NY-13 | A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia | 379 | Harlem Hospital, | Genentech, Inc. | Drug: Placebo, Drug: Tocilizumab |
| New York | NY-13 | Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC) | 3000 | Montefiore-Einstein Center for Heart and Vascular Care, | University of Manitoba, University Health Network, Toronto | Drug: Heparin |
| New York | NY-13 | COVID-19: Human Epidemiology and Response to SARS-CoV-2 | 5605 | Columbia University Medical Center, | National Institute of Allergy and Infectious Diseases (NIAID), Rho Federal Systems Division, Inc. (Rho) | Procedure: Collection of Biological Samples, Procedure: Symptom and Exposure Surveys |
| New York | NY-13 | Immunophenotyping Assessment in a COVID-19 Cohort | 2000 | Icahn School of Medicine at Mount Sinai, | National Institute of Allergy and Infectious Diseases (NIAID), Benaroya Research Institute, Boston Children's Hospital | Procedure: Biological sample collection, Procedure: Data Collection: Clinical Care Assessments |
| New York | NY-13 | SUNLIGHT Study: Online Support Groups for MS to Address COVID-19 | 32 | Columbia University Medical Center, | Columbia University | Behavioral: Online support Group |
| New York | NY-13 | Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. | 62 | Research Site, Research Site, | AstraZeneca, Acerta Pharma B.V. | Drug: Acalabrutinib |
| New York | NY-13 | Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection | 30 | Columbia University Medical Center, | Columbia University, NYU Langone Health, CSL Behring | Drug: Clazakizumab, Other: Placebo |
| New York | NY-13 | Meditation and Kundalini Yoga for Heightened Anxiety Related to COVID-19 | 360 | Columbia University Department of Psychiatry, | Research Foundation for Mental Hygiene, Inc. | Behavioral: Anxiety Reduction Training, Behavioral: Kundalini Yoga and Anxiety Reduction Training, Behavioral: Meditation and Anxiety Reduction Training |
| New York | NY-13 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Montefiore Medical Center - Moses Campus, James J Peters VA Medical Center, NYP/Columbia University Medical Center/Herbert Irving Cancer Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| New York | NY-13 | Interferon Lambda Therapy for COVID-19 | 66 | Icahn School of Medicine at Mount Sinai, | Icahn School of Medicine at Mount Sinai, Eiger BioPharmaceuticals | Drug: Peginterferon Lambda-1A |
| New York | NY-13 | Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19 | 140 | Montefiore Medical Center, | Pluristem Ltd. | Biological: PLX-PAD, Biological: Placebo |
| New York | NY-13 | Early CPAP in COVID-19 Confirmed or Suspected Patients | 200 | Icahn School of Medicine at Mount Sinai, | Icahn School of Medicine at Mount Sinai, Itamar Medical LTD, Community Surgical Supply of Toms River, Inc, Philips Healthcare | Device: Continuous Positive Airway Pressure |
| New York | NY-13 | Convalescent Plasma for COVID-19 Close Contacts | 200 | Columbia University Irving Medical Center, | Columbia University | Biological: Convalescent Plasma (anti-SARS-CoV-2 plasma), Biological: Control (albumin 5%) |
| New York | NY-13 | Incidence of COVID-19 Test Conversion in Post-surgical Patients | 500 | NorthShore University Hospital, | Northwell Health | Diagnostic Test: COVID-19 PCR and Serology |
| New York | NY-13 | Myocardial Injury and Major Adverse Outcomes in Patients With COVID-19 | 5000 | Mount Sinai Medical Center, | Icahn School of Medicine at Mount Sinai | |
| New York | NY-13 | TXA127 for the Treatment of Severe COVID-19 | 100 | Columbia University Irving Medical Center, | Columbia University | Drug: TXA127, Drug: Placebo |
| New York | NY-13 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | Montefiore Medical Center, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| New York | NY-13 | A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19 | 66 | Columbia University, | Apellis Pharmaceuticals, Inc. | Drug: APL-9, Other: Vehicle Control |
| New York | NY-13 | Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19 | 727 | Harlem Prevention Center CRS, Columbia P&S CRS, | HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials Network | Other: Sample collection |
| New York | NY-13 | PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer | 364 | Mount Sinai Medical Center, | CTI BioPharma | Drug: Pacritinib, Drug: Placebo |
| New York | NY-13 | Awake Proning in COVID-19 Patients With Hypoxemic Respiratory Failure | 29 | Columbia University Medical Center, | Columbia University | Other: Awake proning |
| New York | NY-14 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Jacobi Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| New York | NY-14 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Jacobi Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| New York | NY-14 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site 1, Regeneron Study Site 2, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| New York | NY-14 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Montefiore Medical Center, | Gilead Sciences | Drug: Remdesivir |
| New York | NY-14 | Audio Data Collection for Identification and Classification of Coughing | 1000 | Virtual Facility, | HealthMode Inc. | |
| New York | NY-14 | Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease | 479 | Montefiore Medical Center-Weiler, | Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI) | Drug: Hydroxychloroquine, Drug: Placebo |
| New York | NY-14 | Dapagliflozin in Respiratory Failure in Patients With COVID-19 | 900 | Jacobi Medical Center, | Saint Luke's Health System, AstraZeneca, George Clinical Pty Ltd | Drug: Dapagliflozin 10 MG, Drug: Placebo |
| New York | NY-14 | Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID) | 432 | Novartis Investigative Site, | Novartis Pharmaceuticals, Incyte Corporation, Novartis | Drug: Ruxolitinib, Drug: Placebo |
| New York | NY-14 | A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia | 410 | Jacobi Medical Center, | Genentech, Inc. | Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo |
| New York | NY-15 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| New York | NY-15 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Lincoln Medical Center, St Barnabus Hospital, | Gilead Sciences | Drug: Remdesivir |
| New York | NY-15 | Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection | 4000 | RH Medical Urgent Care Professional PLLC, | Romark Laboratories L.C. | Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex |
| New York | NY-15 | A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia | 379 | St. Barnabas Hospital, | Genentech, Inc. | Drug: Placebo, Drug: Tocilizumab |
| New York | NY-15 | A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia | 410 | Lincoln Medical Mental Health Center, | Genentech, Inc. | Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo |
| New York | NY-15 | Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19 | 727 | Bronx Prevention Research Center CRS, | HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials Network | Other: Sample collection |
| New York | NY-17 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| New York | NY-17 | Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19 | 86 | White Plains Hospital, | CytoDyn, Inc. | Drug: Placebos, Drug: Leronlimab (700mg) |
| New York | NY-17 | Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia | 270 | Westchester Medical Center, | Alexion Pharmaceuticals | Biological: Ravulizumab, Other: Best Supportive Care |
| New York | NY-17 | Multi-site Adaptive Trials for COVID-19 | 233 | Northern Westchester Hospital, | Northwell Health | Drug: SOC + Intravenous Famotidine, Drug: SOC + Placebo |
| New York | NY-17 | A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy | 132 | Memorial Sloan Kettering Westchester, | Memorial Sloan Kettering Cancer Center | Drug: Hydroxychloroquine, Other: Placebo, Radiation: Radiation therapy |
| New York | NY-17 | The Use of Oxygen Hoods as Compared to Conventional High-flow Oxygen Delivery Systems, the Effects on Oxygenation, Mechanical Ventilation and Mortality Rates in Hypoxic Patients With COVID-19. A Prospective Controlled Cohort Study. | 136 | Phelps Hospital, | Northwell Health | Device: Oxygen Hood |
| New York | NY-18 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Vassar Brothers Medical Center, | Gilead Sciences | Drug: Remdesivir |
| New York | NY-18 | Convalescent Plasma to Stem Coronavirus (CSSC-001) | 500 | Vassar Brothers Medical Center, | Johns Hopkins University | Biological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma |
| New York | NY-18 | A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia | 100 | Vassar Brothers Medical Center, | Hoffmann-La Roche | Drug: Tociliuzumab |
| New York | NY-18 | Convalescent Plasma to Limit SARS-CoV-2 Associated Complications | 1344 | Vassar Brothers Medical Center, | Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID) | Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor |
| New York | NY-19 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Danbury Hospital, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| New York | NY-19 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Danbury Hospital, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| New York | NY-19 | COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 | 4000 | Bassett Healthcare, | Bassett Healthcare, Reid Health, Goshen Health System | Drug: lopinavir/ritonavir, Drug: Losartan, Drug: Placebos |
| New York | NY-20 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | St. Peter's Hospital, Ellis Hospital, Samaritan Hospital, | Gilead Sciences | Drug: Remdesivir |
| New York | NY-20 | Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. | 62 | Research Site, | AstraZeneca, Acerta Pharma B.V. | Drug: Acalabrutinib |
| New York | NY-20 | A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia | 410 | Albany Medical Center, | Genentech, Inc. | Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo |
| New York | NY-21 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Glens Falls Hospital, | Gilead Sciences | Drug: Remdesivir |
| New York | NY-21 | A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia | 379 | Canton-Potsdam Hospital, | Genentech, Inc. | Drug: Placebo, Drug: Tocilizumab |
| New York | NY-22 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Meridian Clinical Research LLC, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| New York | NY-23 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Meridian Clinical Research LLC, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| New York | NY-24 | Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP) | 829 | SUNY - Upstate Medical University, | University of Washington, Bill and Melinda Gates Foundation | Drug: Hydroxychloroquine Sulfate, Drug: Ascorbic Acid |
| New York | NY-24 | A Study of LY3127804 in Participants With COVID-19 | 95 | State University of New York Hospital, | Eli Lilly and Company | Drug: LY3127804, Drug: Placebo |
| New York | NY-24 | Treatment for COVID-19 in High-Risk Adult Outpatients | 300 | SUNY - Upstate Medical University, | University of Washington, Bill and Melinda Gates Foundation | Drug: Ascorbic Acid, Drug: Hydroxychloroquine Sulfate, Drug: Azithromycin, Drug: Folic Acid, Drug: Lopinavir 200 MG / Ritonavir 50 MG [Kaletra] |
| New York | NY-24 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | SUNY Upstate Medical University, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| New York | NY-24 | A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19 | 270 | SUNY Upstate Medical University, | Janssen Pharmaceutica N.V., Belgium | Drug: Sirukumab, Drug: Placebo, Other: Standard of Care (SOC) |
| New York | NY-24 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Hematology Oncology Associates of Central New York-Auburn, Hematology Oncology Associates of Central New York-East Syracuse, Hematology Oncology Associates of Central New York-Onondaga Hill, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| New York | NY-25 | Adaptive COVID-19 Treatment Trial (ACTT) | 1062 | University of Rochester Medical Center, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir |
| New York | NY-25 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Rochester General Hospital, | Gilead Sciences | Drug: Remdesivir |
| New York | NY-25 | Convalescent Plasma to Stem Coronavirus (CSSC-001) | 500 | University of Rochester, | Johns Hopkins University | Biological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma |
| New York | NY-25 | Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults | 1000 | Rochester General Hospital, | Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS) | Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo |
| New York | NY-25 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Rochester Regional Health, Rochester Regional Health, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| New York | NY-25 | Convalescent Plasma to Limit SARS-CoV-2 Associated Complications | 1344 | University of Rochester, | Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID) | Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor |
| New York | NY-25 | Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) | 500 | University of Rochester Medical Center, | Incyte Corporation | Drug: Placebo, Drug: Ruxolitinib |
| New York | NY-25 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Rochester General Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| New York | NY-25 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | University of Rochester Medical Center, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| New York | NY-25 | Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19 | 727 | University of Rochester Vaccines to Prevent HIV Infection CRS, | HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials Network | Other: Sample collection |
| New York | NY-26 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| New York | NY-26 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Kaleida Health System, | Gilead Sciences | Drug: Remdesivir |
| New York | NY-26 | Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults | 1000 | Buffalo General Medical Center, | Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS) | Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo |
| New York | NY-26 | Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease | 800 | GSK Investigational Site, | GlaxoSmithKline | Biological: Otilimab, Biological: Placebo, Drug: Standard of care |
| New York | NY-26 | A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients | 400 | University of Buffalo, | Covis Pharma S.à.r.l. | Drug: Ciclesonide, Drug: Placebo |
| New York | NY-26 | Rintatolimod and IFN Alpha-2b for the Treatment of Mild or Moderate COVID-19 Infection in Cancer Patients | 44 | Roswell Park Cancer Institute, | Roswell Park Cancer Institute, National Cancer Institute (NCI), AIM ImmunoTech Inc. | Biological: Recombinant Interferon Alfa-2b, Drug: Rintatolimod |
| New York | NY-26 | Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. | 62 | Research Site, | AstraZeneca, Acerta Pharma B.V. | Drug: Acalabrutinib |
| New York | NY-26 | A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19 | 66 | University of Buffalo, | Apellis Pharmaceuticals, Inc. | Drug: APL-9, Other: Vehicle Control |
| New York | NY-26 | Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19) | 124 | Sisters of Charity Hospital/ St. Joseph's Campus, | CSL Behring | Biological: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody, Drug: Placebo |
| New York | NY-07 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Woodhull Medical Center, NYU Langone Hospital – Brooklyn, | Gilead Sciences | Drug: Remdesivir |
| New York | NY-07 | A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia | 500 | Wyckoff Heights Medical Center, | Hoffmann-La Roche, Gilead Sciences | Drug: Remdesivir, Drug: Tocilizumab, Drug: Placebo |
| New York | NY-03 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | North Shore University Hospital, North Shore University Hospital, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| New York | NY-03 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | North Shore University Hospital, North Shore University Hospital, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| New York | NY-03 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site 1, Regeneron Study Site 2, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| New York | NY-03 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | St. Francis Hospital, | Gilead Sciences | Drug: Remdesivir |
| New York | NY-03 | COVID-19 Endoscopy Survey | 163 | Kings County Hospital Center, | Al-Azhar University | Other: Practice details |
| New York | NY-03 | Dapagliflozin in Respiratory Failure in Patients With COVID-19 | 900 | St. Francis Hospital, | Saint Luke's Health System, AstraZeneca, George Clinical Pty Ltd | Drug: Dapagliflozin 10 MG, Drug: Placebo |
| New York | NY-03 | PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine | 850 | ProHealth New York, | UnitedHealth Group, ProHealth Care Associates, University of Pennsylvania Perelman School of Medicine | Drug: Group A HCQ, Drug: Group B Control |
| New York | NY-03 | Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection | 60 | Long Island Jewish Medical Center, | Denver Health and Hospital Authority, Genentech, Inc., University of Colorado, Denver, National Jewish Health, Beth Israel Deaconess Medical Center, Long Island Jewish Medical Center, Scripps Health, St. Mary's Medical Center, University of Miami, Ben Taub Hospital, Methodist Dallas Medical Center | Drug: Alteplase 50 MG [Activase] |
| New York | NY-03 | Multi-site Adaptive Trials for COVID-19 | 233 | North Shore University Hospital, Long Island Jewish Medical Center, | Northwell Health | Drug: SOC + Intravenous Famotidine, Drug: SOC + Placebo |
| New York | NY-03 | Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting | 18 | St. Francis Hospital, | St. Francis Hospital, New York | Drug: Hydroxychloroquine, Drug: Azithromycin, Drug: Zinc Sulfate, Drug: Doxycycline |
| New York | NY-03 | A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy | 132 | Memorial Sloan Kettering Commack, | Memorial Sloan Kettering Cancer Center | Drug: Hydroxychloroquine, Other: Placebo, Radiation: Radiation therapy |
| New York | NY-03 | Advanced Endoscopy During COVID-19 | 670 | Kings County Hospital Center, | Al-Azhar University, Helwan University, National Liver Institute, Egypt | Other: Endoscopic management according to standard of care |
| New York | NY-03 | Dornase Alfa Administered to Patients With COVID-19 (DACOVID) | 5 | Feinstein Insitute for Medical Research at Northwell Health, | Feinstein Institute for Medical Research, Cold Spring Harbor Laboratory, Northwell Health | Drug: Dornase Alfa |
| New York | NY-03 | Famotidine Outpatient COVID-19 Treatment Study | 10 | Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory, | Northwell Health, Cold Spring Harbor Laboratory | Drug: Famotidine |
| New York | NY-03 | Incidence of COVID-19 Test Conversion in Post-surgical Patients | 500 | Long Island Jewish Medical Center, | Northwell Health | Diagnostic Test: COVID-19 PCR and Serology |
| New York | NY-03 | Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients | 308 | Huntington Hospital, Long Island Jewish Medical Center, | Northwell Health | Drug: Enoxaparin, Drug: Prophylactic/Intermediate Dose Enoxaparin |
| New York | NY-09 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Kingsbrook Jewish Medical Center, University Hospital Brooklyn (SUNY), Kings County Hospital Center, Brookdale University Hospital, NewYork-Presbyterian Brooklyn Hospital, Mount Sinai Brooklyn, | Gilead Sciences | Drug: Remdesivir |
| New York | NY-09 | Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19) | 390 | New York Community Hospital of Brooklyn, | CytoDyn, Inc. | Drug: Placebos, Drug: Leronlimab (700mg) |
| New York | NY-09 | Convalescent Plasma in Outpatients With COVID-19 | 600 | SUNY Downstate Medical Center, | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network | Biological: Convalescent Plasma, Biological: Saline |
| New York | NY-09 | Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection | 4000 | Integrative Clinical Trials LLC, | Romark Laboratories L.C. | Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex |
| New York | NY-09 | A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia | 100 | SUNY Downstate Medical Center., | Hoffmann-La Roche | Drug: Tociliuzumab |
| New York | NY-09 | Treating COVID-19 With Hydroxychloroquine (TEACH) | 626 | State University of New York (SUNY) Downstate Medical Center, | NYU Langone Health, State University of New York - Downstate Medical Center | Drug: Hydroxychloroquine (HCQ), Other: Pacebo: Calcium citrate |
| New York | NY-09 | A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia | 379 | SUNY Downstate Medical Center., | Genentech, Inc. | Drug: Placebo, Drug: Tocilizumab |
| New York | NY-02 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Good Samaritan Hospital Medical Center, Southside Hospital, | Gilead Sciences | Drug: Remdesivir |
| New York | NY-02 | Multi-site Adaptive Trials for COVID-19 | 233 | Southside Hospital, | Northwell Health | Drug: SOC + Intravenous Famotidine, Drug: SOC + Placebo |
| New York | NY-02 | Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients | 308 | Southside Hospital, | Northwell Health | Drug: Enoxaparin, Drug: Prophylactic/Intermediate Dose Enoxaparin |
| New York | NY-06 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| New York | NY-06 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | New York Presbyterian- Queens, NYC Health + Hospitals/Queens, | Gilead Sciences | Drug: Remdesivir |
| New York | NY-06 | Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection. | 16 | NewYork-Presbyterian Queens, | Swedish Orphan Biovitrum | Biological: Emapalumab, Biological: Anakinra |
| New York | NY-06 | A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia | 379 | NYC Health + Hospitals/Elmhurst, Flushing Hospital, NYC Health + Hospitals/Queens, | Genentech, Inc. | Drug: Placebo, Drug: Tocilizumab |
| New York | NY-08 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Brooklyn Hospital Center, Interfaith Medical Center, | Gilead Sciences | Drug: Remdesivir |
| New York | NY-08 | CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1) | 1200 | Brooklyn Hospital Center, | Hamilton Health Sciences Corporation, Canadian Blood Services, Héma-Québec, University of Toronto, Université de Montréal, Weill Cornell Medicine/New York-Presbyterian, New York Blood Centre, McMaster University | Biological: Convalescent plasma |
| New York | NY-04 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Nassau University Medical Center, Mount Sinai South Nassau, | Gilead Sciences | Drug: Remdesivir |
| New York | NY-04 | Hyperbaric Oxygen for COVID-19 Patients | 20 | NYU Winthrop Hospital, | NYU Langone Health | Device: hyperbaric oxygen therapy (HBOT) |
| New York | NY-04 | A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy | 132 | Memorial Sloan Kettering Nassau, | Memorial Sloan Kettering Cancer Center | Drug: Hydroxychloroquine, Other: Placebo, Radiation: Radiation therapy |
| New York | NY-04 | Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19 | 140 | Mercy Medical Center, | Pluristem Ltd. | Biological: PLX-PAD, Biological: Placebo |
| New York | NY-01 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| New York | NY-01 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Stony Brook University Hospital, | Gilead Sciences | Drug: Remdesivir |
| New York | NY-01 | Convalescent Plasma vs. Standard Plasma for COVID-19 | 500 | Stony Brook University Hospital, | Stony Brook University | Biological: Convalescent Plasma, Biological: Standard Donor Plasma |
| New York | NY-01 | Evaluating the Use of Polymyxin B Cartridge Hemoperfusion for Patients With Septic Shock and COVID 19 | 0 | Stony Brook University Hospital, | Spectral Diagnostics (US) Inc. | Device: Toraymyxin PMX-20R (PMX Cartridge) |
| New York | NY-01 | Estrogen Patch for COVID-19 Symptoms | 110 | Stony Brook University Hospital, | Sharon Nachman, Stony Brook University | Drug: Estradiol patch |
| New York | NY-01 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Stony Brook University Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| New York | NY-05 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Jamaica Hospital Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| New York | NY-05 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Jamaica Hospital Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| New York | NY-05 | A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE) | 227 | Jamaica Hospital Medical Center, | Kinevant Sciences GmbH, Roivant Sciences, Inc. | Drug: Gimsilumab, Drug: Placebo |
| New York | NY-05 | A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia | 100 | Jamaica Hospital Medical Center, | Hoffmann-La Roche | Drug: Tociliuzumab |
| New York | NY-05 | A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia | 379 | Jamaica Hospital Medical Center, | Genentech, Inc. | Drug: Placebo, Drug: Tocilizumab |
| North Carolina | NC-10 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | PMG Research of Hickory LLC, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| North Carolina | NC-10 | Study of Efficacy and Safety of MAS825 in Patients With COVID-19 | 140 | Novartis Investigative Site, | Novartis Pharmaceuticals, Novartis | Drug: MAS825, Drug: Matching placebo |
| North Carolina | NC-10 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | CaroMont Regional Medical Center, Margaret R. Pardee Memorial Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| North Carolina | NC-12 | Isolation and Culture of Immune Cells and Circulating Tumor Cells From Peripheral Blood and Leukapheresis Products | 1000 | Carolina BioOncology Institute, | BioCytics, Inc. | |
| North Carolina | NC-12 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Atrium Health-Carolinas Medical Center, | Gilead Sciences | Drug: Remdesivir |
| North Carolina | NC-12 | Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection | 202 | Levine Cancer Institute-Atrium Health University City, | Karyopharm Therapeutics Inc | Drug: Selinexor, Other: Placebo |
| North Carolina | NC-12 | Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19 | 300 | Atrium Health, | Humanigen, Inc. | Biological: Lenzilumab, Drug: Standard of Care |
| North Carolina | NC-12 | Atrium COVID-19 Syndromic and Serologic Surveillance | 450000 | Atrium Health, | Michael Runyon, MD, Atrium Health | Other: daily syndromic surveillance, Diagnostic Test: monthly serologic IgM/G test |
| North Carolina | NC-12 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | PMG Research of Charlotte LLC, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| North Carolina | NC-12 | A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia | 379 | Novant Health Presbyterian Medical Center, | Genentech, Inc. | Drug: Placebo, Drug: Tocilizumab |
| North Carolina | NC-12 | Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease | 800 | GSK Investigational Site, | GlaxoSmithKline | Biological: Otilimab, Biological: Placebo, Drug: Standard of care |
| North Carolina | NC-12 | An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic | 0 | Levine Cancer Institute, | Genentech, Inc. | Drug: Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration (PH FDC SC) |
| North Carolina | NC-12 | Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) | 190 | Atea Study Site, | Atea Pharmaceuticals, Inc. | Drug: AT-527, Other: Placebo |
| North Carolina | NC-12 | A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia | 500 | Novant Health Clinical Research, | Hoffmann-La Roche, Gilead Sciences | Drug: Remdesivir, Drug: Tocilizumab, Drug: Placebo |
| North Carolina | NC-13 | Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19 | 20 | Greensboro CRS, | National Institute of Allergy and Infectious Diseases (NIAID), Teva Pharmaceuticals Industries LTD | Drug: Hydroxychloroquine (HCQ), Drug: Azithromycin (Azithro), Drug: Placebo for Hydroxychloroquine, Drug: Placebo for Azithromycin |
| North Carolina | NC-13 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | PharmQuest, PMG Research of Salisbury LLC, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| North Carolina | NC-13 | A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia | 379 | Novant Health Rowan Medical Center, | Genentech, Inc. | Drug: Placebo, Drug: Tocilizumab |
| North Carolina | NC-13 | A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia | 500 | Cone Health Medical Group, | Hoffmann-La Roche, Gilead Sciences | Drug: Remdesivir, Drug: Tocilizumab, Drug: Placebo |
| North Carolina | NC-02 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | PMG Research of Raleigh LLC, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| North Carolina | NC-02 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Vidant Oncology-Richlands, Nash General Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| North Carolina | NC-05 | Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study | 250 | Novant Health, | Ansun Biopharma, Inc. | Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL |
| North Carolina | NC-05 | Mindfulness During COVID-19 | 200 | Wake Forest University Health Sciences, | Wake Forest University Health Sciences | Behavioral: Mindfulness session(s) |
| North Carolina | NC-05 | Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease | 479 | Wake Forest Baptist Medical Center, | Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI) | Drug: Hydroxychloroquine, Drug: Placebo |
| North Carolina | NC-05 | Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine | 1363 | Wake Forest Baptist Health System, | Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke University | Drug: Hydroxychloroquine, Drug: Placebo oral tablet |
| North Carolina | NC-05 | COVID-19 Community Research Partnership | 150000 | Wake Forest University Health Sciences, | Wake Forest University Health Sciences | |
| North Carolina | NC-05 | Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19 | 86 | Novant Health, | CytoDyn, Inc. | Drug: Placebos, Drug: Leronlimab (700mg) |
| North Carolina | NC-05 | Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19) | 390 | Novant Health, | CytoDyn, Inc. | Drug: Placebos, Drug: Leronlimab (700mg) |
| North Carolina | NC-05 | Convalescent Plasma in Outpatients With COVID-19 | 600 | Wake Forest Baptist Medical Center, | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network | Biological: Convalescent Plasma, Biological: Saline |
| North Carolina | NC-05 | A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia | 100 | Wake Forest University Health Sciences, | Hoffmann-La Roche | Drug: Tociliuzumab |
| North Carolina | NC-05 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | PMG Research of Winston-Salem LLC, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| North Carolina | NC-05 | A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia | 379 | Novant Health Foryth Medical Center, | Genentech, Inc. | Drug: Placebo, Drug: Tocilizumab |
| North Carolina | NC-05 | A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19 | 204 | Wake Forest Baptist Health, | Ridgeback Biotherapeutics, LP | Drug: EIDD-2801, Drug: Placebo (PBO) |
| North Carolina | NC-05 | The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID) | 80 | Wake Forest Baptist Health, | Ridgeback Biotherapeutics, LP | Drug: EIDD-2801, Drug: Placebo (PB0) |
| North Carolina | NC-07 | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 5000 | New Hanover Regional Medical Center, | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: |
| North Carolina | NC-07 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | PMG Research of Wilmington LLC, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| North Carolina | NC-07 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Vidant Oncology-Kenansville, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| North Carolina | NC-07 | Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older | 600 | Trial Management Associates, | ModernaTX, Inc., Biomedical Advanced Research and Development Authority | Biological: Biological: mRNA-1273: 50 mcg, Other: Placebo, Biological: Biological: mRNA-1273: 100 mcg |
| North Carolina | NC-01 | Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients | 100 | Duke University Medical Center Oncology, East Carolina University SC, | Novartis Pharmaceuticals, Novartis | Drug: Crizanlizumab |
| North Carolina | NC-01 | Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study | 250 | Duke University, | Ansun Biopharma, Inc. | Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL |
| North Carolina | NC-01 | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 5000 | Duke University Health System, East Carolina University, | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: |
| North Carolina | NC-01 | Adaptive COVID-19 Treatment Trial (ACTT) | 1062 | Duke Human Vaccine Institute, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir |
| North Carolina | NC-01 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Duke University Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| North Carolina | NC-01 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Duke University Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| North Carolina | NC-01 | A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia | 450 | Duke University Medical Center, | Hoffmann-La Roche | Drug: Tocilizumab (TCZ), Drug: Placebo |
| North Carolina | NC-01 | COVID-19 Pandemic Response Network | 200000 | Duke University Medical Center, | Duke University | |
| North Carolina | NC-01 | Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine | 1363 | Duke University Medical Center, | Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke University | Drug: Hydroxychloroquine, Drug: Placebo oral tablet |
| North Carolina | NC-01 | Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects | 120 | Blade Research Site, Blade Research Site, | Blade Therapeutics, Clinipace Worldwide | Drug: BLD-2660 |
| North Carolina | NC-01 | Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection | 11 | Duke Regional Hospital, Duke University Hospital, Durham VA Medical Center, | Duke University | Other: Standard of care, Drug: Hydroxychloroquine, Drug: Azithromycin |
| North Carolina | NC-01 | CAPTION AI to Minimize Risk of COVID Exposure | 0 | Duke Health, Duke University Medical Center, | Duke University, Caption Health, Inc. | Device: Caption AI |
| North Carolina | NC-01 | Healthcare Worker Exposure Response and Outcomes (HERO) Registry Study, COVID-19 | 100000 | Duke Clinical Research Institute, | Duke University, Patient-Centered Outcomes Research Institute | |
| North Carolina | NC-01 | A Study of LY3127804 in Participants With COVID-19 | 95 | East Carolina University, | Eli Lilly and Company | Drug: LY3127804, Drug: Placebo |
| North Carolina | NC-01 | COPING With COVID-19( CWC-19) | 0 | Duke University, | Duke University | Behavioral: Crisis management coaching |
| North Carolina | NC-01 | Longitudinal Energy Expenditure and Metabolic Effects in Patients With COVID-19 (LEEP-COVID) | 120 | Duke University Medial Center, | Duke University | Device: Q-NRG Metobolic Cart Device, Device: MuscleSound Ultrasound, Device: Multifrequency Bioimpedance Spectroscopy |
| North Carolina | NC-01 | Convalescent Plasma in Outpatients With COVID-19 | 600 | Duke University Hospital, | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network | Biological: Convalescent Plasma, Biological: Saline |
| North Carolina | NC-01 | Assessing the System for High-Intensity Evaluation During Radiotherapy During Changes in Response to COVID-19 | 1000 | Duke Cancer Center, | Duke University | Other: Telehealth |
| North Carolina | NC-01 | Duke COVID-19 Shared Data and Specimen Repository | 100000 | Duke University Medical Center, | Duke University | |
| North Carolina | NC-01 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Duke University Medicine Circle, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| North Carolina | NC-01 | MSCs in COVID-19 ARDS | 223 | Duke University Medical Center, | Icahn School of Medicine at Mount Sinai, Mesoblast, Inc., National Heart, Lung, and Blood Institute (NHLBI) | Biological: Remestemcel-L, Drug: Placebo |
| North Carolina | NC-01 | Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) | 500 | Duke University Medical Center, East Carolina University, | Incyte Corporation | Drug: Placebo, Drug: Ruxolitinib |
| North Carolina | NC-01 | A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19 | 270 | East Carolina University, | Janssen Pharmaceutica N.V., Belgium | Drug: Sirukumab, Drug: Placebo, Other: Standard of Care (SOC) |
| North Carolina | NC-01 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Durham VA Medical Center, Duke University Medical Center, East Carolina University, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| North Carolina | NC-01 | Effect of Lactobacillus on the Microbiome of Household Contacts Exposed to COVID-19 | 1000 | Duke University, | Duke University | Dietary Supplement: Lactobaciltus rhamnosus GG, Dietary Supplement: Lactobaciltus rhamnosus GG Placebo |
| North Carolina | NC-01 | hCT-MSCs for COVID19 ARDS | 30 | Duke Hospital, | Joanne Kurtzberg, MD, The Marcus Foundation, Duke University | Biological: human cord tissue mesenchymal stromal cells |
| North Carolina | NC-01 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | Duke Human Vaccine Institute, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| North Carolina | NC-01 | A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19 | 204 | Duke, | Ridgeback Biotherapeutics, LP | Drug: EIDD-2801, Drug: Placebo (PBO) |
| North Carolina | NC-01 | A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19 | 24 | Unified Research Enterprise Brody School of Medicine at ECU, | Eli Lilly and Company, AbCellera Biologics Inc. | Drug: LY3819253, Drug: Placebo |
| North Carolina | NC-08 | Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects | 120 | Blade Research Site, | Blade Therapeutics, Clinipace Worldwide | Drug: BLD-2660 |
| North Carolina | NC-08 | A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia | 379 | Cape Fear Valley Medical Center, | Genentech, Inc. | Drug: Placebo, Drug: Tocilizumab |
| North Carolina | NC-08 | A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia | 410 | Cape Fear Valley Medical Center, | Genentech, Inc. | Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo |
| North Carolina | NC-08 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | Womack Army Medical Center, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| North Carolina | NC-08 | Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19) | 124 | Carolina Institute for Clinical Research, | CSL Behring | Biological: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody, Drug: Placebo |
| North Carolina | NC-03 | Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP) | 0 | Naval Medical Center Camp Lejeune, | U.S. Army Medical Research and Development Command | Biological: Anti-Sars-CoV-2 Convalescent Plasma |
| North Carolina | NC-03 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Vidant Oncology-Kinston, CarolinaEast Medical Center, Marion L Shepard Cancer Center at Vidant Beaufort Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| North Carolina | NC-04 | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 5000 | University of North Carolina at Chapel Hill, | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: |
| North Carolina | NC-04 | Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) | 6000 | University of North Carolina at Chapel Hill, | Montreal Heart Institute, National Heart, Lung, and Blood Institute (NHLBI), Bill and Melinda Gates Foundation, The Government of Quebec, DACIMA Software | Drug: Colchicine, Drug: Placebo oral tablet |
| North Carolina | NC-04 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | UNC Hospitals, | Gilead Sciences | Drug: Remdesivir |
| North Carolina | NC-04 | Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine | 1363 | University of North Carolina, | Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke University | Drug: Hydroxychloroquine, Drug: Placebo oral tablet |
| North Carolina | NC-04 | Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection | 11 | Duke Regional Hospital, | Duke University | Other: Standard of care, Drug: Hydroxychloroquine, Drug: Azithromycin |
| North Carolina | NC-04 | Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease | 20 | Novartis Investigative Site, | Novartis Pharmaceuticals, Novartis | Drug: HCQ, Drug: HCQ+AZT, Drug: Placebo |
| North Carolina | NC-04 | Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia | 451 | Novartis Investigative Site, | Novartis Pharmaceuticals, Novartis | Drug: Canakinumab, Drug: Placebo |
| North Carolina | NC-04 | ScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Causes COVID-19 | 10000 | Center for Environmental Medicine Asthma and Lung Biology, | University of North Carolina, Chapel Hill | Diagnostic Test: To assess for development of IgG antibodies against SARS-CoV2 |
| North Carolina | NC-04 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | PMG Research of Raleigh LLC, M3 Wake Research Inc, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| North Carolina | NC-04 | MSCs in COVID-19 ARDS | 223 | WakeMed, | Icahn School of Medicine at Mount Sinai, Mesoblast, Inc., National Heart, Lung, and Blood Institute (NHLBI) | Biological: Remestemcel-L, Drug: Placebo |
| North Carolina | NC-04 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | UNC Lineberger Comprehensive Cancer Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| North Carolina | NC-04 | Prospective Natural History Study of Smoking, Immune Cell Profiles, Epigenetics and COVID-19 | 200 | NIEHS Clinical Research Unit, | National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health Clinical Center (CC) | |
| North Carolina | NC-04 | Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19 | 727 | Chapel Hill CRS, | HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials Network | Other: Sample collection |
| North Carolina | NC-04 | A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19 | 204 | University of North Carolina School of Medicine, | Ridgeback Biotherapeutics, LP | Drug: EIDD-2801, Drug: Placebo (PBO) |
| North Carolina | NC-04 | A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19 | 24 | University of North Carolina, | Eli Lilly and Company, AbCellera Biologics Inc. | Drug: LY3819253, Drug: Placebo |
| North Dakota | ND-00 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Lillestol Research LLC, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| North Dakota | ND-00 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Sanford Bismarck Medical Center, Sanford Broadway Medical Center, Sanford Roger Maris Cancer Center, Trinity Cancer Care Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| North Dakota | ND-00 | Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression | 208 | Octapharma Research Site, | Octapharma | Biological: Octagam 10%, Other: Placebo |
| Ohio | OH-10 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Kettering Medical Center, | Gilead Sciences | Drug: Remdesivir |
| Ohio | OH-10 | Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP) | 0 | Wright Patterson Medical Center, | U.S. Army Medical Research and Development Command | Biological: Anti-Sars-CoV-2 Convalescent Plasma |
| Ohio | OH-10 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Dayton Clinical Research, PriMED Clinical Research, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Ohio | OH-10 | Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) | 500 | Kettering Cancer Care, | Incyte Corporation | Drug: Placebo, Drug: Ruxolitinib |
| Ohio | OH-10 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Indu and Raj Soin Medical Center, Dayton Physicians LLC-Miami Valley South, Miami Valley Hospital South, Miami Valley Hospital, Dayton Physician LLC-Miami Valley Hospital North, Greater Dayton Cancer Center, First Dayton Cancer Care, Kettering Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Ohio | OH-11 | A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19) | 242 | University Hospitals Seidman Cancer Center, | Millennium Pharmaceuticals, Inc., Takeda | Drug: TAK-981, Drug: Standard of care |
| Ohio | OH-11 | Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study | 250 | Cleveland Clinic Foundation, | Ansun Biopharma, Inc. | Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL |
| Ohio | OH-11 | Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19 | 200000 | OMNI Medical Services, | OMNI Medical Services, LLC, OMNI Medical Services Inc | Drug: Cannabis, Medical |
| Ohio | OH-11 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | University Hospitals Cleveland Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Ohio | OH-11 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | University Hospitals Cleveland Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Ohio | OH-11 | CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment | 243 | University Hospitals of Cleveland, | OncoImmune, Inc. | Drug: CD24Fc, Drug: Placebo |
| Ohio | OH-11 | A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia | 450 | Cleveland Clinic Foundation, | Hoffmann-La Roche | Drug: Tocilizumab (TCZ), Drug: Placebo |
| Ohio | OH-11 | Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease | 479 | Cleveland Clinic Foundation, | Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI) | Drug: Hydroxychloroquine, Drug: Placebo |
| Ohio | OH-11 | Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation | 520 | Cleveland Clinic, | The Cleveland Clinic | Dietary Supplement: Ascorbic Acid, Dietary Supplement: Zinc Gluconate, Dietary Supplement: Ascorbic Acid and Zinc Gluconate, Other: Standard of Care |
| Ohio | OH-11 | A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE) | 227 | University Hospitals Cleveland Medical Center, | Kinevant Sciences GmbH, Roivant Sciences, Inc. | Drug: Gimsilumab, Drug: Placebo |
| Ohio | OH-11 | CoVID-19 Plasma in Treatment of COVID-19 Patients | 100 | University Hospitals Cleveland Medical Center, | The Christ Hospital | Biological: Convalescent COVID 19 Plasma |
| Ohio | OH-11 | Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia | 451 | Novartis Investigative Site, | Novartis Pharmaceuticals, Novartis | Drug: Canakinumab, Drug: Placebo |
| Ohio | OH-11 | A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia | 100 | University Hospitals Cleveland Medical Center, | Hoffmann-La Roche | Drug: Tociliuzumab |
| Ohio | OH-11 | Canakinumab in Covid-19 Cardiac Injury (The Three C Study) | 45 | Cleveland Clinic, | The Cleveland Clinic, Novartis | Drug: Canakinumab Injection 600mg, Drug: Canakinumab Injection 300mg, Drug: Placebos |
| Ohio | OH-11 | MultiStem Administration for COVID-19 Induced ARDS (MACoVIA) | 400 | Athersys Investigational Site 101, Athersys Investigational Site 102, | Athersys, Inc | Biological: MultiStem, Biological: Placebo |
| Ohio | OH-11 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | University Hospitals Cleveland Medical Center, VA Northeast Ohio Healthcare System, Rapid Medical Research, Senders Pediatrics, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Ohio | OH-11 | Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant | 1419 | Rapid Medical Research Inc, | Novavax, Coalition for Epidemic Preparedness Innovations (CEPI) | Biological: SARS-CoV-2 rS - Phase 1, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1, Other: Normal saline solution (NSS), Placebo - Phase 1, Other: Normal saline solution (NSS), Placebo - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1, Other: Normal saline solution (NSS), Placebo, Day 21 - Phase 1, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Days 0 and 21 - Phase 2, Other: Normal saline solution (NSS), Placebo, Day 189 - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 2, Other: Normal saline solution (NSS), Placebo, Day 21 - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Day 189 - Phase 2 |
| Ohio | OH-11 | MSCs in COVID-19 ARDS | 223 | Cleveland Clinic Foundation, | Icahn School of Medicine at Mount Sinai, Mesoblast, Inc., National Heart, Lung, and Blood Institute (NHLBI) | Biological: Remestemcel-L, Drug: Placebo |
| Ohio | OH-11 | Immunophenotyping Assessment in a COVID-19 Cohort | 2000 | University Hospitals Case Medical Center, | National Institute of Allergy and Infectious Diseases (NIAID), Benaroya Research Institute, Boston Children's Hospital | Procedure: Biological sample collection, Procedure: Data Collection: Clinical Care Assessments |
| Ohio | OH-11 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Cleveland Clinic Akron General, Cleveland Clinic Foundation, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Ohio | OH-11 | A Daily Coping Toolkit for Medical Personnel and First-Responders During COVID-19 Pandemic | 1000 | Akron Children's Hospital, Summa Health Systems, | Kent State University | Behavioral: Daily Coping Toolkit |
| Ohio | OH-11 | Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation | 30 | Cleveland Clinic Health System, | The Cleveland Clinic, Kiniksa Pharmaceuticals, Ltd. | Drug: Mavrilimumab, Drug: Placebos |
| Ohio | OH-11 | Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19 | 727 | Case CRS, | HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials Network | Other: Sample collection |
| Ohio | OH-12 | Study of Efficacy and Safety of MAS825 in Patients With COVID-19 | 140 | Novartis Investigative Site, | Novartis Pharmaceuticals, Novartis | Drug: MAS825, Drug: Matching placebo |
| Ohio | OH-12 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Columbus Oncology and Hematology Associates Inc, Riverside Methodist Hospital, Delaware Health Center-Grady Cancer Center, Grady Memorial Hospital, Dublin Methodist Hospital, OhioHealth Mansfield Hospital, Licking Memorial Hospital, Newark Radiation Oncology, Saint Ann's Hospital, Genesis Healthcare System Cancer Care Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Ohio | OH-13 | Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study | 250 | Mercy Health, | Ansun Biopharma, Inc. | Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL |
| Ohio | OH-13 | MultiStem Administration for COVID-19 Induced ARDS (MACoVIA) | 400 | Athersys Investigational Site 103, | Athersys, Inc | Biological: MultiStem, Biological: Placebo |
| Ohio | OH-13 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Summa Health System - Akron Campus, Saint Elizabeth Boardman Hospital, Saint Joseph Warren Hospital, Saint Elizabeth Youngstown Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Ohio | OH-13 | A Daily Coping Toolkit for Medical Personnel and First-Responders During COVID-19 Pandemic | 1000 | Kent State University, | Kent State University | Behavioral: Daily Coping Toolkit |
| Ohio | OH-15 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Adena Regional Medical Center, Mount Carmel Grove City Hospital, Fairfield Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Ohio | OH-02 | Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant | 1419 | Synexus Clinical Research US, | Novavax, Coalition for Epidemic Preparedness Innovations (CEPI) | Biological: SARS-CoV-2 rS - Phase 1, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1, Other: Normal saline solution (NSS), Placebo - Phase 1, Other: Normal saline solution (NSS), Placebo - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1, Other: Normal saline solution (NSS), Placebo, Day 21 - Phase 1, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Days 0 and 21 - Phase 2, Other: Normal saline solution (NSS), Placebo, Day 189 - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 2, Other: Normal saline solution (NSS), Placebo, Day 21 - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Day 189 - Phase 2 |
| Ohio | OH-02 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Oncology Hematology Care Inc-Kenwood, TriHealth Cancer Institute-Anderson, Southern Ohio Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Ohio | OH-03 | CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment | 243 | Ohio State University Medical Center, | OncoImmune, Inc. | Drug: CD24Fc, Drug: Placebo |
| Ohio | OH-03 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Ohio State University College of Medicine, | Gilead Sciences | Drug: Remdesivir |
| Ohio | OH-03 | Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease | 479 | Ohio State University Wexner Medical Center, | Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI) | Drug: Hydroxychloroquine, Drug: Placebo |
| Ohio | OH-03 | Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine | 1363 | Ohio State University Medical Center, | Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke University | Drug: Hydroxychloroquine, Drug: Placebo oral tablet |
| Ohio | OH-03 | Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19 | 86 | OhioHealth Grant Medical Center, | CytoDyn, Inc. | Drug: Placebos, Drug: Leronlimab (700mg) |
| Ohio | OH-03 | Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19) | 390 | OhioHealth Grant Medical Center, | CytoDyn, Inc. | Drug: Placebos, Drug: Leronlimab (700mg) |
| Ohio | OH-03 | SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19 | 0 | Ohio State University Wexner Medical Center, | Alexion Pharmaceuticals | Biological: eculizumab |
| Ohio | OH-03 | Convalescent Plasma in Outpatients With COVID-19 | 600 | OSU Wexner Medical Center, | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network | Biological: Convalescent Plasma, Biological: Saline |
| Ohio | OH-03 | Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults | 1000 | Ohio State University Wexner Medical Center, | Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS) | Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo |
| Ohio | OH-03 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Aventiv Research Inc., | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Ohio | OH-03 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Ohio State University Comprehensive Cancer Center, Mount Carmel East Hospital, Grant Medical Center, Mark H Zangmeister Center, Mount Carmel Health Center West, Doctors Hospital, Central Ohio Breast and Endocrine Surgery, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Ohio | OH-03 | Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) | 190 | Atea Study Site, | Atea Pharmaceuticals, Inc. | Drug: AT-527, Other: Placebo |
| Ohio | OH-03 | Randomized Proof-of-Concept Trial to Evaluate the Safety and Explore the Effectiveness of a Plant Polyphenol for COVID-19 | 200 | Mt Carmel HealthSystems, | Marvin McCreary, MD, Mount Carmel Health System | Drug: Plant Polyphenol, Dietary Supplement: Vitamin D3 |
| Ohio | OH-03 | A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia | 500 | OhioHealth Research Institute, | Hoffmann-La Roche, Gilead Sciences | Drug: Remdesivir, Drug: Tocilizumab, Drug: Placebo |
| Ohio | OH-04 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | OhioHealth Marion General Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Ohio | OH-08 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Dayton Physicians LLC-Wayne, Wayne Hospital, Springfield Regional Cancer Center, Springfield Regional Medical Center, Dayton Physicians LLC-Upper Valley, Upper Valley Medical Center, University Pointe, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Ohio | OH-01 | Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study | 250 | Lindner Center- The Christ Hospital, Cincinnati Children's Hospital Medical Center, University of Cincinnati, | Ansun Biopharma, Inc. | Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL |
| Ohio | OH-01 | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 5000 | Cincinnati Children's Hospital Medical Center, | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: |
| Ohio | OH-01 | Losartan for Patients With COVID-19 Requiring Hospitalization | 200 | University of Cincinnati Medical Center, | University of Minnesota, Bill and Melinda Gates Foundation | Drug: Losartan, Other: Placebo |
| Ohio | OH-01 | CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment | 243 | Christ Hospital, | OncoImmune, Inc. | Drug: CD24Fc, Drug: Placebo |
| Ohio | OH-01 | Convalescent Plasma to Stem Coronavirus (CSSC-001) | 500 | University of Cincinnati Medical Center, | Johns Hopkins University | Biological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma |
| Ohio | OH-01 | Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease | 479 | University of Cincinnati Medical Center, | Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI) | Drug: Hydroxychloroquine, Drug: Placebo |
| Ohio | OH-01 | Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia | 30 | University of Cincinnati, | University of Cincinnati | Drug: Sirolimus, Drug: Placebo |
| Ohio | OH-01 | CoVID-19 Plasma in Treatment of COVID-19 Patients | 100 | The Christ Hospital, | The Christ Hospital | Biological: Convalescent COVID 19 Plasma |
| Ohio | OH-01 | Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19 | 20 | Cincinnati Clinical Research Site, | National Institute of Allergy and Infectious Diseases (NIAID), Teva Pharmaceuticals Industries LTD | Drug: Hydroxychloroquine (HCQ), Drug: Azithromycin (Azithro), Drug: Placebo for Hydroxychloroquine, Drug: Placebo for Azithromycin |
| Ohio | OH-01 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Cincinnati Children's Hospital Medical Center, Sterling Research Group Ltd., Cincinnati Children's Hospital Medical Center, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Ohio | OH-01 | Convalescent Plasma to Limit SARS-CoV-2 Associated Complications | 1344 | University of Cincinnati Medical Center, | Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID) | Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor |
| Ohio | OH-01 | COVID-19: Human Epidemiology and Response to SARS-CoV-2 | 5605 | Cincinnati Children's Hospital Medical Center, | National Institute of Allergy and Infectious Diseases (NIAID), Rho Federal Systems Division, Inc. (Rho) | Procedure: Collection of Biological Samples, Procedure: Symptom and Exposure Surveys |
| Ohio | OH-01 | Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) | 500 | University of Cincinnati, | Incyte Corporation | Drug: Placebo, Drug: Ruxolitinib |
| Ohio | OH-01 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | University of Cincinnati/Barrett Cancer Center, Good Samaritan Hospital – Cincinnati, Cincinnati Children's Hospital Medical Center, Bethesda North Hospital, TriHealth Cancer Institute-Westside, Atrium Medical Center-Middletown Regional Hospital, Dayton Physicians LLC-Atrium, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Ohio | OH-01 | A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection | 100 | Good Samaritan Hospital, Bethesda North Hospital, | TriHealth Inc. | Drug: Convalescent Plasma |
| Ohio | OH-01 | Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) | 190 | Atea Study Site, | Atea Pharmaceuticals, Inc. | Drug: AT-527, Other: Placebo |
| Ohio | OH-01 | PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer | 364 | Carl and Edyth Lindner Center for Research and Education at The Christ Hospital, | CTI BioPharma | Drug: Pacritinib, Drug: Placebo |
| Ohio | OH-01 | Viral Specific T-cells for Treatment of COVID-19 | 100 | Children's Hospital Medical Center, | Children's Hospital Medical Center, Cincinnati, Hoxworth Blood Center | Biological: Viral Specific T-cells (VSTs) |
| Ohio | OH-06 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Strecker Cancer Center-Belpre, Marietta Memorial Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Ohio | OH-05 | Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19 | 200000 | OMNI Medical Services, | OMNI Medical Services, LLC, OMNI Medical Services Inc | Drug: Cannabis, Medical |
| Ohio | OH-05 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Armes Family Cancer Center, Blanchard Valley Hospital, Orion Cancer Care, Toledo Clinic Cancer Centers-Toledo, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Ohio | OH-09 | Outcomes Mandate National Integration With Cannabis as Medicine for Prevention and Treatment of COVID-19 | 200000 | OMNI Medical Services, OMNI Medical Services, OMNI Medical Services, | OMNI Medical Services, LLC, OMNI Medical Services Inc | Drug: Cannabis, Medical |
| Ohio | OH-09 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | MetroHealth Medical Center, | Gilead Sciences | Drug: Remdesivir |
| Ohio | OH-09 | Convalescent Plasma in Outpatients With COVID-19 | 600 | Mercy St. Vincent Medical Center, | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network | Biological: Convalescent Plasma, Biological: Saline |
| Ohio | OH-09 | A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia | 100 | Mercy St. Vincent Medical Center, | Hoffmann-La Roche | Drug: Tociliuzumab |
| Ohio | OH-09 | Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease | 800 | GSK Investigational Site, | GlaxoSmithKline | Biological: Otilimab, Biological: Placebo, Drug: Standard of care |
| Ohio | OH-09 | Fluoxetine to Reduce Intubation and Death After COVID19 Infection | 2000 | University of Toledo, | University of Toledo Health Science Campus | Drug: Fluoxetine |
| Ohio | OH-09 | Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease | 682 | Toledo Hospital and BayPark Hospital, | Algernon Pharmaceuticals, Novotech (Australia) | Drug: NP-120 (Ifenprodil) |
| Ohio | OH-09 | A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia | 410 | Mercy St. Vincent Medical Center, | Genentech, Inc. | Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo |
| Ohio | OH-09 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Ohio | OH-09 | Study of Sargramostim in Patients With COVID-19 | 120 | University of Toledo Medical Center, | Partner Therapeutics, Inc. | Drug: Sargramostim, Drug: Standard of care |
| Ohio | OH-07 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Knox Community Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Oklahoma | OK-05 | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 5000 | Board of Regents of the University of Oklahoma, | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: |
| Oklahoma | OK-05 | Tocilizumab for Patients With Cancer and COVID-19 Disease | 217 | University of Oklahoma Health Sciences Center, | National Cancer Institute (NCI) | Biological: Tocilizumab |
| Oklahoma | OK-05 | Immunophenotyping Assessment in a COVID-19 Cohort | 2000 | University of Oklahoma, | National Institute of Allergy and Infectious Diseases (NIAID), Benaroya Research Institute, Boston Children's Hospital | Procedure: Biological sample collection, Procedure: Data Collection: Clinical Care Assessments |
| Oklahoma | OK-05 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | University of Oklahoma Health Sciences Center, Mercy Hospital Oklahoma City, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Oklahoma | OK-05 | Mobile Health Study and Enhanced Symptom Monitoring in COVID-19 Cancer Patients | 500 | Stephenson Cancer Center, | University of Oklahoma | Other: mHealth Assessments |
| Oklahoma | OK-04 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Lynn Institute of Norman, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Oklahoma | OK-01 | The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection | 100 | Ascension St. John, Ascension St. John, | Pulmotect, Inc. | Drug: PUL-042 Inhalation Solution, Drug: Placebo |
| Oklahoma | OK-01 | The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2 | 200 | Ascension St. John, Ascension St. John, | Pulmotect, Inc. | Drug: PUL-042 Inhalation Solution, Drug: Placebo |
| Oklahoma | OK-01 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| Oklahoma | OK-01 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Saint Francis Hospital, | Gilead Sciences | Drug: Remdesivir |
| Oklahoma | OK-01 | PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer | 364 | St. John Medical Center, | CTI BioPharma | Drug: Pacritinib, Drug: Placebo |
| Oregon | OR-01 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Kaiser Sunnyside Medical Center, Providence St. Vincent Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Oregon | OR-01 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Kaiser Sunnyside Medical Center, Providence St. Vincent Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Oregon | OR-01 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Providence Newberg Medical Center, Providence St. Vincent Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Oregon | OR-01 | A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia | 500 | Providence Saint Vincent's Medical Center, | Hoffmann-La Roche, Gilead Sciences | Drug: Remdesivir, Drug: Tocilizumab, Drug: Placebo |
| Oregon | OR-03 | Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study | 250 | Oregon Health & Science University, | Ansun Biopharma, Inc. | Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL |
| Oregon | OR-03 | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 5000 | Oregon Health and Science University, | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: |
| Oregon | OR-03 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Providence Portland Medical Center, Kaiser Sunnyside Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Oregon | OR-03 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Providence Portland Medical Center, Kaiser Sunnyside Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Oregon | OR-03 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site, Regeneron Study Site, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| Oregon | OR-03 | Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease | 479 | Oregon Health and Science University, | Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI) | Drug: Hydroxychloroquine, Drug: Placebo |
| Oregon | OR-03 | Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care | 13 | Portland Providence Medical Center, | Providence Health & Services, Center for Outcomes Research and Education, Providence Cancer Center, Earle A. Chiles Research Institute | Drug: Hydroxychloroquine, Dietary Supplement: Vitamin C |
| Oregon | OR-03 | Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19) | 384 | Oregon Health and Science University, | I-Mab Biopharma Co. Ltd. | Drug: TJ003234, Drug: Placebo |
| Oregon | OR-03 | Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19 | 86 | Oregon Health and Science University, | CytoDyn, Inc. | Drug: Placebos, Drug: Leronlimab (700mg) |
| Oregon | OR-03 | Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19) | 390 | Oregon Health and Sciences University, | CytoDyn, Inc. | Drug: Placebos, Drug: Leronlimab (700mg) |
| Oregon | OR-03 | Convalescent Plasma in Outpatients With COVID-19 | 600 | Oregon Health & Science University Hospital, | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network | Biological: Convalescent Plasma, Biological: Saline |
| Oregon | OR-03 | Plasma Adsorption in Patients With Confirmed COVID-19 | 2000 | Providence Portland Medical Center, | Marker Therapeutics AG, Terumo BCT | Device: Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol) |
| Oregon | OR-03 | Assessing Hydroxychloroquine in Patients With SARS-CoV-2 (COVID-19) | 0 | Oregon Health and Science University, | Oregon Health and Science University, OHSU Knight Cancer Institute | Drug: Hydroxychloroquine, Drug: Placebo |
| Oregon | OR-03 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Kaiser Permanente Northwest, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Oregon | OR-03 | Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19 | 600 | Oregon Health & Science University, | Vanderbilt University Medical Center, AbbVie | Drug: Lopinavir/Ritonavir 400 mg/100 mg, Other: Placebo |
| Oregon | OR-03 | Immunophenotyping Assessment in a COVID-19 Cohort | 2000 | Oregon Health and Science University, | National Institute of Allergy and Infectious Diseases (NIAID), Benaroya Research Institute, Boston Children's Hospital | Procedure: Biological sample collection, Procedure: Data Collection: Clinical Care Assessments |
| Oregon | OR-03 | A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia | 410 | Providence Portland Medical Center, | Genentech, Inc. | Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo |
| Oregon | OR-03 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Providence Portland Medical Center, Legacy Emanuel Children's Hospital, Oregon Health and Science University, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Oregon | OR-03 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | Kaiser Permanente Northwest, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| Oregon | OR-02 | Study of Efficacy and Safety of MAS825 in Patients With COVID-19 | 140 | Novartis Investigative Site, | Novartis Pharmaceuticals, Novartis | Drug: MAS825, Drug: Matching placebo |
| Oregon | OR-02 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Saint Alphonsus Medical Center-Baker City, Saint Charles Health System, Saint Alphonsus Medical Center-Ontario, Saint Charles Health System-Redmond, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Oregon | OR-04 | Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19) | 390 | Good Samaritan Hospital Corvallis, | CytoDyn, Inc. | Drug: Placebos, Drug: Leronlimab (700mg) |
| Oregon | OR-04 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Bay Area Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Oregon | OR-05 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Clackamas Radiation Oncology Center, Providence Cancer Institute Clackamas Clinic, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Pennsylvania | PA-10 | Adaptive COVID-19 Treatment Trial (ACTT) | 1062 | Penn State Health Milton Hershey Medical, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir |
| Pennsylvania | PA-10 | Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease | 479 | Penn State Health Milton Hershey Medical, | Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI) | Drug: Hydroxychloroquine, Drug: Placebo |
| Pennsylvania | PA-10 | COVID-19 Health Messaging Efficacy and Its Impact on Public Perception, Anxiety, and Behavior | 18251 | Penn State Health Milton Hershey Medical, | Milton S. Hershey Medical Center, The Huck Institutes of the Life Sciences, The Social Science Research Institute, The Department of Family and Community Medicine, Penn State College of Medicine, The College of Healthcare Information Management Executives (CHIME) | |
| Pennsylvania | PA-10 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Penn State Milton S. Hershey Medical Center, WellSpan Health-York Cancer Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Pennsylvania | PA-10 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | Penn State Health Milton Hershey Medical, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| Pennsylvania | PA-11 | Dapagliflozin in Respiratory Failure in Patients With COVID-19 | 900 | Lancaster General Hospital, | Saint Luke's Health System, AstraZeneca, George Clinical Pty Ltd | Drug: Dapagliflozin 10 MG, Drug: Placebo |
| Pennsylvania | PA-11 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Ephrata Cancer Center, Cherry Tree Cancer Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Pennsylvania | PA-12 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Lewistown Hospital, Geisinger Medical Oncology-Lewisburg, Geisinger Medical Oncology-Selinsgrove, Geisinger Medical Group, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Pennsylvania | PA-13 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Adams Cancer Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Pennsylvania | PA-16 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Allegheny Health Network, | Gilead Sciences | Drug: Remdesivir |
| Pennsylvania | PA-16 | Effectiveness of Using a Meditation App in Reducing Anxiety and Improving Well-being During the Covid-19 Pandemic | 200 | LECOM, | Lake Erie College of Osteopathic Medicine | Behavioral: Meditation app usage |
| Pennsylvania | PA-16 | Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms | 20 | AHN Allegheny General Hospital, AHN West Penn Hospital, | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute), ElectroCore INC | Device: gammaCore® Sapphire (non-invasive vagus nerve stimulator), Other: Standard of care therapies |
| Pennsylvania | PA-16 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Saint Vincent Hospital, Allegheny General Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Pennsylvania | PA-16 | A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia | 500 | Allegheny Health Network, | Hoffmann-La Roche, Gilead Sciences | Drug: Remdesivir, Drug: Tocilizumab, Drug: Placebo |
| Pennsylvania | PA-17 | Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) | 500 | Allegheny Health Network, | Incyte Corporation | Drug: Placebo, Drug: Ruxolitinib |
| Pennsylvania | PA-17 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Allegheny Valley Hospital, Wexford Health and Wellness Pavilion, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Pennsylvania | PA-18 | Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia | 7100 | University of Pittsburgh Medical Centre, | MJM Bonten, Australian and New Zealand Intensive Care Research Centre, Medical Research Institute of New Zealand, Unity Health, Berry Consultants, Global Coalition for Adaptive Research, University of Pittsburgh Medical Center, UMC Utrecht | Drug: Fixed-duration Hydrocortisone, Drug: Shock-dependent hydrocortisone, Drug: Ceftriaxone, Drug: Moxifloxacin or Levofloxacin, Drug: Piperacillin-tazobactam, Drug: Ceftaroline, Drug: Amoxicillin-clavulanate, Drug: Macrolide administered for 3-5 days, Drug: Macrolide administered for up to 14 days, Drug: Five-days oseltamivir, Drug: Ten-days oseltamivir, Drug: Lopinavir/ritonavir, Drug: Hydroxychloroquine, Drug: Hydroxychloroquine + lopinavir/ritonavir, Drug: Interferon-β1a, Drug: Anakinra, Drug: Fixed-duration higher dose Hydrocortisone, Drug: Tocilizumab, Drug: Sarilumab, Drug: Vitamin C, Drug: Therapeutic anticoagulation, Drug: Simvastatin, Biological: Convalescent plasma, Other: Protocolised mechanical ventilation strategy, Drug: Eritoran, Drug: Apremilast, Drug: Aspirin, Drug: Clopidogrel, Drug: Prasugrel, Drug: Ticagrelor |
| Pennsylvania | PA-18 | Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study | 250 | University of Pittsburgh Medical Center Health System, | Ansun Biopharma, Inc. | Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL |
| Pennsylvania | PA-18 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | UPMC, | Gilead Sciences | Drug: Remdesivir |
| Pennsylvania | PA-18 | Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease | 479 | UPMC Presbyterian/Mercy/Shadyside, | Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI) | Drug: Hydroxychloroquine, Drug: Placebo |
| Pennsylvania | PA-18 | Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine | 1363 | University of Pittsburgh School of Medicine, | Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke University | Drug: Hydroxychloroquine, Drug: Placebo oral tablet |
| Pennsylvania | PA-18 | SARS-COV2 Pandemic Serosurvey and Blood Sampling | 15000 | University of Pittsburgh, | National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health Clinical Center (CC) | |
| Pennsylvania | PA-18 | Convalescent Plasma in Outpatients With COVID-19 | 600 | UPMC Presbyterian Hospital, University of Pittsburgh, | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network | Biological: Convalescent Plasma, Biological: Saline |
| Pennsylvania | PA-18 | Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19 | 20 | University of Pittsburgh CRS, | National Institute of Allergy and Infectious Diseases (NIAID), Teva Pharmaceuticals Industries LTD | Drug: Hydroxychloroquine (HCQ), Drug: Azithromycin (Azithro), Drug: Placebo for Hydroxychloroquine, Drug: Placebo for Azithromycin |
| Pennsylvania | PA-18 | Provider Burnout During COVID-19 | 250 | University of Pittsburgh Medical Center, | University of Pittsburgh | Behavioral: Coping strategies video |
| Pennsylvania | PA-18 | Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) | 500 | West Penn Hospital, | Incyte Corporation | Drug: Placebo, Drug: Ruxolitinib |
| Pennsylvania | PA-18 | Neurologic Manifestations of COVID 19 in Children | 500 | UPMC Children's Hospital of Pittsburgh, | University of Pittsburgh, University of Utah, Johns Hopkins University | Other: Observational study only |
| Pennsylvania | PA-18 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Jefferson Hospital, Forbes Hospital, West Penn Hospital, University of Pittsburgh Cancer Institute, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Pennsylvania | PA-07 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | St. Luke's Hospital - Bethlehem Campus, | Gilead Sciences | Drug: Remdesivir |
| Pennsylvania | PA-07 | Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection | 202 | Lehigh Valley Hospital, | Karyopharm Therapeutics Inc | Drug: Selinexor, Other: Placebo |
| Pennsylvania | PA-07 | A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia | 100 | Lehigh Valley Hospital, | Hoffmann-La Roche | Drug: Tociliuzumab |
| Pennsylvania | PA-07 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Lehigh Valley Health Network, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Pennsylvania | PA-07 | A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia | 410 | Lehigh Valley Health Network, | Genentech, Inc. | Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo |
| Pennsylvania | PA-07 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Lehigh Valley Hospital-Cedar Crest, Lehigh Valley Hospital – Muhlenberg, Pocono Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Pennsylvania | PA-04 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Holy Redeemer Hospital and Medical Center, Pottstown Hospital, Abington Memorial Hospital-Asplundh Cancer Pavilion, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Pennsylvania | PA-08 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site, Regeneron Study Site, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| Pennsylvania | PA-08 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Northeast Radiation Oncology Center, Geisinger Medical Center-Cancer Center Hazleton, Lehigh Valley Hospital-Hazleton, Community Medical Center, Geisinger Wyoming Valley/Henry Cancer Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Pennsylvania | PA-02 | A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19) | 242 | Fox Chase Cancer Center, | Millennium Pharmaceuticals, Inc., Takeda | Drug: TAK-981, Drug: Standard of care |
| Pennsylvania | PA-02 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Temple University Hospital, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Pennsylvania | PA-02 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Temple University Hospital, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Pennsylvania | PA-02 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| Pennsylvania | PA-02 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Einstein Medical Center Philadelphia, | Gilead Sciences | Drug: Remdesivir |
| Pennsylvania | PA-02 | Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection. | 16 | Temple University Hospital, | Swedish Orphan Biovitrum | Biological: Emapalumab, Biological: Anakinra |
| Pennsylvania | PA-02 | Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease | 479 | Temple University Hospital, | Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI) | Drug: Hydroxychloroquine, Drug: Placebo |
| Pennsylvania | PA-02 | Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine | 1363 | Temple University Hospital, | Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke University | Drug: Hydroxychloroquine, Drug: Placebo oral tablet |
| Pennsylvania | PA-02 | Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects | 120 | Blade Research Site, | Blade Therapeutics, Clinipace Worldwide | Drug: BLD-2660 |
| Pennsylvania | PA-02 | Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19) | 384 | Temple University Hospital, | I-Mab Biopharma Co. Ltd. | Drug: TJ003234, Drug: Placebo |
| Pennsylvania | PA-02 | A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE) | 227 | Temple University Hospital, | Kinevant Sciences GmbH, Roivant Sciences, Inc. | Drug: Gimsilumab, Drug: Placebo |
| Pennsylvania | PA-02 | Convalescent Plasma in Outpatients With COVID-19 | 600 | Temple University Hospital, Einstein Medical Center, | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network | Biological: Convalescent Plasma, Biological: Saline |
| Pennsylvania | PA-02 | Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia | 451 | Novartis Investigative Site, | Novartis Pharmaceuticals, Novartis | Drug: Canakinumab, Drug: Placebo |
| Pennsylvania | PA-02 | A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia | 100 | Temple University Hospital, | Hoffmann-La Roche | Drug: Tociliuzumab |
| Pennsylvania | PA-02 | A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia | 379 | Temple University Hospital, | Genentech, Inc. | Drug: Placebo, Drug: Tocilizumab |
| Pennsylvania | PA-02 | Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease | 800 | GSK Investigational Site, | GlaxoSmithKline | Biological: Otilimab, Biological: Placebo, Drug: Standard of care |
| Pennsylvania | PA-02 | Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) | 500 | Temple University, | Incyte Corporation | Drug: Placebo, Drug: Ruxolitinib |
| Pennsylvania | PA-02 | Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. | 62 | Research Site, | AstraZeneca, Acerta Pharma B.V. | Drug: Acalabrutinib |
| Pennsylvania | PA-02 | Study of Efficacy and Safety of MAS825 in Patients With COVID-19 | 140 | Novartis Investigative Site, | Novartis Pharmaceuticals, Novartis | Drug: MAS825, Drug: Matching placebo |
| Pennsylvania | PA-02 | A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia | 410 | Temple University Hospital, | Genentech, Inc. | Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo |
| Pennsylvania | PA-02 | Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization | 198 | Philadelphia MultiService Center, | VA Office of Research and Development | Drug: Degarelix, Other: Saline |
| Pennsylvania | PA-02 | PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer | 364 | Albert Einstein Medical Center, | CTI BioPharma | Drug: Pacritinib, Drug: Placebo |
| Pennsylvania | PA-02 | A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19 | 24 | Temple University School of Medicine, | Eli Lilly and Company, AbCellera Biologics Inc. | Drug: LY3819253, Drug: Placebo |
| Pennsylvania | PA-09 | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 5000 | Pennsylvania State University--Hershey Children's Hospital, | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: |
| Pennsylvania | PA-09 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| Pennsylvania | PA-09 | Convalescent Plasma in Outpatients With COVID-19 | 600 | Geisinger Medical Center, | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network | Biological: Convalescent Plasma, Biological: Saline |
| Pennsylvania | PA-09 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Geisinger Medical Center, Sechler Family Cancer Center, Geisinger Cancer Services-Pottsville, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Pennsylvania | PA-06 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Paoli Memorial Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Pennsylvania | PA-03 | Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients | 100 | Childrens Hospital of Philadelphia, | Novartis Pharmaceuticals, Novartis | Drug: Crizanlizumab |
| Pennsylvania | PA-03 | Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study | 250 | University of Pennsylvania, | Ansun Biopharma, Inc. | Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL |
| Pennsylvania | PA-03 | Adaptive COVID-19 Treatment Trial (ACTT) | 1062 | Hospital of the University of Pennsylvania, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir |
| Pennsylvania | PA-03 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Hospital of the University of Pennsylvania, Hospital of the University of Pennsylvania, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Pennsylvania | PA-03 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Hospital of the University of Pennsylvania, Hospital of the University of Pennsylvania, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Pennsylvania | PA-03 | A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia | 450 | Thomas Jefferson University, | Hoffmann-La Roche | Drug: Tocilizumab (TCZ), Drug: Placebo |
| Pennsylvania | PA-03 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Philadelphia VA Medical Center, | Gilead Sciences | Drug: Remdesivir |
| Pennsylvania | PA-03 | The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine) | 173 | University of Pennsylvania, | Ravi Amaravadi, MD, University of Pennsylvania | Drug: Hydroxychloroquine Sulfate 400 mg twice a day, Drug: Hydroxychloroquine Sulfate 600 mg twice a day, Drug: Hydroxychloroquine Sulfate 600 mg once a day, Drug: Placebo oral tablet |
| Pennsylvania | PA-03 | Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers | 120 | University of Pennsylvania, | Inovio Pharmaceuticals, Coalition for Epidemic Preparedness Innovations (CEPI) | Drug: INO-4800, Device: CELLECTRA® 2000 |
| Pennsylvania | PA-03 | Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019 | 152 | University of Pennsylvania Health System, | University of Pennsylvania, Jordana B. Cohen, MD, MSCE, Thomas C. Hanff, MD, MPH, Vicente Corrales-Medina, MD, PhD, James Brian Byrd, MD, Roberto Viau Colindres | Other: Discontinuation of ARB/ACEI, Other: Continuation of ARB/ACEI |
| Pennsylvania | PA-03 | COVID-19 Plasma Collection | 2000 | Thomas Jefferson University, | Thomas Jefferson University | Other: Plasma Donation |
| Pennsylvania | PA-03 | Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen | 120 | Thomas Jefferson University Hospital, | Biohaven Pharmaceuticals, Inc. | Drug: Zavegepant (BHV-3500), Drug: Placebo |
| Pennsylvania | PA-03 | MSCs in COVID-19 ARDS | 223 | University of Pennsylvania Health System, | Icahn School of Medicine at Mount Sinai, Mesoblast, Inc., National Heart, Lung, and Blood Institute (NHLBI) | Biological: Remestemcel-L, Drug: Placebo |
| Pennsylvania | PA-03 | Sirolimus in COVID-19 Phase 1 | 0 | Thomas Jefferson University Hospital, | Walter K. Kraft, Thomas Jefferson University | Drug: Sirolimus 1 MG/ML, Drug: Placebo |
| Pennsylvania | PA-03 | Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) | 500 | Jefferson Hospital, | Incyte Corporation | Drug: Placebo, Drug: Ruxolitinib |
| Pennsylvania | PA-03 | Immunophenotyping Assessment in a COVID-19 Cohort | 2000 | Drexel University College of Medicine, | National Institute of Allergy and Infectious Diseases (NIAID), Benaroya Research Institute, Boston Children's Hospital | Procedure: Biological sample collection, Procedure: Data Collection: Clinical Care Assessments |
| Pennsylvania | PA-03 | Prognostic Value of Point of Care Cardiac and Lung Ultrasound in COVID-19 | 105 | University of Pennsylvania Health System, | University of Pennsylvania | Other: Observation only |
| Pennsylvania | PA-03 | COVIDNOCHE Trial (HFNO Versus CPAP Helmet) in COVID-19 Pneumonia | 200 | University of Pennsylvania, | University of Pennsylvania | Device: Helmet Continuous Positive Airway Pressure (CPAP), Device: High Flow Nasal Oxygen (HFNO) |
| Pennsylvania | PA-03 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Thomas Jefferson University Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Pennsylvania | PA-03 | COVID-19 Convalescent Plasma for Mechanically Ventilated Population | 50 | Hospital of the University of Pennsylvania, | University of Pennsylvania | Biological: COVID-19 Convalescent Plasma |
| Pennsylvania | PA-03 | Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19 | 140 | Thomas Jefferson University, | Pluristem Ltd. | Biological: PLX-PAD, Biological: Placebo |
| Pennsylvania | PA-03 | Convalescent Plasma for the Treatment of COVID-19 | 100 | Thomas Jefferson University, | Thomas Jefferson University | Drug: Convalescent Plasma |
| Pennsylvania | PA-03 | COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2. | 80 | Hospital of the University of Pennsylvania, | University of Pennsylvania | Biological: COVID-19 Convalescent Plasma |
| Pennsylvania | PA-03 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | Hospital of the University of Pennsylvania, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| Pennsylvania | PA-03 | Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19 | 727 | Penn Prevention CRS, | HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials Network | Other: Sample collection |
| Pennsylvania | PA-03 | GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19) in Health Care Personnel | 225 | University of Pennsylvania, | GeneOne Life Science, Inc. | Drug: GLS-1200, Drug: Placebo |
| Pennsylvania | PA-03 | A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia | 500 | Thomas Jefferson University, | Hoffmann-La Roche, Gilead Sciences | Drug: Remdesivir, Drug: Tocilizumab, Drug: Placebo |
| Pennsylvania | PA-05 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Mercy Catholic Medical Center, | Gilead Sciences | Drug: Remdesivir |
| Pennsylvania | PA-05 | COVID-19 CHAMPS Study of Healthcare, First Responder and Service Workers | 20000 | Villanova University, | Villanova University | |
| Pennsylvania | PA-05 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Bryn Mawr Hospital, Christiana Care Health System-Concord Health Center, Riddle Memorial Hospital, Lankenau Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Pennsylvania | PA-01 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | St Mary Medical Center, | Gilead Sciences | Drug: Remdesivir |
| Pennsylvania | PA-01 | Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease | 800 | GSK Investigational Site, | GlaxoSmithKline | Biological: Otilimab, Biological: Placebo, Drug: Standard of care |
| Pennsylvania | PA-01 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Doylestown Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Rhode Island | RI-02 | Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study | 250 | Kent Hospital, | Ansun Biopharma, Inc. | Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL |
| Rhode Island | RI-02 | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 5000 | Rhode Island Hospital, | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: |
| Rhode Island | RI-02 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Roger Williams Medical Center, Kent Hospital, | Gilead Sciences | Drug: Remdesivir |
| Rhode Island | RI-02 | Sarilumab for Patients With Moderate COVID-19 Disease | 120 | Providence VA Medical Center, | Westyn Branch-Elliman, VA Boston Healthcare System | Biological: SARILUMAB |
| Rhode Island | RI-02 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Omega Medical Research, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Rhode Island | RI-02 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Women and Infants Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Rhode Island | RI-02 | PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer | 364 | Rhode Island Hospital, | CTI BioPharma | Drug: Pacritinib, Drug: Placebo |
| Rhode Island | RI-01 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Miriam Hospital, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Rhode Island | RI-01 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Miriam Hospital, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Rhode Island | RI-01 | Convalescent Plasma to Stem Coronavirus (CSSC-001) | 500 | Lifespan/Brown University, | Johns Hopkins University | Biological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma |
| Rhode Island | RI-01 | Convalescent Plasma to Limit SARS-CoV-2 Associated Complications | 1344 | Lifespan/Brown University, | Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID) | Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor |
| Rhode Island | RI-01 | PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer | 364 | Miriam Hospital, | CTI BioPharma | Drug: Pacritinib, Drug: Placebo |
| Rhode Island | RI-01 | Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes | 36 | Nursing Home, | Restorbio Inc. | Drug: RTB101, Drug: Placebo |
| South Carolina | SC-06 | Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients | 100 | Medical University of South Carolina, | Novartis Pharmaceuticals, Novartis | Drug: Crizanlizumab |
| South Carolina | SC-06 | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 5000 | Medical University of South Carolina Children's Hospital, University of South Carolina, | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: |
| South Carolina | SC-06 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Prisma Health Richland Hospital, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| South Carolina | SC-06 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Prisma Health Richland Hospital, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| South Carolina | SC-06 | Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease | 479 | Medical University of South Carolina, | Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI) | Drug: Hydroxychloroquine, Drug: Placebo |
| South Carolina | SC-06 | Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen | 120 | Roper Hospital, | Biohaven Pharmaceuticals, Inc. | Drug: Zavegepant (BHV-3500), Drug: Placebo |
| South Carolina | SC-06 | Convalescent Plasma in Outpatients With COVID-19 | 600 | Medical University of South Carolina, | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network | Biological: Convalescent Plasma, Biological: Saline |
| South Carolina | SC-06 | A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia | 100 | Medical University of South Carolina, | Hoffmann-La Roche | Drug: Tociliuzumab |
| South Carolina | SC-06 | Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia | 270 | Medical University of South Carolina, | Alexion Pharmaceuticals | Biological: Ravulizumab, Other: Best Supportive Care |
| South Carolina | SC-06 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Medical University of South Carolina, Prisma Health Richland Hospital, Prisma Health Baptist Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| South Carolina | SC-06 | Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) | 190 | Atea Study Site, Atea Study Site, | Atea Pharmaceuticals, Inc. | Drug: AT-527, Other: Placebo |
| South Carolina | SC-06 | Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization | 198 | Ralph H. Johnson VA Medical Center, | VA Office of Research and Development | Drug: Degarelix, Other: Saline |
| South Carolina | SC-06 | Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression | 208 | Octapharma Research Site, | Octapharma | Biological: Octagam 10%, Other: Placebo |
| South Carolina | SC-06 | A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia | 500 | Medical University of South Carolina, Prisma Health-Midlands, | Hoffmann-La Roche, Gilead Sciences | Drug: Remdesivir, Drug: Tocilizumab, Drug: Placebo |
| South Carolina | SC-03 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | AnMed Health Cancer Center, Prisma Health Cancer Institute – Easley, Self Regional Healthcare, Prisma Health Cancer Institute – Seneca, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| South Carolina | SC-01 | Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects | 120 | Blade Research Site, | Blade Therapeutics, Clinipace Worldwide | Drug: BLD-2660 |
| South Carolina | SC-01 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | South Carolina Cancer Specialists PC, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| South Carolina | SC-02 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Lexington Medical Center, | Gilead Sciences | Drug: Remdesivir |
| South Carolina | SC-07 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Main Street Physician's Care, Main Street Physician's Care, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| South Carolina | SC-04 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Prisma Health Richland Hospital, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| South Carolina | SC-04 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Prisma Health Richland Hospital, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| South Carolina | SC-04 | Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) | 6000 | Prisma Health, | Montreal Heart Institute, National Heart, Lung, and Blood Institute (NHLBI), Bill and Melinda Gates Foundation, The Government of Quebec, DACIMA Software | Drug: Colchicine, Drug: Placebo oral tablet |
| South Carolina | SC-04 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | St. Francis Hospital, | Gilead Sciences | Drug: Remdesivir |
| South Carolina | SC-04 | Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS | 20 | Prisma Health, | Prisma Health-Upstate | Procedure: Therapeutic Plasma Exchange, Drug: Ruxolitinib |
| South Carolina | SC-04 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Prisma Health Cancer Institute - Spartanburg, Saint Francis Hospital, BI-LO Charities Children's Cancer Center, Prisma Health Cancer Institute – Butternut, Prisma Health Cancer Institute – Faris, Saint Francis Cancer Center, Prisma Health Cancer Institute – Eastside, Prisma Health Cancer Institute – Greer, Gibbs Cancer Center-Pelham, Spartanberg Medical Center, Prisma Health Cancer Institute – Spartanburg, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| South Carolina | SC-05 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Gibbs Cancer Center-Gaffney, MGC Hematology Oncology-Union, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| South Dakota | SD-00 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Meridian Clinical Research LLC, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| South Dakota | SD-00 | Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection | 1 | Sanford Health, | Sanford Health | Drug: Hydroxychloroquine, Dietary Supplement: Vitamin D |
| South Dakota | SD-00 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Sanford Cancer Center Oncology Clinic, Sanford USD Medical Center - Sioux Falls, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| South Dakota | SD-00 | Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older | 600 | Meridian Clinical Research, | ModernaTX, Inc., Biomedical Advanced Research and Development Authority | Biological: Biological: mRNA-1273: 50 mcg, Other: Placebo, Biological: Biological: mRNA-1273: 100 mcg |
| South Dakota | SD-00 | Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19) | 124 | Monument Health Clinical Research, | CSL Behring | Biological: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody, Drug: Placebo |
| Tennessee | TN-04 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Trinity Clinical Research, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Tennessee | TN-03 | Compassionate Use of Hyperbaric Oxygen Therapy | 100 | CHI, | SerenaGroup, Inc., SerenaGroup Research Foundation | |
| Tennessee | TN-03 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Thompson Oncology Group-Oak Ridge, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Tennessee | TN-09 | Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients | 100 | St. Jude Children's Research Hosptial, | Novartis Pharmaceuticals, Novartis | Drug: Crizanlizumab |
| Tennessee | TN-09 | St. Jude Tracking of Viral and Host Factors Associated With COVID-19 | 1517 | St. Jude Children's Research Hospital, | St. Jude Children's Research Hospital | |
| Tennessee | TN-09 | Risk Factors, Clinical Characteristics and Outcomes of Acute Infection With Coronavirus 2019 (COVID-19) In Children | 400 | St. Jude Children's Research Hospital, | St. Jude Children's Research Hospital | |
| Tennessee | TN-09 | Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury | 46 | University of Tennessee Health Care System, | AbbVie, Janssen Research & Development, LLC, Pharmacyclics LLC (An AbbVie Company) | Drug: Ibrutinib, Drug: Placebo |
| Tennessee | TN-09 | Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization | 198 | Memphis VA Medical Center, | VA Office of Research and Development | Drug: Degarelix, Other: Saline |
| Tennessee | TN-07 | Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine | 1363 | Clinical Trials Center of Middle Tennessee, | Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke University | Drug: Hydroxychloroquine, Drug: Placebo oral tablet |
| Tennessee | TN-02 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Alliance for Multispecialty Research LLC, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Tennessee | TN-02 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | East Tennessee Childrens Hospital, Thompson Cancer Survival Center, Thompson Cancer Survival Center – West, Thompson Oncology Group-Lenoir City, Thompson Oncology Group-Maryville, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Tennessee | TN-01 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Holston Medical Group, Holston Medical Group, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Tennessee | TN-05 | Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID) | 200 | Vanderbilt University, | Vanderbilt University Medical Center, United States Department of Defense | |
| Tennessee | TN-05 | Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study | 250 | Vanderbilt University Medical Center, | Ansun Biopharma, Inc. | Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL |
| Tennessee | TN-05 | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 5000 | Monroe Carell Jr. Children's Hospital at Vanderbilt, | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: |
| Tennessee | TN-05 | Adaptive COVID-19 Treatment Trial (ACTT) | 1062 | Vanderbilt University Medical Center, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir |
| Tennessee | TN-05 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | TriStar Centennial Medical Center, | Gilead Sciences | Drug: Remdesivir |
| Tennessee | TN-05 | Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease | 479 | Vanderbilt University Medical Center, | Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI) | Drug: Hydroxychloroquine, Drug: Placebo |
| Tennessee | TN-05 | Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine | 1363 | Vanderbilt University Medical Center, | Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke University | Drug: Hydroxychloroquine, Drug: Placebo oral tablet |
| Tennessee | TN-05 | Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects | 120 | Vanderbilt University Medical Center, | Blade Therapeutics, Clinipace Worldwide | Drug: BLD-2660 |
| Tennessee | TN-05 | Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19 | 90 | Vanderblt University Medical Center, | Vanderbilt University Medical Center | Other: Saline Nasal Irrigation, Other: Saline with Baby Shampoo Nasal Irrigation |
| Tennessee | TN-05 | A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE) | 227 | Vanderbilt University Medical Cancer, | Kinevant Sciences GmbH, Roivant Sciences, Inc. | Drug: Gimsilumab, Drug: Placebo |
| Tennessee | TN-05 | COVID-19 and Cancer Consortium Registry | 10000 | Vanderbilt University Medical Center, | Vanderbilt-Ingram Cancer Center | Other: Web-based REDCap survey |
| Tennessee | TN-05 | COVID-19 Patient Positioning Pragmatic Trial | 503 | Vanderbilt University Medical Center, | Vanderbilt University Medical Center | Other: Prone, Other: Usual Care |
| Tennessee | TN-05 | Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults | 1000 | Vanderbilt University Medical Center, | Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS) | Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo |
| Tennessee | TN-05 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Clinical Research Associates, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Tennessee | TN-05 | Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC) | 3000 | Vanderbilt University Medical Center, | University of Manitoba, University Health Network, Toronto | Drug: Heparin |
| Tennessee | TN-05 | Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19 | 600 | Vanderbilt University Medical Center, | Vanderbilt University Medical Center, AbbVie | Drug: Lopinavir/Ritonavir 400 mg/100 mg, Other: Placebo |
| Tennessee | TN-05 | COVID-19: Human Epidemiology and Response to SARS-CoV-2 | 5605 | Vanderbilt University Medical Center, | National Institute of Allergy and Infectious Diseases (NIAID), Rho Federal Systems Division, Inc. (Rho) | Procedure: Collection of Biological Samples, Procedure: Symptom and Exposure Surveys |
| Tennessee | TN-05 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Vanderbilt Breast Center at One Hundred Oaks, Vanderbilt University/Ingram Cancer Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Tennessee | TN-05 | Validity of at Home Visual Acuity Measurements for Telemedicine During Corona Virus (COVID-19) Pandemic | 150 | Vanderbilt Eye Institute, | Vanderbilt University Medical Center | Other: Non invasive visual acuity testing |
| Tennessee | TN-05 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | Vanderbilt University Medical Center, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| Tennessee | TN-05 | Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19 | 727 | Vanderbilt Vaccine CRS, | HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials Network | Other: Sample collection |
| Tennessee | TN-05 | The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID) | 80 | Vanderbilt University, | Ridgeback Biotherapeutics, LP | Drug: EIDD-2801, Drug: Placebo (PB0) |
| Tennessee | TN-08 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Clinical Neuroscience Solutions, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Tennessee | TN-08 | Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia | 270 | Baptist Memorial Hospital, | Alexion Pharmaceuticals | Biological: Ravulizumab, Other: Best Supportive Care |
| Tennessee | TN-08 | INB03 for the Treatment of Pulmonary Complications From COVID-19 | 366 | Baptist Clinical Research Institute, | Inmune Bio, Inc. | Drug: INB03, Drug: Placebo |
| Tennessee | TN-08 | Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. | 62 | Research Site, | AstraZeneca, Acerta Pharma B.V. | Drug: Acalabrutinib |
| Tennessee | TN-08 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Baptist Memorial Hospital and Cancer Center-Collierville, Baptist Memorial Hospital and Cancer Center-Memphis, Baptist Memorial Hospital for Women, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Texas | TX-10 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | ARC Clinical Research at Wilson Parke, Martin Diagnostic Clinic, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Texas | TX-11 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Benchmark Research, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Texas | TX-11 | Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older | 600 | Benchmark Research, | ModernaTX, Inc., Biomedical Advanced Research and Development Authority | Biological: Biological: mRNA-1273: 50 mcg, Other: Placebo, Biological: Biological: mRNA-1273: 100 mcg |
| Texas | TX-12 | Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients | 100 | Cook Childrens Medical Center Oncology, | Novartis Pharmaceuticals, Novartis | Drug: Crizanlizumab |
| Texas | TX-12 | Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study | 250 | Cook Children's, | Ansun Biopharma, Inc. | Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL |
| Texas | TX-12 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Baylor University Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Texas | TX-12 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Baylor University Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Texas | TX-12 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Ventavia Research Group LLC, Benchmark Research, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Texas | TX-12 | A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19 | 270 | Baylor All Saints Medical Center at Fort Worth, | Janssen Pharmaceutica N.V., Belgium | Drug: Sirukumab, Drug: Placebo, Other: Standard of Care (SOC) |
| Texas | TX-12 | Treatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite | 0 | Participating Research Facility, | Hope Pharmaceuticals | Drug: Sodium Nitrite, Drug: Normal Saline |
| Texas | TX-13 | Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19) | 124 | PharmaTex Research, | CSL Behring | Biological: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody, Drug: Placebo |
| Texas | TX-14 | Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery | 600 | MD Anderson League City, | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Other: Questionnaire Administration |
| Texas | TX-14 | Adaptive COVID-19 Treatment Trial (ACTT) | 1062 | University of Texas Medical Branch, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir |
| Texas | TX-14 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Texas Department of Criminal Justice Hospital, | Gilead Sciences | Drug: Remdesivir |
| Texas | TX-14 | Plasma Adsorption in Patients With Confirmed COVID-19 | 2000 | UTMB, | Marker Therapeutics AG, Terumo BCT | Device: Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol) |
| Texas | TX-14 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | University of Texas Medical Branch, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Texas | TX-14 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Baptist Hospitals of Southeast Texas Cancer Center, Baptist Regional Cancer Network, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Texas | TX-14 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | University of Texas Medical Branch, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| Texas | TX-14 | Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19 | 44 | HCA Houston Healthcare Mainland, | ViralClear Pharmaceuticals, Inc. | Drug: Merimepodib, Drug: Matching Placebo, Drug: Remdesivir |
| Texas | TX-15 | Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection | 4000 | Rio Grande Valley Clinical Research Institute, | Romark Laboratories L.C. | Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex |
| Texas | TX-15 | A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia | 379 | McAllen Medical Center, | Genentech, Inc. | Drug: Placebo, Drug: Tocilizumab |
| Texas | TX-16 | A Study of Auxora in Patients With Severe COVID-19 Pneumonia | 400 | Texas Tech University Medical Center, | CalciMedica, Inc. | Drug: Auxora, Drug: Placebo |
| Texas | TX-16 | Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP) | 0 | William Beaumont Army Medical Center, | U.S. Army Medical Research and Development Command | Biological: Anti-Sars-CoV-2 Convalescent Plasma |
| Texas | TX-17 | BCG Vaccine for Health Care Workers as Defense Against COVID 19 | 1800 | Texas A&M Family Care Clinic, | Texas A&M University, Baylor College of Medicine, M.D. Anderson Cancer Center, Cedars-Sinai Medical Center, Harvard University | Biological: BCG Vaccine, Biological: Placebo Vaccine |
| Texas | TX-17 | Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19 | 300 | St. David's North Austin Medical Center, | Humanigen, Inc. | Biological: Lenzilumab, Drug: Standard of Care |
| Texas | TX-17 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Saint Joseph Regional Cancer Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Texas | TX-17 | A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia | 500 | Baylor Scott and White Medical Center, | Hoffmann-La Roche, Gilead Sciences | Drug: Remdesivir, Drug: Tocilizumab, Drug: Placebo |
| Texas | TX-18 | Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study | 250 | Therapeutic Concepts, | Ansun Biopharma, Inc. | Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL |
| Texas | TX-18 | Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) | 6000 | Spring Clinical Research, | Montreal Heart Institute, National Heart, Lung, and Blood Institute (NHLBI), Bill and Melinda Gates Foundation, The Government of Quebec, DACIMA Software | Drug: Colchicine, Drug: Placebo oral tablet |
| Texas | TX-18 | Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19 | 100 | United Memorial Medical Center, | Hope Biosciences, Advanced Diagnostics Healthcare, Hope Biosciences Stem Cell Research Foundation, United Memorial Medical Center | Drug: HB-adMSC, Drug: Placebo |
| Texas | TX-18 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Ventavia Research Group, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Texas | TX-18 | Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. | 62 | Research Site, | AstraZeneca, Acerta Pharma B.V. | Drug: Acalabrutinib |
| Texas | TX-18 | Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants | 52 | Therapeutic Concepts, | BeiGene | Drug: Zanubrutinib, Drug: Supportive Care, Drug: Placebo |
| Texas | TX-18 | Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19 | 44 | HCA Houston Healthcare Medical Center, | ViralClear Pharmaceuticals, Inc. | Drug: Merimepodib, Drug: Matching Placebo, Drug: Remdesivir |
| Texas | TX-19 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Covenant Medical Center, | Gilead Sciences | Drug: Remdesivir |
| Texas | TX-19 | Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants | 52 | Covenant Health System, | BeiGene | Drug: Zanubrutinib, Drug: Supportive Care, Drug: Placebo |
| Texas | TX-19 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Covenant Children's Hospital, UMC Cancer Center / UMC Health System, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Texas | TX-20 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Methodist Healthcare System of San Antonio, | Gilead Sciences | Drug: Remdesivir |
| Texas | TX-20 | Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection | 4000 | BFHC Research, | Romark Laboratories L.C. | Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex |
| Texas | TX-20 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Clinical Trials of Texas Inc, Diagnostics Research Group, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Texas | TX-20 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Audie L. Murphy VA Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Texas | TX-21 | Adaptive COVID-19 Treatment Trial (ACTT) | 1062 | Brooke Army Medical Center, University of Texas Health Science Center at San Antonio, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir |
| Texas | TX-21 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | St. David's South Austin Medical Center, | Gilead Sciences | Drug: Remdesivir |
| Texas | TX-21 | Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP) | 0 | Brooke Army Medical Center, | U.S. Army Medical Research and Development Command | Biological: Anti-Sars-CoV-2 Convalescent Plasma |
| Texas | TX-21 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Tekton Research Inc, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Texas | TX-21 | Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) | 500 | University of Texas Health Science Center, | Incyte Corporation | Drug: Placebo, Drug: Ruxolitinib |
| Texas | TX-21 | Assessing Pediatric Food Insecurity During the COVID-19 Pandemic in Austin | 1000 | Dell Medical School, | University of Texas at Austin | Other: During COVID-19 Pandemic, Other: After COVID-19 Pandemic |
| Texas | TX-21 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | University Hospital, University of Texas Health Science Center at San Antonio, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Texas | TX-21 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | Brooke Army Medical Center, University of Texas Health Science Center at San Antonio, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| Texas | TX-21 | Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19 | 44 | St. David's South Austin Medical Center, | ViralClear Pharmaceuticals, Inc. | Drug: Merimepodib, Drug: Matching Placebo, Drug: Remdesivir |
| Texas | TX-22 | Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery | 600 | MD Anderson in Sugar Land, | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Other: Questionnaire Administration |
| Texas | TX-22 | A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19 | 100 | Hope Biosciences Stem Cell Research Foundation, | Hope Biosciences, Hope Biosciences Stem Cell Research Foundation | Drug: HB-adMSCs, Drug: Placebos |
| Texas | TX-22 | A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19 | 56 | Hope Biosciences Stem Cell Research Foundation, | Hope Biosciences | Drug: HB-adMSCs |
| Texas | TX-22 | Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection | 4000 | LinQ Research LLC, | Romark Laboratories L.C. | Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex |
| Texas | TX-22 | A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia | 100 | Houston Methodist Sugar Land Hospital, | Hoffmann-La Roche | Drug: Tociliuzumab |
| Texas | TX-22 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | LinQ Research, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Texas | TX-24 | A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE) | 227 | Baylor Scott & White All Saints Medical Center, Baylor Scott & White Medical Center, | Kinevant Sciences GmbH, Roivant Sciences, Inc. | Drug: Gimsilumab, Drug: Placebo |
| Texas | TX-25 | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 5000 | Dell Children's Medical Center of Central Texas, | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: |
| Texas | TX-25 | Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19 | 300 | St. David's Healthcare, | Humanigen, Inc. | Biological: Lenzilumab, Drug: Standard of Care |
| Texas | TX-25 | ANTIBODY BASED TESTS FOR SARSCoV-2 COVID-19) - Evaluation of Patients and Healthcare Providers in the Confines of Healthcare Settings | 5000 | St. David's Medical Center, | Texas Cardiac Arrhythmia Research Foundation | Diagnostic Test: CoronaCideTM COVID-19 IgM/IgG Rapid Test and Premier Biotech COVID-19 IgM/IgG Rapid Test |
| Texas | TX-25 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Benchmark Research, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Texas | TX-25 | Comparison of the Efficacy of Rapid Tests to Identify COVID-19 Infection (CATCh COVID-19) | 100 | Texas Cardiac Arrhythmia Institute, | Texas Cardiac Arrhythmia Research Foundation | Diagnostic Test: diagnostic tests for COVID-19 infection |
| Texas | TX-25 | Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) | 500 | St David's Medical Center, | Incyte Corporation | Drug: Placebo, Drug: Ruxolitinib |
| Texas | TX-25 | Immunophenotyping Assessment in a COVID-19 Cohort | 2000 | University of Texas at Austin, | National Institute of Allergy and Infectious Diseases (NIAID), Benaroya Research Institute, Boston Children's Hospital | Procedure: Biological sample collection, Procedure: Data Collection: Clinical Care Assessments |
| Texas | TX-25 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Dell Children's Medical Center of Central Texas, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Texas | TX-25 | Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older | 600 | Benchmark Research, | ModernaTX, Inc., Biomedical Advanced Research and Development Authority | Biological: Biological: mRNA-1273: 50 mcg, Other: Placebo, Biological: Biological: mRNA-1273: 100 mcg |
| Texas | TX-25 | Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19 | 44 | St. David's Medical Center, | ViralClear Pharmaceuticals, Inc. | Drug: Merimepodib, Drug: Matching Placebo, Drug: Remdesivir |
| Texas | TX-26 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Ventavia Research Group LLC, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Texas | TX-27 | A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia | 379 | Crossroads Clinical Research, | Genentech, Inc. | Drug: Placebo, Drug: Tocilizumab |
| Texas | TX-28 | A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19 | 204 | Laguna Clinical Research, | Ridgeback Biotherapeutics, LP | Drug: EIDD-2801, Drug: Placebo (PBO) |
| Texas | TX-30 | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 5000 | University of Texas-Southwestern Medical Center, | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: |
| Texas | TX-30 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | UT Southwestern Medical Center Amelia Court, Baylor University Medical Center, UT Southwestern Medical Center Amelia Court, UT Southwestern Medical Center Amelia Court, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Texas | TX-30 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | UT Southwestern Medical Center Amelia Court, Baylor University Medical Center, UT Southwestern Medical Center Amelia Court, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Texas | TX-30 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site, Regeneron Study Site, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| Texas | TX-30 | Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) | 6000 | Baylor Scott & White Research Institute, University of Texas(UT) Southwestern Medical Center, | Montreal Heart Institute, National Heart, Lung, and Blood Institute (NHLBI), Bill and Melinda Gates Foundation, The Government of Quebec, DACIMA Software | Drug: Colchicine, Drug: Placebo oral tablet |
| Texas | TX-30 | Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers | 228 | Baylor Research Medical Center, | Baylor Research Institute | Drug: Hydroxychloroquine |
| Texas | TX-30 | Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine | 1363 | University of Texas Southwestern Medical Center, | Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke University | Drug: Hydroxychloroquine, Drug: Placebo oral tablet |
| Texas | TX-30 | Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19) | 390 | Baylor Scott & White Research Institute, | CytoDyn, Inc. | Drug: Placebos, Drug: Leronlimab (700mg) |
| Texas | TX-30 | Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection | 202 | Baylor Scott & White Dallas, | Karyopharm Therapeutics Inc | Drug: Selinexor, Other: Placebo |
| Texas | TX-30 | A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE) | 227 | Baylor Jack & Jane Hamilton Heart and Vascular Hospital, Baylor University Medical Center, | Kinevant Sciences GmbH, Roivant Sciences, Inc. | Drug: Gimsilumab, Drug: Placebo |
| Texas | TX-30 | Convalescent Plasma in Outpatients With COVID-19 | 600 | William P. Clements Jr. University Hospital, | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network | Biological: Convalescent Plasma, Biological: Saline |
| Texas | TX-30 | Plasma Adsorption in Patients With Confirmed COVID-19 | 2000 | UT Southwestern/Clements Hospital, | Marker Therapeutics AG, Terumo BCT | Device: Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol) |
| Texas | TX-30 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | North Texas Infectious Diseases Consultants, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Texas | TX-30 | COVID-19: Human Epidemiology and Response to SARS-CoV-2 | 5605 | University of Texas Southwestern Medical Center, | National Institute of Allergy and Infectious Diseases (NIAID), Rho Federal Systems Division, Inc. (Rho) | Procedure: Collection of Biological Samples, Procedure: Symptom and Exposure Surveys |
| Texas | TX-30 | A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19 | 270 | Baylor Scott & White Research Institute, | Janssen Pharmaceutica N.V., Belgium | Drug: Sirukumab, Drug: Placebo, Other: Standard of Care (SOC) |
| Texas | TX-30 | A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia | 410 | Parkland Health & Hospital System, University of Texas Southwestern Medical Center, | Genentech, Inc. | Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo |
| Texas | TX-30 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Parkland Memorial Hospital, UT Southwestern/Simmons Cancer Center-Dallas, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Texas | TX-30 | Predictors of Severe COVID-19 Outcomes | 1500 | University of Texas Southwestern Medical Center, | Verily Life Sciences LLC | |
| Texas | TX-30 | Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization | 198 | VA North Texas Health Care System, | VA Office of Research and Development | Drug: Degarelix, Other: Saline |
| Texas | TX-30 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | Baylor Scott & White Health, University of Texas Southwestern Medical Center, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| Texas | TX-31 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Baylor University Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Texas | TX-31 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Baylor University Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Texas | TX-31 | Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine | 1363 | Baylor Scott & White Medical Center, | Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke University | Drug: Hydroxychloroquine, Drug: Placebo oral tablet |
| Texas | TX-31 | A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE) | 227 | Baylor Scott & White Medical Center - Temple, | Kinevant Sciences GmbH, Roivant Sciences, Inc. | Drug: Gimsilumab, Drug: Placebo |
| Texas | TX-31 | A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19 | 66 | Texas A&M College of Medicine, | Apellis Pharmaceuticals, Inc. | Drug: APL-9, Other: Vehicle Control |
| Texas | TX-31 | A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia | 500 | Baylor Scott & White Health, | Hoffmann-La Roche, Gilead Sciences | Drug: Remdesivir, Drug: Tocilizumab, Drug: Placebo |
| Texas | TX-32 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Texas Health Presbyterian Hospital Dallas, | Gilead Sciences | Drug: Remdesivir |
| Texas | TX-32 | Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19 | 300 | Texas Health, | Humanigen, Inc. | Biological: Lenzilumab, Drug: Standard of Care |
| Texas | TX-32 | A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia | 500 | Baylor University Medical Center, | Hoffmann-La Roche, Gilead Sciences | Drug: Remdesivir, Drug: Tocilizumab, Drug: Placebo |
| Texas | TX-33 | Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study | 250 | Texas Health, | Ansun Biopharma, Inc. | Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL |
| Texas | TX-33 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Liver Institute of Methodist Dallas Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Texas | TX-33 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Liver Institute of Methodist Dallas Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Texas | TX-33 | Convalescent Plasma to Stem Coronavirus (CSSC-001) | 500 | Methodist Dallas Medical Center, | Johns Hopkins University | Biological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma |
| Texas | TX-33 | Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects | 120 | Blade Research Site, | Blade Therapeutics, Clinipace Worldwide | Drug: BLD-2660 |
| Texas | TX-33 | A Study of Auxora in Patients With Severe COVID-19 Pneumonia | 400 | John Peter Smith Hospital, | CalciMedica, Inc. | Drug: Auxora, Drug: Placebo |
| Texas | TX-33 | Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection | 60 | Methodist Dallas Medical Center, | Denver Health and Hospital Authority, Genentech, Inc., University of Colorado, Denver, National Jewish Health, Beth Israel Deaconess Medical Center, Long Island Jewish Medical Center, Scripps Health, St. Mary's Medical Center, University of Miami, Ben Taub Hospital, Methodist Dallas Medical Center | Drug: Alteplase 50 MG [Activase] |
| Texas | TX-33 | Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19 | 20 | Trinity Health and Wellness Center CRS, | National Institute of Allergy and Infectious Diseases (NIAID), Teva Pharmaceuticals Industries LTD | Drug: Hydroxychloroquine (HCQ), Drug: Azithromycin (Azithro), Drug: Placebo for Hydroxychloroquine, Drug: Placebo for Azithromycin |
| Texas | TX-33 | A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study) | 252 | Renibus Therapeutics, | Renibus Therapeutics, Inc. | Drug: RBT-9 (90 mg), Drug: 0.9% sodium chloride (normal saline) |
| Texas | TX-33 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | UT Southwestern/Simmons Cancer Center-Fort Worth, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Texas | TX-33 | Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure | 524 | Texas Health Harris Methodist Hospital Fort Worth, | Chimerix | Drug: Dociparastat sodium, Drug: Placebo |
| Texas | TX-33 | A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia | 500 | Liver Institute at Methodist Dallas, | Hoffmann-La Roche, Gilead Sciences | Drug: Remdesivir, Drug: Tocilizumab, Drug: Placebo |
| Texas | TX-34 | A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia | 379 | Valley Baptist Medical Center, | Genentech, Inc. | Drug: Placebo, Drug: Tocilizumab |
| Texas | TX-35 | Assessing Pediatric Food Insecurity During the COVID-19 Pandemic in Austin | 1000 | CommUnity Care Clinic, CommUnity Care Clinic - Rundberg, | University of Texas at Austin | Other: During COVID-19 Pandemic, Other: After COVID-19 Pandemic |
| Texas | TX-35 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Children's Hospital of San Antonio, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Texas | TX-36 | Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF) | 800 | Centex Studies Inc., | Romark Laboratories L.C. | Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex |
| Texas | TX-36 | Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection | 4000 | Centex Studies Inc., | Romark Laboratories L.C. | Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex |
| Texas | TX-06 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Methodist Mansfield Medical Center, | Gilead Sciences | Drug: Remdesivir |
| Texas | TX-07 | The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection | 100 | Next Level Urgent Care, | Pulmotect, Inc. | Drug: PUL-042 Inhalation Solution, Drug: Placebo |
| Texas | TX-07 | The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2 | 200 | Next Level Urgent Care, | Pulmotect, Inc. | Drug: PUL-042 Inhalation Solution, Drug: Placebo |
| Texas | TX-07 | Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19 | 100 | River Oaks Hospital and Clinics, | Hope Biosciences, Advanced Diagnostics Healthcare, Hope Biosciences Stem Cell Research Foundation, United Memorial Medical Center | Drug: HB-adMSC, Drug: Placebo |
| Texas | TX-07 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Texas Center For Drug Development Inc, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Texas | TX-07 | COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111 | 40 | Memorial Herman Memorial City Hospital, | Veru Inc. | Drug: Veru-111 |
| Texas | TX-05 | Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection | 4000 | SMS Clinical Research LLC, | Romark Laboratories L.C. | Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex |
| Texas | TX-05 | Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID) | 432 | Novartis Investigative Site, | Novartis Pharmaceuticals, Incyte Corporation, Novartis | Drug: Ruxolitinib, Drug: Placebo |
| Texas | TX-05 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | SMS Clinical Research, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Texas | TX-05 | Study of Efficacy and Safety of MAS825 in Patients With COVID-19 | 140 | Novartis Investigative Site, | Novartis Pharmaceuticals, Novartis | Drug: MAS825, Drug: Matching placebo |
| Texas | TX-05 | A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19 | 204 | Care United Research, | Ridgeback Biotherapeutics, LP | Drug: EIDD-2801, Drug: Placebo (PBO) |
| Texas | TX-09 | A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19) | 242 | M D Anderson Cancer Center, | Millennium Pharmaceuticals, Inc., Takeda | Drug: TAK-981, Drug: Standard of care |
| Texas | TX-09 | Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study | 250 | M D Anderson Cancer Center, | Ansun Biopharma, Inc. | Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL |
| Texas | TX-09 | Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery | 600 | M D Anderson Cancer Center, | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Other: Questionnaire Administration |
| Texas | TX-09 | DiaBetter Together for Young Adults With Type 1 Diabetes | 186 | Baylor College of Medicine, | Baylor College of Medicine, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Children's National Research Institute | Behavioral: DiaBetter Together, Behavioral: Peer Mentor Delivery |
| Texas | TX-09 | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 5000 | University of Texas--Memorial Hermann Texas Medical Center, | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: |
| Texas | TX-09 | Adaptive COVID-19 Treatment Trial (ACTT) | 1062 | Baylor College of Medicine, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir |
| Texas | TX-09 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Houston Methodist Hospital, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Texas | TX-09 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Houston Methodist Hospital, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Texas | TX-09 | Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure | 165 | Houston Methodist Hospital, | NeuroRx, Inc., Lavin Consulting, LLC | Drug: Aviptadil by intravenous infusion + standard of care, Drug: Normal Saline Infusion + standard of care |
| Texas | TX-09 | The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection | 100 | M D Anderson Cancer Center, | Pulmotect, Inc. | Drug: PUL-042 Inhalation Solution, Drug: Placebo |
| Texas | TX-09 | The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2 | 200 | M D Anderson Cancer Center, | Pulmotect, Inc. | Drug: PUL-042 Inhalation Solution, Drug: Placebo |
| Texas | TX-09 | CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment | 243 | University of Texas at Houston, | OncoImmune, Inc. | Drug: CD24Fc, Drug: Placebo |
| Texas | TX-09 | A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia | 450 | Baylor St. Luke's Medical Center, Harris Health System - Ben Taub Hospital, | Hoffmann-La Roche | Drug: Tocilizumab (TCZ), Drug: Placebo |
| Texas | TX-09 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | HCA Houston Healthcare West, | Gilead Sciences | Drug: Remdesivir |
| Texas | TX-09 | Convalescent Plasma to Stem Coronavirus (CSSC-001) | 500 | Baylor College of Medicine, University of Texas Health Science Center, | Johns Hopkins University | Biological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma |
| Texas | TX-09 | Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease | 479 | University of Texas Health Science Center, | Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI) | Drug: Hydroxychloroquine, Drug: Placebo |
| Texas | TX-09 | Cardiovascular Manifestations of COVID-19 | 500 | Memorial Hermann Hospital-Texas Medical Center, | Memorial Hermann Health System | Diagnostic Test: Electrocardiogram, telemetry, echocardiogram, laboratory values |
| Texas | TX-09 | Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19) | 384 | Houston Methodist Hospital, | I-Mab Biopharma Co. Ltd. | Drug: TJ003234, Drug: Placebo |
| Texas | TX-09 | Awake Prone Position for Early Hypoxemia in COVID-19 | 560 | Michael E. DeBakey Veteran Affairs Medical Center, | Boston University | Other: Self-prone position recommendation, Other: Usual care |
| Texas | TX-09 | Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease) | 30 | Houston Methodist Hospital, | Baylor College of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital System | Biological: Mesenchymal Stromal Cells, Other: Supportive Care |
| Texas | TX-09 | A Study of Auxora in Patients With Severe COVID-19 Pneumonia | 400 | Ben Taub, | CalciMedica, Inc. | Drug: Auxora, Drug: Placebo |
| Texas | TX-09 | Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19) | 390 | Baylor College of Medicine, University of Texas, | CytoDyn, Inc. | Drug: Placebos, Drug: Leronlimab (700mg) |
| Texas | TX-09 | BCG Vaccine for Health Care Workers as Defense Against COVID 19 | 1800 | Baylor College of Medicine, Baylor St. Luke's Medical Center, Harris Health System - Ben Taub Hospital, M D Anderson Cancer Center, | Texas A&M University, Baylor College of Medicine, M.D. Anderson Cancer Center, Cedars-Sinai Medical Center, Harvard University | Biological: BCG Vaccine, Biological: Placebo Vaccine |
| Texas | TX-09 | Dapagliflozin in Respiratory Failure in Patients With COVID-19 | 900 | Baylor College of Medicine, | Saint Luke's Health System, AstraZeneca, George Clinical Pty Ltd | Drug: Dapagliflozin 10 MG, Drug: Placebo |
| Texas | TX-09 | A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE) | 227 | University of Texas Health Science Center, | Kinevant Sciences GmbH, Roivant Sciences, Inc. | Drug: Gimsilumab, Drug: Placebo |
| Texas | TX-09 | Convalescent Plasma in Outpatients With COVID-19 | 600 | Ben Taub General Hospital, Memorial Hermann Texas Medical Center, | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network | Biological: Convalescent Plasma, Biological: Saline |
| Texas | TX-09 | Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection | 60 | Ben Taub Hospital, | Denver Health and Hospital Authority, Genentech, Inc., University of Colorado, Denver, National Jewish Health, Beth Israel Deaconess Medical Center, Long Island Jewish Medical Center, Scripps Health, St. Mary's Medical Center, University of Miami, Ben Taub Hospital, Methodist Dallas Medical Center | Drug: Alteplase 50 MG [Activase] |
| Texas | TX-09 | Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19 | 50 | Houston Methodist Hospital, | Fujifilm Pharmaceuticals U.S.A., Inc. | Drug: Favipiravir + Standard of Care, Drug: Standard of Care |
| Texas | TX-09 | Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia | 451 | Novartis Investigative Site, | Novartis Pharmaceuticals, Novartis | Drug: Canakinumab, Drug: Placebo |
| Texas | TX-09 | A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia | 100 | Houston Methodist Hospital, Michael E Debakey VA Medical Center, | Hoffmann-La Roche | Drug: Tociliuzumab |
| Texas | TX-09 | CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients | 300 | University of Texas Health Science Center, | NYU Langone Health, National Center for Advancing Translational Science (NCATS), Albert Einstein College of Medicine, Yale University, The University of Texas Health Science Center, Houston, The University of Texas Health Science Center at Tyler, University of Miami | Biological: Convalescent Plasma, Other: Saline solution |
| Texas | TX-09 | A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study) | 252 | Renibus Therapeutics, | Renibus Therapeutics, Inc. | Drug: RBT-9 (90 mg), Drug: 0.9% sodium chloride (normal saline) |
| Texas | TX-09 | Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia | 270 | Houston Methodist Hospital, | Alexion Pharmaceuticals | Biological: Ravulizumab, Other: Best Supportive Care |
| Texas | TX-09 | MSCs in COVID-19 ARDS | 223 | Houston Methodist Hospital, | Icahn School of Medicine at Mount Sinai, Mesoblast, Inc., National Heart, Lung, and Blood Institute (NHLBI) | Biological: Remestemcel-L, Drug: Placebo |
| Texas | TX-09 | A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia | 379 | Michael E Debakey VA Medical Center, | Genentech, Inc. | Drug: Placebo, Drug: Tocilizumab |
| Texas | TX-09 | Convalescent Plasma to Limit SARS-CoV-2 Associated Complications | 1344 | Baylor College of Medicine, University of Texas Health Science Center, | Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID) | Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor |
| Texas | TX-09 | Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease | 800 | GSK Investigational Site, | GlaxoSmithKline | Biological: Otilimab, Biological: Placebo, Drug: Standard of care |
| Texas | TX-09 | Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) | 500 | University of Texas Health Science Center At Houston, | Incyte Corporation | Drug: Placebo, Drug: Ruxolitinib |
| Texas | TX-09 | Immunophenotyping Assessment in a COVID-19 Cohort | 2000 | Baylor College of Medicine, | National Institute of Allergy and Infectious Diseases (NIAID), Benaroya Research Institute, Boston Children's Hospital | Procedure: Biological sample collection, Procedure: Data Collection: Clinical Care Assessments |
| Texas | TX-09 | Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. | 62 | Research Site, | AstraZeneca, Acerta Pharma B.V. | Drug: Acalabrutinib |
| Texas | TX-09 | Study of Efficacy and Safety of MAS825 in Patients With COVID-19 | 140 | Novartis Investigative Site, | Novartis Pharmaceuticals, Novartis | Drug: MAS825, Drug: Matching placebo |
| Texas | TX-09 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Baylor College of Medicine, Ben Taub General Hospital, Michael E DeBakey VA Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Texas | TX-09 | Predictors of Severe COVID-19 Outcomes | 1500 | Baylor College of Medicine, | Verily Life Sciences LLC | |
| Texas | TX-09 | Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization | 198 | Michael E. DeBakey VA Medical Center, | VA Office of Research and Development | Drug: Degarelix, Other: Saline |
| Texas | TX-09 | Anti-SARS Cov-2 T Cell Infusions for COVID 19 | 58 | Houston Methodist Hospital, | Baylor College of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital System, AlloVir | Biological: Dose Finding Phase (MTD), Biological: Partially HLA-matched SARS-CoVSTs, Other: Routine care (no SARS-CoVSTs) |
| Texas | TX-09 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | Baylor College of Medicine, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| Texas | TX-09 | The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID) | 80 | Houston Methodist Hospital, | Ridgeback Biotherapeutics, LP | Drug: EIDD-2801, Drug: Placebo (PB0) |
| Texas | TX-09 | A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia | 500 | Baylor St. Luke's Medical Center, Ben Taub General Hospital, Houston Methodist Hospital, | Hoffmann-La Roche, Gilead Sciences | Drug: Remdesivir, Drug: Tocilizumab, Drug: Placebo |
| Texas | TX-09 | Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19) | 124 | UT Health Science Center, | CSL Behring | Biological: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody, Drug: Placebo |
| Texas | TX-09 | Study of Sargramostim in Patients With COVID-19 | 120 | Memorial Hermann Hospital, | Partner Therapeutics, Inc. | Drug: Sargramostim, Drug: Standard of care |
| Texas | TX-08 | Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery | 600 | MD Anderson in The Woodlands, | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Other: Questionnaire Administration |
| Texas | TX-01 | CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients | 300 | University of Texas Health Science Center, | NYU Langone Health, National Center for Advancing Translational Science (NCATS), Albert Einstein College of Medicine, Yale University, The University of Texas Health Science Center, Houston, The University of Texas Health Science Center at Tyler, University of Miami | Biological: Convalescent Plasma, Other: Saline solution |
| Texas | TX-01 | Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. | 62 | Research Site, | AstraZeneca, Acerta Pharma B.V. | Drug: Acalabrutinib |
| Texas | TX-01 | Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression | 208 | Octapharma Research Site, | Octapharma | Biological: Octagam 10%, Other: Placebo |
| Texas | TX-01 | A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia | 500 | Baylor Scott & White Medical Center - Irving, | Hoffmann-La Roche, Gilead Sciences | Drug: Remdesivir, Drug: Tocilizumab, Drug: Placebo |
| Texas | TX-03 | A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE) | 227 | Baylor Scott & White Heart Hospital, | Kinevant Sciences GmbH, Roivant Sciences, Inc. | Drug: Gimsilumab, Drug: Placebo |
| Texas | TX-03 | MSCs in COVID-19 ARDS | 223 | Baylor Smith & White, | Icahn School of Medicine at Mount Sinai, Mesoblast, Inc., National Heart, Lung, and Blood Institute (NHLBI) | Biological: Remestemcel-L, Drug: Placebo |
| Texas | TX-03 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | UT Southwestern Clinical Center at Richardson/Plano, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Utah | UT-04 | Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID) | 200 | Intermountain Medical Center, | Vanderbilt University Medical Center, United States Department of Defense | |
| Utah | UT-04 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| Utah | UT-04 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Saint Mark's Hospital, | Gilead Sciences | Drug: Remdesivir |
| Utah | UT-04 | Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19 | 85 | Intermountain Health Care Inc., | Intermountain Health Care, Inc., University of Utah | Drug: Hydroxychloroquine, Drug: Azithromycin |
| Utah | UT-04 | Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease | 479 | Intermountain Medical Center, | Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI) | Drug: Hydroxychloroquine, Drug: Placebo |
| Utah | UT-04 | Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19 | 1550 | Intermountain Medical Center, | Intermountain Health Care, Inc., University of Utah, Utah Department of Health | Drug: Hydroxychloroquine, Drug: Azithromycin |
| Utah | UT-04 | Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older | 600 | Advanced Clinical Research, | ModernaTX, Inc., Biomedical Advanced Research and Development Authority | Biological: Biological: mRNA-1273: 50 mcg, Other: Placebo, Biological: Biological: mRNA-1273: 100 mcg |
| Utah | UT-03 | Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults | 1000 | Utah Valley Hospital, | Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS) | Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo |
| Utah | UT-03 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | J. Lewis Research Inc. / Foothill Family Clinic South, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Utah | UT-02 | Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID) | 200 | George Wahlen Salt Lake City Veterans Administration Hospital, | Vanderbilt University Medical Center, United States Department of Defense | |
| Utah | UT-02 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | University of Utah Health, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Utah | UT-02 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | University of Utah Health, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Utah | UT-02 | A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure | 10 | University of Utah Health, | University of Utah | Biological: Human Amniotic Fluid |
| Utah | UT-02 | A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia | 450 | Intermountain Medical Group, Intermountain LDS Hospital, | Hoffmann-La Roche | Drug: Tocilizumab (TCZ), Drug: Placebo |
| Utah | UT-02 | Convalescent Plasma to Stem Coronavirus (CSSC-001) | 500 | University of Utah, | Johns Hopkins University | Biological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma |
| Utah | UT-02 | Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection. | 16 | University of Utah Health, | Swedish Orphan Biovitrum | Biological: Emapalumab, Biological: Anakinra |
| Utah | UT-02 | Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19 | 85 | University of Utah, | Intermountain Health Care, Inc., University of Utah | Drug: Hydroxychloroquine, Drug: Azithromycin |
| Utah | UT-02 | Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease | 479 | University of Utah Hospital, | Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI) | Drug: Hydroxychloroquine, Drug: Placebo |
| Utah | UT-02 | Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19 | 1550 | University of Utah, | Intermountain Health Care, Inc., University of Utah, Utah Department of Health | Drug: Hydroxychloroquine, Drug: Azithromycin |
| Utah | UT-02 | University of Utah COVID-19 Hydrochloroquine Trial | 400 | University of Utah, | University of Utah | Drug: Hydroxychloroquine, Drug: Placebo oral tablet |
| Utah | UT-02 | Convalescent Plasma in Outpatients With COVID-19 | 600 | University of Utah Healthcare, | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network | Biological: Convalescent Plasma, Biological: Saline |
| Utah | UT-02 | Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults | 1000 | University of Utah Health, | Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS) | Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo |
| Utah | UT-02 | Prone Positioning in Awake Patients With COVID-19 Requiring Hospitalization | 30 | University of Utah Health Sciences Center, | University of Utah | Behavioral: Intermittent prone positioning instructions, Behavioral: Usual care positioning with no instructions |
| Utah | UT-02 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | J. Lewis Research Inc. / Foothill Family Clinic, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Utah | UT-02 | Convalescent Plasma to Limit SARS-CoV-2 Associated Complications | 1344 | University of Utah, | Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID) | Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor |
| Utah | UT-02 | Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury | 46 | Intermountain Healthcare, | AbbVie, Janssen Research & Development, LLC, Pharmacyclics LLC (An AbbVie Company) | Drug: Ibrutinib, Drug: Placebo |
| Utah | UT-02 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Farmington Health Center, University of Utah Sugarhouse Health Center, Huntsman Cancer Institute/University of Utah, George E Wahlen Department of Veterans Affairs Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Utah | UT-02 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | University of Utah, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| Utah | UT-02 | A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia | 500 | Intermountain LDS Hospital, | Hoffmann-La Roche, Gilead Sciences | Drug: Remdesivir, Drug: Tocilizumab, Drug: Placebo |
| Utah | UT-02 | Study of Sargramostim in Patients With COVID-19 | 120 | University of Utah Health, | Partner Therapeutics, Inc. | Drug: Sargramostim, Drug: Standard of care |
| Vermont | VT-00 | Sarilumab for Patients With Moderate COVID-19 Disease | 120 | VA Medical Center - White River Junction, | Westyn Branch-Elliman, VA Boston Healthcare System | Biological: SARILUMAB |
| Vermont | VT-00 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Norris Cotton Cancer Center-North, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Vermont | VT-00 | Longitudinal COVID-19 Cohort Study | 225 | University of Vermont College of Medicine, | University of Vermont | Other: COVID-19+ observational |
| Virginia | VA-10 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Shenandoah Oncology PC, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Virginia | VA-11 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Inova Fairfax Medical Campus, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Virginia | VA-11 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Inova Fairfax Medical Campus, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Virginia | VA-11 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| Virginia | VA-11 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Inova Fairfax Medical Campus, | Gilead Sciences | Drug: Remdesivir |
| Virginia | VA-11 | A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE) | 227 | Inova Fairfax Medical Campus, | Kinevant Sciences GmbH, Roivant Sciences, Inc. | Drug: Gimsilumab, Drug: Placebo |
| Virginia | VA-11 | Plasma Adsorption in Patients With Confirmed COVID-19 | 2000 | Inova Fairfax Medical Campus, | Marker Therapeutics AG, Terumo BCT | Device: Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol) |
| Virginia | VA-11 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Clinical Alliance for Research & Education, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Virginia | VA-11 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Kaiser Permanente Tysons Corner Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Virginia | VA-11 | Predictors of Severe COVID-19 Outcomes | 1500 | Inova Health Care Services, | Verily Life Sciences LLC | |
| Virginia | VA-11 | Characteristics of COVID-19 Infection Among PREGnant Women | 100 | INOVA Health System, | Inova Health System | Other: COVID-19 positive via testing |
| Virginia | VA-01 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Bon Secours Memorial Regional Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Virginia | VA-08 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Virginia Hospital Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Virginia | VA-08 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Virginia Hospital Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Virginia | VA-08 | Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP) | 0 | Fort Belvoir Community Hospital, | U.S. Army Medical Research and Development Command | Biological: Anti-Sars-CoV-2 Convalescent Plasma |
| Virginia | VA-08 | Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19) | 124 | Inova Alexandria Hospital, | CSL Behring | Biological: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody, Drug: Placebo |
| Virginia | VA-04 | Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study | 250 | VCU Health System, | Ansun Biopharma, Inc. | Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL |
| Virginia | VA-04 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | VCU Health Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Virginia | VA-04 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | VCU Health Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Virginia | VA-04 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| Virginia | VA-04 | Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease | 479 | VCU Medical Center, | Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI) | Drug: Hydroxychloroquine, Drug: Placebo |
| Virginia | VA-04 | SAFEty Study of Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (SAFE EVICT CORONA-ALI) | 60 | Hunter Holmes McGuire Veteran Affairs Medical Center, Virginia Commonwealth University, | Virginia Commonwealth University | Drug: L-ascorbic acid, Other: Placebo |
| Virginia | VA-04 | Awake Prone Position for Early Hypoxemia in COVID-19 | 560 | VCU Medical Center, | Boston University | Other: Self-prone position recommendation, Other: Usual care |
| Virginia | VA-04 | A Study of Auxora in Patients With Severe COVID-19 Pneumonia | 400 | Virginia Commonwealth University, | CalciMedica, Inc. | Drug: Auxora, Drug: Placebo |
| Virginia | VA-04 | Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation | 20 | Hunter Holmes Mcguire Veteran Affairs Medical Center, | Hunter Holmes Mcguire Veteran Affairs Medical Center, McGuire Research Institute | Drug: L-ascorbic acid |
| Virginia | VA-04 | Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults | 1000 | Virginia Commonwealth University, | Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS) | Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo |
| Virginia | VA-04 | Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia | 451 | Novartis Investigative Site, | Novartis Pharmaceuticals, Novartis | Drug: Canakinumab, Drug: Placebo |
| Virginia | VA-04 | Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. | 62 | Research Site, | AstraZeneca, Acerta Pharma B.V. | Drug: Acalabrutinib |
| Virginia | VA-04 | A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia | 410 | Virginia Commonwealth University, | Genentech, Inc. | Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo |
| Virginia | VA-04 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | VCU Massey Cancer Center at Stony Point, Virginia Commonwealth University/Massey Cancer Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Virginia | VA-07 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Henrico Doctors Hospital, | Gilead Sciences | Drug: Remdesivir |
| Virginia | VA-07 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Virginia Research Center LLC, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Virginia | VA-07 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Bon Secours Saint Francis Medical Center, Bon Secours Saint Mary's Hospital, Bon Secours Cancer Institute at Reynolds Crossing, Virginia Cancer Institute, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Virginia | VA-03 | Adaptive COVID-19 Treatment Trial (ACTT) | 1062 | Naval Medical Center Portsmouth, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir |
| Virginia | VA-03 | Dapagliflozin in Respiratory Failure in Patients With COVID-19 | 900 | Sentara Healthcare, | Saint Luke's Health System, AstraZeneca, George Clinical Pty Ltd | Drug: Dapagliflozin 10 MG, Drug: Placebo |
| Virginia | VA-03 | Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP) | 0 | Naval Medical Center Portsmouth, | U.S. Army Medical Research and Development Command | Biological: Anti-Sars-CoV-2 Convalescent Plasma |
| Virginia | VA-03 | Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults | 1000 | Sentara Norfolk General Hospital, | Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS) | Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo |
| Virginia | VA-03 | Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure | 524 | Sentara Clinical Trials, | Chimerix | Drug: Dociparastat sodium, Drug: Placebo |
| Virginia | VA-03 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | Naval Medical Center Portsmouth, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| Virginia | VA-02 | Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP) | 0 | Naval Surface Force Atlantic, USS Dwight D. Eisenhower CVN 69, USS Gerald R. Ford CVN 78, | U.S. Army Medical Research and Development Command | Biological: Anti-Sars-CoV-2 Convalescent Plasma |
| Virginia | VA-02 | A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia | 379 | Sentara Medical Group, | Genentech, Inc. | Drug: Placebo, Drug: Tocilizumab |
| Virginia | VA-06 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Carilion Medical Center, | Gilead Sciences | Drug: Remdesivir |
| Virginia | VA-06 | Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease | 800 | GSK Investigational Site, | GlaxoSmithKline | Biological: Otilimab, Biological: Placebo, Drug: Standard of care |
| Virginia | VA-06 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Augusta Health Center for Cancer and Blood Disorders, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Virginia | VA-05 | Adaptive COVID-19 Treatment Trial (ACTT) | 1062 | University of Virginia, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir |
| Virginia | VA-05 | Clinical Validation of New Injection Molded Flocked Nasopharyngeal Swabs in Response to the COVID-19 Pandemic | 40 | University of Virginia, | University of Virginia | Device: Control swab, Device: Prototype swab |
| Virginia | VA-05 | MSCs in COVID-19 ARDS | 223 | University of Virginia, | Icahn School of Medicine at Mount Sinai, Mesoblast, Inc., National Heart, Lung, and Blood Institute (NHLBI) | Biological: Remestemcel-L, Drug: Placebo |
| Virginia | VA-05 | Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia | 29 | University of Virginia, | University of Virginia | Drug: High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma |
| Virginia | VA-05 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | University of Virginia, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| Washington | WA-10 | Adaptive COVID-19 Treatment Trial (ACTT) | 1062 | Madigan Army Medical Center, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir |
| Washington | WA-10 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Providence St. Peter Hospital, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Washington | WA-10 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Providence St. Peter Hospital, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Washington | WA-10 | Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP) | 0 | Madigan Army Medical Center, | U.S. Army Medical Research and Development Command | Biological: Anti-Sars-CoV-2 Convalescent Plasma |
| Washington | WA-10 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Providence Regional Cancer System-Lacey, Saint Clare Hospital, Providence Regional Cancer System-Shelton, Providence Regional Cancer System-Yelm, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Washington | WA-10 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | Madigan Army Medical Center, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| Washington | WA-08 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Wenatchee Valley Hospital, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Washington | WA-08 | Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) | 500 | Wenatchee Valley Hospital and Clinics, | Incyte Corporation | Drug: Placebo, Drug: Ruxolitinib |
| Washington | WA-08 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Saint Elizabeth Hospital, Swedish Cancer Institute-Issaquah, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Washington | WA-04 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Kadlec Regional Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Washington | WA-04 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Kadlec Regional Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Washington | WA-04 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Kadlec Clinic Hematology and Oncology, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Washington | WA-01 | Adaptive COVID-19 Treatment Trial (ACTT) | 1062 | EvergreenHealth Infectious Disease Service, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir |
| Washington | WA-01 | A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia | 450 | Evergreen Health Infectious Disease, | Hoffmann-La Roche | Drug: Tocilizumab (TCZ), Drug: Placebo |
| Washington | WA-01 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | EvergreenHealth Infectious Disease Service, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| Washington | WA-05 | Adaptive COVID-19 Treatment Trial (ACTT) | 1062 | Providence Sacred Heart Medical Center, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir |
| Washington | WA-05 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | MultiCare Deaconess Hospital, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Washington | WA-05 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | MultiCare Deaconess Hospital, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Washington | WA-05 | Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects | 120 | Blade Research Site, | Blade Therapeutics, Clinipace Worldwide | Drug: BLD-2660 |
| Washington | WA-05 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Providence Sacred Heart Medical Center and Children's Hospital, Providence Saint Mary Regional Cancer Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Washington | WA-05 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | Providence Sacred Heart Medical Center, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| Washington | WA-07 | Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study | 250 | Seattle Children's Hospital, Fred Hutchinson Cancer Research Center, | Ansun Biopharma, Inc. | Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL |
| Washington | WA-07 | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 5000 | Seattle Children's Hospital, | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: |
| Washington | WA-07 | Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19) | 120 | Kaiser Permanente Washington Health, | National Institute of Allergy and Infectious Diseases (NIAID) | Biological: mRNA-1273 |
| Washington | WA-07 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Virginia Mason Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Washington | WA-07 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Virginia Mason Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Washington | WA-07 | Impact of Swab Site and Sample Collector on Testing Sensitivity for COVID-19 Virus in Symptomatic Individuals | 533 | Everett Clinic, | Dr. Deneen Vojta, Quest Diagnostics, Bill and Melinda Gates Foundation, UnitedHealth Group | Diagnostic Test: Testing Sensitivity for SARS-CoV-2 Virus in Symptomatic Individuals |
| Washington | WA-07 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | University of Washington Medical Center, | Gilead Sciences | Drug: Remdesivir |
| Washington | WA-07 | A Longitudinal Study of COVID-19 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for Research | 120 | Everett Clinic, | Dr. Deneen Vojta, PATH, Mayo Clinic, Bill and Melinda Gates Foundation, UnitedHealth Group | Diagnostic Test: Odd/Even birth year intervention groups |
| Washington | WA-07 | Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP) | 829 | University of Washington Virology Research, | University of Washington, Bill and Melinda Gates Foundation | Drug: Hydroxychloroquine Sulfate, Drug: Ascorbic Acid |
| Washington | WA-07 | An Observational Study of Patients With Coronavirus Disease 2019 | 5000 | University of Washington, | Target PharmaSolutions, Inc. | |
| Washington | WA-07 | Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine | 1363 | Seattle Children's Hospital, | Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke University | Drug: Hydroxychloroquine, Drug: Placebo oral tablet |
| Washington | WA-07 | Collection of Anti-SARS-CoV-2 Immune Plasma | 1500 | Bloodworks Northwest, | National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health Clinical Center (CC) | |
| Washington | WA-07 | Treatment for COVID-19 in High-Risk Adult Outpatients | 300 | University of Washington Virology Research, | University of Washington, Bill and Melinda Gates Foundation | Drug: Ascorbic Acid, Drug: Hydroxychloroquine Sulfate, Drug: Azithromycin, Drug: Folic Acid, Drug: Lopinavir 200 MG / Ritonavir 50 MG [Kaletra] |
| Washington | WA-07 | Use of Telehealth Technology by Mental Health Care Professionals in Times of COVID-19 Pandemic | 10000 | University of Washington, | University of Washington | Behavioral: online survey |
| Washington | WA-07 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Benaroya Research Institute at Virginia Mason, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Washington | WA-07 | Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia | 270 | VA Puget Sound Health Care System, | Alexion Pharmaceuticals | Biological: Ravulizumab, Other: Best Supportive Care |
| Washington | WA-07 | Describing Chinese Herbal Medicine Telehealth Care for Symptoms Related to Infectious Diseases Such as COVID-19 | 500 | Seattle Institute of East Asian Medicine, | Center for Integrated Care, University of Utah, University of California, San Francisco | Dietary Supplement: Chinese Herbal Medicine |
| Washington | WA-07 | A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia | 410 | Virginia Mason Medical Center, | Genentech, Inc. | Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo |
| Washington | WA-07 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Highline Medical Center-Main Campus, Swedish Cancer Institute-Edmonds, Pacific Gynecology Specialists, Swedish Medical Center-Ballard Campus, Fred Hutchinson Cancer Research Center, Seattle Cancer Carolines, University of Washington Medican Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Washington | WA-07 | An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic | 0 | University of Washington Seattle Cancer Care Alliance, | Genentech, Inc. | Drug: Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration (PH FDC SC) |
| Washington | WA-07 | Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19 | 727 | Seattle Vaccine and Prevention CRS, | HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials Network | Other: Sample collection |
| Washington | WA-07 | A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19 | 204 | Fred Hutch, | Ridgeback Biotherapeutics, LP | Drug: EIDD-2801, Drug: Placebo (PBO) |
| Washington | WA-06 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | MultiCare Tacoma General Hospital, St Joseph Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Washington | WA-06 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | MultiCare Tacoma General Hospital, St Joseph Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Washington | WA-06 | Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection | 202 | MultiCare Institute for Research & Innovation, | Karyopharm Therapeutics Inc | Drug: Selinexor, Other: Placebo |
| Washington | WA-06 | Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia | 451 | Novartis Investigative Site, | Novartis Pharmaceuticals, Novartis | Drug: Canakinumab, Drug: Placebo |
| Washington | WA-06 | Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 | 86 | Multicare Health System, | Celularity Incorporated, IDRI, Lung Biotechnology PBC, California Institute for Regenerative Medicine (CIRM) | Biological: CYNK-001 |
| Washington | WA-06 | Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease | 800 | GSK Investigational Site, | GlaxoSmithKline | Biological: Otilimab, Biological: Placebo, Drug: Standard of care |
| Washington | WA-06 | A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia | 410 | MultiCare Institute for Research and Innovation, | Genentech, Inc. | Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo |
| Washington | WA-06 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Providence Regional Cancer System-Aberdeen, Harrison HealthPartners Hematology and Oncology-Bremerton, Harrison Medical Center, Jefferson Healthcare, Harrison HealthPartners Hematology and Oncology-Poulsbo, Franciscan Research Center-Northwest Medical Plaza, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Washington | WA-03 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Providence Regional Cancer System-Centralia, PeaceHealth Saint John Medical Center, PeaceHealth Southwest Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Washington | WA-02 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Providence Medical Research Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Washington | WA-02 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Providence Regional Medical Center Everett, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Washington | WA-02 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| Washington | WA-02 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | PeaceHealth Saint Joseph Medical Center, Providence Regional Cancer Partnership, PeaceHealth United General Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Washington | WA-02 | A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia | 500 | Providence Regional Medical Center Everett, | Hoffmann-La Roche, Gilead Sciences | Drug: Remdesivir, Drug: Tocilizumab, Drug: Placebo |
| Washington | WA-09 | Adaptive COVID-19 Treatment Trial (ACTT) | 1062 | University of Washington, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir |
| Washington | WA-09 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Swedish Center for Comprehensive Care, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Washington | WA-09 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Swedish Center for Comprehensive Care, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Washington | WA-09 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| Washington | WA-09 | A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia | 450 | Swedish Hospital Medical Center, | Hoffmann-La Roche | Drug: Tocilizumab (TCZ), Drug: Placebo |
| Washington | WA-09 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Overlake Hospital Medical Center, | Gilead Sciences | Drug: Remdesivir |
| Washington | WA-09 | Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP) | 829 | University of Washington, | University of Washington, Bill and Melinda Gates Foundation | Drug: Hydroxychloroquine Sulfate, Drug: Ascorbic Acid |
| Washington | WA-09 | Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease | 479 | Harborview Medical Center, Swedish Medical Center-First Hill, | Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI) | Drug: Hydroxychloroquine, Drug: Placebo |
| Washington | WA-09 | Treatment for COVID-19 in High-Risk Adult Outpatients | 300 | University of Washington, | University of Washington, Bill and Melinda Gates Foundation | Drug: Ascorbic Acid, Drug: Hydroxychloroquine Sulfate, Drug: Azithromycin, Drug: Folic Acid, Drug: Lopinavir 200 MG / Ritonavir 50 MG [Kaletra] |
| Washington | WA-09 | Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19 | 20 | University of Washington AIDS CRS, | National Institute of Allergy and Infectious Diseases (NIAID), Teva Pharmaceuticals Industries LTD | Drug: Hydroxychloroquine (HCQ), Drug: Azithromycin (Azithro), Drug: Placebo for Hydroxychloroquine, Drug: Placebo for Azithromycin |
| Washington | WA-09 | Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease | 20 | Novartis Investigative Site, | Novartis Pharmaceuticals, Novartis | Drug: HCQ, Drug: HCQ+AZT, Drug: Placebo |
| Washington | WA-09 | Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID) | 432 | Novartis Investigative Site, | Novartis Pharmaceuticals, Incyte Corporation, Novartis | Drug: Ruxolitinib, Drug: Placebo |
| Washington | WA-09 | Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults | 1000 | University of Washington, | Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS) | Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo |
| Washington | WA-09 | Tocilizumab for Patients With Cancer and COVID-19 Disease | 217 | Valley Medical Center, | National Cancer Institute (NCI) | Biological: Tocilizumab |
| Washington | WA-09 | Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. | 62 | Research Site, | AstraZeneca, Acerta Pharma B.V. | Drug: Acalabrutinib |
| Washington | WA-09 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Overlay Medical Center, Saint Francis Hospital, Valley Medical Center, Swedish Medical Center-Cherry Hill, Swedish Medical Center-First Hill, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Washington | WA-09 | IC14 (Anti-CD14) Treatment in Patients With SARS-CoV-2 (COVID-19) | 300 | University of Washington, University of Washington, | Implicit Bioscience, University of Washington | Biological: IC14, Other: Placebo |
| Washington | WA-09 | Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization | 198 | VA Puget Sound Health Care System Seattle Division, | VA Office of Research and Development | Drug: Degarelix, Other: Saline |
| West Virginia | WV-03 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Princeton Community Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| West Virginia | WV-01 | Convalescent Plasma Collection and Treatment in Pediatrics and Adults | 240 | West Virginia University Medicine, | West Virginia University | Biological: Convalescent Plasma 1 Unit, Biological: Convalescent Plasma 2 Units, Other: Standard of Care |
| West Virginia | WV-01 | Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS) | 5 | West Virginia University Rockefeller Neuroscience Institute, | West Virginia University | Procedure: Stellate Ganglion Block |
| West Virginia | WV-01 | A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia | 500 | West Virginia University Hospital, | Hoffmann-La Roche, Gilead Sciences | Drug: Remdesivir, Drug: Tocilizumab, Drug: Placebo |
| West Virginia | WV-02 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | West Virginia University Charleston Division, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Wisconsin | WI-01 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Aurora Cancer Care-Southern Lakes VLCC, Ascension Saint Francis - Reiman Cancer Center, Aurora Cancer Care-Kenosha South, Ascension All Saints Hospital, Aurora Cancer Care-Racine, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Wisconsin | WI-01 | Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure | 524 | Ascension All Saints Hospital, | Chimerix | Drug: Dociparastat sodium, Drug: Placebo |
| Wisconsin | WI-01 | PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer | 364 | Ascension All Saints, | CTI BioPharma | Drug: Pacritinib, Drug: Placebo |
| Wisconsin | WI-02 | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 5000 | University of Wisconsin, University of Wisconsin, University of Wisconsin, | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: |
| Wisconsin | WI-02 | Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID) | 432 | Novartis Investigative Site, | Novartis Pharmaceuticals, Incyte Corporation, Novartis | Drug: Ruxolitinib, Drug: Placebo |
| Wisconsin | WI-02 | Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19 | 600 | University of Wisconsin, | Vanderbilt University Medical Center, AbbVie | Drug: Lopinavir/Ritonavir 400 mg/100 mg, Other: Placebo |
| Wisconsin | WI-02 | COVID-19: Human Epidemiology and Response to SARS-CoV-2 | 5605 | University of Wisconsin Hospital and Clinics, | National Institute of Allergy and Infectious Diseases (NIAID), Rho Federal Systems Division, Inc. (Rho) | Procedure: Collection of Biological Samples, Procedure: Symptom and Exposure Surveys |
| Wisconsin | WI-02 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | William S Middleton VA Medical Center, University of Wisconsin Hospital and Clinics, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Wisconsin | WI-02 | Home Usability Study of the SARS-CoV-2 (COVID-19) Test | 30 | Exact Sciences Corporation, | Exact Sciences Corporation | Diagnostic Test: SARS-CoV-2 |
| Wisconsin | WI-04 | Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease | 800 | GSK Investigational Site, | GlaxoSmithKline | Biological: Otilimab, Biological: Placebo, Drug: Standard of care |
| Wisconsin | WI-04 | Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) | 500 | Aurora Research Institute, | Incyte Corporation | Drug: Placebo, Drug: Ruxolitinib |
| Wisconsin | WI-04 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Aurora Cancer Care-Milwaukee, Ascension Columbia Saint Mary's Hospital - Milwaukee, Aurora Saint Luke's Medical Center, Aurora Sinai Medical Center, Zablocki Veterans Administration Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Wisconsin | WI-04 | Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure | 524 | Ascension St. Francis Hospital, | Chimerix | Drug: Dociparastat sodium, Drug: Placebo |
| Wisconsin | WI-04 | PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer | 364 | Ascension St. Francis Hospital, | CTI BioPharma | Drug: Pacritinib, Drug: Placebo |
| Wisconsin | WI-06 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Aurora Cancer Care-Grafton, Ascension Columbia Saint Mary's Hospital Ozaukee, Ascension Mercy Hospital, Vince Lombardi Cancer Clinic – Oshkosh, Vince Lombardi Cancer Clinic-Sheboygan, Vince Lombardi Cancer Clinic-Two Rivers, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Wisconsin | WI-08 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | ThedCare Regional Cancer Center, Ascension Saint Elizabeth Hospital, Ascension Calumet Hospital, Saint Vincent Hospital Cancer Center Green Bay, Saint Vincent Hospital Cancer Center at Saint Mary's, Aurora BayCare Medical Center, Aurora Bay Area Medical Group-Marinette, Saint Vincent Hospital Cancer Center at Oconto Falls, Saint Vincent Hospital Cancer Center at Sturgeon Bay, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Wisconsin | WI-03 | Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19 | 0 | Mayo Clinic Health System - Eau Claire, Mayo Clinic Health System - Franciscan Healthercare, | Mayo Clinic | Biological: COVID-19 convalescent plasma |
| Wisconsin | WI-03 | Covid-19 Associated Coagulopathy | 170 | Gundersen Health System, | University of Iowa | Drug: Intermediate dose thromboprophylaxis, Drug: Standard of Care thromboprophylaxis |
| Wisconsin | WI-03 | Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia | 270 | Mayo Clinic Health System in Eau Claire, Mayo Clinic Health System, | Alexion Pharmaceuticals | Biological: Ravulizumab, Other: Best Supportive Care |
| Wisconsin | WI-03 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Marshfield Clinic-Chippewa Center, HSHS Sacred Heart Hospital, Marshfield Medical Center-EC Cancer Center, Mayo Clinic Health System-Eau Claire Clinic, Gundersen Lutheran Medical Center, Mayo Clinic Health System-Franciscan Healthcare, Ascension Saint Michael's Hospital, Marshfield Clinic Stevens Point Center, Aspirus UW Cancer Center, Marshfield Clinic - Wisconsin Rapids Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Wisconsin | WI-07 | Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine | 1363 | Marshfield Clinic Health System, | Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke University | Drug: Hydroxychloroquine, Drug: Placebo oral tablet |
| Wisconsin | WI-07 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Langlade Hospital and Cancer Center, Marshfield Clinic-Ladysmith Center, Marshfield Medical Center-Marshfield, Aspirus Medford Hospital, Marshfield Clinic-Minocqua Center, Cancer Center of Western Wisconsin, Marshfield Medical Center-Rice Lake, Aspirus Regional Cancer Center, Marshfield Clinic -Wausau Center, Marshfield Clinic-Weston Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Wisconsin | WI-05 | A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19) | 242 | Froedtert and the Medical College of Wisconsin, | Millennium Pharmaceuticals, Inc., Takeda | Drug: TAK-981, Drug: Standard of care |
| Wisconsin | WI-05 | Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study | 250 | Froedtert Medical College Pulmonary Clinic, Medical College of Wisconsin, | Ansun Biopharma, Inc. | Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL |
| Wisconsin | WI-05 | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 5000 | Medical College of Wisconsin, | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: |
| Wisconsin | WI-05 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Medical College of Wisconsin, | Gilead Sciences | Drug: Remdesivir |
| Wisconsin | WI-05 | A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection | 131 | Froedtert Hospital, | Medical College of Wisconsin, Froedtert Hospital | Biological: anti-SARS-CoV-2 convalescent plasma |
| Wisconsin | WI-05 | Convalescent Plasma in Outpatients With COVID-19 | 600 | Froedtert Hospital, | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network | Biological: Convalescent Plasma, Biological: Saline |
| Wisconsin | WI-05 | Nudges to Improve Health Behaviors That Limit COVID-19 Spread | 45 | Medical College of Wisconsin, | Medical College of Wisconsin, Advancing a Healthier Wisconsin Endowment | Behavioral: Nudge |
| Wisconsin | WI-05 | Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants | 52 | Medical College of Wisconsin, | BeiGene | Drug: Zanubrutinib, Drug: Supportive Care, Drug: Placebo |
| Wisconsin | WI-05 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Ascension Southeast Wisconsin Hospital - Elmbrook Campus, Aurora Health Care Germantown Health Center, Medical College of Wisconsin, Aurora Medical Center in Summit, Ascension Medical Group Southeast Wisconsin - Mayfair Road, Aurora Cancer Care-Milwaukee West, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Wisconsin | WI-05 | Registry of CytoSorb Therapy in COVID-19 ICU Patients | 500 | Medical College of Wisconsin, | CytoSorbents, Inc | Device: CytoSorb 300 mL device |
| Wyoming | WY-00 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Cheyenne Regional Medical Center-West, Billings Clinic-Cody, Welch Cancer Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Puerto Rico | PR-00 | A Study of Auxora in Patients With Severe COVID-19 Pneumonia | 400 | Hospital San Cristobal, | CalciMedica, Inc. | Drug: Auxora, Drug: Placebo |
| Puerto Rico | PR-00 | The Covid-19 HEalth caRe wOrkErS (HEROES) Study | 2000 | Ponce Health Sciences University, | University of Chile | Other: Exposure to the SARS-CoV-2 and its consequences |
| Puerto Rico | PR-00 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Centro Comprensivo de Cancer de UPR, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| California | CA-10 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Kaiser Permanente-Modesto, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| California | CA-11 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Diablo Clinical Research Inc, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| California | CA-11 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Kaiser Permanente-Richmond, Kaiser Permanente-Walnut Creek, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| California | CA-12 | Adaptive COVID-19 Treatment Trial (ACTT) | 1062 | University of California San Francisco General Hospital, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir |
| California | CA-12 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | California Pacific Medical Center, Kaiser Permanente Oakland Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-12 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | California Pacific Medical Center, Kaiser Permanente Oakland Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-12 | Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) | 6000 | University of California San Francisco, | Montreal Heart Institute, National Heart, Lung, and Blood Institute (NHLBI), Bill and Melinda Gates Foundation, The Government of Quebec, DACIMA Software | Drug: Colchicine, Drug: Placebo oral tablet |
| California | CA-12 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | California Pacific Medical Center, University of California Medical Center, | Gilead Sciences | Drug: Remdesivir |
| California | CA-12 | COVID-19 PRIORITY (Pregnancy CoRonavIrus Outcomes RegIsTrY) | 2000 | University of California - San Francisco, | University of California, San Francisco, University of California, Los Angeles | Other: Pregnant women under investigation for Coronavirus or diagnosed with COVID-19, Other: Postpartum women under investigation for Coronavirus or diagnosed with COVID-19 |
| California | CA-12 | Azithromycin for COVID-19 Treatment in Outpatients Nationwide | 2271 | University of California - San Francisco, | Thomas M. Lietman, Bill and Melinda Gates Foundation, Pfizer, Stanford University, University of California, San Francisco | Drug: Azithromycin, Drug: Placebos |
| California | CA-12 | Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease | 479 | UCSF Medical Center, | Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI) | Drug: Hydroxychloroquine, Drug: Placebo |
| California | CA-12 | Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection | 202 | Kaiser Permanente San Francisco, | Karyopharm Therapeutics Inc | Drug: Selinexor, Other: Placebo |
| California | CA-12 | Long-term Impact of Infection With Novel Coronavirus (COVID-19) | 800 | Zuckerberg San Francisco General Hospital, | University of California, San Francisco | |
| California | CA-12 | Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia | 451 | Novartis Investigative Site, Novartis Investigative Site, | Novartis Pharmaceuticals, Novartis | Drug: Canakinumab, Drug: Placebo |
| California | CA-12 | VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL) | 300 | San Francisco VA, | Salomeh Keyhani MD, San Francisco VA Health Care System | Drug: Hydroxychloroquine, Drug: Azithromycin, Drug: Placebo oral tablet |
| California | CA-12 | Immunophenotyping Assessment in a COVID-19 Cohort | 2000 | University of California - San Francisco, | National Institute of Allergy and Infectious Diseases (NIAID), Benaroya Research Institute, Boston Children's Hospital | Procedure: Biological sample collection, Procedure: Data Collection: Clinical Care Assessments |
| California | CA-12 | Predicting Outcomes for Covid-19 Using Sonography | 200 | University of California - San Francisco, | Stanford University | Diagnostic Test: Lung Ultrasound |
| California | CA-12 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Kaiser Permanente-San Francisco, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| California | CA-12 | Assessing the Safety of Pregnancy In the CoRonavirus (COVID-19) pandEmic | 11000 | University of California - San Francisco, | University of California, San Francisco | |
| California | CA-12 | An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic | 0 | UCSF Helen Diller Family CCC, | Genentech, Inc. | Drug: Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration (PH FDC SC) |
| California | CA-12 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | University of California San Francisco General Hospital, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| California | CA-12 | A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19 | 66 | California Pacific Medical Center, | Apellis Pharmaceuticals, Inc. | Drug: APL-9, Other: Vehicle Control |
| California | CA-12 | Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19 | 727 | Bridge HIV CRS, | HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials Network | Other: Sample collection |
| California | CA-12 | Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19) | 150 | University of California - San Francisco, | University of California, San Francisco | Drug: Oral-B Mouth Sore mouthwash, Drug: Crest Pro-Health Multi-Protection mouthwash, Drug: CloSYS mouthwash, Drug: Distilled water, Drug: Listerine Mouthwash Product |
| California | CA-13 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Alta Bates Summit Medical Center, Kaiser Permanente Oakland Medical Center, Kaiser Permanente Oakland Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-13 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Alta Bates Summit Medical Center, Kaiser Permanente Oakland Medical Center, Kaiser Permanente Oakland Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-13 | Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection | 202 | Kaiser Permanente Oakland, | Karyopharm Therapeutics Inc | Drug: Selinexor, Other: Placebo |
| California | CA-13 | COVID-19 Mortality Prediction Model | 114 | Dascena, | Dascena | Device: COViage |
| California | CA-13 | Classification of COVID-19 Infection in Posteroanterior Chest X-rays | 230 | Dascena, | Dascena | Device: CovX |
| California | CA-13 | A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia | 379 | Highland Hospital Oakland, San Leandro Hospital, | Genentech, Inc. | Drug: Placebo, Drug: Tocilizumab |
| California | CA-13 | A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia | 410 | Alta Bates Summit Medical Center, | Genentech, Inc. | Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo |
| California | CA-13 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Kaiser Permanente Oakland, Kaiser Permanente Oakland-Broadway, Kaiser Permanente San Leandro, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| California | CA-13 | Respiratory Decompensation and Model for the Triage of COVID-19 Patients | 197 | Dascena, | Dascena | Device: COViage |
| California | CA-14 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Mills-Peninsula Medical Center, Kaiser Permanente Oakland Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-14 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Mills-Peninsula Medical Center, Kaiser Permanente Oakland Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-14 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Kaiser Permanente-Redwood City, Kaiser Permanente Cancer Treatment Center, Kaiser Permanente-South San Francisco, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| California | CA-15 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Eden Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-15 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Eden Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-15 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Kaiser Permanente Dublin, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| California | CA-16 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Community Regional Medical Centers, | Gilead Sciences | Drug: Remdesivir |
| California | CA-16 | Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease | 479 | UCSF Fresno, | Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI) | Drug: Hydroxychloroquine, Drug: Placebo |
| California | CA-16 | A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19 | 270 | UCSF Fresno, | Janssen Pharmaceutica N.V., Belgium | Drug: Sirukumab, Drug: Placebo, Other: Standard of Care (SOC) |
| California | CA-16 | A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19 | 66 | University of California at San Francisco - Fresno, | Apellis Pharmaceuticals, Inc. | Drug: APL-9, Other: Vehicle Control |
| California | CA-17 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Kaiser Permanente Oakland Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-17 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Kaiser Permanente Oakland Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-17 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Kaiser Permanente Santa Clara, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| California | CA-17 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Kaiser Permanente-Fremont, Kaiser Permanente Medical Center - Santa Clara, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| California | CA-18 | Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT | 30 | Stanford University, | Stanford University, Pliant Therapeutics, Inc. | Drug: [18F]FP-R01-MG-F2 |
| California | CA-18 | Adaptive COVID-19 Treatment Trial (ACTT) | 1062 | Stanford University Hospital, VA Palo Alto Health Care System, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir |
| California | CA-18 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | El Camino Hospital, Stanford Hospital, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-18 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | El Camino Hospital, Stanford Hospital, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-18 | A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia | 450 | Stanford University, | Hoffmann-La Roche | Drug: Tocilizumab (TCZ), Drug: Placebo |
| California | CA-18 | Behavior, Environment And Treatments for Covid-19 | 100000 | BEAT19.org, | xCures, Genetic Alliance, LunaDNA, Cancer Commons, REDCap Cloud | Other: Observation of patients with known, suspected, or at risk for COVID-19 infection |
| California | CA-18 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | San Mateo Medical Center, | Gilead Sciences | Drug: Remdesivir |
| California | CA-18 | Treating COVID-19 With a Bidirectional Oxygenation Valve | 30 | Stanford University, | TMC HealthCare, PEEP Medical, LLC | Device: bidirectional oxygenation mouthpiece |
| California | CA-18 | Impact of the Coronavirus (COVID-19) on Patients With Cancer | 50 | Stanford University School of Medicine, | Stanford University | |
| California | CA-18 | Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19 | 120 | Stanford University School of Medicine, | Stanford University | Drug: Peginterferon Lambda-1a, Other: Placebo |
| California | CA-18 | Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease | 479 | Stanford University, | Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI) | Drug: Hydroxychloroquine, Drug: Placebo |
| California | CA-18 | Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects | 120 | Blade Research Site, | Blade Therapeutics, Clinipace Worldwide | Drug: BLD-2660 |
| California | CA-18 | Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19 | 120 | Stanford University, | Stanford University | Drug: Favipiravir, Drug: Placebo, Other: Standard of care treatment |
| California | CA-18 | PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19) | 45 | Stanford Health Care, | Stanford University | Drug: Povidone-Iodine 2%, Drug: Povidone-Iodine 0.5%, Drug: Isotonic saline 0.9% |
| California | CA-18 | Convalescent Plasma in Outpatients With COVID-19 | 600 | Stanford University, | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network | Biological: Convalescent Plasma, Biological: Saline |
| California | CA-18 | ACCESS A Master Digital Surveillance Protocol for COVID-19 | 1000000 | Medable Inc., | Medable Inc., Datavant, American Heart Association, BioIntelliSense, PWNHealth | |
| California | CA-18 | MSCs in COVID-19 ARDS | 223 | Stanford University, | Icahn School of Medicine at Mount Sinai, Mesoblast, Inc., National Heart, Lung, and Blood Institute (NHLBI) | Biological: Remestemcel-L, Drug: Placebo |
| California | CA-18 | Understanding Immunity to SARS-CoV-2, the Coronavirus Causing COVID-19 | 1000 | Stanford University Hospital, | Stanford University, National Institute of Allergy and Infectious Diseases (NIAID), National Cancer Institute (NCI) | Other: There is no intervention |
| California | CA-18 | Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury | 46 | Stanford University School of Medicine, | AbbVie, Janssen Research & Development, LLC, Pharmacyclics LLC (An AbbVie Company) | Drug: Ibrutinib, Drug: Placebo |
| California | CA-18 | Immunophenotyping Assessment in a COVID-19 Cohort | 2000 | Stanford University, | National Institute of Allergy and Infectious Diseases (NIAID), Benaroya Research Institute, Boston Children's Hospital | Procedure: Biological sample collection, Procedure: Data Collection: Clinical Care Assessments |
| California | CA-18 | Emergency Ventilator Splitting Between Two or More Patients (COVID-19) | 4 | Stanford University, | Stanford University | Device: Emergency Ventilator Splitter |
| California | CA-18 | Ulinastatin for the Treatment of COVID-19 in Hospitalized Patients | 160 | Stanford University, | Stanford University | Drug: Ulinastatin, Drug: Placebo |
| California | CA-18 | An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic | 0 | Stanford University School of Medicine, | Genentech, Inc. | Drug: Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration (PH FDC SC) |
| California | CA-18 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | Stanford University Hospital, VA Palo Alto Health Care System, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| California | CA-18 | A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia | 500 | Stanford University, | Hoffmann-La Roche, Gilead Sciences | Drug: Remdesivir, Drug: Tocilizumab, Drug: Placebo |
| California | CA-18 | Brief Telehealth CBT-I Intervention in the Context of the COVID-19 Pandemic | 50 | Stanford University, | Stanford University | Behavioral: Remote Cognitive Behavioral Therapy for Insomnia |
| California | CA-19 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Kaiser Permanente Oakland Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-19 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Kaiser Permanente Oakland Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-19 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Regional Medical Center, | Gilead Sciences | Drug: Remdesivir |
| California | CA-19 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Kaiser Permanente-Santa Teresa-San Jose, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| California | CA-20 | Compassionate Use of Hyperbaric Oxygen Therapy | 100 | Community Hospital, | SerenaGroup, Inc., SerenaGroup Research Foundation | |
| California | CA-20 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Salinas Valley Memorial, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| California | CA-22 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Fresno Cancer Center, Kaiser Permanente-Fresno, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| California | CA-23 | Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) | 6000 | Centric Health Resources Inc., | Montreal Heart Institute, National Heart, Lung, and Blood Institute (NHLBI), Bill and Melinda Gates Foundation, The Government of Quebec, DACIMA Software | Drug: Colchicine, Drug: Placebo oral tablet |
| California | CA-24 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Mission Hope Medical Oncology - Arroyo Grande, PCR Oncology, Mission Hope Medical Oncology - Santa Maria, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| California | CA-26 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Los Robles Regional Medical Center, | Gilead Sciences | Drug: Remdesivir |
| California | CA-26 | A Study of Quintuple Therapy to Treat COVID-19 Infection | 600 | ProgeneBiome, | ProgenaBiome, DSCS CRO | Drug: Hydroxychloroquine, Drug: Azithromycin, Dietary Supplement: Vitamin C, Dietary Supplement: Vitamin D, Dietary Supplement: Zinc |
| California | CA-26 | A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection | 600 | ProgeneBiome, | ProgenaBiome, DSCS CRO | Drug: Hydroxychloroquine, Dietary Supplement: Vitamin C, Dietary Supplement: Vitamin D, Dietary Supplement: Zinc |
| California | CA-26 | A Study to Explore the Role of Gut Flora in COVID-19 Infection | 250 | ProgeneBiome, | ProgenaBiome | Other: There is no intervention in this study |
| California | CA-26 | A Study of ResCure™ to Treat COVID-19 Infection | 50 | ProgeneBiome, | ProgenaBiome, Rinati Skin, LLC | Biological: ResCure™ |
| California | CA-26 | A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19 | 204 | FOMAT Medical Research, | Ridgeback Biotherapeutics, LP | Drug: EIDD-2801, Drug: Placebo (PBO) |
| California | CA-27 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Huntington Hospital, | Gilead Sciences | Drug: Remdesivir |
| California | CA-28 | Adaptive COVID-19 Treatment Trial (ACTT) | 1062 | Cedars-Sinai Medical Center, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir |
| California | CA-28 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Kaiser Permanente Los Angeles Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-28 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Kaiser Permanente Los Angeles Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-28 | Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects | 120 | Blade Research Site, | Blade Therapeutics, Clinipace Worldwide | Drug: BLD-2660 |
| California | CA-28 | CAP-1002 in Severe COVID-19 Disease | 0 | Cedars-Sinai Medical Center, | Capricor Inc. | Biological: CAP-1002 Allogeneic Cardiosphere-Derived Cells |
| California | CA-28 | BCG Vaccine for Health Care Workers as Defense Against COVID 19 | 1800 | Cedars-Sinai Medical Center, | Texas A&M University, Baylor College of Medicine, M.D. Anderson Cancer Center, Cedars-Sinai Medical Center, Harvard University | Biological: BCG Vaccine, Biological: Placebo Vaccine |
| California | CA-28 | Clazakizumab (Anti-IL- 6 Monoclonal) Compared to Placebo for COVID19 Disease | 17 | Cedars-Sinai Medical Center, | Cedars-Sinai Medical Center | Drug: Clazakizumab |
| California | CA-28 | Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure | 60 | Cedars-Sinai Medical Center, | Noah Merin, Johns Hopkins University, Cedars-Sinai Medical Center | Biological: Multiple Doses of Anti-SARS-CoV-2 convalescent plasma |
| California | CA-28 | SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19 | 0 | Cedars-Sinai Medical Center, | Alexion Pharmaceuticals | Biological: eculizumab |
| California | CA-28 | Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia | 451 | Novartis Investigative Site, | Novartis Pharmaceuticals, Novartis | Drug: Canakinumab, Drug: Placebo |
| California | CA-28 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Kaiser Permanente Los Angeles Medical Center, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| California | CA-28 | Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. | 62 | Research Site, | AstraZeneca, Acerta Pharma B.V. | Drug: Acalabrutinib |
| California | CA-28 | Study of Efficacy and Safety of MAS825 in Patients With COVID-19 | 140 | Novartis Investigative Site, | Novartis Pharmaceuticals, Novartis | Drug: MAS825, Drug: Matching placebo |
| California | CA-28 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Providence Saint Joseph Medical Center/Disney Family Cancer Center, Kaiser Permanente-Los Angeles Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| California | CA-28 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | Cedars-Sinai Medical Center, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| California | CA-28 | A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19 | 24 | Cedars-Sinai Medical Center, | Eli Lilly and Company, AbCellera Biologics Inc. | Drug: LY3819253, Drug: Placebo |
| California | CA-29 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Kaiser Permanente Los Angeles Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-29 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Kaiser Permanente Los Angeles Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-29 | Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19) | 384 | Olive View-UCLA Medical Center, | I-Mab Biopharma Co. Ltd. | Drug: TJ003234, Drug: Placebo |
| California | CA-29 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Providence Clinical Research, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| California | CA-29 | Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants | 52 | Olive View - UCLA Medical Center, | BeiGene | Drug: Zanubrutinib, Drug: Supportive Care, Drug: Placebo |
| California | CA-29 | Study of Efficacy and Safety of MAS825 in Patients With COVID-19 | 140 | Novartis Investigative Site, | Novartis Pharmaceuticals, Novartis | Drug: MAS825, Drug: Matching placebo |
| California | CA-29 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Kaiser Permanente-Panorama City, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| California | CA-30 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Kaiser Permanente Los Angeles Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-30 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Kaiser Permanente Los Angeles Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-30 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Bayview Research Group, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| California | CA-30 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Kaiser Permanente-Woodland Hills, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| California | CA-30 | A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19 | 204 | Valley Clinical Trials, | Ridgeback Biotherapeutics, LP | Drug: EIDD-2801, Drug: Placebo (PBO) |
| California | CA-31 | The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection | 100 | Premier Urgent Care of California, | Pulmotect, Inc. | Drug: PUL-042 Inhalation Solution, Drug: Placebo |
| California | CA-31 | The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2 | 200 | Premier Urgent Care of California, | Pulmotect, Inc. | Drug: PUL-042 Inhalation Solution, Drug: Placebo |
| California | CA-31 | Convalescent Plasma in Outpatients With COVID-19 | 600 | Loma Linda University Medical Center, | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network | Biological: Convalescent Plasma, Biological: Saline |
| California | CA-31 | Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease | 800 | GSK Investigational Site, | GlaxoSmithKline | Biological: Otilimab, Biological: Placebo, Drug: Standard of care |
| California | CA-31 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Veterans Affairs Loma Linda Healthcare System, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| California | CA-31 | Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression | 208 | Octapharma Research Site, Octapharma Research Site, | Octapharma | Biological: Octagam 10%, Other: Placebo |
| California | CA-31 | A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19 | 204 | Benchmark Research, | Ridgeback Biotherapeutics, LP | Drug: EIDD-2801, Drug: Placebo (PBO) |
| California | CA-32 | Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study | 250 | City of Hope Cancer Center, | Ansun Biopharma, Inc. | Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL |
| California | CA-32 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Kaiser Permanente-Baldwin Park, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| California | CA-33 | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 5000 | University of California, | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: |
| California | CA-33 | Adaptive COVID-19 Treatment Trial (ACTT) | 1062 | University of California Los Angeles Medical Center, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir |
| California | CA-33 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Kaiser Permanente Los Angeles Medical Center, Providence St. Johns Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-33 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Kaiser Permanente Los Angeles Medical Center, Providence St. Johns Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-33 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site, Regeneron Study Site, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| California | CA-33 | A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia | 450 | David Geffen School of Medicine UCLA, | Hoffmann-La Roche | Drug: Tocilizumab (TCZ), Drug: Placebo |
| California | CA-33 | Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) | 6000 | Westside Medical Associates of Los Angeles, | Montreal Heart Institute, National Heart, Lung, and Blood Institute (NHLBI), Bill and Melinda Gates Foundation, The Government of Quebec, DACIMA Software | Drug: Colchicine, Drug: Placebo oral tablet |
| California | CA-33 | Convalescent Plasma to Stem Coronavirus (CSSC-001) | 500 | University of California - Los Angeles, | Johns Hopkins University | Biological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma |
| California | CA-33 | Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP) | 829 | University of California Los Angeles, | University of Washington, Bill and Melinda Gates Foundation | Drug: Hydroxychloroquine Sulfate, Drug: Ascorbic Acid |
| California | CA-33 | Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease | 479 | Ronald Reagan UCLA Medical Center, | Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI) | Drug: Hydroxychloroquine, Drug: Placebo |
| California | CA-33 | Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19 | 86 | University of California - Los Angeles, | CytoDyn, Inc. | Drug: Placebos, Drug: Leronlimab (700mg) |
| California | CA-33 | Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19) | 390 | University of California - Los Angeles, | CytoDyn, Inc. | Drug: Placebos, Drug: Leronlimab (700mg) |
| California | CA-33 | Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection | 202 | University of California - Los Angeles, | Karyopharm Therapeutics Inc | Drug: Selinexor, Other: Placebo |
| California | CA-33 | The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol | 1800 | FHHI-OI-Camelot, | The Camelot Foundation | Drug: Hydroxychloroquine, Azithromycin, Drug: Hydroxychloroquine, Doxycycline, Drug: Hydroxychloroquine, Clindamycin, Drug: Hydroxychloroquine, Clindamycin, Primaquine - low dose., Drug: Hydroxychloroquine, Clindamycin, Primaquine - high dose., Drug: Remdesivir, Drug: Tocilizumab, Drug: Methylprednisolone, Drug: Interferon-Alpha2B, Drug: Losartan, Drug: Convalescent Serum |
| California | CA-33 | A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE) | 227 | UCLA Ronald Reagan Medical Center, | Kinevant Sciences GmbH, Roivant Sciences, Inc. | Drug: Gimsilumab, Drug: Placebo |
| California | CA-33 | Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19) | 150 | UCLA Ronald Reagan Medical Center, UCLA Santa Monica Hospital, | University of California, Los Angeles | Drug: Colchicine Tablets, Other: Current care per UCLA treating physicians |
| California | CA-33 | Convalescent Plasma in Outpatients With COVID-19 | 600 | Ronald Reagan UCLA Medical Center, Cedars-Sinai Medical Center, | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network | Biological: Convalescent Plasma, Biological: Saline |
| California | CA-33 | Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease | 20 | Novartis Investigative Site, | Novartis Pharmaceuticals, Novartis | Drug: HCQ, Drug: HCQ+AZT, Drug: Placebo |
| California | CA-33 | COVID-19 Recovered Volunteer Research Participant Pool Registry | 10000 | Ronald Reagan UCLA Medical Center, | University of California, Los Angeles | |
| California | CA-33 | Understanding Community Considerations, Opinions, Values, Impacts, and Decisions for COVID-19 | 2500 | University of California - Los Angeles, | University of California, Los Angeles | Behavioral: Brief educational video |
| California | CA-33 | Convalescent Plasma to Limit SARS-CoV-2 Associated Complications | 1344 | University of California - Los Angeles, | Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID) | Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor |
| California | CA-33 | Study of Efficacy and Safety of MAS825 in Patients With COVID-19 | 140 | Novartis Investigative Site, | Novartis Pharmaceuticals, Novartis | Drug: MAS825, Drug: Matching placebo |
| California | CA-33 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Kaiser Permanente-Harbor City, UCLA / Jonsson Comprehensive Cancer Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| California | CA-33 | An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic | 0 | Beverly Hills Cancer Center, | Genentech, Inc. | Drug: Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration (PH FDC SC) |
| California | CA-33 | Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization | 198 | VA Greater Los Angeles Healthcare System, | VA Office of Research and Development | Drug: Degarelix, Other: Saline |
| California | CA-33 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | University of California Los Angeles Medical Center, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| California | CA-33 | The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID) | 80 | Ronald Reagan UCLA Medical Center, | Ridgeback Biotherapeutics, LP | Drug: EIDD-2801, Drug: Placebo (PB0) |
| California | CA-33 | Role of Children in Transmission of COVID-19 to Immunocompromised Patients | 300 | University of California - Los Angeles, | Jonsson Comprehensive Cancer Center | |
| California | CA-33 | A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia | 500 | Providence St. John's Health Center, | Hoffmann-La Roche, Gilead Sciences | Drug: Remdesivir, Drug: Tocilizumab, Drug: Placebo |
| California | CA-34 | A Study of Auxora in Patients With Severe COVID-19 Pneumonia | 400 | University of Southern California, | CalciMedica, Inc. | Drug: Auxora, Drug: Placebo |
| California | CA-34 | Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19 | 300 | University of Southern California Medical Center, USC - Los Angeles County Medical Center, | Humanigen, Inc. | Biological: Lenzilumab, Drug: Standard of Care |
| California | CA-34 | A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia | 100 | LAC + USC Medical Center, USC Keck Medical Center Of USC, | Hoffmann-La Roche | Drug: Tociliuzumab |
| California | CA-34 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | National Research Institute, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| California | CA-34 | Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia | 270 | LAC/USC Health Center, | Alexion Pharmaceuticals | Biological: Ravulizumab, Other: Best Supportive Care |
| California | CA-34 | MSCs in COVID-19 ARDS | 223 | University of Southern California, | Icahn School of Medicine at Mount Sinai, Mesoblast, Inc., National Heart, Lung, and Blood Institute (NHLBI) | Biological: Remestemcel-L, Drug: Placebo |
| California | CA-34 | Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19 | 144 | Los Angeles County-USC Medical Center, USC / Norris Comprehensive Cancer Center, | University of Southern California, National Cancer Institute (NCI) | Drug: Baricitinib, Drug: Hydroxychloroquine, Drug: Placebo Administration |
| California | CA-34 | Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19 | 140 | University of Southern California, | Pluristem Ltd. | Biological: PLX-PAD, Biological: Placebo |
| California | CA-34 | Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) | 190 | Atea Study Site, | Atea Pharmaceuticals, Inc. | Drug: AT-527, Other: Placebo |
| California | CA-35 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Kaiser Permanente Los Angeles Medical Center, Kaiser Permanente Los Angeles Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-35 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Kaiser Permanente Los Angeles Medical Center, Kaiser Permanente Los Angeles Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-35 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Kaiser Permanente-Fontana, Kaiser Permanente-Ontario, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| California | CA-36 | Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19 | 86 | Palmtree Clinical Research Inc., Eisenhower Health, | CytoDyn, Inc. | Drug: Placebos, Drug: Leronlimab (700mg) |
| California | CA-36 | Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury | 46 | Desert Regional Medical Center, | AbbVie, Janssen Research & Development, LLC, Pharmacyclics LLC (An AbbVie Company) | Drug: Ibrutinib, Drug: Placebo |
| California | CA-37 | Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study | 250 | University of California - Los Angeles, | Ansun Biopharma, Inc. | Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL |
| California | CA-37 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Kaiser Permanente Los Angeles Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-37 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Kaiser Permanente Los Angeles Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-37 | Progesterone for the Treatment of COVID-19 in Hospitalized Men | 40 | Cedars-Sinai Medical Center, | Sara Ghandehari, IBSA Institut Biochimique SA, Cedars-Sinai Medical Center | Drug: Progesterone 100 MG |
| California | CA-37 | Immunophenotyping Assessment in a COVID-19 Cohort | 2000 | University of California - Los Angeles, | National Institute of Allergy and Infectious Diseases (NIAID), Benaroya Research Institute, Boston Children's Hospital | Procedure: Biological sample collection, Procedure: Data Collection: Clinical Care Assessments |
| California | CA-37 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Kaiser Permanente-Cadillac, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| California | CA-37 | Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19 | 727 | UCLA CARE Center CRS, | HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials Network | Other: Sample collection |
| California | CA-38 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | PIH Health Whittier Hospital, | Gilead Sciences | Drug: Remdesivir |
| California | CA-39 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | St. Jude Medical Center, | Gilead Sciences | Drug: Remdesivir |
| California | CA-39 | Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19) | 390 | St. June Medical Center, | CytoDyn, Inc. | Drug: Placebos, Drug: Leronlimab (700mg) |
| California | CA-39 | Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease | 20 | Novartis Investigative Site, | Novartis Pharmaceuticals, Novartis | Drug: HCQ, Drug: HCQ+AZT, Drug: Placebo |
| California | CA-39 | Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID) | 432 | Novartis Investigative Site, | Novartis Pharmaceuticals, Incyte Corporation, Novartis | Drug: Ruxolitinib, Drug: Placebo |
| California | CA-39 | A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia | 100 | St. Jude Medical Center, | Hoffmann-La Roche | Drug: Tociliuzumab |
| California | CA-39 | Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. | 62 | Research Site, | AstraZeneca, Acerta Pharma B.V. | Drug: Acalabrutinib |
| California | CA-39 | Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants | 52 | St. Jude Medical Center, | BeiGene | Drug: Zanubrutinib, Drug: Supportive Care, Drug: Placebo |
| California | CA-39 | Study of Sargramostim in Patients With COVID-19 | 120 | St. Jude Medical Center, | Partner Therapeutics, Inc. | Drug: Sargramostim, Drug: Standard of care |
| California | CA-40 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Kaiser Permanente Los Angeles Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-40 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Kaiser Permanente Los Angeles Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-40 | Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) | 6000 | Rancho Research Institute, | Montreal Heart Institute, National Heart, Lung, and Blood Institute (NHLBI), Bill and Melinda Gates Foundation, The Government of Quebec, DACIMA Software | Drug: Colchicine, Drug: Placebo oral tablet |
| California | CA-40 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Kaiser Permanente-Bellflower, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| California | CA-41 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Kaiser Permanente Los Angeles Medical Center, Kaiser Permanente Los Angeles Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-41 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Kaiser Permanente Los Angeles Medical Center, Kaiser Permanente Los Angeles Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-41 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Kaiser Permanente-Riverside, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| California | CA-42 | A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia | 379 | St. Joseph'S Hospital, | Genentech, Inc. | Drug: Placebo, Drug: Tocilizumab |
| California | CA-43 | Collection of Anti-SARS-CoV-2 Immune Plasma | 1500 | UCLA Medical Center, | National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health Clinical Center (CC) | |
| California | CA-43 | Convalescent Plasma in Outpatients With COVID-19 | 600 | Harbor-UCLA Medical Center, | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network | Biological: Convalescent Plasma, Biological: Saline |
| California | CA-43 | Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19 | 20 | Harbor-UCLA CRS, | National Institute of Allergy and Infectious Diseases (NIAID), Teva Pharmaceuticals Industries LTD | Drug: Hydroxychloroquine (HCQ), Drug: Azithromycin (Azithro), Drug: Placebo for Hydroxychloroquine, Drug: Placebo for Azithromycin |
| California | CA-43 | International Registry of Coronavirus (COVID-19) Exposure in Pregnancy | 25000 | Pregistry, Pregistry, | Pregistry, Harvard School of Public Health | Other: Tested for SARS-CoV-2 (regardless of the result), Other: Clinical diagnosis of COVID-19 by a health care professional |
| California | CA-43 | Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease | 800 | GSK Investigational Site, | GlaxoSmithKline | Biological: Otilimab, Biological: Placebo, Drug: Standard of care |
| California | CA-43 | Study of Efficacy and Safety of MAS825 in Patients With COVID-19 | 140 | Novartis Investigative Site, | Novartis Pharmaceuticals, Novartis | Drug: MAS825, Drug: Matching placebo |
| California | CA-43 | Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic | 7000 | Pregistry, | Pregistry, Harvard School of Public Health | Other: This is an online survey with no intervention. |
| California | CA-43 | A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia | 410 | Torrance Memorial Medical Center, | Genentech, Inc. | Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo |
| California | CA-44 | Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation | 45 | St. Francis Medical Center, | NantKwest, Inc. | Biological: BM-Allo.MSC, Biological: Placebo |
| California | CA-45 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Mission Hospital Regional Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-45 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Mission Hospital Regional Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-45 | Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure | 165 | University of California Irvine, | NeuroRx, Inc., Lavin Consulting, LLC | Drug: Aviptadil by intravenous infusion + standard of care, Drug: Normal Saline Infusion + standard of care |
| California | CA-45 | Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects | 120 | Blade Research Site, | Blade Therapeutics, Clinipace Worldwide | Drug: BLD-2660 |
| California | CA-45 | Harnessing Online Peer Education Online Support Intervention for COVID-19 (HOPE COVID-19) | 300 | University of California - Irvine, | University of California, Irvine | Behavioral: HOPE intervention |
| California | CA-45 | Study of Efficacy and Safety of MAS825 in Patients With COVID-19 | 140 | Novartis Investigative Site, | Novartis Pharmaceuticals, Novartis | Drug: MAS825, Drug: Matching placebo |
| California | CA-45 | A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia | 500 | Hoag Hospital Irvine, | Hoffmann-La Roche, Gilead Sciences | Drug: Remdesivir, Drug: Tocilizumab, Drug: Placebo |
| California | CA-46 | Adaptive COVID-19 Treatment Trial (ACTT) | 1062 | University of California Irvine Medical Center, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir |
| California | CA-46 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Kaiser Permanente Los Angeles Medical Center, Center for Cancer Prevention and Treatment at St. Joseph Hospital, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-46 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Kaiser Permanente Los Angeles Medical Center, Center for Cancer Prevention and Treatment at St. Joseph Hospital, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-46 | The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection | 100 | University of California Irvine, | Pulmotect, Inc. | Drug: PUL-042 Inhalation Solution, Drug: Placebo |
| California | CA-46 | The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2 | 200 | University of California Irvine, | Pulmotect, Inc. | Drug: PUL-042 Inhalation Solution, Drug: Placebo |
| California | CA-46 | Convalescent Plasma to Stem Coronavirus (CSSC-001) | 500 | University of California - Irvine Health, | Johns Hopkins University | Biological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma |
| California | CA-46 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Anaheim Clinical Trials LLC, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| California | CA-46 | Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia | 270 | UC Irvine Medical Center, | Alexion Pharmaceuticals | Biological: Ravulizumab, Other: Best Supportive Care |
| California | CA-46 | Convalescent Plasma to Limit SARS-CoV-2 Associated Complications | 1344 | University of California - Irvine Health, | Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID) | Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor |
| California | CA-46 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Kaiser Permanente-Anaheim, UC Irvine Health Chao Family Comprehensive Cancer Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| California | CA-46 | Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19 | 140 | University of California Irvine, | Pluristem Ltd. | Biological: PLX-PAD, Biological: Placebo |
| California | CA-46 | Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression | 208 | Octapharma Research Site, | Octapharma | Biological: Octagam 10%, Other: Placebo |
| California | CA-46 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | University of California Irvine Medical Center, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| California | CA-46 | PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer | 364 | St. Jude Hospital Yorba Linda, | CTI BioPharma | Drug: Pacritinib, Drug: Placebo |
| California | CA-46 | Study of Sargramostim in Patients With COVID-19 | 120 | St. Joseph Hospital of Orange, | Partner Therapeutics, Inc. | Drug: Sargramostim, Drug: Standard of care |
| California | CA-47 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Long Beach Memorial Medical Center, | Gilead Sciences | Drug: Remdesivir |
| California | CA-47 | Awake Prone Position for Early Hypoxemia in COVID-19 | 560 | Long Beach Medical Center - MemorialCare, | Boston University | Other: Self-prone position recommendation, Other: Usual care |
| California | CA-47 | A Study of Auxora in Patients With Severe COVID-19 Pneumonia | 400 | Long Beach Memorial, | CalciMedica, Inc. | Drug: Auxora, Drug: Placebo |
| California | CA-47 | Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection | 4000 | Long Beach Clinical Trials, | Romark Laboratories L.C. | Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex |
| California | CA-47 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Long Beach Clinical Trials Services Inc., Collaborative Neuroscience Research, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| California | CA-47 | A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19 | 270 | MemorialCare Research Miller Children's and Women's Hospital, | Janssen Pharmaceutica N.V., Belgium | Drug: Sirukumab, Drug: Placebo, Other: Standard of Care (SOC) |
| California | CA-47 | Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization | 198 | VA Long Beach Healthcare System, | VA Office of Research and Development | Drug: Degarelix, Other: Saline |
| California | CA-48 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Hoag Memorial Hospital Presbyterian, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-48 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Hoag Memorial Hospital Presbyterian, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-48 | Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection | 4000 | So Cal Clinical Research, | Romark Laboratories L.C. | Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex |
| California | CA-48 | Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 | 86 | UC Irvine, | Celularity Incorporated, IDRI, Lung Biotechnology PBC, California Institute for Regenerative Medicine (CIRM) | Biological: CYNK-001 |
| California | CA-48 | A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia | 379 | Harper University Hospital, | Genentech, Inc. | Drug: Placebo, Drug: Tocilizumab |
| California | CA-48 | Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. | 62 | Research Site, | AstraZeneca, Acerta Pharma B.V. | Drug: Acalabrutinib |
| California | CA-48 | A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19 | 270 | Hoag Memorial Hospital, | Janssen Pharmaceutica N.V., Belgium | Drug: Sirukumab, Drug: Placebo, Other: Standard of Care (SOC) |
| California | CA-48 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | UC Irvine Health Cancer Center-Newport, Kaiser Permanente-Irvine, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| California | CA-48 | Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression | 208 | Octapharma Research Site, | Octapharma | Biological: Octagam 10%, Other: Placebo |
| California | CA-49 | A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19) | 242 | University of California San Diego Moores Cancer Center, | Millennium Pharmaceuticals, Inc., Takeda | Drug: TAK-981, Drug: Standard of care |
| California | CA-49 | A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia | 450 | University of California San Diego, | Hoffmann-La Roche | Drug: Tocilizumab (TCZ), Drug: Placebo |
| California | CA-49 | Convalescent Plasma to Stem Coronavirus (CSSC-001) | 500 | University of California - San Diego, | Johns Hopkins University | Biological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma |
| California | CA-49 | Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP) | 0 | Naval Hospital Camp Pendleton, | U.S. Army Medical Research and Development Command | Biological: Anti-Sars-CoV-2 Convalescent Plasma |
| California | CA-49 | Ramipril for the Treatment of COVID-19 | 560 | University of California - San Diego, | University of California, San Diego, Pfizer | Drug: Ramipril 2.5 MG Oral Capsule, Drug: Placebo oral capsule |
| California | CA-49 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | University of California San Diego Moores Cancer Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| California | CA-49 | LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19) | 60 | VA San Diego Healthcare System, | Arch Biopartners Inc. | Drug: LSALT peptide, Drug: Placebo |
| California | CA-49 | A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19 | 24 | Veterans Affairs Medical Center, | Eli Lilly and Company, AbCellera Biologics Inc. | Drug: LY3819253, Drug: Placebo |
| California | CA-50 | Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. | 62 | Research Site, | AstraZeneca, Acerta Pharma B.V. | Drug: Acalabrutinib |
| California | CA-50 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Kaiser Permanente-San Marcos, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| California | CA-51 | Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP) | 0 | USS Abraham Lincoln CVN 72, USS Boxer LHD 4, USS Carl Vinson CVN 70, USS Essex LHD 2, USS Makin Island LHD 8, USS Nimitz CVN 68, USS Theodore Roosevelt CVN 71, USS Tripoli LHA 7, | U.S. Army Medical Research and Development Command | Biological: Anti-Sars-CoV-2 Convalescent Plasma |
| California | CA-51 | A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia | 379 | El Centro Regional Medical Center, | Genentech, Inc. | Drug: Placebo, Drug: Tocilizumab |
| California | CA-51 | A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia | 500 | El Centro Regional Medical Center, | Hoffmann-La Roche, Gilead Sciences | Drug: Remdesivir, Drug: Tocilizumab, Drug: Placebo |
| California | CA-52 | Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study | 250 | University of California San Diego Medical Center, | Ansun Biopharma, Inc. | Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL |
| California | CA-52 | Adaptive COVID-19 Treatment Trial (ACTT) | 1062 | University of California San Diego Health, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir |
| California | CA-52 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Kaiser Permanente Los Angeles Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-52 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Kaiser Permanente Los Angeles Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-52 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Scripps Memorial Hospital La Jolla, Scripps Mercy Hospital, | Gilead Sciences | Drug: Remdesivir |
| California | CA-52 | Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection | 200 | Sharp Coronado Hospital, | Sharp HealthCare | Drug: Losartan |
| California | CA-52 | Convalescent Plasma in Outpatients With COVID-19 | 600 | UCSD Health La Jolla, | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network | Biological: Convalescent Plasma, Biological: Saline |
| California | CA-52 | Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection | 60 | Scripps Memorial Hospital La Jolla, | Denver Health and Hospital Authority, Genentech, Inc., University of Colorado, Denver, National Jewish Health, Beth Israel Deaconess Medical Center, Long Island Jewish Medical Center, Scripps Health, St. Mary's Medical Center, University of Miami, Ben Taub Hospital, Methodist Dallas Medical Center | Drug: Alteplase 50 MG [Activase] |
| California | CA-52 | Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults | 1000 | Scripps Health, | Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS) | Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo |
| California | CA-52 | Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 | 86 | Scripps Health, | Celularity Incorporated, IDRI, Lung Biotechnology PBC, California Institute for Regenerative Medicine (CIRM) | Biological: CYNK-001 |
| California | CA-52 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | California Research Foundation, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| California | CA-52 | Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression | 208 | Octapharma Research Site, | Octapharma | Biological: Octagam 10%, Other: Placebo |
| California | CA-52 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | University of California San Diego Health, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| California | CA-53 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Kaiser Permanente Los Angeles Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-53 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Kaiser Permanente Los Angeles Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-53 | A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia | 450 | eStudySite, | Hoffmann-La Roche | Drug: Tocilizumab (TCZ), Drug: Placebo |
| California | CA-53 | Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection | 200 | Sharp Grossmont Hospital, Sharp Chula Vista Medical Center, Sharp Memorial Hospital, | Sharp HealthCare | Drug: Losartan |
| California | CA-53 | Awake Prone Position for Early Hypoxemia in COVID-19 | 560 | Alvarado Hospital, | Boston University | Other: Self-prone position recommendation, Other: Usual care |
| California | CA-53 | A Study of Auxora in Patients With Severe COVID-19 Pneumonia | 400 | Sharp Memorial San Diego, | CalciMedica, Inc. | Drug: Auxora, Drug: Placebo |
| California | CA-53 | Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19 | 20 | UCSD Antiviral Research Center CRS, | National Institute of Allergy and Infectious Diseases (NIAID), Teva Pharmaceuticals Industries LTD | Drug: Hydroxychloroquine (HCQ), Drug: Azithromycin (Azithro), Drug: Placebo for Hydroxychloroquine, Drug: Placebo for Azithromycin |
| California | CA-53 | Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP) | 0 | Navy Medical Center San Diego, | U.S. Army Medical Research and Development Command | Biological: Anti-Sars-CoV-2 Convalescent Plasma |
| California | CA-53 | A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia | 379 | eStudySite, | Genentech, Inc. | Drug: Placebo, Drug: Tocilizumab |
| California | CA-53 | Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) | 500 | Sharp Memorial Hospital, | Incyte Corporation | Drug: Placebo, Drug: Ruxolitinib |
| California | CA-53 | Study of Efficacy and Safety of MAS825 in Patients With COVID-19 | 140 | Novartis Investigative Site, Novartis Investigative Site, | Novartis Pharmaceuticals, Novartis | Drug: MAS825, Drug: Matching placebo |
| California | CA-53 | A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia | 410 | eStudySite - Chula Vista - PPDS, eStudySite, | Genentech, Inc. | Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo |
| California | CA-53 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Kaiser Permanente-San Diego Mission, Kaiser Permanente-San Diego Zion, Sharp Memorial Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| California | CA-53 | IgG/IgM Antibody Test in Patients Who Have Tested Negative or Positive for COVID-19 With the Standard Method of COVID19 Testing. | 90 | Fadi A. Haddad MD Inc., Sharp Grossmont Hospital, Sharp Memorial Hosptial, | Fadi Haddad, M.D., Sharp HealthCare | Diagnostic Test: Clungene rapid test cassette |
| California | CA-53 | A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia | 500 | eStudySite - Chula Vista - PPDS, | Hoffmann-La Roche, Gilead Sciences | Drug: Remdesivir, Drug: Tocilizumab, Drug: Placebo |
| California | CA-53 | Study of SOC Plus IVIG Compared to SOC Alone in the Treatment of COVID-19 | 34 | Sharp Grossmont Hospital, Sharp Memorial Hospital, | George Sakoulas, MD, Octapharma, Sharp HealthCare | Drug: Octagam |
| California | CA-03 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Kaiser Permanente Medical Center-Vacaville, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| California | CA-06 | Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients | 100 | UC Davis Medical Center, | Novartis Pharmaceuticals, Novartis | Drug: Crizanlizumab |
| California | CA-06 | Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study | 250 | University of California Davis Health System, | Ansun Biopharma, Inc. | Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL |
| California | CA-06 | Adaptive COVID-19 Treatment Trial (ACTT) | 1062 | University of California Davis Medical Center, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir |
| California | CA-06 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Sutter Medical Center Sacramento, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-06 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Sutter Medical Center Sacramento, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-06 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| California | CA-06 | Convalescent Plasma to Stem Coronavirus (CSSC-001) | 500 | University of California - Davis, | Johns Hopkins University | Biological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma |
| California | CA-06 | Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease | 479 | UC Davis Medical Center, | Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI) | Drug: Hydroxychloroquine, Drug: Placebo |
| California | CA-06 | Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection | 202 | UC Davis Health, | Karyopharm Therapeutics Inc | Drug: Selinexor, Other: Placebo |
| California | CA-06 | Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 | 86 | UC Davis Medical Center, | Celularity Incorporated, IDRI, Lung Biotechnology PBC, California Institute for Regenerative Medicine (CIRM) | Biological: CYNK-001 |
| California | CA-06 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | UC Davis Medical Center, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| California | CA-06 | Convalescent Plasma to Limit SARS-CoV-2 Associated Complications | 1344 | University of California - Davis, | Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID) | Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor |
| California | CA-06 | PET/CT Imaging in COVID-19 Patients | 10 | University of California - Davis, | University of California, Davis | Drug: 18F-αvβ6-BP |
| California | CA-06 | Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease | 800 | GSK Investigational Site, | GlaxoSmithKline | Biological: Otilimab, Biological: Placebo, Drug: Standard of care |
| California | CA-06 | A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19 | 270 | Sutter Medical Foundation, | Janssen Pharmaceutica N.V., Belgium | Drug: Sirukumab, Drug: Placebo, Other: Standard of Care (SOC) |
| California | CA-06 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Kaiser Permanente Downtown Commons, University of California Davis Comprehensive Cancer Center, Kaiser Permanente-South Sacramento, South Sacramento Cancer Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| California | CA-06 | Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19 | 140 | University of California Davis, | Pluristem Ltd. | Biological: PLX-PAD, Biological: Placebo |
| California | CA-06 | Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) | 190 | Atea Study Site, | Atea Pharmaceuticals, Inc. | Drug: AT-527, Other: Placebo |
| California | CA-06 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | University of California Davis Medical Center, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| California | CA-08 | Adaptive COVID-19 Treatment Trial (ACTT) | 1062 | Naval Medical Center San Diego, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir |
| California | CA-08 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | Naval Medical Center San Diego, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| California | CA-01 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Paradigm Clinical Research Center, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| California | CA-01 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Enloe Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| California | CA-09 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Kaiser Permanente-Deer Valley Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| California | CA-04 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Sutter Medical Center Sacramento, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-04 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Sutter Medical Center Sacramento, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-04 | A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19 | 270 | Sutter Institute for Medical Research, | Janssen Pharmaceutica N.V., Belgium | Drug: Sirukumab, Drug: Placebo, Other: Standard of Care (SOC) |
| California | CA-04 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Kaiser Permanente-Roseville, Permanente Medical Group-Roseville Radiation Oncology, Kaiser Permanente-Stockton, Gene Upshaw Memorial Tahoe Forest Cancer Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| California | CA-02 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | St Joseph Hospital Eureka, Sutter Santa Rose Regional Hospital, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-02 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | St Joseph Hospital Eureka, Sutter Santa Rosa Regional Hospital, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| California | CA-02 | Predicting Outcomes for Covid-19 Using Sonography | 200 | Stanford University, | Stanford University | Diagnostic Test: Lung Ultrasound |
| California | CA-02 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Kaiser San Rafael-Gallinas, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| California | CA-07 | Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection | 202 | Kaiser Permanente Sacramento, | Karyopharm Therapeutics Inc | Drug: Selinexor, Other: Placebo |
| California | CA-07 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Kaiser Permanente-Rancho Cordova Cancer Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| California | CA-05 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Santa Rosa Memorial Hospital, | Gilead Sciences | Drug: Remdesivir |
| California | CA-05 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Rohnert Park Cancer Center, Kaiser Permanente-Santa Rosa, Kaiser Permanente-Vallejo, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Alabama | AL-07 | Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients | 100 | University of Alabama, | Novartis Pharmaceuticals, Novartis | Drug: Crizanlizumab |
| Alabama | AL-07 | Adaptive COVID-19 Treatment Trial (ACTT) | 1062 | University of Alabama at Birmingham, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir |
| Alabama | AL-07 | Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19 | 200 | University of Alabama, | Massachusetts General Hospital, Xijing Hospital, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Niguarda Hospital | Drug: Nitric Oxide Gas |
| Alabama | AL-07 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | University of Alabama - Birmingham, | Gilead Sciences | Drug: Remdesivir |
| Alabama | AL-07 | Convalescent Plasma to Stem Coronavirus (CSSC-001) | 500 | University of Alabama at Birmingham, | Johns Hopkins University | Biological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma |
| Alabama | AL-07 | SARS-COV2 Pandemic Serosurvey and Blood Sampling | 15000 | University of Alabama, | National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health Clinical Center (CC) | |
| Alabama | AL-07 | TXA and Corona Virus 2019 (COVID19) in Outpatients | 100 | University of Alabama at Birmingham, | University of Alabama at Birmingham | Drug: Tranexamic acid tablets, Drug: Placebo oral tablet |
| Alabama | AL-07 | Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients | 60 | University of Alabama at Birmingham, | University of Alabama at Birmingham | Drug: Tranexamic acid, Drug: Placebo oral tablet |
| Alabama | AL-07 | Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19 | 20 | Alabama CRS, | National Institute of Allergy and Infectious Diseases (NIAID), Teva Pharmaceuticals Industries LTD | Drug: Hydroxychloroquine (HCQ), Drug: Azithromycin (Azithro), Drug: Placebo for Hydroxychloroquine, Drug: Placebo for Azithromycin |
| Alabama | AL-07 | Early Treatment of Cytokine Storm Syndrome in Covid-19 | 30 | University of Alabama at Birmingham, | University of Alabama at Birmingham | Drug: Anakinra, Drug: Normal saline |
| Alabama | AL-07 | Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia | 451 | Novartis Investigative Site, | Novartis Pharmaceuticals, Novartis | Drug: Canakinumab, Drug: Placebo |
| Alabama | AL-07 | Convalescent Plasma to Limit SARS-CoV-2 Associated Complications | 1344 | University of Alabama at Birmingham, | Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID) | Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor |
| Alabama | AL-07 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | University of Alabama at Birmingham Cancer Center, Veterans Administration Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Alabama | AL-07 | Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure | 524 | University of Alabama at Birmingham, | Chimerix | Drug: Dociparastat sodium, Drug: Placebo |
| Alabama | AL-07 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | University of Alabama at Birmingham, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| Alabama | AL-07 | Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19 | 727 | Alabama Vaccine CRS, | HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials Network | Other: Sample collection |
| Alabama | AL-04 | Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression | 208 | Octapharma Research Site, | Octapharma | Biological: Octagam 10%, Other: Placebo |
| Alabama | AL-01 | Dapagliflozin in Respiratory Failure in Patients With COVID-19 | 900 | Heart Group of the Eastern Shore, | Saint Luke's Health System, AstraZeneca, George Clinical Pty Ltd | Drug: Dapagliflozin 10 MG, Drug: Placebo |
| Alabama | AL-01 | Trial of Hydroxychloroquine In Covid-19 Kinetics | 58 | University of South Alabama, | University of South Alabama | Drug: Hydroxychloroquine, Other: Placebo |
| Alabama | AL-01 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Alliance for Multispecialty Research LLC, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Alabama | AL-01 | Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease | 800 | GSK Investigational Site, | GlaxoSmithKline | Biological: Otilimab, Biological: Placebo, Drug: Standard of care |
| Alabama | AL-01 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | USA Health Strada Patient Care Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Alabama | AL-06 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Birmingham Clinical Research Unit, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Alabama | AL-03 | Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19) | 390 | Advanced Cardiovascular LLC, | CytoDyn, Inc. | Drug: Placebos, Drug: Leronlimab (700mg) |
| Alabama | AL-03 | Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. | 62 | Research Site, | AstraZeneca, Acerta Pharma B.V. | Drug: Acalabrutinib |
| Alabama | AL-05 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | North Alabama Research Center, LLC, Medical Affiliated Research Center, Optimal Research LLC, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Colorado | CO-05 | Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP) | 0 | Evans Army Community Hospital, | U.S. Army Medical Research and Development Command | Biological: Anti-Sars-CoV-2 Convalescent Plasma |
| Colorado | CO-05 | Convalescent Plasma for the Treatment of Patients With COVID-19 | 0 | UCHealth Memorial Hospital North, | University of Colorado, Denver | Biological: COVID-19 Convalescent Plasma |
| Colorado | CO-05 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Penrose-Saint Francis Healthcare, Rocky Mountain Cancer Centers-Penrose, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Colorado | CO-06 | Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study | 250 | Children's Hospital Colorado, | Ansun Biopharma, Inc. | Drug: DAS181, Drug: Placebo, Drug: DAS181 COVID-19, Drug: DAS181 OL |
| Colorado | CO-06 | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 5000 | Colorado University Denver, | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: |
| Colorado | CO-06 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | University of Colorado Hospital, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Colorado | CO-06 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | University of Colorado Hospital, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Colorado | CO-06 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| Colorado | CO-06 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | The Medical Center Of Aurora, | Gilead Sciences | Drug: Remdesivir |
| Colorado | CO-06 | Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease | 479 | Medical Center of Aurora, University of Colorado Hospital, | Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI) | Drug: Hydroxychloroquine, Drug: Placebo |
| Colorado | CO-06 | Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine | 1363 | Children's Hospital Colorado/University of Colorado Denver, | Adrian Hernandez, Patient-Centered Outcomes Research Institute, Duke University | Drug: Hydroxychloroquine, Drug: Placebo oral tablet |
| Colorado | CO-06 | Safety and Efficacy of Baricitinib for COVID-19 | 80 | University of Colorado - Denver, | University of Colorado, Denver | Drug: Baricitinib |
| Colorado | CO-06 | The Use of Ultrasound in Establishing COVID-19 Infection as Part of a Trauma Evaluation | 20 | Children's Hospital Colorado, | University of Colorado, Denver | Diagnostic Test: Ultrasound lung imaging as part of FAST+ evaluation |
| Colorado | CO-06 | Convalescent Plasma in Outpatients With COVID-19 | 600 | University of Colorado, | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network | Biological: Convalescent Plasma, Biological: Saline |
| Colorado | CO-06 | Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection | 60 | University of Colorado - Denver, | Denver Health and Hospital Authority, Genentech, Inc., University of Colorado, Denver, National Jewish Health, Beth Israel Deaconess Medical Center, Long Island Jewish Medical Center, Scripps Health, St. Mary's Medical Center, University of Miami, Ben Taub Hospital, Methodist Dallas Medical Center | Drug: Alteplase 50 MG [Activase] |
| Colorado | CO-06 | Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID) | 432 | Novartis Investigative Site, | Novartis Pharmaceuticals, Incyte Corporation, Novartis | Drug: Ruxolitinib, Drug: Placebo |
| Colorado | CO-06 | Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults | 1000 | University of Colorado Denver, | Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS) | Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo |
| Colorado | CO-06 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Lynn Institute of Denver, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Colorado | CO-06 | Convalescent Plasma for the Treatment of Patients With COVID-19 | 0 | Children's Hospital Colorado, University of Colorado Hospital, UCHealth Highlands Ranch Hospital, | University of Colorado, Denver | Biological: COVID-19 Convalescent Plasma |
| Colorado | CO-06 | Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19 | 600 | University of Colorado School of Medicine, | Vanderbilt University Medical Center, AbbVie | Drug: Lopinavir/Ritonavir 400 mg/100 mg, Other: Placebo |
| Colorado | CO-06 | COVID-19: Human Epidemiology and Response to SARS-CoV-2 | 5605 | Children's Hospital Colorado, | National Institute of Allergy and Infectious Diseases (NIAID), Rho Federal Systems Division, Inc. (Rho) | Procedure: Collection of Biological Samples, Procedure: Symptom and Exposure Surveys |
| Colorado | CO-06 | Surgical Telemedicine in the COVID-19 Pandemic Era | 180 | Children's Hospital Colorado, | University of Colorado, Denver | Other: Completion of pre-pandemic survey, Other: Completion of survey after peak of pandemic, Other: Completion of post telemedicine encounter survey |
| Colorado | CO-06 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Medical Center of Aurora, Rocky Mountain Cancer Centers-Aurora, Rocky Mountain Regional VA Medical Center, Rocky Mountain Cancer Centers-Centennial, Rocky Mountain Cancer Centers-Littleton, Littleton Adventist Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Colorado | CO-06 | Registry of CytoSorb Therapy in COVID-19 ICU Patients | 500 | Medical Center of Aurora, | CytoSorbents, Inc | Device: CytoSorb 300 mL device |
| Colorado | CO-06 | An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic | 0 | University Of Colorado, | Genentech, Inc. | Drug: Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration (PH FDC SC) |
| Colorado | CO-06 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | Rocky Mountain Regional Veteran Affairs Medical Center, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| Colorado | CO-04 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | North Colorado Medical Center, Kaiser Permanente-Lone Tree, Rocky Mountain Cancer Centers-Sky Ridge, Sky Ridge Medical Center, Longmont United Hospital, Rocky Mountain Cancer Centers-Longmont, Parker Adventist Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Colorado | CO-02 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | SCL Health St. Joseph Hospital, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Colorado | CO-02 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | SCL Health St. Joseph Hospital, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Colorado | CO-02 | Convalescent Plasma for the Treatment of Patients With COVID-19 | 0 | UCHealth Poudre Valley Hospital, | University of Colorado, Denver | Biological: COVID-19 Convalescent Plasma |
| Colorado | CO-02 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Boulder Community Hospital, Rocky Mountain Cancer Centers-Boulder, Good Samaritan Medical Center, Kaiser Permanente-Rock Creek, McKee Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Colorado | CO-01 | Adaptive COVID-19 Treatment Trial (ACTT) | 1062 | Denver Health Medical Center, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir |
| Colorado | CO-01 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | SCL Health St. Joseph Hospital, SCL Health St. Joseph Hospital, Rose Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Colorado | CO-01 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | SCL Health St. Joseph Hospital, SCL Health St. Joseph Hospital, Rose Medical Center, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Colorado | CO-01 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| Colorado | CO-01 | A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia | 450 | Denver Health Medical Center, | Hoffmann-La Roche | Drug: Tocilizumab (TCZ), Drug: Placebo |
| Colorado | CO-01 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Rose Medical Center, Swedish Medical Center, | Gilead Sciences | Drug: Remdesivir |
| Colorado | CO-01 | Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease | 479 | Denver Health Medical Center, St. Joseph Hospital, | Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI) | Drug: Hydroxychloroquine, Drug: Placebo |
| Colorado | CO-01 | A Study of LY3127804 in Participants With COVID-19 | 95 | National Jewish Medical and Research Center, | Eli Lilly and Company | Drug: LY3127804, Drug: Placebo |
| Colorado | CO-01 | Awake Prone Position for Early Hypoxemia in COVID-19 | 560 | St. Joseph's Hospital National Jewish Health, | Boston University | Other: Self-prone position recommendation, Other: Usual care |
| Colorado | CO-01 | Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection | 60 | Denver Health Medical Center, National Jewish Health, | Denver Health and Hospital Authority, Genentech, Inc., University of Colorado, Denver, National Jewish Health, Beth Israel Deaconess Medical Center, Long Island Jewish Medical Center, Scripps Health, St. Mary's Medical Center, University of Miami, Ben Taub Hospital, Methodist Dallas Medical Center | Drug: Alteplase 50 MG [Activase] |
| Colorado | CO-01 | Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID) | 432 | Novartis Investigative Site, | Novartis Pharmaceuticals, Incyte Corporation, Novartis | Drug: Ruxolitinib, Drug: Placebo |
| Colorado | CO-01 | Convalescent Plasma for the Treatment of Patients With COVID-19 | 0 | Denver Health Medical Center, | University of Colorado, Denver | Biological: COVID-19 Convalescent Plasma |
| Colorado | CO-01 | Study of Efficacy and Safety of MAS825 in Patients With COVID-19 | 140 | Novartis Investigative Site, | Novartis Pharmaceuticals, Novartis | Drug: MAS825, Drug: Matching placebo |
| Colorado | CO-01 | International SARS-CoV-2 (COVID-19) Infection Observational Study | 10000 | Denver Public Health, | University of Minnesota, National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) | Other: Data Collection |
| Colorado | CO-01 | A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia | 410 | Denver Health Medical Center, | Genentech, Inc. | Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo |
| Colorado | CO-01 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Cancer Center of Colorado at Sloan's Lake, Kaiser Permanente-Franklin, National Jewish Health-Main Campus, The Women's Imaging Center, Porter Adventist Hospital, Colorado Blood Cancer Institute, Presbyterian - Saint Lukes Medical Center - Health One, Rocky Mountain Cancer Centers-Midtown, SCL Health Saint Joseph Hospital, Rocky Mountain Cancer Centers-Rose, Rose Medical Center, Western Surgical Care, Mountain Blue Cancer Care Center – Swedish, Swedish Medical Center, Saint Anthony Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Colorado | CO-01 | Adaptive COVID-19 Treatment Trial 2 (ACTT-2) | 1034 | Denver Health Medical Center, | National Institute of Allergy and Infectious Diseases (NIAID) | Other: Placebo, Drug: Remdesivir, Drug: Baricitinib |
| Colorado | CO-07 | COVID-19 Diagnostic Self-testing Using Virtual Point-of-care | 200 | Neuroganics, | Neuroganics LLC, Neuroganics Diagnostics LLC | Diagnostic Test: COVID-19 Antigen/Antibody Rapid Testing, mobile device image capture and telemedicine support, Other: Telemedicine |
| Colorado | CO-07 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | National Jewish Health-Western Hematology Oncology, National Jewish Health-Northern Hematology Oncology, SCL Health Lutheran Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Colorado | CO-03 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Mercy Medical Center, Southwest Oncology PC, Saint Mary's Hospital and Regional Medical Center, Saint Mary Corwin Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Alaska | AK-00 | Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19 | 70 | Providence Health Network, | Massachusetts General Hospital, University of Alabama at Birmingham | Drug: Nitric Oxide |
| Alaska | AK-00 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Anchorage Associates in Radiation Medicine, Anchorage Radiation Therapy Center, Alaska Breast Care and Surgery LLC, Alaska Oncology and Hematology LLC, Alaska Women's Cancer Care, Anchorage Oncology Centre, Katmai Oncology Group, Providence Alaska Medical Center, Fairbanks Memorial Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Arizona | AZ-09 | A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE) | 227 | HonorHealth John C. Lincoln Medical Center, | Kinevant Sciences GmbH, Roivant Sciences, Inc. | Drug: Gimsilumab, Drug: Placebo |
| Arizona | AZ-09 | Convalescent Plasma in Outpatients With COVID-19 | 600 | Chandler Regional Medical Center, | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network | Biological: Convalescent Plasma, Biological: Saline |
| Arizona | AZ-09 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Alliance for Multispecialty Research LLC, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Arizona | AZ-09 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Banner Children's at Desert, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Arizona | AZ-09 | Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization | 198 | Phoenix VA Health Care System, | VA Office of Research and Development | Drug: Degarelix, Other: Saline |
| Arizona | AZ-09 | Vitamin D Testing and Treatment for COVID 19 | 41 | Arizona State University, | Arizona State University, Southwest College of Naturopathic Medicine | Dietary Supplement: Vitamin D3 |
| Arizona | AZ-01 | Convalescent Plasma to Stem Coronavirus (CSSC-001) | 500 | Center for American Indian Health, Center for American Indian Health, | Johns Hopkins University | Biological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma |
| Arizona | AZ-01 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Chinle Comprehensive Health Care Facility, Johns Hopkins Center for American Indian Health, Whiteriver Indian Hospital, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Arizona | AZ-01 | Convalescent Plasma to Limit SARS-CoV-2 Associated Complications | 1344 | Center for American Indian Health, Center for American Indian Health, | Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID) | Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor |
| Arizona | AZ-02 | Convalescent Plasma to Stem Coronavirus (CSSC-001) | 500 | University of Arizona - Phoenix, | Johns Hopkins University | Biological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma |
| Arizona | AZ-02 | Treating COVID-19 With a Bidirectional Oxygenation Valve | 30 | TMC HealthCare, | TMC HealthCare, PEEP Medical, LLC | Device: bidirectional oxygenation mouthpiece |
| Arizona | AZ-02 | A Study of LY3127804 in Participants With COVID-19 | 95 | Banner University Medica Center, | Eli Lilly and Company | Drug: LY3127804, Drug: Placebo |
| Arizona | AZ-02 | A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE) | 227 | Banner University Medical Center, | Kinevant Sciences GmbH, Roivant Sciences, Inc. | Drug: Gimsilumab, Drug: Placebo |
| Arizona | AZ-02 | Convalescent Plasma to Limit SARS-CoV-2 Associated Complications | 1344 | University of Arizona, | Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID) | Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor |
| Arizona | AZ-06 | Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) | 6000 | Mayo Clinic - Arizona, | Montreal Heart Institute, National Heart, Lung, and Blood Institute (NHLBI), Bill and Melinda Gates Foundation, The Government of Quebec, DACIMA Software | Drug: Colchicine, Drug: Placebo oral tablet |
| Arizona | AZ-06 | Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry | 50000 | Mayo Clinic in Arizona, | Mayo Clinic, Society of Critical Care Medicine, Boston University | Other: observational |
| Arizona | AZ-06 | Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19 | 0 | Mayo Clinic in Arizona, | Mayo Clinic | Biological: COVID-19 convalescent plasma |
| Arizona | AZ-06 | Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection | 25 | HonorHealth, | HonorHealth Research Institute | Drug: Atovaquone/Azithromycin |
| Arizona | AZ-06 | Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19 | 80 | Perseverance Research Center, Perseverance Research Center, | Perseverance Research Center, LLC, Athena Medical Group | Drug: Hydroxychloroquine, Drug: Indomethacin, Drug: Zithromax Oral Product |
| Arizona | AZ-06 | Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19 | 300 | Mayo Clinic, | Humanigen, Inc. | Biological: Lenzilumab, Drug: Standard of Care |
| Arizona | AZ-06 | A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE) | 227 | HonorHealth Scottsdale Osborn Medical Center, HonorHealth, HonorHealth Scottsdale Shea Medical Center, | Kinevant Sciences GmbH, Roivant Sciences, Inc. | Drug: Gimsilumab, Drug: Placebo |
| Arizona | AZ-06 | Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19 | 50 | HonorHealth, | Fujifilm Pharmaceuticals U.S.A., Inc. | Drug: Favipiravir + Standard of Care, Drug: Standard of Care |
| Arizona | AZ-06 | A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia | 100 | Mayo Clinic - Arizona, | Hoffmann-La Roche | Drug: Tociliuzumab |
| Arizona | AZ-06 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | HOPE Research institute, Pain Center of Arizona, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Arizona | AZ-06 | Convalescent Plasma to Limit SARS-CoV-2 Associated Complications | 1344 | Mayo Clinic, | Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID) | Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor |
| Arizona | AZ-06 | Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) | 500 | Honor Health Research Institute, | Incyte Corporation | Drug: Placebo, Drug: Ruxolitinib |
| Arizona | AZ-06 | Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants | 52 | Honor Health, | BeiGene | Drug: Zanubrutinib, Drug: Supportive Care, Drug: Placebo |
| Arizona | AZ-06 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Mayo Clinic Hospital in Arizona, Mayo Clinic in Arizona, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Arizona | AZ-06 | COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111 | 40 | HonorHealth, | Veru Inc. | Drug: Veru-111 |
| Arizona | AZ-06 | Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19) | 190 | Atea Study Site, | Atea Pharmaceuticals, Inc. | Drug: AT-527, Other: Placebo |
| Arizona | AZ-06 | A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia | 500 | Valleywise Health Medical Center, | Hoffmann-La Roche, Gilead Sciences | Drug: Remdesivir, Drug: Tocilizumab, Drug: Placebo |
| Arizona | AZ-06 | Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19 | 44 | Mayo Clinic in Arizona, | ViralClear Pharmaceuticals, Inc. | Drug: Merimepodib, Drug: Matching Placebo, Drug: Remdesivir |
| Arizona | AZ-05 | MSCs in COVID-19 ARDS | 223 | Dignity Health, | Icahn School of Medicine at Mount Sinai, Mesoblast, Inc., National Heart, Lung, and Blood Institute (NHLBI) | Biological: Remestemcel-L, Drug: Placebo |
| Arizona | AZ-04 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Kingman Regional Medical Center, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Arizona | AZ-03 | Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) | 6000 | Yuma Regional Medical Center Cancer Center, | Montreal Heart Institute, National Heart, Lung, and Blood Institute (NHLBI), Bill and Melinda Gates Foundation, The Government of Quebec, DACIMA Software | Drug: Colchicine, Drug: Placebo oral tablet |
| Arizona | AZ-03 | Convalescent Plasma to Stem Coronavirus (CSSC-001) | 500 | University of Arizona - Tucson, | Johns Hopkins University | Biological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma |
| Arizona | AZ-03 | Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease | 479 | University of Arizona, | Massachusetts General Hospital, National Heart, Lung, and Blood Institute (NHLBI) | Drug: Hydroxychloroquine, Drug: Placebo |
| Arizona | AZ-03 | A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia | 379 | Univ of AZ Coll of Med, | Genentech, Inc. | Drug: Placebo, Drug: Tocilizumab |
| Arizona | AZ-03 | Convalescent Plasma to Limit SARS-CoV-2 Associated Complications | 1344 | University of Arizona, | Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID) | Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor |
| Arizona | AZ-03 | Immunophenotyping Assessment in a COVID-19 Cohort | 2000 | University of Arizona College of Medicine, | National Institute of Allergy and Infectious Diseases (NIAID), Benaroya Research Institute, Boston Children's Hospital | Procedure: Biological sample collection, Procedure: Data Collection: Clinical Care Assessments |
| Arizona | AZ-07 | Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients | 100 | Phoenix Childrens Hospital, | Novartis Pharmaceuticals, Novartis | Drug: Crizanlizumab |
| Arizona | AZ-07 | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 5000 | Phoenix Children's Hospital, | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: |
| Arizona | AZ-07 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Banner-University Medical Center, | Gilead Sciences | Drug: Remdesivir |
| Arizona | AZ-07 | Effects of Using Mobile App on Perceived Stress During COVID-19 Pandemic | 101 | Banner University Medicine Women's Institute, | University of Arizona | Other: "Calm" is a mindfulness meditation mobile app |
| Arizona | AZ-07 | A Study of LY3127804 in Participants With COVID-19 | 95 | Banner University Medica Center, | Eli Lilly and Company | Drug: LY3127804, Drug: Placebo |
| Arizona | AZ-07 | A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE) | 227 | Banner University Medical Center, | Kinevant Sciences GmbH, Roivant Sciences, Inc. | Drug: Gimsilumab, Drug: Placebo |
| Arizona | AZ-07 | Convalescent Plasma in Outpatients With COVID-19 | 600 | Valleywise Health Medical Center, | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Network | Biological: Convalescent Plasma, Biological: Saline |
| Arizona | AZ-07 | Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults | 1000 | University of Arizona, | Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS) | Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo |
| Arizona | AZ-07 | Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 | 86 | Banner University Medical Center, | Celularity Incorporated, IDRI, Lung Biotechnology PBC, California Institute for Regenerative Medicine (CIRM) | Biological: CYNK-001 |
| Arizona | AZ-07 | A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia | 379 | Banner University Medica Center, | Genentech, Inc. | Drug: Placebo, Drug: Tocilizumab |
| Arizona | AZ-07 | Effects of Mobile App in House Staff Health and Well-being During COVID-19 Pandemic | 328 | Banner University Medica Center, | University of Arizona | Device: Calm Meditation App |
| Arizona | AZ-07 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Cancer Center at Saint Joseph's, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Arkansas | AR-03 | Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 | 86 | University of Arkansas, | Celularity Incorporated, IDRI, Lung Biotechnology PBC, California Institute for Regenerative Medicine (CIRM) | Biological: CYNK-001 |
| Arkansas | AR-03 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Mercy Hospital Fort Smith, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Arkansas | AR-02 | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 5000 | Arkansas Children's Hospital Research Institute, | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: |
| Arkansas | AR-02 | Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) | 6000 | University of Arkansas for Medical Sciences, | Montreal Heart Institute, National Heart, Lung, and Blood Institute (NHLBI), Bill and Melinda Gates Foundation, The Government of Quebec, DACIMA Software | Drug: Colchicine, Drug: Placebo oral tablet |
| Arkansas | AR-02 | Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults | 1000 | University of Arkansas for Medical Sciences, | Vanderbilt University Medical Center, Dolly Parton, National Center for Advancing Translational Science (NCATS) | Biological: pathogen reduced SARS-CoV-2 convalescent plasma, Biological: Placebo |
| Arkansas | AR-02 | Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia | 270 | Central Arkansas Veterans Healthcare System, | Alexion Pharmaceuticals | Biological: Ravulizumab, Other: Best Supportive Care |
| Arkansas | AR-02 | Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease | 800 | GSK Investigational Site, | GlaxoSmithKline | Biological: Otilimab, Biological: Placebo, Drug: Standard of care |
| Arkansas | AR-02 | A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia | 410 | University of Arkansas For Medical Sciences, | Genentech, Inc. | Drug: MSTT1041A, Drug: MSTT1041A-matched Placebo, Drug: UTTR1147A, Drug: UTTR1147A-matched Placebo |
| Arkansas | AR-02 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | University of Arkansas for Medical Sciences, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Arkansas | AR-02 | Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial) | 20 | Baptist Health Center for Clinical Research, | Beyond Air Inc. | Device: Nitric Oxide delivered via LungFit™ system |
| Arkansas | AR-02 | Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization | 198 | Central Arkansas VHS John L. McClellan Memorial Veterans Hospital, | VA Office of Research and Development | Drug: Degarelix, Other: Saline |
| Arkansas | AR-04 | Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection | 4000 | HealthStar Research LLC, | Romark Laboratories L.C. | Drug: Nitazoxanide, Drug: Placebo, Dietary Supplement: Vitamin Super B-Complex |
| Arkansas | AR-04 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | CHI Saint Vincent Cancer Center Hot Springs, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Arkansas | AR-01 | INB03 for the Treatment of Pulmonary Complications From COVID-19 | 366 | NEA Baptist, | Inmune Bio, Inc. | Drug: INB03, Drug: Placebo |
| Arkansas | AR-01 | Compassionate Use of Hyperbaric Oxygen Therapy | 100 | White River Wound Healing Center, | SerenaGroup, Inc., SerenaGroup Research Foundation | |
| Arkansas | AR-01 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Baptist Memorial Hospital and Fowler Family Cancer Center – Jonesboro, NEA Baptist Memorial Hospital, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Connecticut | CT-01 | Convalescent Plasma in the Treatment of COVID 19 | 48 | Trinity Health Of New England, | Saint Francis Care | Biological: Convalescent Plasma |
| Connecticut | CT-05 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | The Hospital of Central Connecticut, | Gilead Sciences | Drug: Remdesivir |
| Connecticut | CT-05 | Convalescent Plasma to Stem Coronavirus (CSSC-001) | 500 | Danbury Hospital, | Johns Hopkins University | Biological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma |
| Connecticut | CT-05 | A Study of LY3127804 in Participants With COVID-19 | 95 | Nuvance Danbury Hospital, | Eli Lilly and Company | Drug: LY3127804, Drug: Placebo |
| Connecticut | CT-05 | Evaluating the Use of Polymyxin B Cartridge Hemoperfusion for Patients With Septic Shock and COVID 19 | 0 | University of Connecticut Health Center, | Spectral Diagnostics (US) Inc. | Device: Toraymyxin PMX-20R (PMX Cartridge) |
| Connecticut | CT-05 | Convalescent Plasma to Limit SARS-CoV-2 Associated Complications | 1344 | Danbury Hospital, | Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID) | Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor |
| Connecticut | CT-03 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment | 1113 | Yale-New Haven Hospital, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Connecticut | CT-03 | Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19) | 4891 | Yale-New Haven Hospital, | Gilead Sciences | Drug: Remdesivir, Drug: Standard of Care |
| Connecticut | CT-03 | Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19 | 1912 | Regeneron Study Site, | Regeneron Pharmaceuticals, Sanofi | Drug: Sarilumab, Drug: Placebo |
| Connecticut | CT-03 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Middlesex Health, | Gilead Sciences | Drug: Remdesivir |
| Connecticut | CT-03 | The Role of Resistant Starch in COVID-19 Infection | 1500 | Yale University, | Yale University, University of Michigan, University of Minnesota | Drug: Dietary Supplement containing resistant starch, Dietary Supplement: Placebo Starch |
| Connecticut | CT-03 | Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19 | 86 | Yale University, | CytoDyn, Inc. | Drug: Placebos, Drug: Leronlimab (700mg) |
| Connecticut | CT-03 | Camostat Mesylate in COVID-19 Outpatients | 114 | Yale University, | Yale University | Drug: Camostat Mesilate, Other: Placebo |
| Connecticut | CT-03 | Sarilumab for Patients With Moderate COVID-19 Disease | 120 | VA Connecticut Health System, | Westyn Branch-Elliman, VA Boston Healthcare System | Biological: SARILUMAB |
| Connecticut | CT-03 | CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients | 300 | Yale University, | NYU Langone Health, National Center for Advancing Translational Science (NCATS), Albert Einstein College of Medicine, Yale University, The University of Texas Health Science Center, Houston, The University of Texas Health Science Center at Tyler, University of Miami | Biological: Convalescent Plasma, Other: Saline solution |
| Connecticut | CT-03 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals | 43998 | Clinical Research Consulting, Yale-New Haven Hospital, | BioNTech SE, Pfizer | Biological: BNT162b1, Biological: BNT162b2, Other: Placebo |
| Connecticut | CT-03 | Immunophenotyping Assessment in a COVID-19 Cohort | 2000 | Yale School of Medicine, | National Institute of Allergy and Infectious Diseases (NIAID), Benaroya Research Institute, Boston Children's Hospital | Procedure: Biological sample collection, Procedure: Data Collection: Clinical Care Assessments |
| Connecticut | CT-03 | NCI COVID-19 in Cancer Patients, NCCAPS Study | 2000 | Veterans Affairs Connecticut Healthcare System-West Haven Campus, | National Cancer Institute (NCI) | Procedure: Biospecimen Collection, Other: Data Collection, Other: Quality-of-Life Assessment, Other: Questionnaire Administration |
| Connecticut | CT-03 | A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia | 500 | Yale University School of Medicine, | Hoffmann-La Roche, Gilead Sciences | Drug: Remdesivir, Drug: Tocilizumab, Drug: Placebo |
| Connecticut | CT-04 | Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) | 0 | Greenwich Hospital, The Stamford Health Medical Group, | Gilead Sciences | Drug: Remdesivir |
| Connecticut | CT-04 | Convalescent Plasma to Stem Coronavirus (CSSC-001) | 500 | Norwalk Hospital, | Johns Hopkins University | Biological: Anti- SARS-CoV-2 Plasma, Biological: SARS-CoV-2 non-immune Plasma |
| Connecticut | CT-04 | A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia | 100 | Norwalk Hospital, | Hoffmann-La Roche | Drug: Tociliuzumab |
| Connecticut | CT-04 | Convalescent Plasma to Limit SARS-CoV-2 Associated Complications | 1344 | Norwalk Hospital, | Johns Hopkins University, State of Maryland, Bloomberg Foundation, United States Department of Defense, National Institute of Allergy and Infectious Diseases (NIAID) | Biological: SARS-CoV-2 convalescent plasma, Biological: Plasma from a volunteer donor |
You may be surprised to learn the search for safe and effective treatments and cures for COVID is very much a local story. All across the country, America’s innovation community has mobilized like never before to fight the coronavirus pandemic.
The scope is as impressive as the speed. To date, scientists have conducted clinical trials of potential coronavirus solutions in all 50 states, across approximately 96 percent of congressional districts.
American innovators are doing their part to fight the pandemic. But they can’t do it alone.
They’re relying on legislators to support smart innovation policy – that means maintaining strong intellectual property protections; removing trade barriers, like unnecessary regulations, tariffs, and export bans; and encouraging strategic collaboration through public-private partnership.
With the right innovation policy agenda in place, we’ll help ensure that the medical discoveries happening today can be delivered to patients tomorrow.
Healthy people can help in the fight against the pandemic by volunteering for a clinical trial to find safe and effective new vaccines.
Even though the FDA has authorized some vaccines to prevent COVID-19, we still need volunteers for vaccine clinical trials. If we have several vaccines that work, we can end the pandemic sooner. We also need vaccines that can work for many different people.
Discover the latest resources and insights to help American businesses, workers, and families.
From shipping to staffing, the Chamber and its partners have the tools to save your business money and the solutions to help you run it more efficiently. Join the U.S. Chamber of Commerce today to start saving.
